{"2c1a9f676d37dfc26cf5accc1c421ab722368284": [["IntroductionThe outbreak of COVID-19, caused by a 2019-nCoV, is an urgent global health crisis which requires a timely solution.", [["COVID-19", "CHEMICAL", 28, 36], ["COVID-19", "SPECIES", 28, 36], ["COVID", "TEST", 28, 33], ["an urgent global health crisis", "PROBLEM", 64, 94], ["a timely solution", "TREATMENT", 110, 127], ["global", "OBSERVATION_MODIFIER", 74, 80], ["health crisis", "OBSERVATION", 81, 94]]], ["As end of July 2020, there are approximately eighteen million confirmed cases and seven hundred thousand deaths worldwide.", [["deaths", "DISEASE", 105, 111]]], ["Currently, the target-based therapeutics and effective treatment regimens for COVID-19 are still limited.", [["COVID-19", "CHEMICAL", 78, 86], ["effective treatment regimens", "TREATMENT", 45, 73], ["COVID", "TEST", 78, 83]]], ["One of the potential strategies is to target the proteins which are essential for life cycle of 2019-nCoV, such as main protease (M pro ) and papain-like protease (PL pro ) [1] .", [["2019-nCoV", "GENE_OR_GENE_PRODUCT", 96, 105], ["M pro", "GENE_OR_GENE_PRODUCT", 130, 135], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 142, 162], ["protease", "PROTEIN", 120, 128], ["M pro", "PROTEIN", 130, 135], ["papain", "PROTEIN", 142, 148], ["protease", "PROTEIN", 154, 162], ["PL pro", "PROTEIN", 164, 170], ["the proteins", "TEST", 45, 57], ["nCoV", "TREATMENT", 101, 105], ["main protease (M pro )", "TREATMENT", 115, 137], ["papain-like protease (PL pro )", "TREATMENT", 142, 172]]], ["M pro is the viral protease involved in production of functional polyproteins required for viral replication, and no human homolog of this protein exists [2] .", [["M pro", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 117, 122], ["M pro", "PROTEIN", 0, 5], ["viral protease", "PROTEIN", 13, 27], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["the viral protease", "TREATMENT", 9, 27], ["functional polyproteins", "PROBLEM", 54, 77], ["viral replication", "TREATMENT", 91, 108]]], ["Remarkably, protein sequence of 2019-nCoV M pro is highly similar to that of the SARS-CoV M pro which is a proven target for reducing viral load of SARS [2, 3] .", [["SARS", "DISEASE", 148, 152], ["SARS-CoV", "ORGANISM", 81, 89], ["SARS-CoV M pro", "PROTEIN", 81, 95], ["SARS-CoV", "SPECIES", 81, 89], ["protein sequence", "TEST", 12, 28], ["the SARS", "PROBLEM", 77, 85], ["CoV M pro", "TREATMENT", 86, 95]]], ["Therefore, 2019-nCoV M pro is a promising target for therapeutic intervention against COVID-19.", [["therapeutic intervention", "TREATMENT", 53, 77], ["COVID", "TEST", 86, 91]]], ["Indeed, in vitro and in silico studies on identifying potential M pro inhibitors are rapidly growing in numbers [3] [4] [5] .", [["[3] [4] [5]", "SIMPLE_CHEMICAL", 112, 123], ["silico studies", "TEST", 24, 38], ["potential M pro inhibitors", "TREATMENT", 54, 80]]], ["Moreover, lopinavir/ritonavir, previously identified as HIV protease inhibitors and found to exhibit anti-SARS-CoV activity in vitro and in clinical, have been proposed to bind 2019-nCoV M pro and are being investigated for COVID-19 treatments [6, 7] .", [["lopinavir/ritonavir", "CHEMICAL", 10, 29], ["lopinavir", "CHEMICAL", 10, 19], ["ritonavir", "CHEMICAL", 20, 29], ["lopinavir", "SIMPLE_CHEMICAL", 10, 19], ["ritonavir", "SIMPLE_CHEMICAL", 20, 29], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 101, 114], ["HIV", "SPECIES", 56, 59], ["lopinavir", "TREATMENT", 10, 19], ["ritonavir", "TREATMENT", 20, 29], ["HIV protease inhibitors", "TREATMENT", 56, 79], ["anti-SARS", "TEST", 101, 110]]], ["However, several clinical trials indicate that they have limited efficacy in treating COVID-19 and caused significant adverse effects, such as gastrointestinal intolerance and hepatotoxicity [8] .IntroductionRecently, a three-dimensional (3D) structure of 2019-nCoV M pro including the substrate-binding pocket has been illustrated [4] .", [["gastrointestinal", "ANATOMY", 143, 159], ["COVID-19", "CHEMICAL", 86, 94], ["gastrointestinal intolerance", "DISEASE", 143, 171], ["hepatotoxicity", "DISEASE", 176, 190], ["COVID-19", "CHEMICAL", 86, 94], ["gastrointestinal", "ORGANISM_SUBDIVISION", 143, 159], ["2019-nCoV M pro", "PROTEIN", 256, 271], ["substrate-binding pocket", "PROTEIN", 286, 310], ["COVID", "TEST", 86, 91], ["significant adverse effects", "PROBLEM", 106, 133], ["gastrointestinal intolerance", "PROBLEM", 143, 171], ["hepatotoxicity", "PROBLEM", 176, 190], ["nCoV M pro", "TREATMENT", 261, 271], ["the substrate-binding pocket", "PROBLEM", 282, 310], ["gastrointestinal", "ANATOMY", 143, 159]]], ["In addition, M pro in SARS-CoV or 2019-nCoV is classified as a cysteine protease which involves an active site cysteine in its catalytic dyad.", [["cysteine", "CHEMICAL", 111, 119], ["cysteine", "CHEMICAL", 63, 71], ["cysteine", "CHEMICAL", 111, 119], ["M pro", "GENE_OR_GENE_PRODUCT", 13, 18], ["SARS-CoV", "ORGANISM", 22, 30], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 34, 43], ["cysteine", "AMINO_ACID", 111, 119], ["M pro", "PROTEIN", 13, 18], ["nCoV", "DNA", 39, 43], ["cysteine protease", "PROTEIN", 63, 80], ["catalytic dyad", "PROTEIN", 127, 141], ["SARS-CoV", "SPECIES", 22, 30], ["SARS", "TEST", 22, 26], ["a cysteine protease", "TREATMENT", 61, 80], ["an active site cysteine", "PROBLEM", 96, 119], ["active", "OBSERVATION_MODIFIER", 99, 105]]], ["It has been shown that M pro could be inactivated by the inhibitors initiating a Michael addition reaction on the active site cysteine [2, 4] .", [["cysteine", "CHEMICAL", 126, 134], ["M pro", "GENE_OR_GENE_PRODUCT", 23, 28], ["cysteine", "AMINO_ACID", 126, 134], ["2, 4]", "SIMPLE_CHEMICAL", 136, 141], ["the inhibitors", "TREATMENT", 53, 67], ["a Michael addition reaction", "TREATMENT", 79, 106], ["the active site cysteine", "TREATMENT", 110, 134]]], ["Therefore, the Michael acceptor-containing compounds which can fit in the catalytic pocket of 2019-nCoV M pro may serve as attractive drug candidates for treating COVID-19.IntroductionPlant-derived natural products play crucial roles in new drug development [9] .", [["COVID-19", "CHEMICAL", 163, 171], ["the Michael acceptor-containing compounds", "TREATMENT", 11, 52], ["nCoV M pro", "TREATMENT", 99, 109], ["COVID", "TEST", 163, 168], ["natural products", "TREATMENT", 198, 214]]], ["Andrographolide, a lactone diterpenoid compound highly abundant in leaves of medicinal plant Andrographis paniculata, has been demonstrated to exhibit diverse pharmacological activities, including anti-inflammatory, anti-viral, anti-cancer and hepatoprotective effects [10] .", [["leaves", "ANATOMY", 67, 73], ["Andrographolide", "CHEMICAL", 0, 15], ["lactone diterpenoid", "CHEMICAL", 19, 38], ["Andrographis paniculata", "CHEMICAL", 93, 116], ["Andrographolide", "CHEMICAL", 0, 15], ["lactone", "CHEMICAL", 19, 26], ["diterpenoid", "CHEMICAL", 27, 38], ["Andrographolide", "SIMPLE_CHEMICAL", 0, 15], ["lactone diterpenoid", "SIMPLE_CHEMICAL", 19, 38], ["leaves", "ORGANISM_SUBDIVISION", 67, 73], ["Andrographis paniculata", "ORGANISM", 93, 116], ["Andrographis paniculata", "SPECIES", 93, 116], ["Andrographis paniculata", "SPECIES", 93, 116], ["Andrographolide", "TREATMENT", 0, 15], ["a lactone diterpenoid", "TREATMENT", 17, 38], ["anti-inflammatory", "TREATMENT", 197, 214], ["anti-viral, anti-cancer", "TREATMENT", 216, 239], ["hepatoprotective effects", "TREATMENT", 244, 268]]], ["Both A. paniculata extract and andrographolide alone are currently used worldwide for treating upper respiratory diseases as well as inflammatory diseases [10] [11] [12] .", [["respiratory", "ANATOMY", 101, 112], ["A. paniculata extract", "CHEMICAL", 5, 26], ["andrographolide", "CHEMICAL", 31, 46], ["upper respiratory diseases", "DISEASE", 95, 121], ["inflammatory diseases", "DISEASE", 133, 154], ["andrographolide", "CHEMICAL", 31, 46], ["A. paniculata", "ORGANISM", 5, 18], ["andrographolide", "SIMPLE_CHEMICAL", 31, 46], ["A. paniculata", "SPECIES", 5, 18], ["A. paniculata", "SPECIES", 5, 18], ["Both A. paniculata extract", "TREATMENT", 0, 26], ["andrographolide alone", "TREATMENT", 31, 52], ["upper respiratory diseases", "PROBLEM", 95, 121], ["inflammatory diseases", "PROBLEM", 133, 154], ["upper", "ANATOMY_MODIFIER", 95, 100], ["respiratory", "ANATOMY", 101, 112], ["diseases", "OBSERVATION", 113, 121], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145]]], ["In addition, their clinical trials demonstrate that no significant adverse effects were observed in patients [10] [11] [12] .", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["significant adverse effects", "PROBLEM", 55, 82]]], ["More importantly, andrographolide which contains a Michael acceptor group has been shown to react with the Cys 62 of NF-\u03baB-p50 through covalent linkage [13, 14] , rendering it as a potential inhibitor of 2019-nCoV M pro .", [["andrographolide", "CHEMICAL", 18, 33], ["andrographolide", "CHEMICAL", 18, 33], ["Cys", "CHEMICAL", 107, 110], ["andrographolide", "SIMPLE_CHEMICAL", 18, 33], ["NF-\u03baB-p50", "GENE_OR_GENE_PRODUCT", 117, 126], ["NF-\u03baB", "PROTEIN", 117, 122], ["p50", "PROTEIN", 123, 126], ["andrographolide", "TREATMENT", 18, 33], ["a Michael acceptor group", "TREATMENT", 49, 73], ["the Cys", "TEST", 103, 110], ["NF", "TEST", 117, 119]]], ["In this study, we investigated the inhibitory J o u r n a l P r e -p r o o f effects of andrographolide and its fluorescent derivative on the in vitro activity of 2019-nCoV M pro .Chemicals and reagentsAndrographolide and disulfiram were purchased from Sigma-Aldrich (USA).", [["andrographolide", "CHEMICAL", 88, 103], ["Andrographolide", "CHEMICAL", 202, 217], ["disulfiram", "CHEMICAL", 222, 232], ["andrographolide", "CHEMICAL", 88, 103], ["Andrographolide", "CHEMICAL", 202, 217], ["disulfiram", "CHEMICAL", 222, 232], ["andrographolide", "SIMPLE_CHEMICAL", 88, 103], ["Andrographolide", "SIMPLE_CHEMICAL", 202, 217], ["disulfiram", "SIMPLE_CHEMICAL", 222, 232], ["Sigma-Aldrich (USA", "ORGANISM", 253, 271], ["this study", "TEST", 3, 13], ["andrographolide", "TREATMENT", 88, 103], ["its fluorescent derivative", "TREATMENT", 108, 134], ["Andrographolide", "TREATMENT", 202, 217], ["disulfiram", "TREATMENT", 222, 232]]], ["Chemical syntheses of ANDRO-NBD and NCTU-048 were performed based on our previous studies [15, 16] .", [["ANDRO-NBD", "CHEMICAL", 22, 31], ["NCTU-048", "CHEMICAL", 36, 44], ["ANDRO-NBD", "CHEMICAL", 22, 31], ["NCTU-048", "CHEMICAL", 36, 44], ["ANDRO-NBD", "SIMPLE_CHEMICAL", 22, 31], ["NCTU-048", "SIMPLE_CHEMICAL", 36, 44], ["ANDRO", "TEST", 22, 27], ["NCTU", "TEST", 36, 40], ["our previous studies", "TEST", 69, 89]]], ["Sequencing grade chymotrypsin was obtained from Promega (USA).Protein expression and purification of SARS-CoV M pro and 2019-nCoV M proPreparation of the recombinant SARS-CoV M pro was performed following a previous report [17] .", [["SARS", "DISEASE", 166, 170], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 17, 29], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["chymotrypsin", "PROTEIN", 17, 29], ["SARS-CoV", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 166, 174], ["Sequencing grade chymotrypsin", "PROBLEM", 0, 29], ["Protein expression", "TEST", 62, 80], ["SARS", "PROBLEM", 101, 105]]], ["Moreover, the DNA sequence of 2019-nCoV M pro was cloned into a pET-29a vector to encode recombinant protease with a C-terminal His 6 -tag.", [["C", "CHEMICAL", 117, 118], ["His", "CHEMICAL", 128, 131], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["pET-29a", "GENE_OR_GENE_PRODUCT", 64, 71], ["DNA sequence", "DNA", 14, 26], ["2019-nCoV M pro", "DNA", 30, 45], ["pET-29a vector", "DNA", 64, 78], ["recombinant protease", "PROTEIN", 89, 109], ["C-terminal His 6 -tag", "PROTEIN", 117, 138], ["pET-29a", "SPECIES", 64, 71], ["the DNA sequence", "TEST", 10, 26], ["a pET-29a vector", "TREATMENT", 62, 78], ["recombinant protease", "TREATMENT", 89, 109]]], ["Upon plasmid transformation and IPTG induction in BL21 E. coli strain, the collected lysate supernatant was further purified by Ni-NTA affinity column (Qiagen, Germany) and S-100 size-exclusion chromatography column (GE Healthcare, USA) to produce pure 2019-nCoV M pro .Protease activity assayActivities of 2019-nCoV M pro and SARS-CoV M pro were measured following a previous cleavage assay which used a fluorogenic peptide substrate (Abz-TSAVLQSGFRK-Dnp) in phosphate buffered saline (PBS) buffer (20 mM, pH 7.6) at 30 o C for 3 min as [18] .Protease activity assayUpon the cleavage by protease, the quencher dinitrophenyl (Dnp) at C-terminal was released from the N-terminal fluorophore aminobenzoyl (Abz).", [["plasmid", "ANATOMY", 5, 12], ["lysate supernatant", "ANATOMY", 85, 103], ["IPTG", "CHEMICAL", 32, 36], ["Ni-NTA", "CHEMICAL", 128, 134], ["Abz-TSAVLQSGFRK-Dnp", "CHEMICAL", 436, 455], ["phosphate", "CHEMICAL", 460, 469], ["dinitrophenyl", "CHEMICAL", 611, 624], ["Dnp", "CHEMICAL", 626, 629], ["aminobenzoyl", "CHEMICAL", 690, 702], ["Abz", "CHEMICAL", 704, 707], ["IPTG", "CHEMICAL", 32, 36], ["Ni-NTA", "CHEMICAL", 128, 134], ["phosphate", "CHEMICAL", 460, 469], ["dinitrophenyl", "CHEMICAL", 611, 624], ["Dnp", "CHEMICAL", 626, 629], ["C", "CHEMICAL", 634, 635], ["N", "CHEMICAL", 667, 668], ["aminobenzoyl", "CHEMICAL", 690, 702], ["Abz", "CHEMICAL", 704, 707], ["IPTG", "SIMPLE_CHEMICAL", 32, 36], ["BL21 E. coli", "ORGANISM", 50, 62], ["strain", "ORGANISM", 63, 69], ["Ni-NTA", "SIMPLE_CHEMICAL", 128, 134], ["Protease", "GENE_OR_GENE_PRODUCT", 270, 278], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 327, 335], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 460, 485], ["Protease", "GENE_OR_GENE_PRODUCT", 544, 552], ["quencher dinitrophenyl", "SIMPLE_CHEMICAL", 602, 624], ["Dnp", "SIMPLE_CHEMICAL", 626, 629], ["C-terminal", "SIMPLE_CHEMICAL", 634, 644], ["aminobenzoyl", "SIMPLE_CHEMICAL", 690, 702], ["Abz", "SIMPLE_CHEMICAL", 704, 707], ["TSAVLQSGFRK", "PROTEIN", 440, 451], ["protease", "PROTEIN", 588, 596], ["Abz", "PROTEIN", 704, 707], ["BL21 E. coli", "SPECIES", 50, 62], ["BL21 E. coli", "SPECIES", 50, 62], ["SARS-CoV", "SPECIES", 327, 335], ["plasmid transformation", "TREATMENT", 5, 27], ["IPTG induction", "TREATMENT", 32, 46], ["BL21 E. coli strain", "PROBLEM", 50, 69], ["the collected lysate supernatant", "TREATMENT", 71, 103], ["S", "TEST", 173, 174], ["Protease activity assayActivities", "TEST", 270, 303], ["SARS", "PROBLEM", 327, 331], ["CoV M pro", "TEST", 332, 341], ["a previous cleavage assay", "TEST", 366, 391], ["a fluorogenic peptide substrate (Abz-TSAVLQSGFRK-Dnp", "TREATMENT", 403, 455], ["phosphate buffered saline (PBS) buffer", "TREATMENT", 460, 498], ["pH", "TEST", 507, 509], ["Protease activity", "TREATMENT", 544, 561], ["the cleavage", "TREATMENT", 572, 584], ["protease", "TREATMENT", 588, 596], ["the quencher dinitrophenyl (Dnp) at C-terminal", "TREATMENT", 598, 644], ["the N-terminal fluorophore aminobenzoyl (Abz)", "TREATMENT", 663, 708], ["plasmid transformation", "OBSERVATION", 5, 27], ["coli strain", "OBSERVATION", 58, 69]]], ["Subsequently, the fluorescence at 423 nm was detected with excitation at 321 nm using a Perkin-Elmer LS 50B luminescence spectrometer (UK).", [["the fluorescence", "TEST", 14, 30], ["a Perkin-Elmer LS", "TREATMENT", 86, 103]]], ["The reaction concentrations of peptide substrate were ranged from 2 \u03bcM to 40 \u03bcM in PBS buffer (20 mM, pH 7.6), whereas the concentration of 2019-nCoV M pro and SARS-CoV M pro were respectively kept as 0.12 \u03bcM and 0.48 \u03bcM.", [["The reaction concentrations of peptide substrate", "PROBLEM", 0, 48], ["pH", "TEST", 102, 104], ["the concentration", "TEST", 119, 136], ["SARS", "TEST", 160, 164], ["CoV M pro", "TEST", 165, 174], ["concentrations", "OBSERVATION_MODIFIER", 13, 27]]], ["Kinetics parameters like K m and k cat were determined by fitting the initial velocities at different substrate concentrations to a Michaelis-Menten equation, as described previously [18] .Inhibition of M pro activity and determination of the half-maximal inhibitory concentration (IC 50 )To determine inhibition of M pro activity, inhibitor (0 \u03bcM to 20 \u03bcM) and fluorogenic peptide substrate (5 \u03bcM) in PBS buffer (20 mM, pH 7.6) were first equilibrated at \u03bcM SARS-CoV M pro ) and further incubation at 30 o C for 3 min.", [["K m", "GENE_OR_GENE_PRODUCT", 25, 28], ["M pro", "GENE_OR_GENE_PRODUCT", 203, 208], ["M pro", "GENE_OR_GENE_PRODUCT", 316, 321], ["Kinetics parameters", "TEST", 0, 19], ["K m", "TEST", 25, 28], ["k cat", "TEST", 33, 38], ["a Michaelis", "TEST", 130, 141], ["M pro activity", "TREATMENT", 203, 217], ["the half-maximal inhibitory concentration (IC", "TREATMENT", 239, 284], ["M pro activity, inhibitor", "TREATMENT", 316, 341], ["fluorogenic peptide substrate", "TREATMENT", 362, 391], ["pH", "TEST", 421, 423], ["CoV M pro", "TREATMENT", 464, 473], ["further incubation", "TREATMENT", 480, 498]]], ["As described above, enzymatic activity was determined and the measured velocities at different inhibitor concentrations were fitted to obtain IC 50 according to the following equation:Inhibition of M pro activity and determination of the half-maximal inhibitory concentration (IC 50 )in which \u03bd is the velocity with incubation of inhibitor at different concentration [I] and the v 0 is the initial velocity without incubation of inhibitor, while n is the Hill constant.Fluorescence detection of main proteases upon inhibition with Andro-NBDA total of 3 \u03bcM M pro was treated with Andro-NBD in various molar ratios at 25 o C for 1 h and then analyzed by 12% SDS-PAGE.", [["Andro-NBDA", "CHEMICAL", 531, 541], ["Andro-NBD", "CHEMICAL", 579, 588], ["Andro-NBDA", "CHEMICAL", 531, 541], ["Andro-NBD", "CHEMICAL", 579, 588], ["Andro-NBDA", "SIMPLE_CHEMICAL", 531, 541], ["Andro-NBD", "SIMPLE_CHEMICAL", 579, 588], ["enzymatic activity", "PROBLEM", 20, 38], ["the measured velocities at different inhibitor concentrations", "PROBLEM", 58, 119], ["Inhibition of M pro activity", "TREATMENT", 184, 212], ["the half-maximal inhibitory concentration", "TREATMENT", 234, 275], ["inhibitor", "TREATMENT", 330, 339], ["inhibitor", "TREATMENT", 429, 438], ["Fluorescence detection", "TEST", 469, 491], ["main proteases", "PROBLEM", 495, 509], ["Andro", "TEST", 531, 536], ["Andro", "TREATMENT", 579, 584], ["NBD in various molar ratios", "TREATMENT", 585, 612], ["enzymatic activity", "OBSERVATION", 20, 38]]], ["The resulting polyacrylamide gels were scanned for fluorescence at 520 nm under excitation at 488 nm using Amersham Imager 680 (GE healthcare, USA).Docking analysisThe 3D structures of viral main protease were downloaded from the protein data bank (PDB, https://www.rcsb.org) which collects the published X-ray structures of SARS-CoV M pro and 2019-nCoV M pro [4, 19] .", [["polyacrylamide", "CHEMICAL", 14, 28], ["viral main protease", "PROTEIN", 185, 204], ["SARS-CoV", "SPECIES", 325, 333], ["The resulting polyacrylamide gels", "TREATMENT", 0, 33], ["Docking analysis", "TEST", 148, 164], ["viral main protease", "PROBLEM", 185, 204], ["SARS", "PROBLEM", 325, 329], ["viral main", "OBSERVATION", 185, 195], ["PDB", "ANATOMY", 249, 252]]], ["Water molecules, ions, co-crystalized ligand were first removed from original structure prior to docking experiment, and chemical structure of andrographolide was added.", [["andrographolide", "CHEMICAL", 143, 158], ["andrographolide", "CHEMICAL", 143, 158], ["ions", "SIMPLE_CHEMICAL", 17, 21], ["andrographolide", "SIMPLE_CHEMICAL", 143, 158], ["ions, co-crystalized ligand", "PROBLEM", 17, 44], ["andrographolide", "TREATMENT", 143, 158]]], ["The resulted complex of protein/andrographolide was subjected to molecular docking using Arguslab 4.0.1 to evaluate the putative ligand-binding site and release of free energy [20] .", [["andrographolide", "CHEMICAL", 32, 47], ["andrographolide", "CHEMICAL", 32, 47], ["andrographolide", "SIMPLE_CHEMICAL", 32, 47], ["protein/andrographolide", "TREATMENT", 24, 47], ["Arguslab", "TREATMENT", 89, 97]]], ["The optimal docking sites for ligand were accordingly predicted.Statistical analysisAll of the data were represented as the mean \u00b1 standard derivation (SD) from three independent experiments. * represents p-value <0.05; ** represents p-value <0.01; *** represents p-value <0.001 by Student's t-test.2019-nCoV M pro and SARS-CoV M pro shares similar consensus substrate sequence and enzyme kineticsRecent genome analysis of 2019-nCoV revealed the organization of its open reading frame 1 (ORF1) which encodes two polyproteins consisting of all the non-structural proteins needed for virus replication and is very similar to SARS-CoV [21, 22] (Fig. S1 ).2019-nCoV M pro and SARS-CoV M pro shares similar consensus substrate sequence and enzyme kineticsIn addition, sequence alignment of main proteases from 2019-nCoV, SARS-CoV and whereas the identity between 2019-nCoV M pro and MERS-CoV M pro is only 51% (Fig. S2 ).", [["SARS", "DISEASE", 623, 627], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 423, 432], ["open reading frame 1", "GENE_OR_GENE_PRODUCT", 466, 486], ["ORF1", "GENE_OR_GENE_PRODUCT", 488, 492], ["M pro", "GENE_OR_GENE_PRODUCT", 662, 667], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 672, 680], ["SARS-CoV", "ORGANISM", 816, 824], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 878, 886], ["consensus substrate sequence", "DNA", 349, 377], ["2019", "DNA", 423, 427], ["nCoV", "DNA", 428, 432], ["open reading frame 1", "DNA", 466, 486], ["ORF1", "DNA", 488, 492], ["non-structural proteins", "PROTEIN", 547, 570], ["consensus substrate sequence", "DNA", 702, 730], ["main proteases", "PROTEIN", 785, 799], ["2019", "PROTEIN", 805, 809], ["nCoV", "PROTEIN", 810, 814], ["MERS", "PROTEIN", 878, 882], ["SARS-CoV", "SPECIES", 319, 327], ["SARS-CoV", "SPECIES", 623, 631], ["SARS-CoV", "SPECIES", 672, 680], ["SARS-CoV", "SPECIES", 816, 824], ["Statistical analysis", "TEST", 64, 84], ["the mean \u00b1 standard derivation", "TREATMENT", 120, 150], ["p-value", "TEST", 205, 212], ["p-value", "TEST", 234, 241], ["Student's t-test", "TEST", 282, 298], ["SARS", "PROBLEM", 319, 323], ["substrate sequence", "TEST", 359, 377], ["enzyme kinetics", "TEST", 382, 397], ["Recent genome analysis", "TEST", 397, 419], ["two polyproteins", "PROBLEM", 508, 524], ["all the non-structural proteins", "TREATMENT", 539, 570], ["virus replication", "TREATMENT", 582, 599], ["SARS", "TEST", 623, 627], ["CoV", "TEST", 628, 631], ["SARS", "PROBLEM", 672, 676], ["substrate sequence", "TEST", 712, 730], ["enzyme kinetics", "TEST", 735, 750], ["sequence alignment of main proteases", "TEST", 763, 799], ["nCoV", "TEST", 810, 814], ["SARS", "TEST", 816, 820], ["the identity", "TEST", 837, 849], ["MERS", "TEST", 878, 882], ["CoV M pro", "TEST", 883, 892], ["main", "OBSERVATION_MODIFIER", 785, 789]]], ["Because M pro is the essential protease which is responsible to produce the individual non-structural proteins upon proteolytic cleavage on the primary polyproteins, we further aligned amino acid sequences of all the 12 cleavage sites by 2019-nCoV M pro (Fig. S3A ).", [["amino acid", "CHEMICAL", 185, 195], ["amino acid", "CHEMICAL", 185, 195], ["M pro", "GENE_OR_GENE_PRODUCT", 8, 13], ["amino acid", "AMINO_ACID", 185, 195], ["M pro", "PROTEIN", 8, 13], ["protease", "PROTEIN", 31, 39], ["non-structural proteins", "PROTEIN", 87, 110], ["primary polyproteins", "PROTEIN", 144, 164], ["the essential protease", "PROBLEM", 17, 39], ["the individual non-structural proteins", "PROBLEM", 72, 110], ["proteolytic cleavage", "PROBLEM", 116, 136], ["the primary polyproteins", "TREATMENT", 140, 164], ["further aligned amino acid sequences", "TREATMENT", 169, 205]]], ["Among these sites, 8 of them are completely conserved between 2019-nCoV M pro and SARS-CoV M pro , including the peptide sequence between nsp4 and nsp5 (-TSITSAVLQSGFRKMAFP-) (Fig. S3B) .", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["nsp4", "GENE_OR_GENE_PRODUCT", 138, 142], ["SARS-CoV M pro", "DNA", 82, 96], ["nsp4", "DNA", 138, 142], ["nsp5", "DNA", 147, 151], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "TEST", 82, 86], ["the peptide sequence", "TEST", 109, 129], ["nsp4", "TEST", 138, 142], ["nsp5", "TEST", 147, 151], ["TSITSAVLQSGFRKMAFP", "TEST", 154, 172]]], ["Previously, a fluorogenic peptide (Abz-TSAVLQSGFRK-Dnp) which contains both a fluorophore (Abz) and its quencher (Dnp), has been used to determine the protease activity of SARS-CoV M pro (Fig. S3C ) [23] .", [["Abz-TSAVLQSGFRK-Dnp", "CHEMICAL", 35, 54], ["Abz", "CHEMICAL", 91, 94], ["Abz", "CHEMICAL", 91, 94], ["Abz", "SIMPLE_CHEMICAL", 91, 94], ["TSAVLQSGFRK", "PROTEIN", 39, 50], ["Dnp", "PROTEIN", 51, 54], ["protease", "PROTEIN", 151, 159], ["SARS-CoV", "SPECIES", 172, 180], ["a fluorogenic peptide (Abz", "TEST", 12, 38], ["a fluorophore (Abz)", "TREATMENT", 76, 95], ["its quencher (Dnp)", "TREATMENT", 100, 118], ["SARS", "PROBLEM", 172, 176], ["CoV M pro", "TREATMENT", 177, 186]]], ["Upon the cleavage of this peptide probe by protease, the fluorophore (Abz) was separated from its quencher and thus emitted fluorescence under UV excitation.", [["Abz", "CHEMICAL", 70, 73], ["Abz", "CHEMICAL", 70, 73], ["Abz", "SIMPLE_CHEMICAL", 70, 73], ["protease", "PROTEIN", 43, 51], ["this peptide probe", "TREATMENT", 21, 39], ["protease", "TREATMENT", 43, 51], ["the fluorophore (Abz)", "TREATMENT", 53, 74], ["UV excitation", "TREATMENT", 143, 156], ["UV excitation", "OBSERVATION", 143, 156]]], ["We therefore prepared the recombinant 2019-nCoV M pro and SARS-CoV M pro , and measured their protease activities using this fluorogenic probe (Fig. 1A) .", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["recombinant 2019-nCoV M pro", "PROTEIN", 26, 53], ["protease", "PROTEIN", 94, 102], ["SARS-CoV", "SPECIES", 58, 66], ["CoV M pro", "TREATMENT", 63, 72], ["their protease activities", "TREATMENT", 88, 113], ["this fluorogenic probe", "TREATMENT", 120, 142]]], ["Results of the protease activity assay revealed that 2019-nCoV M pro exhibits higher activity and catalytic efficiency than SARS-CoV M pro ( Fig. 1B and Table 1 ).Sedimentation coefficient distribution suggests a dimeric quaternary structure of 2019-nCoV M proSARS-CoV M pro was previously shown to function in a dimeric form.", [["protease", "PROTEIN", 15, 23], ["proSARS", "PROTEIN", 257, 264], ["dimeric form", "PROTEIN", 313, 325], ["SARS-CoV", "SPECIES", 124, 132], ["the protease activity assay", "TEST", 11, 38], ["higher activity", "PROBLEM", 78, 93], ["catalytic efficiency", "PROBLEM", 98, 118], ["CoV M pro", "TREATMENT", 129, 138], ["Sedimentation coefficient distribution", "TEST", 163, 201], ["a dimeric quaternary structure", "PROBLEM", 211, 241], ["quaternary structure", "OBSERVATION", 221, 241]]], ["We therefore measured the continuous sedimentation coefficient distribution using analytical ultracentrifugation (AUC) to determine whether 2019-nCoV M pro forms a homodimer (Fig. 1C) .", [["homodimer", "PROTEIN", 164, 173], ["analytical ultracentrifugation", "TEST", 82, 112]]], ["The profiles of quaternary structure at different concentrations suggest that 2019-nCoV M pro exists predominantly in a dimeric structure (Fig. 1D) , using SARS-CoV M pro as a reference (Fig. 1E ).", [["dimeric structure", "PROTEIN", 120, 137], ["SARS-CoV M pro", "PROTEIN", 156, 170], ["quaternary structure", "OBSERVATION", 16, 36], ["predominantly", "OBSERVATION_MODIFIER", 101, 114]]], ["In addition, SARS-CoV M pro was previously shown to increase its monomeric form when existed in acidic environment [23] .Sedimentation coefficient distribution suggests a dimeric quaternary structure of 2019-nCoV M proHowever, further AUC experiments of 2019-nCoV M pro under acidic condition (pH 6) only slightly increased its monomeric ratio.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["SARS-CoV M pro", "PROTEIN", 13, 27], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["Sedimentation coefficient distribution", "TEST", 121, 159], ["a dimeric quaternary structure", "PROBLEM", 169, 199], ["further AUC experiments", "TEST", 227, 250], ["pH", "TEST", 294, 296], ["slightly increased its monomeric ratio", "PROBLEM", 305, 343], ["quaternary structure", "OBSERVATION", 179, 199], ["increased", "OBSERVATION_MODIFIER", 314, 323], ["monomeric ratio", "OBSERVATION", 328, 343]]], ["(Fig. S4 ).Andrographolide inhibits protease activities of 2019-nCoV M pro and SARS-CoV M proAndrographolide has been reported to inhibit protein function through a Michael addition reaction with the free thiol side chain of cysteine [13, 14] .", [["Andrographolide", "CHEMICAL", 11, 26], ["proAndrographolide", "CHEMICAL", 90, 108], ["thiol", "CHEMICAL", 205, 210], ["cysteine", "CHEMICAL", 225, 233], ["Andrographolide", "CHEMICAL", 11, 26], ["proAndrographolide", "CHEMICAL", 90, 108], ["thiol", "CHEMICAL", 205, 210], ["cysteine", "CHEMICAL", 225, 233], ["Andrographolide", "SIMPLE_CHEMICAL", 11, 26], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["proAndrographolide", "SIMPLE_CHEMICAL", 90, 108], ["cysteine [13, 14]", "SIMPLE_CHEMICAL", 225, 242], ["protease", "PROTEIN", 36, 44], ["SARS-CoV", "SPECIES", 79, 87], ["Andrographolide", "TREATMENT", 11, 26], ["protease activities", "TEST", 36, 55], ["SARS", "PROBLEM", 79, 83], ["CoV M proAndrographolide", "TREATMENT", 84, 108], ["a Michael addition reaction", "TREATMENT", 163, 190], ["the free thiol side chain of cysteine", "TREATMENT", 196, 233], ["S4", "ANATOMY", 6, 8]]], ["We thus further M pro in a Michael addition-dependent manner, a thiol-insensitive andrographolide derivative (NCTU-048) was also examined in the protease activity assay and it exhibited relatively low protease inhibition (Fig. 2C) .", [["thiol", "CHEMICAL", 64, 69], ["andrographolide", "CHEMICAL", 82, 97], ["NCTU-048", "CHEMICAL", 110, 118], ["thiol", "CHEMICAL", 64, 69], ["andrographolide", "CHEMICAL", 82, 97], ["NCTU-048", "CHEMICAL", 110, 118], ["thiol", "SIMPLE_CHEMICAL", 64, 69], ["andrographolide derivative", "SIMPLE_CHEMICAL", 82, 108], ["NCTU-048", "SIMPLE_CHEMICAL", 110, 118], ["protease", "PROTEIN", 145, 153], ["protease", "PROTEIN", 201, 209], ["a thiol-insensitive andrographolide derivative", "TREATMENT", 62, 108], ["the protease activity assay", "TEST", 141, 168]]], ["Moreover, a previously reported SARS-CoV M pro inhibitor (disulfiram) was also investigated for its inhibition on 2019-nCoV M pro and the result showed an IC 50 of 5.61\u00b10.34 \u03bcM (Fig. 2D ).Andro-NBD and andrographolide form covalent linkages with 2019-nCoV M pro and SARS-CoV M proAs described above, both andrographolide and Andro-NBD were shown to inhibit the activity of 2019-nCoV M pro .", [["disulfiram", "CHEMICAL", 58, 68], ["Andro-NBD", "CHEMICAL", 188, 197], ["andrographolide", "CHEMICAL", 202, 217], ["andrographolide", "CHEMICAL", 305, 320], ["Andro-NBD", "CHEMICAL", 325, 334], ["disulfiram", "CHEMICAL", 58, 68], ["Andro-NBD", "CHEMICAL", 188, 197], ["andrographolide", "CHEMICAL", 202, 217], ["andrographolide", "CHEMICAL", 305, 320], ["Andro-NBD", "CHEMICAL", 325, 334], ["disulfiram", "SIMPLE_CHEMICAL", 58, 68], ["Andro-NBD", "SIMPLE_CHEMICAL", 188, 197], ["andrographolide", "SIMPLE_CHEMICAL", 202, 217], ["andrographolide", "SIMPLE_CHEMICAL", 305, 320], ["Andro-NBD", "SIMPLE_CHEMICAL", 325, 334], ["a previously reported SARS", "PROBLEM", 10, 36], ["CoV M pro inhibitor (disulfiram", "TREATMENT", 37, 68], ["an IC", "TEST", 152, 157], ["andrographolide form covalent linkages", "TREATMENT", 202, 240], ["SARS", "PROBLEM", 266, 270], ["CoV M pro", "TREATMENT", 271, 280]]], ["We have previously demonstrated that Andro-NBD forms a covalent bond with p50 subunit of NF-kB [15] .", [["Andro-NBD", "CHEMICAL", 37, 46], ["Andro-NBD", "SIMPLE_CHEMICAL", 37, 46], ["p50", "GENE_OR_GENE_PRODUCT", 74, 77], ["NF-kB", "GENE_OR_GENE_PRODUCT", 89, 94], ["Andro-NBD", "PROTEIN", 37, 46], ["p50 subunit", "PROTEIN", 74, 85], ["NF", "PROTEIN", 89, 91]]], ["Whether Andro-NBD also inhibits 2019-nCoV M pro through a covalent linkage was herein investigated.", [["Andro-NBD", "CHEMICAL", 8, 17], ["Andro-NBD", "CHEMICAL", 8, 17], ["Andro-NBD", "SIMPLE_CHEMICAL", 8, 17], ["2019-nCoV M pro", "PROTEIN", 32, 47], ["a covalent linkage", "TREATMENT", 56, 74]]], ["As shown inAndrographolide can dock into the catalytic pockets of 2019-nCoV M pro and SARS-CoV M proWe further carried out the docking experiment using Arguslab modeling program [20] to study whether andrographolide enters the catalytic pockets of 2019-nCoV M pro (PDB 6LU7) and SARS-CoV M pro (PDB 1UK4) [4, 22] .", [["inAndrographolide", "CHEMICAL", 9, 26], ["andrographolide", "CHEMICAL", 200, 215], ["inAndrographolide", "CHEMICAL", 9, 26], ["andrographolide", "CHEMICAL", 200, 215], ["inAndrographolide", "SIMPLE_CHEMICAL", 9, 26], ["andrographolide", "SIMPLE_CHEMICAL", 200, 215], ["inAndrographolide", "PROTEIN", 9, 26], ["catalytic pockets", "PROTEIN", 45, 62], ["PDB 6LU7", "PROTEIN", 265, 273], ["SARS-CoV", "SPECIES", 279, 287], ["SARS", "PROBLEM", 86, 90], ["Arguslab modeling program", "TREATMENT", 152, 177], ["andrographolide", "TREATMENT", 200, 215], ["the catalytic pockets", "TEST", 223, 244], ["PDB", "TEST", 265, 268], ["SARS-CoV M pro (PDB 1UK4)", "TREATMENT", 279, 304]]], ["As shown in Fig. 4A estimated to be -9.72 kcal/mol (\u0394G) and the distance between Cys 145 and the acceptor carbon of Michael reaction (C12 of andrographolide) is 3.7\u00c5 (Fig. 4B and 4C) .", [["Cys 145", "CHEMICAL", 81, 88], ["C12 of andrographolide", "CHEMICAL", 134, 156], ["Cys", "CHEMICAL", 81, 84], ["carbon", "CHEMICAL", 106, 112], ["andrographolide", "CHEMICAL", 141, 156], ["andrographolide", "SIMPLE_CHEMICAL", 141, 156], ["Cys", "TEST", 81, 84], ["andrographolide", "TEST", 141, 156], ["Fig", "OBSERVATION", 12, 15]]], ["Similarly, SARS-CoV M pro exhibits comparable binding affinity of andrographolide at -7.85 kcal/mol and its Cys 145 is 4.8\u00c5 away from Michael addition site (Fig. 4E and 4F) .", [["SARS", "DISEASE", 11, 15], ["andrographolide", "CHEMICAL", 66, 81], ["andrographolide", "CHEMICAL", 66, 81], ["Cys", "CHEMICAL", 108, 111], ["andrographolide", "SIMPLE_CHEMICAL", 66, 81], ["Michael addition site", "PROTEIN", 134, 155], ["4F", "PROTEIN", 169, 171], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "PROBLEM", 11, 15], ["andrographolide", "TREATMENT", 66, 81], ["its Cys", "TEST", 104, 111]]], ["Together, these results support our findings of andrographolide-mediated inhibition and covalent linkage of 2019-nCoV M pro and SARS-CoV M pro .DiscussionOur results demonstrated that andrographolide can inhibit the activity of 2019-nCoV M pro (IC 50 = 15.05\u00b11.58 \u00b5M; Fig. 2A ).", [["andrographolide", "CHEMICAL", 48, 63], ["andrographolide", "CHEMICAL", 184, 199], ["andrographolide", "CHEMICAL", 48, 63], ["andrographolide", "CHEMICAL", 184, 199], ["andrographolide", "SIMPLE_CHEMICAL", 48, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 128, 136], ["andrographolide", "SIMPLE_CHEMICAL", 184, 199], ["SARS-CoV", "SPECIES", 128, 136], ["andrographolide-mediated inhibition", "TREATMENT", 48, 83], ["covalent linkage", "TEST", 88, 104], ["SARS", "PROBLEM", 128, 132], ["andrographolide", "TREATMENT", 184, 199], ["IC", "TEST", 245, 247]]], ["Molecular modeling data further support that andrographolide can enter the proposed substrate-binding pocket of 2019-nCoV M pro (Fig. 4) , such observation is consistent with a recent in silico study suggesting that andrographolide can dock in the binding site of 2019-nCoV M pro [24] .DiscussionFurthermore, we also found that Andro-NBD, but not compound 048, strongly inhibited the activity of 2019-nCoV M pro (IC 50 = 2.79 \u00b10.3 \u00b5M for Andro-NBD; > 240 \u00b5M for NCTU-048) (Fig. 2) .", [["andrographolide", "CHEMICAL", 45, 60], ["andrographolide", "CHEMICAL", 216, 231], ["Andro-NBD", "CHEMICAL", 328, 337], ["compound 048", "CHEMICAL", 347, 359], ["Andro-NBD", "CHEMICAL", 438, 447], ["NCTU-048", "CHEMICAL", 462, 470], ["andrographolide", "CHEMICAL", 45, 60], ["andrographolide", "CHEMICAL", 216, 231], ["Andro-NBD", "CHEMICAL", 328, 337], ["Andro-NBD", "CHEMICAL", 438, 447], ["NCTU-048", "CHEMICAL", 462, 470], ["andrographolide", "SIMPLE_CHEMICAL", 45, 60], ["andrographolide", "SIMPLE_CHEMICAL", 216, 231], ["Andro-NBD", "SIMPLE_CHEMICAL", 328, 337], ["compound 048", "SIMPLE_CHEMICAL", 347, 359], ["Andro-NBD", "SIMPLE_CHEMICAL", 438, 447], ["andrographolide", "TREATMENT", 45, 60], ["silico study", "TEST", 187, 199], ["andrographolide", "TREATMENT", 216, 231], ["IC", "TEST", 413, 415], ["Andro", "TEST", 438, 443], ["NBD", "TEST", 444, 447], ["NCTU", "TEST", 462, 466], ["consistent with", "UNCERTAINTY", 159, 174]]], ["2019-nCoV M pro is a cysteine protease known to be inactivated by Michael acceptor inhibitor N3 [4] .", [["cysteine", "CHEMICAL", 21, 29], ["N3", "CHEMICAL", 93, 95], ["M pro", "GENE_OR_GENE_PRODUCT", 10, 15], ["M pro", "PROTEIN", 10, 15], ["cysteine protease", "PROTEIN", 21, 38], ["a cysteine protease", "TREATMENT", 19, 38]]], ["Andrographolide belongs to the Michael acceptor category of electrophilic natural compounds and it has been reported to react with Cys62 of NF-\u03baB-p50 at C12-13 exocyclic double bond to form a covalent adduct through a Michael addition [13, 14] .", [["Andrographolide", "CHEMICAL", 0, 15], ["Cys62", "CHEMICAL", 131, 136], ["C12-13 exocyclic", "CHEMICAL", 153, 169], ["Andrographolide", "CHEMICAL", 0, 15], ["Cys62", "CHEMICAL", 131, 136], ["Andrographolide", "SIMPLE_CHEMICAL", 0, 15], ["Cys62", "SIMPLE_CHEMICAL", 131, 136], ["C12-13 exocyclic double bond", "SIMPLE_CHEMICAL", 153, 181], ["NF-\u03baB", "PROTEIN", 140, 145], ["Andrographolide", "TREATMENT", 0, 15], ["NF", "TEST", 140, 142], ["B", "TEST", 144, 145], ["C12", "TEST", 153, 156], ["exocyclic double bond", "TREATMENT", 160, 181], ["electrophilic natural compounds", "OBSERVATION", 60, 91]]], ["Andro-NBD also can covalently bond to the p50, presumably through a similar mechanism [15] .", [["Andro-NBD", "CHEMICAL", 0, 9], ["Andro-NBD", "CHEMICAL", 0, 9], ["Andro-NBD", "SIMPLE_CHEMICAL", 0, 9], ["p50", "GENE_OR_GENE_PRODUCT", 42, 45], ["p50", "PROTEIN", 42, 45]]], ["On the other hand, the compound NCTU-048 with much weaker bioactivity than andrographolide is suggested to interact with NF-\u03baB-p50 through different mechanism [25] .", [["NCTU-048", "CHEMICAL", 32, 40], ["andrographolide", "CHEMICAL", 75, 90], ["NCTU-048", "CHEMICAL", 32, 40], ["andrographolide", "CHEMICAL", 75, 90], ["NCTU-048", "SIMPLE_CHEMICAL", 32, 40], ["andrographolide", "SIMPLE_CHEMICAL", 75, 90], ["NF-\u03baB-p50", "GENE_OR_GENE_PRODUCT", 121, 130], ["NF-\u03baB", "PROTEIN", 121, 126], ["p50", "PROTEIN", 127, 130], ["the compound NCTU", "TEST", 19, 36], ["andrographolide", "TREATMENT", 75, 90], ["NF", "TEST", 121, 123]]], ["Accordingly, Andro-NBD was shown capable of forming covalent linkage with 2019-nCoV M pro , whereas C145A mutation of protease abolished such covalent bond (Fig. 3) .", [["Andro", "CHEMICAL", 13, 18], ["Andro-NBD", "CHEMICAL", 13, 22], ["Andro-NBD", "SIMPLE_CHEMICAL", 13, 22], ["C145A", "AMINO_ACID", 100, 105], ["protease", "PROTEIN", 118, 126], ["nCoV M pro", "TREATMENT", 79, 89], ["protease", "TREATMENT", 118, 126]]], ["Furthermore, MS-based sequencing analysis suggested that andrographolide forms a covalent bond with active site Cys 145 of 2019-nCoV M pro (Fig. S6) .", [["andrographolide", "CHEMICAL", 57, 72], ["andrographolide", "CHEMICAL", 57, 72], ["Cys", "CHEMICAL", 112, 115], ["andrographolide", "SIMPLE_CHEMICAL", 57, 72], ["S6", "PROTEIN", 145, 147], ["MS", "TEST", 13, 15], ["sequencing analysis", "TEST", 22, 41], ["andrographolide", "TREATMENT", 57, 72], ["active site Cys", "TEST", 100, 115]]], ["Notably, such covalent linkage of andrographolide with reactive cysteine of protein target has also been reported previously [26] .", [["andrographolide", "CHEMICAL", 34, 49], ["andrographolide", "CHEMICAL", 34, 49], ["cysteine", "CHEMICAL", 64, 72], ["andrographolide", "SIMPLE_CHEMICAL", 34, 49], ["cysteine", "AMINO_ACID", 64, 72], ["andrographolide", "TREATMENT", 34, 49], ["reactive cysteine of protein target", "PROBLEM", 55, 90], ["reactive cysteine", "OBSERVATION", 55, 72], ["protein target", "OBSERVATION", 76, 90]]], ["Together, our data support a model that Andro and Andro-NBD could enter the substrate-binding pocket and initiate Michael reaction with 2019-nCoV M pro , leading to the inactivation of protease activity.DiscussionLopinavir/ritonavir, the HIV protease inhibitors previously identified with anti-SARS-CoV activity in vitro and in clinical, was proposed to bind 2019-nCoV M pro and thus has been investigated for COVID-19 treatments [6, 7] .", [["Andro", "CHEMICAL", 40, 45], ["Andro", "CHEMICAL", 50, 55], ["DiscussionLopinavir", "CHEMICAL", 203, 222], ["ritonavir", "CHEMICAL", 223, 232], ["DiscussionLopinavir", "CHEMICAL", 203, 222], ["ritonavir", "CHEMICAL", 223, 232], ["Andro", "SIMPLE_CHEMICAL", 40, 45], ["Andro-NBD", "SIMPLE_CHEMICAL", 50, 59], ["DiscussionLopinavir", "SIMPLE_CHEMICAL", 203, 222], ["ritonavir", "SIMPLE_CHEMICAL", 223, 232], ["anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 289, 302], ["protease", "PROTEIN", 185, 193], ["HIV", "SPECIES", 238, 241], ["NBD", "PROBLEM", 56, 59], ["nCoV M pro", "TREATMENT", 141, 151], ["protease activity", "TREATMENT", 185, 202], ["DiscussionLopinavir", "TREATMENT", 203, 222], ["ritonavir", "TREATMENT", 223, 232], ["the HIV protease inhibitors", "TREATMENT", 234, 261], ["anti-SARS", "TREATMENT", 289, 298], ["COVID-19 treatments", "TREATMENT", 410, 429]]], ["Currently, inhibition of 2019-nCoV by Lopinavir/ritonavir has not been experimentally demonstrated.J o u r n a l P r e -p r o o fData of several clinical trials indicate their roles in treating COVID-19 are limited and their significant adverse effects, such as gastrointestinal intolerance and hepatotoxicity, have been observed [8] .", [["gastrointestinal", "ANATOMY", 262, 278], ["Lopinavir/ritonavir", "CHEMICAL", 38, 57], ["COVID-19", "CHEMICAL", 194, 202], ["gastrointestinal intolerance", "DISEASE", 262, 290], ["hepatotoxicity", "DISEASE", 295, 309], ["Lopinavir", "CHEMICAL", 38, 47], ["ritonavir", "CHEMICAL", 48, 57], ["COVID-19", "CHEMICAL", 194, 202], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 25, 34], ["Lopinavir", "SIMPLE_CHEMICAL", 38, 47], ["ritonavir", "SIMPLE_CHEMICAL", 48, 57], ["gastrointestinal", "ORGANISM_SUBDIVISION", 262, 278], ["Lopinavir/ritonavir", "TREATMENT", 38, 57], ["COVID", "TEST", 194, 199], ["gastrointestinal intolerance", "PROBLEM", 262, 290], ["hepatotoxicity", "PROBLEM", 295, 309], ["gastrointestinal", "ANATOMY", 262, 278]]], ["Disulfiram, an FDA-approved drug for treating alcohol addiction, has been reported to inhibit 2019-nCoV M pro [4] but its clinical efficacy against COVID-19 remains to be determined.", [["Disulfiram", "CHEMICAL", 0, 10], ["alcohol addiction", "DISEASE", 46, 63], ["COVID-19", "CHEMICAL", 148, 156], ["Disulfiram", "CHEMICAL", 0, 10], ["alcohol", "CHEMICAL", 46, 53], ["COVID-19", "CHEMICAL", 148, 156], ["Disulfiram", "SIMPLE_CHEMICAL", 0, 10], ["alcohol", "SIMPLE_CHEMICAL", 46, 53], ["COVID-19", "SIMPLE_CHEMICAL", 148, 156], ["Disulfiram", "TREATMENT", 0, 10], ["COVID", "TEST", 148, 153]]], ["Therefore, development of 2019-nCoV M pro inhibitors from clinically available medicine is still in great demand.J o u r n a l P r e -p r o o fAndrographis paniculata along with its major ingredient, andrographolide, have been used as herbal medicine for treating anti-inflammatory diseases in Asia and in Europe [10] .", [["fAndrographis paniculata", "CHEMICAL", 142, 166], ["andrographolide", "CHEMICAL", 200, 215], ["anti-inflammatory diseases", "DISEASE", 264, 290], ["andrographolide", "CHEMICAL", 200, 215], ["fAndrographis paniculata", "ORGANISM", 142, 166], ["andrographolide", "SIMPLE_CHEMICAL", 200, 215], ["fAndrographis paniculata", "SPECIES", 142, 166], ["nCoV M pro inhibitors", "TREATMENT", 31, 52], ["fAndrographis paniculata", "TREATMENT", 142, 166], ["andrographolide", "TREATMENT", 200, 215], ["herbal medicine", "TREATMENT", 235, 250], ["anti-inflammatory diseases", "PROBLEM", 264, 290]]], ["Accumulating evidences from clinical studies indicate that Andrographis paniculata extract and andrographolide reduce symptoms in patients with HIV, upper respiratory infection, ulcerative colitis or rheumatoid arthritis with considerable safety [10, [27] [28] [29] [30] .", [["respiratory", "ANATOMY", 155, 166], ["Andrographis paniculata extract", "CHEMICAL", 59, 90], ["andrographolide", "CHEMICAL", 95, 110], ["HIV", "DISEASE", 144, 147], ["upper respiratory infection", "DISEASE", 149, 176], ["ulcerative colitis", "DISEASE", 178, 196], ["rheumatoid arthritis", "DISEASE", 200, 220], ["andrographolide", "CHEMICAL", 95, 110], ["Andrographis paniculata", "ORGANISM", 59, 82], ["andrographolide", "SIMPLE_CHEMICAL", 95, 110], ["patients", "ORGANISM", 130, 138], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 178, 196], ["[27] [28] [29] [30]", "SIMPLE_CHEMICAL", 251, 270], ["Andrographis paniculata", "SPECIES", 59, 82], ["patients", "SPECIES", 130, 138], ["HIV", "SPECIES", 144, 147], ["Andrographis paniculata", "SPECIES", 59, 82], ["HIV", "SPECIES", 144, 147], ["clinical studies", "TEST", 28, 44], ["Andrographis paniculata extract", "TREATMENT", 59, 90], ["andrographolide reduce symptoms", "PROBLEM", 95, 126], ["HIV", "PROBLEM", 144, 147], ["upper respiratory infection", "PROBLEM", 149, 176], ["ulcerative colitis", "PROBLEM", 178, 196], ["rheumatoid arthritis", "PROBLEM", 200, 220], ["upper", "ANATOMY_MODIFIER", 149, 154], ["respiratory", "ANATOMY", 155, 166], ["infection", "OBSERVATION", 167, 176], ["ulcerative", "OBSERVATION_MODIFIER", 178, 188], ["colitis", "OBSERVATION", 189, 196], ["rheumatoid arthritis", "OBSERVATION", 200, 220]]], ["Furthermore, experimental data from preclinical studies demonstrated the diverse pharmacological mechanisms of A. paniculata and andrographolide, including those in anti-inflammation, antiviral activity, hepatoprotection, anti-pulmonary fibrosis, and cardiopretection [10, 12, [31] [32] [33] Particularly, their safety profile in clinical uses are well accepted and andrographolide up to 30 \u00b5M did not cause cytotoxicity on human peripheral blood mononuclear cells (PBMC) [10, 34] .J o u r n a l P r e -p r o o fIn this study, we revealed that andrographolide and its derivative inhibits the activity of main protease and thus likely to impair the replication of SARS-CoV and 2019-nCoV.", [["peripheral blood mononuclear cells", "ANATOMY", 430, 464], ["PBMC", "ANATOMY", 466, 470], ["A. paniculata", "CHEMICAL", 111, 124], ["andrographolide", "CHEMICAL", 129, 144], ["fibrosis", "DISEASE", 237, 245], ["10, 12, [31] [32]", "CHEMICAL", 269, 286], ["andrographolide", "CHEMICAL", 366, 381], ["andrographolide", "CHEMICAL", 544, 559], ["andrographolide", "CHEMICAL", 129, 144], ["andrographolide", "CHEMICAL", 366, 381], ["andrographolide", "CHEMICAL", 544, 559], ["A. paniculata", "ORGANISM", 111, 124], ["andrographolide", "SIMPLE_CHEMICAL", 129, 144], ["[31] [32] [33]", "SIMPLE_CHEMICAL", 277, 291], ["andrographolide", "SIMPLE_CHEMICAL", 366, 381], ["human", "ORGANISM", 424, 429], ["peripheral blood mononuclear cells", "CELL", 430, 464], ["PBMC", "CELL", 466, 470], ["andrographolide", "SIMPLE_CHEMICAL", 544, 559], ["SARS-CoV", "ORGANISM", 663, 671], ["2019-nCoV", "GENE_OR_GENE_PRODUCT", 676, 685], ["human peripheral blood mononuclear cells", "CELL_TYPE", 424, 464], ["PBMC", "CELL_TYPE", 466, 470], ["protease", "PROTEIN", 609, 617], ["A. paniculata", "SPECIES", 111, 124], ["human", "SPECIES", 424, 429], ["A. paniculata", "SPECIES", 111, 124], ["human", "SPECIES", 424, 429], ["SARS-CoV", "SPECIES", 663, 671], ["preclinical studies", "TEST", 36, 55], ["andrographolide", "TREATMENT", 129, 144], ["those in anti-inflammation", "TREATMENT", 156, 182], ["antiviral activity", "TREATMENT", 184, 202], ["hepatoprotection", "TREATMENT", 204, 220], ["anti-pulmonary fibrosis", "PROBLEM", 222, 245], ["cardiopretection", "TEST", 251, 267], ["andrographolide", "TREATMENT", 366, 381], ["cytotoxicity", "PROBLEM", 408, 420], ["human peripheral blood mononuclear cells", "TEST", 424, 464], ["PBMC", "TEST", 466, 470], ["fIn this study", "TEST", 511, 525], ["andrographolide", "TREATMENT", 544, 559], ["main protease", "TREATMENT", 604, 617], ["CoV", "TEST", 668, 671], ["nCoV", "TREATMENT", 681, 685], ["antiviral activity", "OBSERVATION", 184, 202], ["fibrosis", "OBSERVATION", 237, 245]]], ["Considering that andrographolide is widely demonstrated in clinical application with acceptable safety and exhibits diverse pharmacological activities which could be beneficial for attenuating COVID-19 symptoms, application of andrographolide on COVID-19 therapy certainly merit further investigation.", [["andrographolide", "CHEMICAL", 17, 32], ["andrographolide", "CHEMICAL", 227, 242], ["COVID-19", "CHEMICAL", 246, 254], ["andrographolide", "CHEMICAL", 17, 32], ["andrographolide", "CHEMICAL", 227, 242], ["COVID-19", "CHEMICAL", 246, 254], ["andrographolide", "SIMPLE_CHEMICAL", 17, 32], ["andrographolide", "SIMPLE_CHEMICAL", 227, 242], ["COVID-19", "SIMPLE_CHEMICAL", 246, 254], ["andrographolide", "TREATMENT", 17, 32], ["diverse pharmacological activities", "PROBLEM", 116, 150], ["attenuating COVID-19 symptoms", "PROBLEM", 181, 210], ["andrographolide", "TREATMENT", 227, 242], ["COVID-19 therapy", "TREATMENT", 246, 262], ["further investigation", "TEST", 279, 300]]]], "226ab5769c42bf2415e5e8650d1043c7c6f6a057": [["The nuclear receptor heterodimers of liver X receptors (LXRs) are recently identified as key transcriptional regulators of genes involved in lipid homeostasis and inflammation.", [["nuclear", "ANATOMY", 4, 11], ["inflammation", "DISEASE", 163, 175], ["liver X receptors", "GENE_OR_GENE_PRODUCT", 37, 54], ["LXRs", "GENE_OR_GENE_PRODUCT", 56, 60], ["lipid", "SIMPLE_CHEMICAL", 141, 146], ["nuclear receptor heterodimers", "PROTEIN", 4, 33], ["liver X receptors", "PROTEIN", 37, 54], ["LXRs", "PROTEIN", 56, 60], ["transcriptional regulators", "PROTEIN", 93, 119], ["lipid homeostasis", "PROBLEM", 141, 158], ["inflammation", "PROBLEM", 163, 175], ["liver", "ANATOMY", 37, 42], ["lipid homeostasis", "OBSERVATION", 141, 158], ["inflammation", "OBSERVATION", 163, 175]]], ["LXRs and their ligands are negative regulators of macrophage inflammatory gene expression.", [["macrophage", "ANATOMY", 50, 60], ["LXRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophage", "CELL", 50, 60], ["LXRs", "PROTEIN", 0, 4], ["macrophage inflammatory gene expression", "PROBLEM", 50, 89], ["macrophage", "OBSERVATION_MODIFIER", 50, 60], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73]]], ["Multiple sclerosis (MS), a demyelinating disease of the central nervous system of unknown cause, is characterized by recurrent inflammation involving macrophages and their inflammatory mediators.", [["central nervous system", "ANATOMY", 56, 78], ["macrophages", "ANATOMY", 150, 161], ["Multiple sclerosis", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["demyelinating disease of the central nervous system", "DISEASE", 27, 78], ["inflammation", "DISEASE", 127, 139], ["central nervous system", "ANATOMICAL_SYSTEM", 56, 78], ["macrophages", "CELL", 150, 161], ["macrophages", "CELL_TYPE", 150, 161], ["inflammatory mediators", "PROTEIN", 172, 194], ["Multiple sclerosis (MS)", "PROBLEM", 0, 23], ["a demyelinating disease of the central nervous system", "PROBLEM", 25, 78], ["recurrent inflammation involving macrophages", "PROBLEM", 117, 161], ["sclerosis", "OBSERVATION", 9, 18], ["demyelinating disease", "OBSERVATION", 27, 48], ["central", "ANATOMY_MODIFIER", 56, 63], ["nervous system", "ANATOMY", 64, 78], ["recurrent", "OBSERVATION_MODIFIER", 117, 126], ["inflammation", "OBSERVATION", 127, 139], ["macrophages", "OBSERVATION_MODIFIER", 150, 161], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["Sweden belongs to the countries with a high MS incidence.", [["MS", "DISEASE", 44, 46], ["a high MS incidence", "PROBLEM", 37, 56]]], ["In Italy, incidence is lower, with an exception for Sardinia where the incidence is even higher than that in Sweden.", [["lower", "OBSERVATION_MODIFIER", 23, 28], ["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["We studied LXRs and their related molecules of blood mononuclear cells (MNCs) from female patients with untreated relapsing-remitting MS from Sassari, Sardinia and Stockholm, Sweden.", [["blood mononuclear cells", "ANATOMY", 47, 70], ["MNCs", "ANATOMY", 72, 76], ["relapsing-remitting MS", "DISEASE", 114, 136], ["LXRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["blood mononuclear cells", "CELL", 47, 70], ["MNCs", "CELL", 72, 76], ["patients", "ORGANISM", 90, 98], ["LXRs", "PROTEIN", 11, 15], ["blood mononuclear cells", "CELL_TYPE", 47, 70], ["MNCs", "CELL_TYPE", 72, 76], ["patients", "SPECIES", 90, 98], ["blood mononuclear cells", "PROBLEM", 47, 70], ["untreated relapsing-remitting MS", "PROBLEM", 104, 136], ["blood mononuclear cells", "OBSERVATION", 47, 70], ["relapsing", "OBSERVATION_MODIFIER", 114, 123]]], ["Sex-and age-matched healthy controls (HCs) were from both areas. mRNA expression was evaluated by real-time PCR.", [["controls", "ORGANISM", 28, 36], ["mRNA", "RNA", 65, 69], ["mRNA expression", "PROBLEM", 65, 80]]], ["LXR-a was lower (P < 0.05) in MS (mean AE SEM: 3.1 AE 0.2; n \u00bc 37) compared to HC (3.6 AE 0.1; n \u00bc 37).", [["MS", "DISEASE", 30, 32], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["MS", "TEST", 30, 32], ["mean AE SEM", "TEST", 34, 45], ["AE", "TEST", 51, 53], ["n \u00bc", "TEST", 59, 62], ["HC", "TEST", 79, 81]]], ["LXR-a was lower in MS from Stockholm (2.6 AE 0.2; n \u00bc 22) compared to corresponding HC (3.4 AE 0.1; n \u00bc 22; P < 0.01) and compared to MS (3.8 AE 0.2; n \u00bc 15; P < 0.001) and HC (4 AE 0.2; n \u00bc 15; P < 0.001) from Sardinia.", [["MS", "DISEASE", 19, 21], ["MS", "DISEASE", 134, 136], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["AE", "TEST", 42, 44], ["HC", "TEST", 84, 86], ["AE", "TEST", 92, 94], ["n \u00bc", "TEST", 100, 103], ["P", "TEST", 108, 109], ["MS", "TEST", 134, 136], ["AE", "TEST", 142, 144], ["n", "TEST", 150, 151], ["\u00bc", "TEST", 152, 153], ["P", "TEST", 158, 159], ["HC", "TEST", 173, 175], ["AE", "TEST", 179, 181], ["n \u00bc", "TEST", 187, 190], ["P", "TEST", 195, 196], ["Sardinia", "PROBLEM", 211, 219], ["lower", "OBSERVATION_MODIFIER", 10, 15]]], ["MS patients from Stockholm, but not from Sassari, also expressed lower (P < 0.05) LXR-b (\u00c04.1 AE 0.4) compared to corresponding HC (\u00c02.9 AE 0.3).", [["MS", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["LXR-b", "GENE_OR_GENE_PRODUCT", 82, 87], ["LXR", "PROTEIN", 82, 85], ["patients", "SPECIES", 3, 11], ["LXR-b (\u00c04.1 AE", "TEST", 82, 96], ["HC", "TEST", 128, 130]]], ["MS from Stockholm was associated with higher ABCA-1 (6.1 AE 0.4 versus 5.0 AE 0.3; P < 0.05) and higher estrogen receptor-b-Cx (2.4 AE 0.4 versus 0.8 AE 0.4; P < 0.01) compared to corresponding HC.", [["MS", "DISEASE", 0, 2], ["estrogen", "CHEMICAL", 104, 112], ["estrogen", "CHEMICAL", 104, 112], ["ABCA-1", "GENE_OR_GENE_PRODUCT", 45, 51], ["estrogen receptor-b-Cx", "GENE_OR_GENE_PRODUCT", 104, 126], ["estrogen receptor", "PROTEIN", 104, 121], ["ABCA", "TEST", 45, 49], ["AE", "TEST", 57, 59], ["AE", "TEST", 75, 77], ["P", "TEST", 83, 84], ["higher estrogen receptor", "TEST", 97, 121], ["Cx", "TEST", 124, 126], ["AE", "TEST", 132, 134], ["AE", "TEST", 150, 152], ["P", "TEST", 158, 159]]], ["The HC from Sassari had higher androgen receptor (2.9 AE 0.2) compared to MS from Sassari (1.4 AE 0.3; P < 0.01), MS (1.3 AE 0.4; P < 0.01) and HC from Stockholm (1.2 AE 0.3; P < 0.01).", [["MS", "DISEASE", 74, 76], ["MS", "DISEASE", 114, 116], ["androgen", "CHEMICAL", 31, 39], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 31, 48], ["androgen receptor", "PROTEIN", 31, 48], ["The HC", "TEST", 0, 6], ["Sassari", "TEST", 12, 19], ["higher androgen receptor", "PROBLEM", 24, 48], ["MS", "TEST", 74, 76], ["Sassari", "TEST", 82, 89], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["MS", "TEST", 114, 116], ["AE", "TEST", 122, 124], ["P", "TEST", 130, 131], ["HC", "TEST", 144, 146], ["Stockholm", "TEST", 152, 161], ["AE", "TEST", 167, 169], ["P", "TEST", 175, 176]]], ["MS from Sassari had lower cyclooxygenase-1 compared to corresponding HC (5.1 AE 0.4 versus 6.6 AE 0.3; P < 0.01) and lower prostaglandin-E (\u00c00.03 AE 0.5) compared to the HC (1.4 AE 0.5; P < 0.05) and MS (2.7 AE 0.4; P < 0.05) and HC from Stockholm (1.9 AE 0.4, P < 0.001).", [["MS", "DISEASE", 0, 2], ["prostaglandin-E", "CHEMICAL", 123, 138], ["prostaglandin-E", "CHEMICAL", 123, 138], ["cyclooxygenase-1", "GENE_OR_GENE_PRODUCT", 26, 42], ["prostaglandin-E", "SIMPLE_CHEMICAL", 123, 138], ["cyclooxygenase-1", "PROTEIN", 26, 42], ["lower cyclooxygenase", "PROBLEM", 20, 40], ["HC", "TEST", 69, 71], ["AE", "TEST", 77, 79], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["lower prostaglandin", "TEST", 117, 136], ["AE", "TEST", 146, 148], ["the HC", "TEST", 166, 172], ["AE", "TEST", 178, 180], ["P", "TEST", 186, 187], ["MS", "TEST", 200, 202], ["AE", "TEST", 208, 210], ["P", "TEST", 216, 217], ["HC", "TEST", 230, 232], ["Stockholm", "TEST", 238, 247], ["AE", "TEST", 253, 255], ["P", "TEST", 261, 262]]], ["Our findings identify LXRs and their related molecules as being involved in MS from Stockholm but not from Sassari, while sex hormone receptors seem to be involved in MS in Sassari.A U T O I M M U N I T Y 5Multiple Sclerosis: IFN-b Induces CD123 + BDCA2 -Dendritic Cells that Produce IL-6 and IL-10 and have No Enhanced Type I Interferon Production Y. M. Huang, 1 S. Adikari, 1 U. B\u00e5ve, 2 A. Sanna 1,3 & G. Alm 4 DC antigens (BDCA) and investigate their ability to produce Type I IFN in response to virus stimulation.", [["Cells", "ANATOMY", 265, 270], ["MS", "DISEASE", 76, 78], ["MS", "DISEASE", 167, 169], ["Sclerosis", "DISEASE", 215, 224], ["LXRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["sex hormone receptors", "GENE_OR_GENE_PRODUCT", 122, 143], ["CD123", "GENE_OR_GENE_PRODUCT", 240, 245], ["IL-6", "GENE_OR_GENE_PRODUCT", 284, 288], ["IL-10", "GENE_OR_GENE_PRODUCT", 293, 298], ["Alm 4 DC antigens", "GENE_OR_GENE_PRODUCT", 407, 424], ["BDCA", "CELL", 426, 430], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 473, 483], ["LXRs", "PROTEIN", 22, 26], ["sex hormone receptors", "PROTEIN", 122, 143], ["IFN", "PROTEIN", 226, 229], ["CD123", "PROTEIN", 240, 245], ["BDCA2", "PROTEIN", 248, 253], ["Dendritic Cells", "CELL_TYPE", 255, 270], ["IL-6", "PROTEIN", 284, 288], ["IL", "PROTEIN", 293, 295], ["DC antigens", "PROTEIN", 413, 424], ["BDCA", "PROTEIN", 426, 430], ["Type I IFN", "PROTEIN", 473, 483], ["Sassari", "TREATMENT", 107, 114], ["Sclerosis", "PROBLEM", 215, 224], ["IFN-b", "TEST", 226, 231], ["CD123", "TEST", 240, 245], ["BDCA2", "TEST", 248, 253], ["Dendritic Cells", "PROBLEM", 255, 270], ["IL", "TEST", 284, 286], ["IL", "TEST", 293, 295], ["Adikari", "TEST", 367, 374], ["Sanna", "TEST", 392, 397], ["Type I IFN", "PROBLEM", 473, 483], ["virus stimulation", "TREATMENT", 499, 516], ["Sclerosis", "OBSERVATION", 215, 224], ["Dendritic Cells", "OBSERVATION", 255, 270], ["No", "UNCERTAINTY", 308, 310]]], ["We show that IFN-b induces development of CD123 \u00fe DC from human blood monocytes, which coexpress BDCA4 \u00fe but are negative for BDCA2 -, a specific marker for plasmacytoid DC.", [["CD123 \u00fe DC", "ANATOMY", 42, 52], ["blood monocytes", "ANATOMY", 64, 79], ["plasmacytoid DC", "ANATOMY", 157, 172], ["IFN-b", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD123 \u00fe DC", "CELL", 42, 52], ["human", "ORGANISM", 58, 63], ["blood monocytes", "CELL", 64, 79], ["BDCA4", "GENE_OR_GENE_PRODUCT", 97, 102], ["BDCA2", "GENE_OR_GENE_PRODUCT", 126, 131], ["plasmacytoid DC", "CELL", 157, 172], ["IFN", "PROTEIN", 13, 16], ["CD123 \u00fe DC", "CELL_TYPE", 42, 52], ["human blood monocytes", "CELL_TYPE", 58, 79], ["BDCA4", "PROTEIN", 97, 102], ["BDCA2", "PROTEIN", 126, 131], ["plasmacytoid DC", "CELL_TYPE", 157, 172], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["human blood monocytes", "TEST", 58, 79], ["BDCA2", "PROBLEM", 126, 131], ["plasmacytoid DC", "TREATMENT", 157, 172]]], ["Such IFN-b-modulated DC produce large amounts of IL-6 and IL-10, but no IL-12p40 and have no enhanced IFN-b and IFN-b production.", [["DC", "ANATOMY", 21, 23], ["IFN", "CHEMICAL", 5, 8], ["IFN-b-", "GENE_OR_GENE_PRODUCT", 5, 11], ["DC", "CELL", 21, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 72, 80], ["IFN-b", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN-b", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN", "PROTEIN", 5, 8], ["DC", "CELL_TYPE", 21, 23], ["IL-12p40", "PROTEIN", 72, 80], ["IFN", "PROTEIN", 102, 105], ["IFN", "PROTEIN", 112, 115], ["IL", "TEST", 49, 51], ["IL", "TEST", 58, 60], ["IL", "TEST", 72, 74], ["enhanced IFN", "PROBLEM", 93, 105], ["IFN", "PROBLEM", 112, 115], ["large", "OBSERVATION_MODIFIER", 32, 37], ["amounts", "OBSERVATION_MODIFIER", 38, 45], ["no", "UNCERTAINTY", 90, 92]]], ["The findings indicate that IFN-bmodulated DC represent a myeloid DC subset with diminished CD11c, BDCA-1 and CD1a expression, having potent Th2-promoting function but lacking antiviral capacity.", [["DC", "ANATOMY", 42, 44], ["myeloid DC", "ANATOMY", 57, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["DC", "CELL", 42, 44], ["myeloid DC", "CELL", 57, 67], ["CD11c", "GENE_OR_GENE_PRODUCT", 91, 96], ["BDCA-1", "GENE_OR_GENE_PRODUCT", 98, 104], ["CD1a", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFN", "PROTEIN", 27, 30], ["bmodulated DC", "CELL_TYPE", 31, 44], ["myeloid DC subset", "CELL_TYPE", 57, 74], ["CD11c", "PROTEIN", 91, 96], ["BDCA", "PROTEIN", 98, 102], ["CD1a", "PROTEIN", 109, 113], ["IFN", "PROBLEM", 27, 30], ["diminished CD11c", "PROBLEM", 80, 96], ["BDCA", "TEST", 98, 102], ["lacking antiviral capacity", "PROBLEM", 167, 193], ["myeloid", "OBSERVATION", 57, 64], ["diminished", "OBSERVATION_MODIFIER", 80, 90], ["CD11c", "OBSERVATION", 91, 96], ["antiviral capacity", "OBSERVATION", 175, 193]]], ["The association of psoriasis with throat infections by streptococcus pyogenes suggests a potential antigenic target for the T cells that are known to infiltrate dermis and epidermis of psoriatic skin.", [["throat", "ANATOMY", 34, 40], ["T cells", "ANATOMY", 124, 131], ["infiltrate dermis", "ANATOMY", 150, 167], ["epidermis", "ANATOMY", 172, 181], ["psoriatic skin", "ANATOMY", 185, 199], ["psoriasis", "DISEASE", 19, 28], ["throat infections", "DISEASE", 34, 51], ["streptococcus pyogenes", "DISEASE", 55, 77], ["throat", "ORGANISM_SUBDIVISION", 34, 40], ["streptococcus pyogenes", "ORGANISM", 55, 77], ["T cells", "CELL", 124, 131], ["dermis", "TISSUE", 161, 167], ["epidermis", "TISSUE", 172, 181], ["skin", "ORGAN", 195, 199], ["T cells", "CELL_TYPE", 124, 131], ["streptococcus pyogenes", "SPECIES", 55, 77], ["streptococcus pyogenes", "SPECIES", 55, 77], ["psoriasis", "PROBLEM", 19, 28], ["throat infections", "PROBLEM", 34, 51], ["streptococcus pyogenes", "PROBLEM", 55, 77], ["the T cells", "PROBLEM", 120, 131], ["infiltrate dermis", "PROBLEM", 150, 167], ["epidermis of psoriatic skin", "PROBLEM", 172, 199], ["psoriasis", "OBSERVATION", 19, 28], ["throat", "ANATOMY", 34, 40], ["infections", "OBSERVATION", 41, 51], ["streptococcus pyogenes", "OBSERVATION", 55, 77], ["known to", "UNCERTAINTY", 141, 149], ["infiltrate", "OBSERVATION", 150, 160], ["epidermis", "OBSERVATION_MODIFIER", 172, 181], ["psoriatic", "OBSERVATION_MODIFIER", 185, 194], ["skin", "ANATOMY", 195, 199]]], ["Streptococcal M protein shares an extensive sequence homology with human epidermal keratins.", [["epidermal keratins", "ANATOMY", 73, 91], ["Streptococcal M protein", "GENE_OR_GENE_PRODUCT", 0, 23], ["human", "ORGANISM", 67, 72], ["epidermal keratins", "GENE_OR_GENE_PRODUCT", 73, 91], ["Streptococcal M protein", "PROTEIN", 0, 23], ["human epidermal keratins", "PROTEIN", 67, 91], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Streptococcal M protein", "TEST", 0, 23], ["human epidermal keratins", "TREATMENT", 67, 91], ["epidermal keratins", "OBSERVATION", 73, 91]]], ["Keratins 16 (K16) and 17 (K17) are mostly absent from uninvolved skin but are upregulated in psoriatic lesions.", [["skin", "ANATOMY", 65, 69], ["psoriatic lesions", "ANATOMY", 93, 110], ["psoriatic lesions", "DISEASE", 93, 110], ["Keratins 16", "GENE_OR_GENE_PRODUCT", 0, 11], ["K16", "GENE_OR_GENE_PRODUCT", 13, 16], ["17", "GENE_OR_GENE_PRODUCT", 22, 24], ["K17", "GENE_OR_GENE_PRODUCT", 26, 29], ["skin", "ORGAN", 65, 69], ["psoriatic lesions", "PATHOLOGICAL_FORMATION", 93, 110], ["K16", "PROTEIN", 13, 16], ["K17", "PROTEIN", 26, 29], ["Keratins", "TEST", 0, 8], ["psoriatic lesions", "PROBLEM", 93, 110], ["skin", "ANATOMY", 65, 69], ["upregulated", "OBSERVATION_MODIFIER", 78, 89], ["psoriatic", "OBSERVATION_MODIFIER", 93, 102], ["lesions", "OBSERVATION", 103, 110]]], ["There is increasing evidence that CD8 \u00fe T cells play an important effector role in psoriasis and M proteinprimed T cells may recognize these shared epitopes in skin via molecular mimicry.", [["CD8 \u00fe T cells", "ANATOMY", 34, 47], ["T cells", "ANATOMY", 113, 120], ["skin", "ANATOMY", 160, 164], ["psoriasis", "DISEASE", 83, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["T cells", "CELL", 40, 47], ["M proteinprimed T cells", "CELL", 97, 120], ["skin", "ORGAN", 160, 164], ["CD8 \u00fe T cells", "CELL_TYPE", 34, 47], ["T cells", "CELL_TYPE", 113, 120], ["CD8 \u00fe T cells", "PROBLEM", 34, 47], ["psoriasis", "PROBLEM", 83, 92], ["M proteinprimed T cells", "TREATMENT", 97, 120], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["skin", "ANATOMY", 160, 164], ["molecular mimicry", "OBSERVATION", 169, 186]]], ["To identify candidate epitopes, peptides with sequences from K17 were selected on the basis of predicted binding to HLA-Cw6 and sequence similarities with M6 protein.", [["K17", "GENE_OR_GENE_PRODUCT", 61, 64], ["HLA-Cw6", "GENE_OR_GENE_PRODUCT", 116, 123], ["K17", "DNA", 61, 64], ["Cw6", "DNA", 120, 123], ["M6 protein", "PROTEIN", 155, 165], ["sequences from K17", "TEST", 46, 64], ["HLA", "TEST", 116, 119]]], ["Matched peptides from the sequence of M6 protein and a set of peptides with poor predicted binding were also selected.", [["M6 protein", "PROTEIN", 38, 48], ["Matched peptides", "PROBLEM", 0, 16], ["M6 protein", "TEST", 38, 48], ["poor predicted binding", "PROBLEM", 76, 98]]], ["Cw6 \u00fe individuals with psoriasis and Cw6 \u00fe healthy controls, having a family history of psoriasis, were recruited.", [["psoriasis", "DISEASE", 23, 32], ["psoriasis", "DISEASE", 88, 97], ["Cw6", "GENE_OR_GENE_PRODUCT", 0, 3], ["psoriasis", "PROBLEM", 23, 32], ["psoriasis", "PROBLEM", 88, 97], ["psoriasis", "OBSERVATION", 23, 32], ["psoriasis", "OBSERVATION", 88, 97]]], ["PBMCs were incubated with the peptide antigens.", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["PBMCs", "CELL_TYPE", 0, 5], ["PBMCs", "TREATMENT", 0, 5], ["the peptide antigens", "TEST", 26, 46]]], ["T-cell activation in the CD4 \u00fe , CD8 \u00fe and later the skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells was evaluated by CD69 expression and intracellular IFN-g accumulation using flow cytometry.", [["T-cell", "ANATOMY", 0, 6], ["CD4 \u00fe", "ANATOMY", 25, 30], ["CD8 \u00fe", "ANATOMY", 33, 38], ["skin", "ANATOMY", 53, 57], ["CD8 \u00fe T cells", "ANATOMY", 131, 144], ["intracellular", "ANATOMY", 182, 195], ["T-cell", "CELL", 0, 6], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["skin", "ORGAN", 53, 57], ["cutaneous lymphocyteassociated antigen", "GENE_OR_GENE_PRODUCT", 65, 103], ["CLA", "GENE_OR_GENE_PRODUCT", 105, 108], ["CD8", "GENE_OR_GENE_PRODUCT", 131, 134], ["CD69", "GENE_OR_GENE_PRODUCT", 162, 166], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["IFN-g", "GENE_OR_GENE_PRODUCT", 196, 201], ["CD4", "PROTEIN", 25, 28], ["CD8", "PROTEIN", 33, 36], ["skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells", "CELL_TYPE", 53, 144], ["CD69", "PROTEIN", 162, 166], ["IFN", "PROTEIN", 196, 199], ["T-cell activation", "TEST", 0, 17], ["the CD4", "TEST", 21, 28], ["CD8", "TEST", 33, 36], ["homing cutaneous lymphocyteassociated antigen", "PROBLEM", 58, 103], ["T cells", "PROBLEM", 137, 144], ["CD69 expression", "TEST", 162, 177], ["intracellular IFN", "TEST", 182, 199], ["flow cytometry", "TEST", 221, 235], ["cell activation", "OBSERVATION", 2, 17], ["CD4", "ANATOMY", 25, 28], ["skin", "ANATOMY", 53, 57], ["homing", "ANATOMY_MODIFIER", 58, 64], ["cutaneous", "ANATOMY", 65, 74], ["flow cytometry", "OBSERVATION", 221, 235]]], ["We demonstrate that Cw6 \u00fe psoriasis patients had significant CD8 \u00fe T-cell IFN-g responses to peptides from K17 and M6 protein selected on the basis of sequence homology and predicted HLA-Cw1501 and HLA-B1501 and HLA-B0204 was measured by a radioimmunoassay (RIA).", [["CD8 \u00fe T-cell", "ANATOMY", 61, 73], ["psoriasis", "DISEASE", 26, 35], ["Cw6", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 36, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["K17", "GENE_OR_GENE_PRODUCT", 107, 110], ["HLA-B1501", "GENE_OR_GENE_PRODUCT", 198, 207], ["HLA-B0204", "GENE_OR_GENE_PRODUCT", 212, 221], ["CD8", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 74, 77], ["M6 protein", "PROTEIN", 115, 125], ["HLA-Cw1501", "DNA", 183, 193], ["HLA-B1501 and HLA-B0204", "DNA", 198, 221], ["patients", "SPECIES", 36, 44], ["Cw6 \u00fe psoriasis", "PROBLEM", 20, 35], ["IFN", "TEST", 74, 77], ["peptides", "TEST", 93, 101], ["K17", "TEST", 107, 110], ["M6 protein", "TEST", 115, 125], ["sequence homology", "TEST", 151, 168], ["HLA", "TEST", 183, 186], ["HLA", "TEST", 198, 201], ["HLA", "TEST", 212, 215], ["a radioimmunoassay (RIA", "TEST", 238, 261]]], ["This data was used to develop multiple first generation ANNs, which formed a virtual committee.", [["multiple first generation ANNs", "PROBLEM", 30, 60]]], ["This committee was used to screen (or 'queried') for peptides, where the ANNs agreed ('low-QBC'), or disagreed ('high-QBC'), on their HLA-binding potential.", [["peptides", "PROBLEM", 53, 61]]], ["Seventeen low-QBC peptides and 17 high-QBC peptides were synthesized and tested.", [["QBC peptides", "TEST", 14, 26]]], ["The high-or low-QBC data were added to the original data, and new high-or low-QBC second generation ANNs were developed, respectively.", [["the original data", "TEST", 39, 56], ["new high-or low-QBC second generation ANNs", "PROBLEM", 62, 104], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["This procedure was repeated 40 times.Results:The high-QBC-enriched ANN performed significantly better than the low-QBC-enriched ANN in 37 of the 40 tests.", [["QBC", "DNA", 115, 118], ["This procedure", "TREATMENT", 0, 14], ["the 40 tests", "TEST", 141, 153]]], ["Conclusion: These results demonstrate that high-QBCenriched networks perform better than low-QBC-enriched networks in selecting informative data for developing peptide-MHC-binding predictors.", [["QBC", "PROTEIN", 93, 96], ["MHC", "PROTEIN", 168, 171], ["high-QBCenriched networks", "PROBLEM", 43, 68]]], ["This improvement in selecting data is not due to differences in network training performance but due to the difference in information content in the high-QBC experiment and in the low-QBC experiment.", [["selecting data", "TEST", 20, 34], ["the difference in information content", "PROBLEM", 104, 141]]], ["Finally, it should be noted that this strategy could be used in many contexts where generation of data is difficult and costly.", [["this strategy", "TREATMENT", 33, 46]]], ["Interleukin-18 (IL-18), a pro-inflammatory cytokine that is produced by both lymphoid and nonlymphoid cells, has a critical role in modulation of innate and adaptive immunity.", [["lymphoid", "ANATOMY", 77, 85], ["nonlymphoid cells", "ANATOMY", 90, 107], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 0, 14], ["IL-18", "GENE_OR_GENE_PRODUCT", 16, 21], ["lymphoid", "CELL", 77, 85], ["nonlymphoid cells", "CELL", 90, 107], ["Interleukin-18 (IL-18", "PROTEIN", 0, 21], ["pro-inflammatory cytokine", "PROTEIN", 26, 51], ["lymphoid and nonlymphoid cells", "CELL_TYPE", 77, 107], ["Interleukin", "TEST", 0, 11], ["IL", "TEST", 16, 18], ["a pro-inflammatory cytokine", "TEST", 24, 51], ["innate and adaptive immunity", "TREATMENT", 146, 174], ["both lymphoid", "OBSERVATION", 72, 85], ["nonlymphoid cells", "OBSERVATION", 90, 107]]], ["Its primary function in stimulation of IFN-g production and stimulation of NK-cell-cytotoxic activities makes this cytokine a candidate for cancer immunotherapy.", [["NK", "ANATOMY", 75, 77], ["cell", "ANATOMY", 78, 82], ["cancer", "ANATOMY", 140, 146], ["cancer", "DISEASE", 140, 146], ["IFN-g", "GENE_OR_GENE_PRODUCT", 39, 44], ["NK-cell", "CELL", 75, 82], ["cancer", "CANCER", 140, 146], ["IFN", "PROTEIN", 39, 42], ["cytokine", "PROTEIN", 115, 123], ["IFN-g production", "TREATMENT", 39, 55], ["NK", "TEST", 75, 77], ["cytotoxic activities", "PROBLEM", 83, 103], ["cancer immunotherapy", "TREATMENT", 140, 160]]], ["In oral cavity, this cytokine is produced by oral epithelia and carcinoma cells and is related to tumour regression in nude mice bearing salivary adenocarcinoma.", [["oral cavity", "ANATOMY", 3, 14], ["oral epithelia", "ANATOMY", 45, 59], ["carcinoma cells", "ANATOMY", 64, 79], ["tumour", "ANATOMY", 98, 104], ["salivary adenocarcinoma", "ANATOMY", 137, 160], ["carcinoma", "DISEASE", 64, 73], ["tumour", "DISEASE", 98, 104], ["salivary adenocarcinoma", "DISEASE", 137, 160], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 3, 14], ["oral epithelia", "CELL", 45, 59], ["carcinoma cells", "CELL", 64, 79], ["tumour", "CANCER", 98, 104], ["nude mice", "ORGANISM", 119, 128], ["salivary adenocarcinoma", "CANCER", 137, 160], ["cytokine", "PROTEIN", 21, 29], ["carcinoma cells", "CELL_TYPE", 64, 79], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["oral epithelia", "PROBLEM", 45, 59], ["carcinoma cells", "PROBLEM", 64, 79], ["tumour regression in nude mice bearing salivary adenocarcinoma", "PROBLEM", 98, 160], ["oral cavity", "ANATOMY", 3, 14], ["carcinoma cells", "OBSERVATION", 64, 79], ["related to", "UNCERTAINTY", 87, 97], ["tumour regression", "OBSERVATION", 98, 115], ["salivary adenocarcinoma", "OBSERVATION", 137, 160]]], ["However, direct effects of this cytokine on oral cancer cells have not been elucidated.", [["oral cancer cells", "ANATOMY", 44, 61], ["oral cancer", "DISEASE", 44, 55], ["oral cancer cells", "CELL", 44, 61], ["cytokine", "PROTEIN", 32, 40], ["oral cancer cells", "CELL_TYPE", 44, 61], ["this cytokine", "TREATMENT", 27, 40], ["oral cancer cells", "PROBLEM", 44, 61]]], ["In this project, we investigated IL-18 effect on an oral carcinoma (KB) cell line.", [["oral carcinoma (KB) cell line", "ANATOMY", 52, 81], ["oral carcinoma", "DISEASE", 52, 66], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["oral carcinoma (KB) cell line", "CELL", 52, 81], ["IL-18", "PROTEIN", 33, 38], ["oral carcinoma (KB) cell line", "CELL_LINE", 52, 81], ["IL", "TEST", 33, 35], ["an oral carcinoma", "PROBLEM", 49, 66], ["cell line", "TREATMENT", 72, 81], ["oral", "ANATOMY", 52, 56], ["carcinoma", "OBSERVATION", 57, 66], ["cell line", "OBSERVATION", 72, 81]]], ["With RT-PCR technique, KB-cell line was found to express IL-18 receptors (IL-18Ra and IL-18Rb), indicating that this oral carcinoma line is a target for IL-18 study.", [["KB-cell line", "ANATOMY", 23, 35], ["oral carcinoma line", "ANATOMY", 117, 136], ["oral carcinoma", "DISEASE", 117, 131], ["KB-cell line", "CELL", 23, 35], ["IL-18 receptors", "GENE_OR_GENE_PRODUCT", 57, 72], ["IL-18Ra", "GENE_OR_GENE_PRODUCT", 74, 81], ["IL-18Rb", "GENE_OR_GENE_PRODUCT", 86, 93], ["oral carcinoma line", "CELL", 117, 136], ["IL-18", "GENE_OR_GENE_PRODUCT", 153, 158], ["KB-cell line", "CELL_LINE", 23, 35], ["IL-18 receptors", "PROTEIN", 57, 72], ["IL", "PROTEIN", 74, 76], ["18Ra", "PROTEIN", 77, 81], ["IL", "PROTEIN", 86, 88], ["18Rb", "PROTEIN", 89, 93], ["oral carcinoma line", "CELL_LINE", 117, 136], ["IL", "PROTEIN", 153, 155], ["RT-PCR technique", "TREATMENT", 5, 21], ["KB-cell line", "TREATMENT", 23, 35], ["IL", "TEST", 57, 59], ["IL", "TEST", 74, 76], ["IL", "TREATMENT", 86, 88], ["this oral carcinoma line", "PROBLEM", 112, 136], ["IL-18 study", "TEST", 153, 164], ["cell line", "OBSERVATION", 26, 35], ["carcinoma", "OBSERVATION", 122, 131]]], ["We showed that recombinant human IL-18 inhibited KB-cell proliferation by 17% at concentration of 100 ng/ml (P < 0.05), whereas LDH release by these cells in treatment group and control groups was comparable, indicating that IL-18 suppression of cell proliferation was not mediated by the induction of cell death.", [["KB-cell", "ANATOMY", 49, 56], ["cells", "ANATOMY", 149, 154], ["cell", "ANATOMY", 246, 250], ["cell", "ANATOMY", 302, 306], ["death", "DISEASE", 307, 312], ["human", "ORGANISM", 27, 32], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["KB-cell", "CELL", 49, 56], ["LDH", "SIMPLE_CHEMICAL", 128, 131], ["cells", "CELL", 149, 154], ["IL-18", "GENE_OR_GENE_PRODUCT", 225, 230], ["cell", "CELL", 246, 250], ["cell", "CELL", 302, 306], ["recombinant human IL-18", "PROTEIN", 15, 38], ["KB-cell", "CELL_LINE", 49, 56], ["LDH", "PROTEIN", 128, 131], ["IL-18", "PROTEIN", 225, 230], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["recombinant human IL", "TEST", 15, 35], ["KB", "TEST", 49, 51], ["cell proliferation", "TEST", 52, 70], ["LDH release", "TEST", 128, 139], ["treatment group and control groups", "TREATMENT", 158, 192], ["IL", "TEST", 225, 227], ["cell proliferation", "PROBLEM", 246, 264], ["cell death", "PROBLEM", 302, 312], ["cell proliferation", "OBSERVATION", 52, 70], ["cell proliferation", "OBSERVATION", 246, 264]]], ["To further address this hypothesis, we found that IL-18 treatment did not induce apoptotic cell death, as studied by DNA laddering and TUNEL assays.", [["cell", "ANATOMY", 91, 95], ["IL-18", "GENE_OR_GENE_PRODUCT", 50, 55], ["cell", "CELL", 91, 95], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["IL", "PROTEIN", 50, 52], ["IL-18 treatment", "TREATMENT", 50, 65], ["apoptotic cell death", "PROBLEM", 81, 101], ["TUNEL assays", "TEST", 135, 147], ["apoptotic cell death", "OBSERVATION", 81, 101]]], ["In addition, expression pattern of cell death-controlling genes (bcl-2 and bax) was not altered by this cytokine.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["bcl-2", "GENE_OR_GENE_PRODUCT", 65, 70], ["bax", "GENE_OR_GENE_PRODUCT", 75, 78], ["bcl", "DNA", 65, 68], ["bax", "DNA", 75, 78], ["cytokine", "PROTEIN", 104, 112], ["cell death", "PROBLEM", 35, 45], ["bcl", "TEST", 65, 68], ["cell death", "OBSERVATION", 35, 45]]], ["Findings in these studies indicated that suppression of KB-cell proliferation may be attributed to control of cell cycle, growth arrest or induction of cell differentiation.", [["KB-cell", "ANATOMY", 56, 63], ["cell", "ANATOMY", 110, 114], ["cell", "ANATOMY", 152, 156], ["KB-cell", "CELL", 56, 63], ["cell", "CELL", 110, 114], ["cell", "CELL", 152, 156], ["these studies", "TEST", 12, 25], ["KB-cell proliferation", "PROBLEM", 56, 77], ["cell cycle", "PROBLEM", 110, 120], ["growth arrest", "PROBLEM", 122, 135], ["cell differentiation", "PROBLEM", 152, 172], ["cell proliferation", "OBSERVATION", 59, 77], ["cell cycle", "OBSERVATION", 110, 120], ["cell differentiation", "OBSERVATION", 152, 172]]], ["The data presented in this project could provide an insight of how cancer cell directly responds to IL-18, as this cytokine is an important regulator of anticancer mechanisms.Results:Aloe emodin (AE) is a naturally occurring compound with wide spectrum of biological properties, including antimicrobial, vasorelaxant, immunosuppressive and anticancer actions.", [["cancer cell", "ANATOMY", 67, 78], ["anticancer", "ANATOMY", 153, 163], ["anticancer", "ANATOMY", 340, 350], ["cancer", "DISEASE", 67, 73], ["Aloe emodin", "CHEMICAL", 183, 194], ["AE", "CHEMICAL", 196, 198], ["emodin", "CHEMICAL", 188, 194], ["cancer cell", "CELL", 67, 78], ["IL-18", "GENE_OR_GENE_PRODUCT", 100, 105], ["anticancer", "CANCER", 153, 163], ["Aloe emodin", "SIMPLE_CHEMICAL", 183, 194], ["AE", "SIMPLE_CHEMICAL", 196, 198], ["anticancer", "CANCER", 340, 350], ["cancer cell", "CELL_TYPE", 67, 78], ["IL-18", "PROTEIN", 100, 105], ["cytokine", "PROTEIN", 115, 123], ["how cancer cell", "PROBLEM", 63, 78], ["Aloe emodin", "TREATMENT", 183, 194], ["antimicrobial", "TREATMENT", 289, 302], ["vasorelaxant", "TREATMENT", 304, 316], ["immunosuppressive", "TREATMENT", 318, 335], ["anticancer actions", "TREATMENT", 340, 358], ["Aloe emodin", "OBSERVATION_MODIFIER", 183, 194]]], ["This anthraquinone induces apoptosis in several tumour cell lines with special affinity to tumours of neuroectodermal origin.", [["tumour cell lines", "ANATOMY", 48, 65], ["tumours", "ANATOMY", 91, 98], ["neuroectodermal", "ANATOMY", 102, 117], ["anthraquinone", "CHEMICAL", 5, 18], ["tumour", "DISEASE", 48, 54], ["anthraquinone", "CHEMICAL", 5, 18], ["anthraquinone", "SIMPLE_CHEMICAL", 5, 18], ["tumour cell lines", "CELL", 48, 65], ["tumours", "CANCER", 91, 98], ["neuroectodermal", "CANCER", 102, 117], ["tumour cell lines", "CELL_LINE", 48, 65], ["This anthraquinone", "TREATMENT", 0, 18], ["apoptosis", "PROBLEM", 27, 36], ["several tumour cell lines", "TREATMENT", 40, 65], ["apoptosis", "OBSERVATION_MODIFIER", 27, 36], ["several", "OBSERVATION_MODIFIER", 40, 47], ["tumour cell lines", "OBSERVATION", 48, 65], ["neuroectodermal origin", "OBSERVATION", 102, 124]]], ["High amounts of nitric oxide (NO) released by activated macrophages induce tumour cell death.", [["macrophages", "ANATOMY", 56, 67], ["tumour cell", "ANATOMY", 75, 86], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["tumour", "DISEASE", 75, 81], ["death", "DISEASE", 87, 92], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["nitric oxide", "SIMPLE_CHEMICAL", 16, 28], ["NO", "SIMPLE_CHEMICAL", 30, 32], ["macrophages", "CELL", 56, 67], ["tumour cell", "CELL", 75, 86], ["activated macrophages", "CELL_TYPE", 46, 67], ["nitric oxide", "TREATMENT", 16, 28], ["tumour cell death", "PROBLEM", 75, 92], ["tumour cell death", "OBSERVATION", 75, 92]]], ["Therefore, we explored the capacity of AE to modulate NO-mediated antitumour response in vitro.", [["NO", "CHEMICAL", 54, 56], ["NO", "CHEMICAL", 54, 56], ["AE", "SIMPLE_CHEMICAL", 39, 41], ["NO", "SIMPLE_CHEMICAL", 54, 56], ["antitumour", "CANCER", 66, 76]]], ["Interestingly, while AE markedly suppressed NO release from macrophages alone, it significantly potentiated NO production in cocultures of macrophages and C6 cells, after 48 h of cultivation.", [["macrophages", "ANATOMY", 60, 71], ["macrophages", "ANATOMY", 139, 150], ["C6 cells", "ANATOMY", 155, 163], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["AE", "SIMPLE_CHEMICAL", 21, 23], ["NO", "SIMPLE_CHEMICAL", 44, 46], ["macrophages", "CELL", 60, 71], ["NO", "SIMPLE_CHEMICAL", 108, 110], ["macrophages", "CELL", 139, 150], ["C6 cells", "CELL", 155, 163], ["macrophages", "CELL_TYPE", 60, 71], ["macrophages", "CELL_TYPE", 139, 150], ["C6 cells", "CELL_LINE", 155, 163], ["macrophages", "PROBLEM", 139, 150], ["C6 cells", "PROBLEM", 155, 163], ["cultivation", "TREATMENT", 179, 190], ["macrophages", "OBSERVATION", 60, 71]]], ["Accordingly, the viability of C6 cells cocultivated with macrophages was reduced in the presence of AE.", [["C6 cells", "ANATOMY", 30, 38], ["macrophages", "ANATOMY", 57, 68], ["C6 cells", "CELL", 30, 38], ["macrophages", "CELL", 57, 68], ["C6 cells", "CELL_LINE", 30, 38], ["macrophages", "CELL_TYPE", 57, 68], ["the viability of C6 cells", "TEST", 13, 38], ["macrophages", "PROBLEM", 57, 68], ["C6 cells", "OBSERVATION", 30, 38], ["macrophages", "OBSERVATION", 57, 68]]], ["Moreover, the observed AE-imposed potentiation of NO production in macrophages was closely related to macrophage culture cell density.", [["macrophages", "ANATOMY", 67, 78], ["macrophage culture cell", "ANATOMY", 102, 125], ["NO", "CHEMICAL", 50, 52], ["NO", "CHEMICAL", 50, 52], ["NO", "SIMPLE_CHEMICAL", 50, 52], ["macrophages", "CELL", 67, 78], ["macrophage culture cell", "CELL", 102, 125], ["macrophages", "CELL_TYPE", 67, 78], ["production in macrophages", "PROBLEM", 53, 78], ["macrophage culture cell density", "TEST", 102, 133], ["NO", "UNCERTAINTY", 50, 52], ["production", "OBSERVATION_MODIFIER", 53, 63], ["cell density", "OBSERVATION", 121, 133]]], ["According to these data, we proposed that NO modulator capacity of AE strongly depended on intercellular contact, indicating that macrophage antitumour response was not compromised but even potentiated by AE.Results:Immunotherapy represents an attractive fourth-modality therapeutic approach, especially in the light of the shortcomings of conventional surgery, radiation and chemotherapies in the management of metastatic cancer.", [["intercellular", "ANATOMY", 91, 104], ["macrophage", "ANATOMY", 130, 140], ["metastatic cancer", "ANATOMY", 412, 429], ["NO", "CHEMICAL", 42, 44], ["cancer", "DISEASE", 423, 429], ["NO", "CHEMICAL", 42, 44], ["NO", "SIMPLE_CHEMICAL", 42, 44], ["AE", "SIMPLE_CHEMICAL", 67, 69], ["macrophage", "CELL", 130, 140], ["metastatic cancer", "CANCER", 412, 429], ["Immunotherapy", "TREATMENT", 216, 229], ["an attractive fourth-modality therapeutic approach", "TREATMENT", 241, 291], ["conventional surgery", "TREATMENT", 340, 360], ["radiation", "TREATMENT", 362, 371], ["chemotherapies", "TREATMENT", 376, 390], ["the management", "TREATMENT", 394, 408], ["metastatic cancer", "PROBLEM", 412, 429], ["metastatic", "OBSERVATION_MODIFIER", 412, 422], ["cancer", "OBSERVATION", 423, 429]]], ["To this end, a large number of peptide antigens derived from TAA have been applied in immunotherapeutic trials for the treatment of various malignancies, e.g. cancers of the breast, prostate and kidney, in addition to haematological cancers.", [["malignancies", "ANATOMY", 140, 152], ["cancers", "ANATOMY", 159, 166], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological cancers", "ANATOMY", 218, 240], ["TAA", "DISEASE", 61, 64], ["malignancies", "DISEASE", 140, 152], ["cancers of the breast, prostate and kidney", "DISEASE", 159, 201], ["haematological cancers", "DISEASE", 218, 240], ["TAA", "SIMPLE_CHEMICAL", 61, 64], ["malignancies", "CANCER", 140, 152], ["cancers", "CANCER", 159, 166], ["breast", "CANCER", 174, 180], ["prostate", "CANCER", 182, 190], ["kidney", "ORGAN", 195, 201], ["haematological cancers", "CANCER", 218, 240], ["peptide antigens", "PROTEIN", 31, 47], ["peptide antigens", "TREATMENT", 31, 47], ["TAA", "TREATMENT", 61, 64], ["immunotherapeutic trials", "TREATMENT", 86, 110], ["the treatment", "TREATMENT", 115, 128], ["various malignancies", "PROBLEM", 132, 152], ["e.g. cancers of the breast, prostate and kidney", "PROBLEM", 154, 201], ["haematological cancers", "PROBLEM", 218, 240], ["large", "OBSERVATION_MODIFIER", 15, 20], ["various", "OBSERVATION_MODIFIER", 132, 139], ["malignancies", "OBSERVATION", 140, 152], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological", "ANATOMY", 218, 232], ["cancers", "OBSERVATION", 233, 240]]], ["In some cases the response rates have been impressive and no adverse autoimmunity have been observed.", [["autoimmunity", "DISEASE", 69, 81], ["adverse autoimmunity", "PROBLEM", 61, 81], ["no", "UNCERTAINTY", 58, 60]]], ["A major strategic difficulty associated with these trials relates to the choice of best-suited peptide antigens.", [["A major strategic difficulty", "PROBLEM", 0, 28]]], ["The vast majority of the antigens described thus far is not vital for survival and growth of the tumour cells, and immunoselection of antigen-loss variants may therefore prove to be an additional obstacle for the clinical applicability of most of the known peptide epitopes.", [["tumour cells", "ANATOMY", 97, 109], ["tumour", "DISEASE", 97, 103], ["tumour cells", "CELL", 97, 109], ["antigen", "GENE_OR_GENE_PRODUCT", 134, 141], ["antigens", "PROTEIN", 25, 33], ["tumour cells", "CELL_TYPE", 97, 109], ["the tumour cells", "PROBLEM", 93, 109], ["antigen-loss variants", "PROBLEM", 134, 155], ["the known peptide epitopes", "PROBLEM", 247, 273], ["tumour cells", "OBSERVATION", 97, 109]]], ["In this respect, the development of acquired antigen loss during immunotherapy has been demonstrated in several cases.", [["antigen loss", "DISEASE", 45, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 45, 52], ["acquired antigen loss", "PROBLEM", 36, 57], ["immunotherapy", "TREATMENT", 65, 78], ["antigen loss", "OBSERVATION", 45, 57]]], ["Obviously, the development of loss-variant tumour cells implies that these cells acquire a pronounced growth advantage and are left unaffected by further treatment.", [["loss-variant tumour cells", "ANATOMY", 30, 55], ["cells", "ANATOMY", 75, 80], ["tumour", "DISEASE", 43, 49], ["tumour cells", "CELL", 43, 55], ["cells", "CELL", 75, 80], ["loss-variant tumour cells", "CELL_TYPE", 30, 55], ["loss-variant tumour cells", "PROBLEM", 30, 55], ["these cells", "PROBLEM", 69, 80], ["a pronounced growth advantage", "PROBLEM", 89, 118], ["further treatment", "TREATMENT", 146, 163], ["loss", "OBSERVATION", 30, 34], ["variant", "OBSERVATION_MODIFIER", 35, 42], ["tumour cells", "OBSERVATION", 43, 55], ["pronounced", "OBSERVATION_MODIFIER", 91, 101], ["growth", "OBSERVATION_MODIFIER", 102, 108], ["left", "ANATOMY_MODIFIER", 127, 131]]], ["Ideally, target antigens should be derived from proteins required for survival and growth of tumour cells, as antigens with these characteristics would not be inflicted by the development of loss-variant tumour cells.", [["tumour cells", "ANATOMY", 93, 105], ["loss-variant tumour cells", "ANATOMY", 191, 216], ["tumour", "DISEASE", 93, 99], ["tumour", "DISEASE", 204, 210], ["tumour cells", "CELL", 93, 105], ["tumour cells", "CELL", 204, 216], ["tumour cells", "CELL_TYPE", 93, 105], ["loss-variant tumour cells", "CELL_TYPE", 191, 216], ["survival", "TREATMENT", 70, 78], ["tumour cells", "PROBLEM", 93, 105], ["loss-variant tumour cells", "PROBLEM", 191, 216], ["tumour cells", "OBSERVATION", 93, 105], ["tumour cells", "OBSERVATION", 204, 216]]], ["In this respect, several inhibitors of apoptosis proteins (IAPs) are universally expressed among tumours and play an important role in tumour cell escape from apoptosis.", [["tumours", "ANATOMY", 97, 104], ["tumour cell", "ANATOMY", 135, 146], ["tumour", "DISEASE", 135, 141], ["IAPs", "GENE_OR_GENE_PRODUCT", 59, 63], ["tumours", "CANCER", 97, 104], ["tumour cell", "CELL", 135, 146], ["apoptosis proteins", "PROTEIN", 39, 57], ["IAPs", "PROTEIN", 59, 63], ["apoptosis proteins", "PROBLEM", 39, 57], ["apoptosis", "PROBLEM", 159, 168], ["tumour cell escape", "OBSERVATION", 135, 153]]], ["We have characterized spontaneous T-cell reactivity against IAPderived peptides in cancer patients.", [["T-cell", "ANATOMY", 34, 40], ["cancer", "ANATOMY", 83, 89], ["cancer", "DISEASE", 83, 89], ["T-cell", "CELL", 34, 40], ["cancer", "CANCER", 83, 89], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["spontaneous T-cell reactivity", "PROBLEM", 22, 51], ["IAPderived peptides in cancer patients", "PROBLEM", 60, 98], ["spontaneous", "OBSERVATION_MODIFIER", 22, 33], ["T-cell reactivity", "OBSERVATION", 34, 51], ["cancer", "OBSERVATION", 83, 89]]], ["From the IAP survivin, we have characterized peptides restricted to the Class I molecules HLA-A1, A2, A3, A11, B7 and B35.", [["IAP", "GENE_OR_GENE_PRODUCT", 9, 12], ["survivin", "GENE_OR_GENE_PRODUCT", 13, 21], ["HLA-A1", "GENE_OR_GENE_PRODUCT", 90, 96], ["A2", "GENE_OR_GENE_PRODUCT", 98, 100], ["A3", "GENE_OR_GENE_PRODUCT", 102, 104], ["A11", "GENE_OR_GENE_PRODUCT", 106, 109], ["B7", "GENE_OR_GENE_PRODUCT", 111, 113], ["B35", "GENE_OR_GENE_PRODUCT", 118, 121], ["IAP survivin", "PROTEIN", 9, 21], ["Class I molecules", "PROTEIN", 72, 89], ["HLA", "PROTEIN", 90, 93], ["A1", "PROTEIN", 94, 96], ["A2", "PROTEIN", 98, 100], ["A3", "PROTEIN", 102, 104], ["A11", "PROTEIN", 106, 109], ["B7", "PROTEIN", 111, 113], ["B35", "PROTEIN", 118, 121], ["the IAP survivin", "TREATMENT", 5, 21], ["HLA", "TEST", 90, 93], ["A2", "TEST", 98, 100], ["A11", "TEST", 106, 109], ["A2", "ANATOMY", 98, 100], ["A3", "ANATOMY", 102, 104]]], ["Furthermore, we have demonstrated that survivin-specific T cells infiltrate metastatic lesions and that isolated survivinspecific CTLs are capable of killing HLA-matched tumour cells.", [["T cells", "ANATOMY", 57, 64], ["metastatic lesions", "ANATOMY", 76, 94], ["CTLs", "ANATOMY", 130, 134], ["tumour cells", "ANATOMY", 170, 182], ["tumour", "DISEASE", 170, 176], ["survivin", "GENE_OR_GENE_PRODUCT", 39, 47], ["T cells", "CELL", 57, 64], ["metastatic lesions", "CANCER", 76, 94], ["CTLs", "CELL", 130, 134], ["tumour cells", "CELL", 170, 182], ["survivin", "PROTEIN", 39, 47], ["T cells", "CELL_TYPE", 57, 64], ["survivinspecific CTLs", "CELL_TYPE", 113, 134], ["HLA-matched tumour cells", "CELL_TYPE", 158, 182], ["survivin-specific T cells infiltrate metastatic lesions", "PROBLEM", 39, 94], ["isolated survivinspecific CTLs", "PROBLEM", 104, 134], ["killing HLA-matched tumour cells", "PROBLEM", 150, 182], ["metastatic", "OBSERVATION_MODIFIER", 76, 86], ["tumour cells", "OBSERVATION", 170, 182]]], ["Survivin-derived peptides are now in clinical trial, and continued work in our lab has demonstrated that other IAPs are targets for spontaneous T-cell reactivity in cancer patients.", [["T-cell", "ANATOMY", 144, 150], ["cancer", "ANATOMY", 165, 171], ["cancer", "DISEASE", 165, 171], ["Survivin", "GENE_OR_GENE_PRODUCT", 0, 8], ["IAPs", "GENE_OR_GENE_PRODUCT", 111, 115], ["T-cell", "CELL", 144, 150], ["cancer", "CANCER", 165, 171], ["patients", "ORGANISM", 172, 180], ["Survivin", "PROTEIN", 0, 8], ["IAPs", "PROTEIN", 111, 115], ["patients", "SPECIES", 172, 180], ["Survivin", "TREATMENT", 0, 8], ["other IAPs", "TEST", 105, 115], ["spontaneous T-cell reactivity", "PROBLEM", 132, 161]]], ["We previously reported that in mice with large progressing T-cell lymphoma tumours, dysfunctions in the antitumour CTL activity occur, associated with an accumulation of splenic arginase-producing myeloid suppressor cells (MSCs).", [["T-cell lymphoma tumours", "ANATOMY", 59, 82], ["splenic", "ANATOMY", 170, 177], ["myeloid suppressor cells", "ANATOMY", 197, 221], ["MSCs", "ANATOMY", 223, 227], ["T-cell lymphoma tumours", "DISEASE", 59, 82], ["mice", "ORGANISM", 31, 35], ["T-cell lymphoma tumours", "CANCER", 59, 82], ["antitumour", "CANCER", 104, 114], ["arginase", "GENE_OR_GENE_PRODUCT", 178, 186], ["myeloid suppressor cells", "CELL", 197, 221], ["MSCs", "CELL", 223, 227], ["splenic arginase-producing myeloid suppressor cells", "CELL_TYPE", 170, 221], ["MSCs", "CELL_TYPE", 223, 227], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["large progressing T-cell lymphoma tumours", "PROBLEM", 41, 82], ["dysfunctions", "PROBLEM", 84, 96], ["the antitumour CTL activity", "PROBLEM", 100, 127], ["an accumulation of splenic arginase", "PROBLEM", 151, 186], ["myeloid suppressor cells", "PROBLEM", 197, 221], ["large", "OBSERVATION_MODIFIER", 41, 46], ["progressing", "OBSERVATION_MODIFIER", 47, 58], ["T-cell lymphoma tumours", "OBSERVATION", 59, 82], ["antitumour CTL activity", "OBSERVATION", 104, 127], ["accumulation", "OBSERVATION_MODIFIER", 154, 166], ["splenic", "ANATOMY", 170, 177], ["arginase", "OBSERVATION", 178, 186], ["myeloid suppressor cells", "OBSERVATION", 197, 221]]], ["In this study, we first demonstrate that both the presence and the activation state of these MSC depends on tumour evolution.", [["MSC", "ANATOMY", 93, 96], ["tumour", "ANATOMY", 108, 114], ["tumour", "DISEASE", 108, 114], ["MSC", "CELL", 93, 96], ["tumour", "CANCER", 108, 114], ["MSC", "CELL_TYPE", 93, 96], ["this study", "TEST", 3, 13], ["tumour", "OBSERVATION", 108, 114]]], ["While in tumour regressors hardly any arginase-producing MSC can be found, both the amount and the arginase activity of this population expands from early over late progressors.", [["tumour", "ANATOMY", 9, 15], ["MSC", "ANATOMY", 57, 60], ["tumour", "DISEASE", 9, 15], ["tumour", "CANCER", 9, 15], ["arginase", "GENE_OR_GENE_PRODUCT", 38, 46], ["MSC", "CELL", 57, 60], ["arginase", "GENE_OR_GENE_PRODUCT", 99, 107], ["arginase", "PROTEIN", 38, 46], ["MSC", "CELL_TYPE", 57, 60], ["arginase", "PROTEIN", 99, 107], ["any arginase", "PROBLEM", 34, 46], ["MSC", "PROBLEM", 57, 60], ["arginase activity", "OBSERVATION", 99, 116]]], ["This gradual induction of MSCs is paralleled by an increasing suppression of CTL activity and Th1, but not Th2, cytokine production.", [["MSCs", "ANATOMY", 26, 30], ["MSCs", "CELL", 26, 30], ["CTL", "GENE_OR_GENE_PRODUCT", 77, 80], ["Th1", "GENE_OR_GENE_PRODUCT", 94, 97], ["Th2", "GENE_OR_GENE_PRODUCT", 107, 110], ["MSCs", "CELL_TYPE", 26, 30], ["cytokine", "PROTEIN", 112, 120], ["This gradual induction of MSCs", "TREATMENT", 0, 30], ["MSCs", "OBSERVATION", 26, 30]]], ["Upon analysing the molecular repertoire of MSC in vitro, we found, besides arginase1, a well-established marker for alternatively activated myeloid cells or M2, a strong upregulation of FIZZ1 and Ym, two additional recently identified markers for M2.", [["MSC", "ANATOMY", 43, 46], ["myeloid cells", "ANATOMY", 140, 153], ["MSC", "CELL", 43, 46], ["arginase1", "GENE_OR_GENE_PRODUCT", 75, 84], ["myeloid cells", "CELL", 140, 153], ["M2", "CELL", 157, 159], ["FIZZ1", "GENE_OR_GENE_PRODUCT", 186, 191], ["Ym", "GENE_OR_GENE_PRODUCT", 196, 198], ["M2", "GENE_OR_GENE_PRODUCT", 247, 249], ["MSC", "CELL_TYPE", 43, 46], ["arginase1", "PROTEIN", 75, 84], ["myeloid cells", "CELL_TYPE", 140, 153], ["M2", "PROTEIN", 157, 159], ["FIZZ1", "PROTEIN", 186, 191], ["Ym", "PROTEIN", 196, 198], ["M2", "PROTEIN", 247, 249], ["activated myeloid cells", "PROBLEM", 130, 153], ["myeloid cells", "OBSERVATION", 140, 153]]], ["Further evaluation of molecular markers by microarray analysis in MSC yielded genes involved in wound healing (e.g. coagulation factor XIIIa), anti-inflammation (e.g. selenoprotein P), immunomodulation (e.g. PD-L2) and fat and sugar metabolism (e.g. leptin receptor).", [["MSC", "ANATOMY", 66, 69], ["wound", "ANATOMY", 96, 101], ["fat", "ANATOMY", 219, 222], ["sugar", "CHEMICAL", 227, 232], ["MSC", "CELL", 66, 69], ["wound", "PATHOLOGICAL_FORMATION", 96, 101], ["coagulation factor XIIIa", "GENE_OR_GENE_PRODUCT", 116, 140], ["selenoprotein P", "GENE_OR_GENE_PRODUCT", 167, 182], ["PD-L2", "GENE_OR_GENE_PRODUCT", 208, 213], ["fat", "TISSUE", 219, 222], ["sugar", "SIMPLE_CHEMICAL", 227, 232], ["leptin receptor", "GENE_OR_GENE_PRODUCT", 250, 265], ["MSC", "CELL_TYPE", 66, 69], ["coagulation factor XIIIa", "PROTEIN", 116, 140], ["selenoprotein P", "PROTEIN", 167, 182], ["leptin receptor", "PROTEIN", 250, 265], ["Further evaluation", "TEST", 0, 18], ["molecular markers", "TEST", 22, 39], ["microarray analysis", "TEST", 43, 62], ["wound healing", "PROBLEM", 96, 109], ["coagulation factor XIIIa", "TEST", 116, 140], ["anti-inflammation", "PROBLEM", 143, 160], ["immunomodulation (e.g. PD", "TEST", 185, 210], ["fat and sugar metabolism", "PROBLEM", 219, 243], ["leptin receptor", "TREATMENT", 250, 265], ["wound healing", "OBSERVATION_MODIFIER", 96, 109], ["fat", "ANATOMY", 219, 222]]], ["Of note, many of these genes are regulated by type 2 cytokines (IL-4, IL-13 and IL-10) and are therefore rather M2 associated.", [["IL-4", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-13", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["M2", "GENE_OR_GENE_PRODUCT", 112, 114], ["type 2 cytokines", "PROTEIN", 46, 62], ["IL", "PROTEIN", 64, 66], ["IL", "PROTEIN", 70, 72], ["IL", "PROTEIN", 80, 82], ["M2", "PROTEIN", 112, 114], ["IL", "TEST", 64, 66], ["IL", "TEST", 70, 72], ["rather M2", "OBSERVATION_MODIFIER", 105, 114]]], ["Overall, our data provide new markers for MSC in cancer and further establish their M2 activation state. study.", [["MSC", "ANATOMY", 42, 45], ["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["MSC", "CELL", 42, 45], ["cancer", "CANCER", 49, 55], ["M2", "GENE_OR_GENE_PRODUCT", 84, 86], ["MSC", "CELL_TYPE", 42, 45], ["M2", "PROTEIN", 84, 86], ["our data", "TEST", 9, 17], ["new markers", "TEST", 26, 37], ["MSC in cancer", "PROBLEM", 42, 55], ["study", "TEST", 105, 110], ["cancer", "OBSERVATION", 49, 55]]], ["Only SP-A showed a significant expression in normal mucosa which was downregulated in CRC.", [["mucosa", "ANATOMY", 52, 58], ["CRC", "ANATOMY", 86, 89], ["CRC", "DISEASE", 86, 89], ["SP-A", "GENE_OR_GENE_PRODUCT", 5, 9], ["mucosa", "MULTI-TISSUE_STRUCTURE", 52, 58], ["CRC", "CANCER", 86, 89], ["SP", "PROTEIN", 5, 7], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["expression", "OBSERVATION", 31, 41], ["normal mucosa", "OBSERVATION", 45, 58], ["CRC", "OBSERVATION", 86, 89]]], ["As the absolute signal level was below the noise threshold, these results have to be interpreted with caution and require confirmation by direct measurenment of the proteins.", [["the absolute signal level", "TEST", 3, 28], ["confirmation", "TEST", 122, 134]]], ["Our results suggest that there is no major role for the human collectins in colorectal cancer.", [["colorectal cancer", "ANATOMY", 76, 93], ["colorectal cancer", "DISEASE", 76, 93], ["human", "ORGANISM", 56, 61], ["collectins", "CELL", 62, 72], ["colorectal cancer", "CANCER", 76, 93], ["human collectins", "PROTEIN", 56, 72], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["colorectal cancer", "PROBLEM", 76, 93], ["no major", "UNCERTAINTY", 34, 42], ["colorectal", "ANATOMY", 76, 86], ["cancer", "OBSERVATION", 87, 93]]]], "PMC7347481": [["Case presentationWe present the case of a 60-year-old female, with history of diabetes and hypertension, taking losartan, gabapentin, insulin glulisine, and metformin daily.", [["diabetes", "DISEASE", 78, 86], ["hypertension", "DISEASE", 91, 103], ["losartan", "CHEMICAL", 112, 120], ["gabapentin", "CHEMICAL", 122, 132], ["insulin glulisine", "CHEMICAL", 134, 151], ["metformin", "CHEMICAL", 157, 166], ["losartan", "CHEMICAL", 112, 120], ["gabapentin", "CHEMICAL", 122, 132], ["metformin", "CHEMICAL", 157, 166], ["female", "ORGANISM", 54, 60], ["losartan", "SIMPLE_CHEMICAL", 112, 120], ["gabapentin", "SIMPLE_CHEMICAL", 122, 132], ["insulin glulisine", "SIMPLE_CHEMICAL", 134, 151], ["metformin", "SIMPLE_CHEMICAL", 157, 166], ["diabetes", "PROBLEM", 78, 86], ["hypertension", "PROBLEM", 91, 103], ["losartan", "TREATMENT", 112, 120], ["gabapentin", "TREATMENT", 122, 132], ["insulin glulisine", "TREATMENT", 134, 151], ["metformin", "TREATMENT", 157, 166], ["diabetes", "OBSERVATION", 78, 86], ["hypertension", "OBSERVATION", 91, 103]]], ["Reports no history of cigarette or alcohol consumption and no known drug allergies.", [["alcohol", "CHEMICAL", 35, 42], ["drug allergies", "DISEASE", 68, 82], ["alcohol", "CHEMICAL", 35, 42], ["cigarette", "ORGANISM_SUBDIVISION", 22, 31], ["alcohol", "SIMPLE_CHEMICAL", 35, 42], ["known drug allergies", "PROBLEM", 62, 82]]], ["Surgical history: C-section and hysterectomy. (see Table 1, Fig. 1)Case presentationThe patient sought medical care at the Hospital Samaritano Botafogo on 3/31/2020 presenting dry cough, dyspnea, prostration, fever (not measured), and dizziness.", [["dry cough", "DISEASE", 176, 185], ["dyspnea", "DISEASE", 187, 194], ["prostration", "DISEASE", 196, 207], ["fever", "DISEASE", 209, 214], ["dizziness", "DISEASE", 235, 244], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["C-section", "TREATMENT", 18, 27], ["hysterectomy", "TREATMENT", 32, 44], ["dry cough", "PROBLEM", 176, 185], ["dyspnea", "PROBLEM", 187, 194], ["prostration", "PROBLEM", 196, 207], ["fever", "PROBLEM", 209, 214], ["dizziness", "PROBLEM", 235, 244], ["hysterectomy", "OBSERVATION", 32, 44], ["cough", "OBSERVATION", 180, 185], ["dyspnea", "OBSERVATION", 187, 194], ["fever", "OBSERVATION", 209, 214]]], ["She reported that the reason for seeking medical care was the worsening of dyspnea and the onset of dizziness on 3/31/2020.", [["dyspnea", "DISEASE", 75, 82], ["dizziness", "DISEASE", 100, 109], ["dyspnea", "PROBLEM", 75, 82], ["dizziness", "PROBLEM", 100, 109], ["dizziness", "OBSERVATION", 100, 109]]], ["Physical examination revealed dyspnea and tachypnea when breathing room air.", [["dyspnea", "DISEASE", 30, 37], ["tachypnea", "DISEASE", 42, 51], ["Physical examination", "TEST", 0, 20], ["dyspnea", "PROBLEM", 30, 37], ["tachypnea", "PROBLEM", 42, 51], ["dyspnea", "OBSERVATION", 30, 37], ["tachypnea", "OBSERVATION", 42, 51]]], ["On lung auscultation: bilateral crackles in the lower segments of the lungs bilaterally, blood pressure (BP) 112/57 mmHg, heart rate (HR) 81 bpm, respiratory rate (RR) 18 rpm, Sat O2 77%, and a temperature of 36\u00b0C (96.8\u00b0F).", [["lung", "ANATOMY", 3, 7], ["crackles", "ANATOMY", 32, 40], ["lower segments", "ANATOMY", 48, 62], ["lungs", "ANATOMY", 70, 75], ["blood", "ANATOMY", 89, 94], ["heart", "ANATOMY", 122, 127], ["lung", "ORGAN", 3, 7], ["lower segments", "ORGANISM_SUBDIVISION", 48, 62], ["lungs", "ORGAN", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["heart", "ORGAN", 122, 127], ["lung auscultation", "TEST", 3, 20], ["bilateral crackles in the lower segments of the lungs bilaterally", "PROBLEM", 22, 87], ["blood pressure", "TEST", 89, 103], ["BP", "TEST", 105, 107], ["mmHg", "TEST", 116, 120], ["heart rate", "TEST", 122, 132], ["HR", "TEST", 134, 136], ["bpm", "TEST", 141, 144], ["respiratory rate", "TEST", 146, 162], ["RR", "TEST", 164, 166], ["Sat O2", "TEST", 176, 182], ["a temperature", "TEST", 192, 205], ["lung", "ANATOMY", 3, 7], ["auscultation", "OBSERVATION", 8, 20], ["bilateral", "ANATOMY_MODIFIER", 22, 31], ["crackles", "OBSERVATION", 32, 40], ["lower", "ANATOMY_MODIFIER", 48, 53], ["segments", "ANATOMY_MODIFIER", 54, 62], ["lungs", "ANATOMY", 70, 75], ["bilaterally", "ANATOMY_MODIFIER", 76, 87], ["pressure", "OBSERVATION_MODIFIER", 95, 103], ["heart", "ANATOMY", 122, 127]]], ["A high concentration oxygen mask was offered, with O2 at 10 L/min, thereby improving O2 saturation up to 94%.", [["oxygen", "CHEMICAL", 21, 27], ["O2", "CHEMICAL", 51, 53], ["O2", "CHEMICAL", 85, 87], ["oxygen", "CHEMICAL", 21, 27], ["O2", "CHEMICAL", 51, 53], ["O2", "CHEMICAL", 85, 87], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["O2", "SIMPLE_CHEMICAL", 51, 53], ["O2", "SIMPLE_CHEMICAL", 85, 87], ["A high concentration oxygen mask", "TREATMENT", 0, 32], ["O2", "TREATMENT", 51, 53], ["O2 saturation", "TEST", 85, 98], ["high", "OBSERVATION_MODIFIER", 2, 6], ["concentration", "OBSERVATION_MODIFIER", 7, 20], ["oxygen mask", "OBSERVATION", 21, 32]]], ["The diagnostic impression was a coronavirus infection; a swab specimen collection for coronavirus was ordered, along with a respiratory virus panel; blood cell count; blood chemistry; chest computed tomography (CT) (report: diffuse ground glass infiltrates in over 50% of lung fields, mosaic paving pattern, basilar consolidations, and linear atelectasis in the lower lobes).", [["swab specimen", "ANATOMY", 57, 70], ["blood cell", "ANATOMY", 149, 159], ["blood", "ANATOMY", 167, 172], ["lung", "ANATOMY", 272, 276], ["basilar", "ANATOMY", 308, 315], ["lower lobes", "ANATOMY", 362, 373], ["coronavirus infection", "DISEASE", 32, 53], ["basilar consolidations", "DISEASE", 308, 330], ["atelectasis", "DISEASE", 343, 354], ["coronavirus", "ORGANISM", 32, 43], ["coronavirus", "ORGANISM", 86, 97], ["blood cell", "CELL", 149, 159], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["lung", "ORGAN", 272, 276], ["basilar", "MULTI-TISSUE_STRUCTURE", 308, 315], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 362, 373], ["coronavirus", "SPECIES", 86, 97], ["a coronavirus infection", "PROBLEM", 30, 53], ["a swab specimen collection", "TEST", 55, 81], ["coronavirus", "PROBLEM", 86, 97], ["a respiratory virus panel", "TEST", 122, 147], ["blood cell count", "TEST", 149, 165], ["blood chemistry", "TEST", 167, 182], ["chest computed tomography", "TEST", 184, 209], ["CT", "TEST", 211, 213], ["diffuse ground glass infiltrates", "PROBLEM", 224, 256], ["mosaic paving pattern", "PROBLEM", 285, 306], ["basilar consolidations", "PROBLEM", 308, 330], ["linear atelectasis in the lower lobes", "PROBLEM", 336, 373], ["coronavirus infection", "OBSERVATION", 32, 53], ["chest", "ANATOMY", 184, 189], ["diffuse", "OBSERVATION_MODIFIER", 224, 231], ["ground glass infiltrates", "OBSERVATION", 232, 256], ["lung", "ANATOMY", 272, 276], ["fields", "ANATOMY_MODIFIER", 277, 283], ["mosaic paving", "OBSERVATION", 285, 298], ["basilar", "ANATOMY_MODIFIER", 308, 315], ["consolidations", "OBSERVATION", 316, 330], ["linear", "OBSERVATION_MODIFIER", 336, 342], ["atelectasis", "OBSERVATION", 343, 354], ["lower lobes", "ANATOMY", 362, 373]]], ["The patient was admitted to the intensive care unit (ICU).", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Azithromycin and hydroxychloroquine were initiated on 3/31/2020 while in the ICU.Case presentationNon-invasive ventilation (NIV) and dexmedetomidine were started on 1/4/2020 due to oxygen desaturation with the use of a high concentration oxygen mask.", [["Azithromycin", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["dexmedetomidine", "CHEMICAL", 133, 148], ["oxygen", "CHEMICAL", 181, 187], ["desaturation", "DISEASE", 188, 200], ["oxygen", "CHEMICAL", 238, 244], ["Azithromycin", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["dexmedetomidine", "CHEMICAL", 133, 148], ["oxygen", "CHEMICAL", 181, 187], ["oxygen", "CHEMICAL", 238, 244], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 17, 35], ["dexmedetomidine", "SIMPLE_CHEMICAL", 133, 148], ["oxygen", "SIMPLE_CHEMICAL", 181, 187], ["oxygen", "SIMPLE_CHEMICAL", 238, 244], ["Azithromycin", "TREATMENT", 0, 12], ["hydroxychloroquine", "TREATMENT", 17, 35], ["invasive ventilation", "TREATMENT", 102, 122], ["NIV", "TREATMENT", 124, 127], ["dexmedetomidine", "TREATMENT", 133, 148], ["oxygen desaturation", "PROBLEM", 181, 200], ["a high concentration oxygen mask", "TREATMENT", 217, 249], ["oxygen desaturation", "OBSERVATION", 181, 200]]], ["However, due to persistent desaturation despite NIV, endotracheal intubation was indicated with a McGrath blade and bougie; the patient was adapted to ventilatory support, sedated with lidocaine, etomidate, and rocuronium; central venous catheterization was performed in the right internal jugular vein (IJV), an arterial line was placed for mean arterial pressure (MAP) monitoring; a urinary catheter and a nasoenteric tube were inserted.", [["endotracheal", "ANATOMY", 53, 65], ["venous", "ANATOMY", 231, 237], ["right internal jugular vein", "ANATOMY", 275, 302], ["IJV", "ANATOMY", 304, 307], ["arterial line", "ANATOMY", 313, 326], ["arterial", "ANATOMY", 347, 355], ["urinary", "ANATOMY", 385, 392], ["nasoenteric tube", "ANATOMY", 408, 424], ["desaturation", "DISEASE", 27, 39], ["lidocaine", "CHEMICAL", 185, 194], ["etomidate", "CHEMICAL", 196, 205], ["rocuronium", "CHEMICAL", 211, 221], ["NIV", "CHEMICAL", 48, 51], ["lidocaine", "CHEMICAL", 185, 194], ["etomidate", "CHEMICAL", 196, 205], ["rocuronium", "CHEMICAL", 211, 221], ["patient", "ORGANISM", 128, 135], ["lidocaine", "SIMPLE_CHEMICAL", 185, 194], ["etomidate", "SIMPLE_CHEMICAL", 196, 205], ["rocuronium", "SIMPLE_CHEMICAL", 211, 221], ["central venous", "MULTI-TISSUE_STRUCTURE", 223, 237], ["right internal jugular vein", "MULTI-TISSUE_STRUCTURE", 275, 302], ["IJV", "MULTI-TISSUE_STRUCTURE", 304, 307], ["arterial line", "CELL", 313, 326], ["arterial", "MULTI-TISSUE_STRUCTURE", 347, 355], ["urinary", "ORGANISM_SUBDIVISION", 385, 392], ["nasoenteric tube", "TISSUE", 408, 424], ["patient", "SPECIES", 128, 135], ["persistent desaturation", "PROBLEM", 16, 39], ["NIV", "TREATMENT", 48, 51], ["endotracheal intubation", "TREATMENT", 53, 76], ["a McGrath blade", "TREATMENT", 96, 111], ["bougie", "TREATMENT", 116, 122], ["ventilatory support", "TREATMENT", 151, 170], ["sedated", "TREATMENT", 172, 179], ["lidocaine", "TREATMENT", 185, 194], ["etomidate", "TREATMENT", 196, 205], ["rocuronium", "TREATMENT", 211, 221], ["central venous catheterization", "TREATMENT", 223, 253], ["an arterial line", "TREATMENT", 310, 326], ["mean arterial pressure", "TEST", 342, 364], ["a urinary catheter", "TREATMENT", 383, 401], ["a nasoenteric tube", "TREATMENT", 406, 424], ["persistent", "OBSERVATION_MODIFIER", 16, 26], ["desaturation", "OBSERVATION", 27, 39], ["venous", "ANATOMY", 231, 237], ["catheterization", "OBSERVATION", 238, 253], ["right", "ANATOMY_MODIFIER", 275, 280], ["internal jugular vein", "ANATOMY", 281, 302], ["IJV", "ANATOMY", 304, 307], ["arterial line", "OBSERVATION", 313, 326], ["urinary", "ANATOMY", 385, 392], ["catheter", "OBSERVATION", 393, 401], ["nasoenteric tube", "OBSERVATION", 408, 424]]], ["The following tests were ordered: chest X-ray, sample collection for culture, and arterial blood gas (ABG).", [["chest", "ANATOMY", 34, 39], ["sample", "ANATOMY", 47, 53], ["arterial blood", "ANATOMY", 82, 96], ["arterial", "MULTI-TISSUE_STRUCTURE", 82, 90], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["The following tests", "TEST", 0, 19], ["chest X-ray", "TEST", 34, 45], ["sample collection", "TEST", 47, 64], ["culture", "TEST", 69, 76], ["arterial blood gas", "TEST", 82, 100], ["ABG", "TEST", 102, 105], ["chest", "ANATOMY", 34, 39]]], ["Therapy was initiated with amoxicillin/clavulanic acid, norepinephrine, fentanyl-midazolam, enoxaparin sodium, azithromycin and hydroxychloroquine.Case presentationOn 4/2/2020, insulin infusion was started and a transthoracic echocardiogram (TTE) was ordered, which showed mild to moderate systolic dysfunction, with signs of congestion in the inferior vena cava.", [["inferior vena cava", "ANATOMY", 344, 362], ["amoxicillin/clavulanic acid", "CHEMICAL", 27, 54], ["norepinephrine", "CHEMICAL", 56, 70], ["fentanyl", "CHEMICAL", 72, 80], ["midazolam", "CHEMICAL", 81, 90], ["enoxaparin sodium", "CHEMICAL", 92, 109], ["azithromycin", "CHEMICAL", 111, 123], ["hydroxychloroquine", "CHEMICAL", 128, 146], ["systolic dysfunction", "DISEASE", 290, 310], ["congestion", "DISEASE", 326, 336], ["amoxicillin", "CHEMICAL", 27, 38], ["clavulanic acid", "CHEMICAL", 39, 54], ["norepinephrine", "CHEMICAL", 56, 70], ["fentanyl", "CHEMICAL", 72, 80], ["midazolam", "CHEMICAL", 81, 90], ["enoxaparin sodium", "CHEMICAL", 92, 109], ["azithromycin", "CHEMICAL", 111, 123], ["hydroxychloroquine", "CHEMICAL", 128, 146], ["amoxicillin", "SIMPLE_CHEMICAL", 27, 38], ["clavulanic acid", "SIMPLE_CHEMICAL", 39, 54], ["norepinephrine", "SIMPLE_CHEMICAL", 56, 70], ["fentanyl", "SIMPLE_CHEMICAL", 72, 80], ["midazolam", "SIMPLE_CHEMICAL", 81, 90], ["enoxaparin", "SIMPLE_CHEMICAL", 92, 102], ["sodium", "SIMPLE_CHEMICAL", 103, 109], ["azithromycin", "SIMPLE_CHEMICAL", 111, 123], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 128, 146], ["insulin", "GENE_OR_GENE_PRODUCT", 177, 184], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 344, 362], ["Therapy", "TREATMENT", 0, 7], ["amoxicillin", "TREATMENT", 27, 38], ["clavulanic acid", "TREATMENT", 39, 54], ["norepinephrine", "TREATMENT", 56, 70], ["fentanyl", "TREATMENT", 72, 80], ["midazolam", "TREATMENT", 81, 90], ["enoxaparin sodium", "TREATMENT", 92, 109], ["azithromycin", "TREATMENT", 111, 123], ["hydroxychloroquine", "TREATMENT", 128, 146], ["insulin infusion", "TREATMENT", 177, 193], ["a transthoracic echocardiogram", "TEST", 210, 240], ["TTE", "TEST", 242, 245], ["mild to moderate systolic dysfunction", "PROBLEM", 273, 310], ["congestion in the inferior vena cava", "PROBLEM", 326, 362], ["mild", "OBSERVATION_MODIFIER", 273, 277], ["moderate", "OBSERVATION_MODIFIER", 281, 289], ["systolic dysfunction", "OBSERVATION", 290, 310], ["congestion", "OBSERVATION", 326, 336], ["inferior vena cava", "ANATOMY", 344, 362]]], ["A lung ultrasonography was also carried out, showing consolidation in the lower two-thirds of the right lung, with coalescent B-lines in the right lung apex and lower two-thirds of the left lung.", [["lung", "ANATOMY", 2, 6], ["right lung", "ANATOMY", 98, 108], ["B-lines", "ANATOMY", 126, 133], ["right lung apex", "ANATOMY", 141, 156], ["left lung", "ANATOMY", 185, 194], ["lung", "ORGAN", 2, 6], ["lung", "ORGAN", 104, 108], ["B-lines", "CELL", 126, 133], ["lung apex", "MULTI-TISSUE_STRUCTURE", 147, 156], ["lung", "ORGAN", 190, 194], ["A lung ultrasonography", "TEST", 0, 22], ["consolidation", "PROBLEM", 53, 66], ["coalescent B-lines in the right lung apex", "PROBLEM", 115, 156], ["lung", "ANATOMY", 2, 6], ["consolidation", "OBSERVATION", 53, 66], ["lower two", "ANATOMY_MODIFIER", 74, 83], ["thirds", "ANATOMY_MODIFIER", 84, 90], ["right", "ANATOMY_MODIFIER", 98, 103], ["lung", "ANATOMY", 104, 108], ["coalescent", "OBSERVATION_MODIFIER", 115, 125], ["B", "OBSERVATION_MODIFIER", 126, 127], ["-lines", "OBSERVATION", 127, 133], ["right", "ANATOMY_MODIFIER", 141, 146], ["lung", "ANATOMY", 147, 151], ["apex", "ANATOMY_MODIFIER", 152, 156], ["lower", "ANATOMY_MODIFIER", 161, 166], ["two-", "ANATOMY_MODIFIER", 167, 171], ["thirds", "ANATOMY_MODIFIER", 171, 177], ["left", "ANATOMY_MODIFIER", 185, 189], ["lung", "ANATOMY", 190, 194]]], ["ECG recorded on 4/2/2020: QTc 530 msec; azithromycin was discontinued.", [["azithromycin", "CHEMICAL", 40, 52], ["azithromycin", "CHEMICAL", 40, 52], ["azithromycin", "SIMPLE_CHEMICAL", 40, 52], ["ECG", "TEST", 0, 3], ["QTc", "TEST", 26, 29], ["azithromycin", "TREATMENT", 40, 52]]], ["Vascular Surgery rotated the femoral access placed the previous day (4/1/2020) due to a slight hematoma at the site of MAP line insertion, slight distal cyanosis in both lower limbs, reduced perfusion; a EV100 kit was placed in the femoral artery without complications, maintaining normal blood flow, backflow, and pedal pulse after procedure completion.", [["Vascular", "ANATOMY", 0, 8], ["femoral", "ANATOMY", 29, 36], ["lower limbs", "ANATOMY", 170, 181], ["femoral artery", "ANATOMY", 232, 246], ["blood", "ANATOMY", 289, 294], ["hematoma", "DISEASE", 95, 103], ["cyanosis", "DISEASE", 153, 161], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["femoral", "MULTI-TISSUE_STRUCTURE", 29, 36], ["hematoma", "PATHOLOGICAL_FORMATION", 95, 103], ["lower limbs", "ORGANISM_SUBDIVISION", 170, 181], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 232, 246], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["Vascular Surgery", "TREATMENT", 0, 16], ["the femoral access", "TREATMENT", 25, 43], ["a slight hematoma", "PROBLEM", 86, 103], ["MAP line insertion", "TREATMENT", 119, 137], ["slight distal cyanosis in both lower limbs", "PROBLEM", 139, 181], ["reduced perfusion", "PROBLEM", 183, 200], ["a EV100 kit", "TREATMENT", 202, 213], ["complications", "PROBLEM", 255, 268], ["procedure completion", "TREATMENT", 333, 353], ["femoral", "ANATOMY", 29, 36], ["slight", "OBSERVATION_MODIFIER", 88, 94], ["hematoma", "OBSERVATION", 95, 103], ["MAP line", "OBSERVATION", 119, 127], ["insertion", "OBSERVATION", 128, 137], ["slight", "OBSERVATION_MODIFIER", 139, 145], ["distal", "OBSERVATION_MODIFIER", 146, 152], ["cyanosis", "OBSERVATION", 153, 161], ["both", "ANATOMY_MODIFIER", 165, 169], ["lower limbs", "ANATOMY", 170, 181], ["reduced", "OBSERVATION_MODIFIER", 183, 190], ["perfusion", "OBSERVATION_MODIFIER", 191, 200], ["femoral artery", "ANATOMY", 232, 246], ["without", "UNCERTAINTY", 247, 254], ["complications", "OBSERVATION", 255, 268], ["normal", "OBSERVATION", 282, 288], ["blood flow", "OBSERVATION", 289, 299], ["pedal", "ANATOMY", 315, 320]]], ["The left IJV was cannulated, a new chest X-ray was ordered, along with ABG, lactate, and electrolytes.", [["left IJV", "ANATOMY", 4, 12], ["chest", "ANATOMY", 35, 40], ["lactate", "CHEMICAL", 76, 83], ["ABG", "CHEMICAL", 71, 74], ["lactate", "CHEMICAL", 76, 83], ["left IJV", "MULTI-TISSUE_STRUCTURE", 4, 12], ["lactate", "SIMPLE_CHEMICAL", 76, 83], ["The left IJV", "TREATMENT", 0, 12], ["a new chest X-ray", "TEST", 29, 46], ["ABG", "TEST", 71, 74], ["lactate", "TEST", 76, 83], ["electrolytes", "TEST", 89, 101], ["left", "ANATOMY_MODIFIER", 4, 8], ["IJV", "ANATOMY", 9, 12], ["cannulated", "OBSERVATION", 17, 27], ["chest", "ANATOMY", 35, 40]]], ["Therapy with enoxaparin sodium + azithromycin + hydroxychloroquine, dobutamine, fentanyl-midazolam, insulin (infusion pump), and norepinephrine was maintained.Case presentationOn 4/3/2020, the parameters on EV1000 showed a low cardiac index: 1.9; dobutamine 6 mcg/kg/min was indicated, continuous infusion of cisatracurium besilate; FiO2 was increased to 80%.", [["cardiac", "ANATOMY", 227, 234], ["enoxaparin sodium", "CHEMICAL", 13, 30], ["azithromycin", "CHEMICAL", 33, 45], ["hydroxychloroquine", "CHEMICAL", 48, 66], ["dobutamine", "CHEMICAL", 68, 78], ["fentanyl", "CHEMICAL", 80, 88], ["midazolam", "CHEMICAL", 89, 98], ["insulin", "CHEMICAL", 100, 107], ["norepinephrine", "CHEMICAL", 129, 143], ["low cardiac index", "DISEASE", 223, 240], ["dobutamine", "CHEMICAL", 247, 257], ["cisatracurium", "CHEMICAL", 309, 322], ["FiO2", "CHEMICAL", 333, 337], ["enoxaparin sodium", "CHEMICAL", 13, 30], ["azithromycin", "CHEMICAL", 33, 45], ["hydroxychloroquine", "CHEMICAL", 48, 66], ["dobutamine", "CHEMICAL", 68, 78], ["fentanyl", "CHEMICAL", 80, 88], ["midazolam", "CHEMICAL", 89, 98], ["norepinephrine", "CHEMICAL", 129, 143], ["dobutamine", "CHEMICAL", 247, 257], ["cisatracurium", "CHEMICAL", 309, 322], ["FiO2", "CHEMICAL", 333, 337], ["enoxaparin", "SIMPLE_CHEMICAL", 13, 23], ["sodium", "SIMPLE_CHEMICAL", 24, 30], ["azithromycin", "SIMPLE_CHEMICAL", 33, 45], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 48, 66], ["dobutamine", "SIMPLE_CHEMICAL", 68, 78], ["fentanyl", "SIMPLE_CHEMICAL", 80, 88], ["midazolam", "SIMPLE_CHEMICAL", 89, 98], ["insulin", "GENE_OR_GENE_PRODUCT", 100, 107], ["norepinephrine", "SIMPLE_CHEMICAL", 129, 143], ["cardiac", "ORGAN", 227, 234], ["Therapy", "TREATMENT", 0, 7], ["enoxaparin sodium", "TREATMENT", 13, 30], ["azithromycin", "TREATMENT", 33, 45], ["hydroxychloroquine", "TREATMENT", 48, 66], ["dobutamine", "TREATMENT", 68, 78], ["fentanyl", "TREATMENT", 80, 88], ["midazolam", "TREATMENT", 89, 98], ["insulin (infusion pump", "TREATMENT", 100, 122], ["norepinephrine", "TREATMENT", 129, 143], ["a low cardiac index", "PROBLEM", 221, 240], ["dobutamine", "TREATMENT", 247, 257], ["cisatracurium besilate", "TREATMENT", 309, 331], ["FiO2", "TREATMENT", 333, 337]]], ["The patient showed a persistent high fever; dependent on high-dose vasopressors; oliguria: 300 mL with fluid balance + 2200 mL; high-dose insulin infusion.", [["fluid", "ANATOMY", 103, 108], ["fever", "DISEASE", 37, 42], ["oliguria", "DISEASE", 81, 89], ["patient", "ORGANISM", 4, 11], ["insulin", "GENE_OR_GENE_PRODUCT", 138, 145], ["patient", "SPECIES", 4, 11], ["a persistent high fever", "PROBLEM", 19, 42], ["high-dose vasopressors", "TREATMENT", 57, 79], ["oliguria", "PROBLEM", 81, 89], ["fluid balance", "TEST", 103, 116], ["high-dose insulin infusion", "TREATMENT", 128, 154], ["persistent", "OBSERVATION_MODIFIER", 21, 31], ["high", "OBSERVATION_MODIFIER", 32, 36], ["fever", "OBSERVATION", 37, 42], ["oliguria", "OBSERVATION", 81, 89]]], ["EV1000 showed cardiac index 2.0, systemic vascular resistance index (SVRI) 2800, stroke volume variation (SVV) 14, central venous pressure (CVP) 8.", [["cardiac", "ANATOMY", 14, 21], ["vascular", "ANATOMY", 42, 50], ["central venous", "ANATOMY", 115, 129], ["EV1000", "CHEMICAL", 0, 6], ["stroke", "DISEASE", 81, 87], ["EV1000", "SIMPLE_CHEMICAL", 0, 6], ["cardiac", "ORGAN", 14, 21], ["vascular", "MULTI-TISSUE_STRUCTURE", 42, 50], ["venous", "MULTI-TISSUE_STRUCTURE", 123, 129], ["cardiac index", "TEST", 14, 27], ["systemic vascular resistance index", "TEST", 33, 67], ["SVRI", "TEST", 69, 73], ["stroke volume variation", "TEST", 81, 104], ["SVV", "TEST", 106, 109], ["central venous pressure", "TEST", 115, 138], ["CVP", "TEST", 140, 143], ["cardiac", "ANATOMY", 14, 21], ["index", "OBSERVATION", 22, 27], ["vascular", "ANATOMY", 42, 50], ["resistance index", "OBSERVATION", 51, 67], ["central", "ANATOMY_MODIFIER", 115, 122], ["venous", "ANATOMY", 123, 129], ["pressure", "OBSERVATION_MODIFIER", 130, 138]]], ["Worsening kidney function was observed, along with low P++ level and worsening inflammatory markers.", [["kidney", "ANATOMY", 10, 16], ["kidney", "ORGAN", 10, 16], ["inflammatory markers", "PROTEIN", 79, 99], ["Worsening kidney function", "PROBLEM", 0, 25], ["low P++ level", "PROBLEM", 51, 64], ["worsening inflammatory markers", "PROBLEM", 69, 99], ["kidney", "ANATOMY", 10, 16], ["function", "OBSERVATION", 17, 25], ["worsening", "OBSERVATION_MODIFIER", 69, 78], ["inflammatory markers", "OBSERVATION", 79, 99]]], ["Based on a microbiological search, piperacillin/tazobactam and teicoplanin were initiated.", [["piperacillin/tazobactam", "CHEMICAL", 35, 58], ["teicoplanin", "CHEMICAL", 63, 74], ["piperacillin", "CHEMICAL", 35, 47], ["tazobactam", "CHEMICAL", 48, 58], ["teicoplanin", "CHEMICAL", 63, 74], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 35, 58], ["teicoplanin", "SIMPLE_CHEMICAL", 63, 74], ["a microbiological search", "TEST", 9, 33], ["piperacillin", "TREATMENT", 35, 47], ["tazobactam", "TREATMENT", 48, 58], ["teicoplanin", "TREATMENT", 63, 74]]], ["ABG was ordered due to the progressive worsening of metabolic acidosis, worsening PaO2/FiO2 ratio, positive fluid balance, and oligoanuria.", [["fluid", "ANATOMY", 108, 113], ["metabolic acidosis", "DISEASE", 52, 70], ["oligoanuria", "DISEASE", 127, 138], ["ABG", "CHEMICAL", 0, 3], ["FiO2", "CHEMICAL", 87, 91], ["PaO2", "SIMPLE_CHEMICAL", 82, 86], ["FiO2", "SIMPLE_CHEMICAL", 87, 91], ["fluid", "ORGANISM_SUBSTANCE", 108, 113], ["ABG", "TEST", 0, 3], ["metabolic acidosis", "PROBLEM", 52, 70], ["worsening PaO2", "PROBLEM", 72, 86], ["FiO2 ratio", "TEST", 87, 97], ["positive fluid balance", "PROBLEM", 99, 121], ["oligoanuria", "PROBLEM", 127, 138], ["progressive", "OBSERVATION_MODIFIER", 27, 38], ["worsening", "OBSERVATION_MODIFIER", 39, 48], ["metabolic acidosis", "OBSERVATION", 52, 70], ["worsening", "OBSERVATION_MODIFIER", 72, 81], ["PaO2", "OBSERVATION_MODIFIER", 82, 86], ["positive", "OBSERVATION_MODIFIER", 99, 107], ["fluid balance", "OBSERVATION", 108, 121]]], ["Hemodialysis was considered and furosemide infusion was increased.", [["furosemide", "CHEMICAL", 32, 42], ["furosemide", "CHEMICAL", 32, 42], ["furosemide", "SIMPLE_CHEMICAL", 32, 42], ["Hemodialysis", "TREATMENT", 0, 12], ["furosemide infusion", "TREATMENT", 32, 51]]], ["The diagnosis of COVID-19 was confirmed.Case presentationOn 4/4/2020, the placement of a hemodialysis catheter was indicated (urine output: 400 ml and fluid balance + 330 mL).", [["urine", "ANATOMY", 126, 131], ["fluid", "ANATOMY", 151, 156], ["COVID-19", "CHEMICAL", 17, 25], ["urine", "ORGANISM_SUBSTANCE", 126, 131], ["COVID-19", "DNA", 17, 25], ["COVID", "TEST", 17, 22], ["a hemodialysis catheter", "TREATMENT", 87, 110], ["urine output", "TEST", 126, 138], ["fluid balance", "TEST", 151, 164], ["catheter", "OBSERVATION", 102, 110]]], ["Hemodialysis was started with an UF rate of 100 mL/h.", [["Hemodialysis", "TREATMENT", 0, 12], ["an UF rate", "TREATMENT", 30, 40]]], ["Azithromycin was indicated again for severe COVID-19.", [["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["Azithromycin", "TREATMENT", 0, 12], ["severe COVID", "PROBLEM", 37, 49]]], ["Hydrocortisone was stopped due to a lack of blood sugar control without reducing the dose of norepinephrine once it was initiated.Case presentationOn 4/5/2020, the patient was hemodynamically unstable, with norepinephrine and amiodarone infusion; highest fever value 100.2\u00b0F (37.9\u00b0C); glucose level 137 to 249, requiring regular insulin 8 IU SC; receiving hydroxychloroquine + azithromycin + piperacillin/tazobactam + teicoplanin; urine output 0 mL, hemodialysis 1,000 mL, fluid balance +699 mL.", [["blood", "ANATOMY", 44, 49], ["urine", "ANATOMY", 431, 436], ["fluid", "ANATOMY", 473, 478], ["Hydrocortisone", "CHEMICAL", 0, 14], ["norepinephrine", "CHEMICAL", 93, 107], ["norepinephrine", "CHEMICAL", 207, 221], ["amiodarone", "CHEMICAL", 226, 236], ["fever", "DISEASE", 255, 260], ["glucose", "CHEMICAL", 285, 292], ["hydroxychloroquine", "CHEMICAL", 356, 374], ["azithromycin", "CHEMICAL", 377, 389], ["piperacillin/tazobactam", "CHEMICAL", 392, 415], ["teicoplanin", "CHEMICAL", 418, 429], ["Hydrocortisone", "CHEMICAL", 0, 14], ["sugar", "CHEMICAL", 50, 55], ["norepinephrine", "CHEMICAL", 93, 107], ["norepinephrine", "CHEMICAL", 207, 221], ["amiodarone", "CHEMICAL", 226, 236], ["glucose", "CHEMICAL", 285, 292], ["hydroxychloroquine", "CHEMICAL", 356, 374], ["azithromycin", "CHEMICAL", 377, 389], ["piperacillin", "CHEMICAL", 392, 404], ["tazobactam", "CHEMICAL", 405, 415], ["teicoplanin", "CHEMICAL", 418, 429], ["Hydrocortisone", "SIMPLE_CHEMICAL", 0, 14], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["sugar", "SIMPLE_CHEMICAL", 50, 55], ["norepinephrine", "SIMPLE_CHEMICAL", 93, 107], ["patient", "ORGANISM", 164, 171], ["norepinephrine", "SIMPLE_CHEMICAL", 207, 221], ["amiodarone", "SIMPLE_CHEMICAL", 226, 236], ["glucose", "SIMPLE_CHEMICAL", 285, 292], ["insulin", "GENE_OR_GENE_PRODUCT", 329, 336], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 356, 374], ["azithromycin", "SIMPLE_CHEMICAL", 377, 389], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 392, 415], ["teicoplanin", "SIMPLE_CHEMICAL", 418, 429], ["urine", "ORGANISM_SUBSTANCE", 431, 436], ["patient", "SPECIES", 164, 171], ["Hydrocortisone", "TREATMENT", 0, 14], ["blood sugar control", "TREATMENT", 44, 63], ["norepinephrine", "TREATMENT", 93, 107], ["hemodynamically unstable", "PROBLEM", 176, 200], ["norepinephrine", "TREATMENT", 207, 221], ["amiodarone infusion", "TREATMENT", 226, 245], ["highest fever value", "TEST", 247, 266], ["glucose level", "TEST", 285, 298], ["regular insulin", "TREATMENT", 321, 336], ["hydroxychloroquine", "TREATMENT", 356, 374], ["azithromycin", "TREATMENT", 377, 389], ["piperacillin", "TREATMENT", 392, 404], ["tazobactam", "TREATMENT", 405, 415], ["teicoplanin", "TREATMENT", 418, 429], ["urine output", "TEST", 431, 443], ["hemodialysis", "TREATMENT", 450, 462], ["fluid balance", "TEST", 473, 486]]], ["EV1000: SVV: 9, CO: 3.9.", [["CO", "CHEMICAL", 16, 18], ["SVV", "TEST", 8, 11], ["CO", "TEST", 16, 18]]], ["On hemodialysis, the patient continued with 100 mL volume reduction.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["hemodialysis", "TREATMENT", 3, 15], ["100 mL volume reduction", "TREATMENT", 44, 67]]], ["The patient presented supraventricular tachycardia with an HR of 190 bpm; vagal stimulation was unsuccessful, and a 300 mg amiodarone loading infusion was administered in 20 min. and a maintenance infusion was continued at 20 mL/h.Case presentationOn 4/6/2020, the patient was anuric and without bowel movements.", [["supraventricular", "ANATOMY", 22, 38], ["bowel", "ANATOMY", 296, 301], ["supraventricular tachycardia", "DISEASE", 22, 50], ["amiodarone", "CHEMICAL", 123, 133], ["bowel movements", "DISEASE", 296, 311], ["amiodarone", "CHEMICAL", 123, 133], ["patient", "ORGANISM", 4, 11], ["amiodarone", "SIMPLE_CHEMICAL", 123, 133], ["patient", "ORGANISM", 265, 272], ["bowel", "ORGAN", 296, 301], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 265, 272], ["supraventricular tachycardia", "PROBLEM", 22, 50], ["an HR", "TEST", 56, 61], ["vagal stimulation", "TREATMENT", 74, 91], ["a 300 mg amiodarone loading infusion", "TREATMENT", 114, 150], ["a maintenance infusion", "TREATMENT", 183, 205], ["anuric", "PROBLEM", 277, 283], ["supraventricular tachycardia", "OBSERVATION", 22, 50], ["anuric", "OBSERVATION", 277, 283], ["without", "UNCERTAINTY", 288, 295], ["bowel", "ANATOMY", 296, 301]]], ["Fluid balance +1480 mL/24 h.", [["Fluid", "ORGANISM_SUBSTANCE", 0, 5], ["Fluid balance", "TEST", 0, 13]]], ["Vascular Surgery removed the hemodialysis catheter from the left common femoral vein due to catheter blockade; an 11F x 20 cm double lumen catheter was inserted, with good flow and backflow in both lumen; no complications occurred, and the catheter was heparinized and ready for use.Case presentationOn 4/7/2020, a PTT test was ordered to plan heparin infusion.", [["Vascular", "ANATOMY", 0, 8], ["left common femoral vein", "ANATOMY", 60, 84], ["catheter", "ANATOMY", 92, 100], ["lumen", "ANATOMY", 133, 138], ["lumen", "ANATOMY", 198, 203], ["heparin", "CHEMICAL", 344, 351], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["femoral vein", "MULTI-TISSUE_STRUCTURE", 72, 84], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 203], ["heparin", "SIMPLE_CHEMICAL", 344, 351], ["Vascular Surgery", "TREATMENT", 0, 16], ["the hemodialysis catheter", "TREATMENT", 25, 50], ["catheter blockade", "TREATMENT", 92, 109], ["an 11F x 20 cm double lumen catheter", "TREATMENT", 111, 147], ["complications", "PROBLEM", 208, 221], ["the catheter", "TREATMENT", 236, 248], ["a PTT test", "TEST", 313, 323], ["heparin infusion", "TREATMENT", 344, 360], ["hemodialysis catheter", "OBSERVATION", 29, 50], ["left", "ANATOMY_MODIFIER", 60, 64], ["common femoral vein", "ANATOMY", 65, 84], ["catheter blockade", "OBSERVATION", 92, 109], ["lumen", "OBSERVATION_MODIFIER", 133, 138], ["catheter", "OBSERVATION", 139, 147], ["good flow", "OBSERVATION", 167, 176], ["backflow", "OBSERVATION_MODIFIER", 181, 189], ["both lumen", "OBSERVATION", 193, 203], ["no", "UNCERTAINTY", 205, 207], ["complications", "OBSERVATION", 208, 221], ["catheter", "OBSERVATION", 240, 248]]], ["The following actions were taken: Micafungin was started, with calcium gluconate replacement.", [["Micafungin", "CHEMICAL", 34, 44], ["calcium gluconate", "CHEMICAL", 63, 80], ["Micafungin", "CHEMICAL", 34, 44], ["calcium gluconate", "CHEMICAL", 63, 80], ["Micafungin", "SIMPLE_CHEMICAL", 34, 44], ["calcium gluconate", "SIMPLE_CHEMICAL", 63, 80], ["Micafungin", "TREATMENT", 34, 44], ["calcium gluconate replacement", "TREATMENT", 63, 92]]], ["Heparin IV was also initiated.", [["Heparin IV", "CHEMICAL", 0, 10], ["Heparin IV", "SIMPLE_CHEMICAL", 0, 10], ["Heparin IV", "TREATMENT", 0, 10]]], ["Tocilizumab was dosed.Case presentationOn 4/8/2020, the patient was exhibiting an uncontrolled inflammatory response, dependent on high-dose norepinephrine.", [["Tocilizumab", "CHEMICAL", 0, 11], ["norepinephrine", "CHEMICAL", 141, 155], ["Tocilizumab", "CHEMICAL", 0, 11], ["norepinephrine", "CHEMICAL", 141, 155], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["patient", "ORGANISM", 56, 63], ["norepinephrine", "SIMPLE_CHEMICAL", 141, 155], ["patient", "SPECIES", 56, 63], ["Tocilizumab", "TREATMENT", 0, 11], ["an uncontrolled inflammatory response", "PROBLEM", 79, 116], ["high-dose norepinephrine", "TREATMENT", 131, 155], ["uncontrolled", "OBSERVATION_MODIFIER", 82, 94], ["inflammatory response", "OBSERVATION", 95, 116]]], ["Hemodialysis was continued with UF at 200 mL/h, coagulating the tubing and with a hemoglobin fall to 7.1.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 82, 92], ["hemoglobin", "PROTEIN", 82, 92], ["Hemodialysis", "TREATMENT", 0, 12], ["UF", "TREATMENT", 32, 34], ["coagulating the tubing", "TREATMENT", 48, 70], ["a hemoglobin fall", "TEST", 80, 97], ["tubing", "OBSERVATION", 64, 70]]], ["Heparin IV was initiated on 4/7/2020.", [["Heparin IV", "CHEMICAL", 0, 10], ["Heparin IV", "SIMPLE_CHEMICAL", 0, 10], ["Heparin IV", "TREATMENT", 0, 10]]], ["The patient received 2 packed red blood cells units and was switched from piperacillin/tazobactam to meropenem, as scheduled.", [["red blood cells", "ANATOMY", 30, 45], ["piperacillin/tazobactam", "CHEMICAL", 74, 97], ["meropenem", "CHEMICAL", 101, 110], ["piperacillin", "CHEMICAL", 74, 86], ["tazobactam", "CHEMICAL", 87, 97], ["meropenem", "CHEMICAL", 101, 110], ["patient", "ORGANISM", 4, 11], ["red blood cells", "CELL", 30, 45], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 74, 97], ["meropenem", "SIMPLE_CHEMICAL", 101, 110], ["packed red blood cells", "CELL_TYPE", 23, 45], ["patient", "SPECIES", 4, 11], ["2 packed red blood cells units", "TREATMENT", 21, 51], ["piperacillin", "TREATMENT", 74, 86], ["tazobactam", "TREATMENT", 87, 97], ["meropenem", "TREATMENT", 101, 110]]], ["A bedside abdominal ultrasound was carried out; a bone marrow biopsy was also performed, exhibiting macrophage activity secondary to the syndrome.", [["abdominal", "ANATOMY", 10, 19], ["bone marrow", "ANATOMY", 50, 61], ["macrophage", "ANATOMY", 100, 110], ["abdominal", "ORGAN", 10, 19], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 50, 61], ["macrophage", "CELL", 100, 110], ["A bedside abdominal ultrasound", "TEST", 0, 30], ["a bone marrow biopsy", "TEST", 48, 68], ["macrophage activity", "PROBLEM", 100, 119], ["the syndrome", "PROBLEM", 133, 145], ["abdominal", "ANATOMY", 10, 19], ["bone", "ANATOMY", 50, 54], ["macrophage activity", "OBSERVATION", 100, 119], ["syndrome", "OBSERVATION", 137, 145]]], ["Midazolam was held, and tocilizumab was initiated at a dose of 400 mg IV.Case presentationOn 4/9/2020, midazolam was combined with fentanyl to optimize sedation.", [["Midazolam", "CHEMICAL", 0, 9], ["tocilizumab", "CHEMICAL", 24, 35], ["midazolam", "CHEMICAL", 103, 112], ["fentanyl", "CHEMICAL", 131, 139], ["Midazolam", "CHEMICAL", 0, 9], ["midazolam", "CHEMICAL", 103, 112], ["fentanyl", "CHEMICAL", 131, 139], ["Midazolam", "SIMPLE_CHEMICAL", 0, 9], ["tocilizumab", "SIMPLE_CHEMICAL", 24, 35], ["midazolam", "SIMPLE_CHEMICAL", 103, 112], ["fentanyl", "SIMPLE_CHEMICAL", 131, 139], ["Midazolam", "TREATMENT", 0, 9], ["tocilizumab", "TREATMENT", 24, 35], ["midazolam", "TREATMENT", 103, 112], ["fentanyl", "TREATMENT", 131, 139], ["sedation", "TREATMENT", 152, 160]]], ["Sodium glycerophosphate was replaced and immunoglobulin was started.", [["Sodium glycerophosphate", "CHEMICAL", 0, 23], ["Sodium glycerophosphate", "CHEMICAL", 0, 23], ["Sodium glycerophosphate", "SIMPLE_CHEMICAL", 0, 23], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 41, 55], ["immunoglobulin", "PROTEIN", 41, 55], ["Sodium glycerophosphate", "TREATMENT", 0, 23], ["immunoglobulin", "TREATMENT", 41, 55]]], ["Vascular Surgery prepared the vascular access for hemodialysis.", [["Vascular", "ANATOMY", 0, 8], ["vascular", "ANATOMY", 30, 38], ["Vascular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 30, 38], ["Vascular Surgery", "TREATMENT", 0, 16], ["hemodialysis", "TREATMENT", 50, 62], ["Surgery", "OBSERVATION", 9, 16], ["vascular", "ANATOMY", 30, 38]]], ["The patient presented ventricular tachycardia with an HR of 190 bpm; vagal stimulation was unsuccessful, and a 300 mg amiodarone loading infusion was administered in 20 min. and a maintenance infusion was continued at 20 mL/h.", [["ventricular", "ANATOMY", 22, 33], ["ventricular tachycardia", "DISEASE", 22, 45], ["amiodarone", "CHEMICAL", 118, 128], ["amiodarone", "CHEMICAL", 118, 128], ["patient", "ORGANISM", 4, 11], ["ventricular", "ORGAN", 22, 33], ["amiodarone", "SIMPLE_CHEMICAL", 118, 128], ["patient", "SPECIES", 4, 11], ["ventricular tachycardia", "PROBLEM", 22, 45], ["an HR", "TEST", 51, 56], ["vagal stimulation", "TREATMENT", 69, 86], ["a 300 mg amiodarone loading infusion", "TREATMENT", 109, 145], ["a maintenance infusion", "TREATMENT", 178, 200], ["ventricular", "ANATOMY", 22, 33], ["tachycardia", "OBSERVATION", 34, 45]]], ["Immunoglobulin was started and planned to end on 4/13.Case presentationOn 4/10/2020, the patient did not have a fever throughout the day and was hemodynamically dependent on norepinephrine.", [["fever", "DISEASE", 112, 117], ["norepinephrine", "CHEMICAL", 174, 188], ["norepinephrine", "CHEMICAL", 174, 188], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["patient", "ORGANISM", 89, 96], ["norepinephrine", "SIMPLE_CHEMICAL", 174, 188], ["Immunoglobulin", "PROTEIN", 0, 14], ["patient", "SPECIES", 89, 96], ["Immunoglobulin", "TREATMENT", 0, 14], ["a fever", "PROBLEM", 110, 117], ["hemodynamically dependent", "PROBLEM", 145, 170], ["norepinephrine", "TREATMENT", 174, 188], ["fever", "OBSERVATION", 112, 117], ["dependent", "OBSERVATION", 161, 170]]], ["Hemodialysis of 200 mL/h, urine output 0 mL.Case presentationOn 4/11/2020, midazolam, fentanyl, amiodarone, regular metamizole, and hemodialysis were stopped.", [["urine", "ANATOMY", 26, 31], ["midazolam", "CHEMICAL", 75, 84], ["fentanyl", "CHEMICAL", 86, 94], ["amiodarone", "CHEMICAL", 96, 106], ["metamizole", "CHEMICAL", 116, 126], ["midazolam", "CHEMICAL", 75, 84], ["fentanyl", "CHEMICAL", 86, 94], ["amiodarone", "CHEMICAL", 96, 106], ["metamizole", "CHEMICAL", 116, 126], ["urine", "ORGANISM_SUBSTANCE", 26, 31], ["midazolam", "SIMPLE_CHEMICAL", 75, 84], ["fentanyl", "SIMPLE_CHEMICAL", 86, 94], ["amiodarone", "SIMPLE_CHEMICAL", 96, 106], ["metamizole", "SIMPLE_CHEMICAL", 116, 126], ["Hemodialysis", "TREATMENT", 0, 12], ["urine output", "TEST", 26, 38], ["midazolam", "TREATMENT", 75, 84], ["fentanyl", "TREATMENT", 86, 94], ["amiodarone", "TREATMENT", 96, 106], ["regular metamizole", "TREATMENT", 108, 126], ["hemodialysis", "TREATMENT", 132, 144]]], ["A blanket was used to increase the temperature to 105\u00b0F (40\u00b0C).", [["A blanket", "TREATMENT", 0, 9], ["the temperature", "TEST", 31, 46], ["blanket", "OBSERVATION", 2, 9]]], ["Dobutamine was added and norepinephrine was increased to 12 mL/h.", [["Dobutamine", "CHEMICAL", 0, 10], ["norepinephrine", "CHEMICAL", 25, 39], ["Dobutamine", "CHEMICAL", 0, 10], ["norepinephrine", "CHEMICAL", 25, 39], ["Dobutamine", "SIMPLE_CHEMICAL", 0, 10], ["norepinephrine", "SIMPLE_CHEMICAL", 25, 39], ["Dobutamine", "TREATMENT", 0, 10], ["norepinephrine", "TREATMENT", 25, 39]]], ["Insulin and IV heparin were administered per the local protocol.", [["Insulin", "CHEMICAL", 0, 7], ["heparin", "CHEMICAL", 15, 22], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["IV heparin", "SIMPLE_CHEMICAL", 12, 22], ["Insulin", "TREATMENT", 0, 7], ["IV heparin", "TREATMENT", 12, 22]]], ["The patient presented cardiopulmonary (CP) arrest with asystole following the return from hemodialysis without UF; cardiopulmonary resuscitation maneuvers were carried out for 6 minutes.", [["cardiopulmonary", "ANATOMY", 115, 130], ["cardiopulmonary (CP) arrest", "DISEASE", 22, 49], ["asystole", "DISEASE", 55, 63], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["cardiopulmonary (CP) arrest", "PROBLEM", 22, 49], ["asystole", "PROBLEM", 55, 63], ["hemodialysis", "TREATMENT", 90, 102], ["UF", "TREATMENT", 111, 113], ["cardiopulmonary resuscitation maneuvers", "TREATMENT", 115, 154], ["cardiopulmonary", "ANATOMY", 22, 37]]], ["Two vials of atropine 1 mg and 2 vials of epinephrine 1 mg were used; IV heparin was withheld; PTT was non-coagulable.", [["atropine", "CHEMICAL", 13, 21], ["epinephrine", "CHEMICAL", 42, 53], ["heparin", "CHEMICAL", 73, 80], ["atropine", "CHEMICAL", 13, 21], ["epinephrine", "CHEMICAL", 42, 53], ["atropine", "SIMPLE_CHEMICAL", 13, 21], ["epinephrine", "SIMPLE_CHEMICAL", 42, 53], ["IV heparin", "SIMPLE_CHEMICAL", 70, 80], ["atropine", "TREATMENT", 13, 21], ["epinephrine", "TREATMENT", 42, 53], ["IV heparin", "TREATMENT", 70, 80], ["PTT", "TEST", 95, 98]]], ["A Vscan examination showed no evidence of cardiac tamponade, pleural effusion, or pneumothorax.", [["cardiac", "ANATOMY", 42, 49], ["pleural", "ANATOMY", 61, 68], ["cardiac tamponade", "DISEASE", 42, 59], ["pleural effusion", "DISEASE", 61, 77], ["pneumothorax", "DISEASE", 82, 94], ["cardiac", "ORGAN", 42, 49], ["pleural", "ORGAN", 61, 68], ["A Vscan examination", "TEST", 0, 19], ["cardiac tamponade", "PROBLEM", 42, 59], ["pleural effusion", "PROBLEM", 61, 77], ["pneumothorax", "PROBLEM", 82, 94], ["no evidence of", "UNCERTAINTY", 27, 41], ["cardiac", "ANATOMY", 42, 49], ["tamponade", "OBSERVATION", 50, 59], ["pleural", "ANATOMY", 61, 68], ["effusion", "OBSERVATION", 69, 77], ["pneumothorax", "OBSERVATION", 82, 94]]], ["CP arrest with resuscitation maneuvers, a percutaneous pacemaker was inserted, 8 vials of atropine and 3 vials of adrenaline, saline 0.9% 1500 mL, norepinephrine at 100 mL/h at the moment of the CP arrest, and 15 mL/h after CP arrest, without sedation, FiO2 100% in CV mode.", [["percutaneous", "ANATOMY", 42, 54], ["CP arrest", "DISEASE", 0, 9], ["atropine", "CHEMICAL", 90, 98], ["adrenaline", "CHEMICAL", 114, 124], ["norepinephrine", "CHEMICAL", 147, 161], ["CP arrest", "DISEASE", 195, 204], ["CP arrest", "DISEASE", 224, 233], ["atropine", "CHEMICAL", 90, 98], ["adrenaline", "CHEMICAL", 114, 124], ["norepinephrine", "CHEMICAL", 147, 161], ["atropine", "SIMPLE_CHEMICAL", 90, 98], ["adrenaline", "SIMPLE_CHEMICAL", 114, 124], ["saline", "SIMPLE_CHEMICAL", 126, 132], ["norepinephrine", "SIMPLE_CHEMICAL", 147, 161], ["CP arrest", "PROBLEM", 0, 9], ["resuscitation maneuvers", "TREATMENT", 15, 38], ["a percutaneous pacemaker", "TREATMENT", 40, 64], ["atropine", "TREATMENT", 90, 98], ["adrenaline", "TREATMENT", 114, 124], ["saline", "TREATMENT", 126, 132], ["norepinephrine", "TREATMENT", 147, 161], ["the CP arrest", "TREATMENT", 191, 204], ["CP arrest", "PROBLEM", 224, 233], ["sedation", "TREATMENT", 243, 251], ["FiO2", "TREATMENT", 253, 257], ["arrest", "OBSERVATION", 3, 9], ["percutaneous pacemaker", "OBSERVATION", 42, 64], ["without", "UNCERTAINTY", 235, 242]]], ["At 11:30 pm, another CP arrest for 3 minutes; 8 vials of atropine were administered along with 2 vials of epinephrine, sodium gluconate 30 mL, and sodium bicarbonate 20 mL, increasing norepinephrine up to 40 mL/h.Case presentationOn 4/12/2020, the patient had the transcutaneous pacemaker implanted during CP resuscitation; there are difficulties with capture, even with maximum output.", [["CP arrest", "DISEASE", 21, 30], ["atropine", "CHEMICAL", 57, 65], ["epinephrine", "CHEMICAL", 106, 117], ["sodium gluconate", "CHEMICAL", 119, 135], ["sodium bicarbonate", "CHEMICAL", 147, 165], ["norepinephrine", "CHEMICAL", 184, 198], ["atropine", "CHEMICAL", 57, 65], ["epinephrine", "CHEMICAL", 106, 117], ["sodium gluconate", "CHEMICAL", 119, 135], ["sodium bicarbonate", "CHEMICAL", 147, 165], ["norepinephrine", "CHEMICAL", 184, 198], ["atropine", "SIMPLE_CHEMICAL", 57, 65], ["epinephrine", "SIMPLE_CHEMICAL", 106, 117], ["sodium gluconate", "SIMPLE_CHEMICAL", 119, 135], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 147, 165], ["norepinephrine", "SIMPLE_CHEMICAL", 184, 198], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 248, 255], ["another CP arrest", "PROBLEM", 13, 30], ["atropine", "TREATMENT", 57, 65], ["epinephrine", "TREATMENT", 106, 117], ["sodium gluconate", "TREATMENT", 119, 135], ["sodium bicarbonate", "TREATMENT", 147, 165], ["increasing norepinephrine", "TREATMENT", 173, 198], ["the transcutaneous pacemaker", "TREATMENT", 260, 288], ["CP resuscitation", "TREATMENT", 306, 322], ["maximum output", "TEST", 371, 385], ["pacemaker", "OBSERVATION", 279, 288]]], ["Respiratory minute volume was reduced in the ventilator; noradrenaline 40 mL/h \u2013 2 mcg/kg/min, achieving MAP 62, HR 80, CI 2.5, SVRI 1900, CVP 8 (EV1000), sodium bicarbonate 250 ml IV at a high rate; warm saline 1500 mL at a high rate.", [["Respiratory", "ANATOMY", 0, 11], ["noradrenaline", "CHEMICAL", 57, 70], ["sodium bicarbonate", "CHEMICAL", 155, 173], ["noradrenaline", "CHEMICAL", 57, 70], ["sodium bicarbonate", "CHEMICAL", 155, 173], ["noradrenaline", "SIMPLE_CHEMICAL", 57, 70], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 155, 173], ["Respiratory minute volume", "TEST", 0, 25], ["the ventilator", "TREATMENT", 41, 55], ["noradrenaline", "TREATMENT", 57, 70], ["MAP", "TEST", 105, 108], ["HR", "TEST", 113, 115], ["CI", "TEST", 120, 122], ["SVRI", "TEST", 128, 132], ["CVP", "TEST", 139, 142], ["sodium bicarbonate", "TREATMENT", 155, 173], ["warm saline", "TREATMENT", 200, 211], ["minute volume", "OBSERVATION", 12, 25]]], ["The patient died at 7:00 am.DiscussionHemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation.", [["Hemophagocytic lymphohistiocytosis", "DISEASE", 38, 72], ["HLH", "DISEASE", 74, 77], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Hemophagocytic lymphohistiocytosis", "PROBLEM", 38, 72], ["HLH", "PROBLEM", 74, 77], ["excessive immune activation", "PROBLEM", 129, 156], ["Hemophagocytic lymphohistiocytosis", "OBSERVATION", 38, 72], ["aggressive", "OBSERVATION_MODIFIER", 85, 95], ["excessive immune activation", "OBSERVATION", 129, 156]]], ["It most frequently affects infants from birth to 18 months of age, but the disease is also observed in children and adults of all ages.DiscussionThe pathophysiology of HLH is related to the failure to control the immune response that results in a hyperinflammatory state and consequently to tissue destruction [1].", [["tissue", "ANATOMY", 291, 297], ["HLH", "DISEASE", 168, 171], ["infants", "ORGANISM", 27, 34], ["children", "ORGANISM", 103, 111], ["tissue", "TISSUE", 291, 297], ["infants", "SPECIES", 27, 34], ["children", "SPECIES", 103, 111], ["HLH", "PROBLEM", 168, 171], ["the failure", "PROBLEM", 186, 197], ["a hyperinflammatory state", "PROBLEM", 245, 270], ["tissue destruction", "PROBLEM", 291, 309], ["disease", "OBSERVATION", 75, 82], ["HLH", "OBSERVATION", 168, 171]]], ["The dysregulation of the immune system is characterized by a persistent activation of Cytotoxic T lymphocytes (CTLs), Natural Killers cells (NK), and Macrophages.DiscussionAfter encountering a virally infected cell or tumor cell, CD8+ CTLs and NK promote cytolytic destruction by releasing proteins involved in triggering the apoptosis of the target cells.", [["immune system", "ANATOMY", 25, 38], ["Cytotoxic T lymphocytes", "ANATOMY", 86, 109], ["CTLs", "ANATOMY", 111, 115], ["Natural Killers cells", "ANATOMY", 118, 139], ["NK", "ANATOMY", 141, 143], ["Macrophages", "ANATOMY", 150, 161], ["cell", "ANATOMY", 210, 214], ["tumor cell", "ANATOMY", 218, 228], ["CD8+ CTLs", "ANATOMY", 230, 239], ["NK", "ANATOMY", 244, 246], ["cells", "ANATOMY", 350, 355], ["tumor", "DISEASE", 218, 223], ["Cytotoxic T lymphocytes", "CELL", 86, 109], ["CTLs", "CELL", 111, 115], ["Natural Killers cells", "CELL", 118, 139], ["NK", "CELL", 141, 143], ["Macrophages", "CELL", 150, 161], ["cell", "CELL", 210, 214], ["tumor cell", "CELL", 218, 228], ["CD8", "GENE_OR_GENE_PRODUCT", 230, 233], ["NK", "CELL", 244, 246], ["cells", "CELL", 350, 355], ["Cytotoxic T lymphocytes", "CELL_TYPE", 86, 109], ["CTLs", "CELL_TYPE", 111, 115], ["Natural Killers cells", "CELL_TYPE", 118, 139], ["NK", "CELL_TYPE", 141, 143], ["Macrophages", "CELL_TYPE", 150, 161], ["tumor cell", "CELL_TYPE", 218, 228], ["CD8", "PROTEIN", 230, 233], ["CTLs", "CELL_TYPE", 235, 239], ["NK", "CELL_TYPE", 244, 246], ["target cells", "CELL_TYPE", 343, 355], ["The dysregulation of the immune system", "PROBLEM", 0, 38], ["Cytotoxic T lymphocytes", "PROBLEM", 86, 109], ["a virally infected cell", "PROBLEM", 191, 214], ["tumor cell", "PROBLEM", 218, 228], ["CD8", "TEST", 230, 233], ["CTLs", "PROBLEM", 235, 239], ["NK", "PROBLEM", 244, 246], ["cytolytic destruction", "PROBLEM", 255, 276], ["releasing proteins", "PROBLEM", 280, 298], ["dysregulation", "OBSERVATION", 4, 17], ["immune system", "OBSERVATION", 25, 38], ["persistent", "OBSERVATION_MODIFIER", 61, 71], ["Cytotoxic T lymphocytes", "OBSERVATION", 86, 109], ["Killers cells", "OBSERVATION", 126, 139], ["Macrophages", "ANATOMY", 150, 161], ["tumor cell", "OBSERVATION", 218, 228], ["cytolytic destruction", "OBSERVATION", 255, 276], ["target cells", "OBSERVATION", 343, 355]]], ["The consequence is the elimination of the immune-activating stimulus - the virally infected or tumor cell, for example.", [["tumor cell", "ANATOMY", 95, 105], ["tumor", "DISEASE", 95, 100], ["tumor cell", "CELL", 95, 105], ["tumor cell", "CELL_TYPE", 95, 105], ["activating stimulus", "PROBLEM", 49, 68], ["the virally infected or tumor cell", "PROBLEM", 71, 105], ["virally", "OBSERVATION_MODIFIER", 75, 82], ["infected", "OBSERVATION_MODIFIER", 83, 91], ["tumor cell", "OBSERVATION", 95, 105]]], ["This physiologic downregulation is critical for the control of the immune response [2].DiscussionHLH is characterized by the inability to clear the antigenic stimulus, resulting in the persistence and amplification of the immune response.", [["This physiologic downregulation", "TREATMENT", 0, 31], ["the immune response", "PROBLEM", 218, 237], ["downregulation", "OBSERVATION", 17, 31]]], ["Proinflammatory cytokines released by the activated immune cells results in a high level of macrophage activation, which result in hemophagocytosis, tissue damage, organ failure, and the other inflammatory manifestations of the syndrome [2].DiscussionHLH can occur as a familial or sporadic disorder.", [["immune cells", "ANATOMY", 52, 64], ["macrophage", "ANATOMY", 92, 102], ["tissue", "ANATOMY", 149, 155], ["organ", "ANATOMY", 164, 169], ["hemophagocytosis", "DISEASE", 131, 147], ["tissue damage", "DISEASE", 149, 162], ["organ failure", "DISEASE", 164, 177], ["sporadic disorder", "DISEASE", 282, 299], ["immune cells", "CELL", 52, 64], ["macrophage", "CELL", 92, 102], ["tissue", "TISSUE", 149, 155], ["organ", "ORGAN", 164, 169], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["activated immune cells", "CELL_TYPE", 42, 64], ["Proinflammatory cytokines", "PROBLEM", 0, 25], ["the activated immune cells", "TEST", 38, 64], ["macrophage activation", "PROBLEM", 92, 113], ["hemophagocytosis", "PROBLEM", 131, 147], ["tissue damage", "PROBLEM", 149, 162], ["organ failure", "PROBLEM", 164, 177], ["the other inflammatory manifestations", "PROBLEM", 183, 220], ["the syndrome", "PROBLEM", 224, 236], ["a familial or sporadic disorder", "PROBLEM", 268, 299], ["macrophage activation", "OBSERVATION", 92, 113], ["hemophagocytosis", "OBSERVATION", 131, 147], ["tissue", "OBSERVATION_MODIFIER", 149, 155], ["damage", "OBSERVATION", 156, 162], ["organ", "ANATOMY", 164, 169], ["failure", "OBSERVATION", 170, 177], ["inflammatory", "OBSERVATION_MODIFIER", 193, 205]]], ["Genetic mutations that disrupt the ability of CD8+ CTLs and NK to release the proteins involved in cytolytic destruction predisposes the familial HLH.", [["CD8+ CTLs", "ANATOMY", 46, 55], ["NK", "ANATOMY", 60, 62], ["HLH", "DISEASE", 146, 149], ["CD8", "GENE_OR_GENE_PRODUCT", 46, 49], ["NK", "CELL", 60, 62], ["CD8", "PROTEIN", 46, 49], ["CTLs", "CELL_TYPE", 51, 55], ["NK", "CELL_TYPE", 60, 62], ["Genetic mutations", "PROBLEM", 0, 17], ["CTLs", "PROBLEM", 51, 55], ["NK", "PROBLEM", 60, 62], ["the proteins", "TEST", 74, 86], ["cytolytic destruction", "PROBLEM", 99, 120], ["the familial HLH", "PROBLEM", 133, 149], ["cytolytic destruction", "OBSERVATION", 99, 120], ["familial", "OBSERVATION_MODIFIER", 137, 145], ["HLH", "OBSERVATION", 146, 149]]], ["Sporadic disorder may be caused by diseases that affect the activity of CTLs and NK, like lymphomas and virus infection; or by a disease that increases the activation of macrophages, like macrophage activation syndrome (MAS); or by conditions that increase immune activation, like autoimmune disorders and allogeneic hematopoietic stem cell transplantation (HSCT) [2].DiscussionA variety of events that disrupt immune homeostasis can trigger HLH, such as infection, which is a common trigger both in those with a genetic predisposition and in sporadic cases.", [["CTLs", "ANATOMY", 72, 76], ["NK", "ANATOMY", 81, 83], ["lymphomas", "ANATOMY", 90, 99], ["macrophages", "ANATOMY", 170, 181], ["macrophage", "ANATOMY", 188, 198], ["hematopoietic stem cell", "ANATOMY", 317, 340], ["Sporadic disorder", "DISEASE", 0, 17], ["lymphomas", "DISEASE", 90, 99], ["infection", "DISEASE", 110, 119], ["MAS", "DISEASE", 220, 223], ["autoimmune disorders", "DISEASE", 281, 301], ["HLH", "DISEASE", 442, 445], ["infection", "DISEASE", 455, 464], ["CTLs", "CELL", 72, 76], ["NK", "CELL", 81, 83], ["lymphomas", "CANCER", 90, 99], ["macrophages", "CELL", 170, 181], ["macrophage", "CELL", 188, 198], ["hematopoietic stem cell", "CELL", 317, 340], ["CTLs", "CELL_TYPE", 72, 76], ["NK", "CELL_TYPE", 81, 83], ["macrophages", "CELL_TYPE", 170, 181], ["Sporadic disorder", "PROBLEM", 0, 17], ["diseases", "PROBLEM", 35, 43], ["CTLs", "PROBLEM", 72, 76], ["NK", "PROBLEM", 81, 83], ["lymphomas", "PROBLEM", 90, 99], ["virus infection", "PROBLEM", 104, 119], ["a disease", "PROBLEM", 127, 136], ["macrophages", "PROBLEM", 170, 181], ["macrophage activation syndrome", "PROBLEM", 188, 218], ["immune activation", "PROBLEM", 257, 274], ["autoimmune disorders", "PROBLEM", 281, 301], ["allogeneic hematopoietic stem cell transplantation", "TREATMENT", 306, 356], ["immune homeostasis", "PROBLEM", 411, 429], ["HLH", "PROBLEM", 442, 445], ["infection", "PROBLEM", 455, 464], ["disorder", "OBSERVATION", 9, 17], ["may be caused", "UNCERTAINTY", 18, 31], ["diseases", "OBSERVATION", 35, 43], ["macrophage activation syndrome", "OBSERVATION", 188, 218], ["allogeneic hematopoietic stem cell transplantation", "OBSERVATION", 306, 356], ["infection", "OBSERVATION", 455, 464]]], ["HLH is often associated with viral infections, including Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus, herpes simplex virus, varicella-zoster virus, measles virus, human herpes virus 8, H1N1 influenza virus, parechovirus, and HIV, alone or in combination.", [["HLH", "DISEASE", 0, 3], ["viral infections", "DISEASE", 29, 45], ["Epstein-Barr virus (EBV), cytomegalovirus (CMV), parvovirus, herpes simplex virus", "DISEASE", 57, 138], ["varicella-zoster virus", "DISEASE", 140, 162], ["measles virus", "DISEASE", 164, 177], ["human herpes virus", "DISEASE", 179, 197], ["influenza virus", "DISEASE", 206, 221], ["Epstein-Barr virus", "ORGANISM", 57, 75], ["EBV", "ORGANISM", 77, 80], ["cytomegalovirus", "ORGANISM", 83, 98], ["CMV", "ORGANISM", 100, 103], ["parvovirus", "ORGANISM", 106, 116], ["herpes simplex virus", "ORGANISM", 118, 138], ["varicella-zoster virus", "ORGANISM", 140, 162], ["measles virus", "ORGANISM", 164, 177], ["human herpes virus 8", "ORGANISM", 179, 199], ["H1N1 influenza virus", "ORGANISM", 201, 221], ["HIV", "ORGANISM", 241, 244], ["Barr virus", "SPECIES", 65, 75], ["herpes simplex virus", "SPECIES", 118, 138], ["varicella-zoster virus", "SPECIES", 140, 162], ["measles virus", "SPECIES", 164, 177], ["human", "SPECIES", 179, 184], ["herpes virus", "SPECIES", 185, 197], ["H1N1 influenza virus", "SPECIES", 201, 221], ["HIV", "SPECIES", 241, 244], ["Epstein-Barr virus", "SPECIES", 57, 75], ["EBV", "SPECIES", 77, 80], ["CMV", "SPECIES", 100, 103], ["herpes simplex virus", "SPECIES", 118, 138], ["varicella-zoster virus", "SPECIES", 140, 162], ["measles virus", "SPECIES", 164, 177], ["human herpes virus", "SPECIES", 179, 197], ["H1N1 influenza virus", "SPECIES", 201, 221], ["HIV", "SPECIES", 241, 244], ["HLH", "PROBLEM", 0, 3], ["viral infections", "PROBLEM", 29, 45], ["Epstein-Barr virus", "PROBLEM", 57, 75], ["cytomegalovirus (CMV)", "PROBLEM", 83, 104], ["parvovirus", "PROBLEM", 106, 116], ["herpes simplex virus", "PROBLEM", 118, 138], ["varicella", "PROBLEM", 140, 149], ["zoster virus", "PROBLEM", 150, 162], ["measles virus", "PROBLEM", 164, 177], ["human herpes virus", "PROBLEM", 179, 197], ["H1N1 influenza virus", "PROBLEM", 201, 221], ["parechovirus", "PROBLEM", 223, 235], ["HIV", "PROBLEM", 241, 244], ["often associated with", "UNCERTAINTY", 7, 28], ["viral", "OBSERVATION_MODIFIER", 29, 34], ["infections", "OBSERVATION", 35, 45], ["Barr virus", "OBSERVATION", 65, 75], ["cytomegalovirus", "OBSERVATION", 83, 98], ["herpes simplex virus", "OBSERVATION", 118, 138], ["zoster virus", "OBSERVATION", 150, 162]]], ["An HLH-like syndrome has been reported in association with SARS-CoV-2 (the novel coronavirus that causes COVID-19) [3, 4].", [["HLH-like syndrome", "DISEASE", 3, 20], ["coronavirus", "DISEASE", 81, 92], ["SARS-CoV-2", "ORGANISM", 59, 69], ["coronavirus", "ORGANISM", 81, 92], ["coronavirus", "SPECIES", 81, 92], ["SARS-CoV", "SPECIES", 59, 67], ["An HLH-like syndrome", "PROBLEM", 0, 20], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["the novel coronavirus", "PROBLEM", 71, 92], ["COVID", "TEST", 105, 110], ["HLH", "OBSERVATION", 3, 6]]], ["The development of HLH shortly after the initiation of antiretroviral therapy (ART) for the treatment of HIV infection has also been reported [5].", [["HLH", "DISEASE", 19, 22], ["HIV infection", "DISEASE", 105, 118], ["HIV", "ORGANISM", 105, 108], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 105, 108], ["HLH", "PROBLEM", 19, 22], ["antiretroviral therapy (ART)", "TREATMENT", 55, 83], ["HIV infection", "PROBLEM", 105, 118], ["HLH", "OBSERVATION", 19, 22], ["infection", "OBSERVATION", 109, 118]]], ["The underlying mechanism associated to infection is related to the toll-like receptors (TLR).", [["infection", "DISEASE", 39, 48], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 67, 86], ["TLR", "GENE_OR_GENE_PRODUCT", 88, 91], ["toll-like receptors", "PROTEIN", 67, 86], ["TLR", "PROTEIN", 88, 91], ["infection", "PROBLEM", 39, 48], ["infection", "OBSERVATION", 39, 48]]], ["TLR are non-antigen-specific receptors on the surface of NK cells that are activated by components of bacteria, fungi, viruses, or mycoplasma.", [["surface", "ANATOMY", 46, 53], ["NK cells", "ANATOMY", 57, 65], ["mycoplasma", "DISEASE", 131, 141], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["surface", "CELLULAR_COMPONENT", 46, 53], ["NK cells", "CELL", 57, 65], ["TLR", "PROTEIN", 0, 3], ["non-antigen-specific receptors", "PROTEIN", 8, 38], ["NK cells", "CELL_TYPE", 57, 65], ["NK cells", "PROBLEM", 57, 65], ["bacteria", "PROBLEM", 102, 110], ["fungi", "PROBLEM", 112, 117], ["viruses", "PROBLEM", 119, 126], ["mycoplasma", "PROBLEM", 131, 141], ["NK cells", "OBSERVATION", 57, 65], ["bacteria", "OBSERVATION", 102, 110]]], ["TLR excessive activation by infection can trigger HLH [6].DiscussionPatients with HLH have dramatically elevated levels of numerous proinflammatory cytokines, particularly interferon gamma (IFN- \u03b3).", [["infection", "DISEASE", 28, 37], ["HLH", "DISEASE", 50, 53], ["HLH", "DISEASE", 82, 85], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 172, 188], ["IFN- \u03b3", "GENE_OR_GENE_PRODUCT", 190, 196], ["TLR", "PROTEIN", 0, 3], ["proinflammatory cytokines", "PROTEIN", 132, 157], ["interferon gamma", "PROTEIN", 172, 188], ["IFN", "PROTEIN", 190, 193], ["\u03b3", "PROTEIN", 195, 196], ["infection", "PROBLEM", 28, 37], ["HLH", "PROBLEM", 50, 53], ["dramatically elevated levels", "PROBLEM", 91, 119], ["numerous proinflammatory cytokines", "PROBLEM", 123, 157], ["infection", "OBSERVATION", 28, 37], ["numerous", "OBSERVATION_MODIFIER", 123, 131], ["proinflammatory cytokines", "OBSERVATION", 132, 157]]], ["High levels of INF-\u03b3, results in macrophage activation and the subsequent increased production of other proinflammatory cytokines.", [["macrophage", "ANATOMY", 33, 43], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 15, 20], ["macrophage", "CELL", 33, 43], ["INF-\u03b3", "PROTEIN", 15, 20], ["proinflammatory cytokines", "PROTEIN", 104, 129], ["High levels of INF", "PROBLEM", 0, 18], ["macrophage activation", "PROBLEM", 33, 54], ["other proinflammatory cytokines", "PROBLEM", 98, 129], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["proinflammatory cytokines", "OBSERVATION", 104, 129]]], ["The persistent activation of macrophages, NK cells, and CTLs in patients with HLH leads to excessive cytokine production by all those cells, a phenomenon named cytokine storm, and is thought to be responsible for multiorgan failure and the high mortality of this syndrome [1, 7, 8].", [["macrophages", "ANATOMY", 29, 40], ["NK cells", "ANATOMY", 42, 50], ["CTLs", "ANATOMY", 56, 60], ["cells", "ANATOMY", 134, 139], ["multiorgan", "ANATOMY", 213, 223], ["HLH", "DISEASE", 78, 81], ["multiorgan failure", "DISEASE", 213, 231], ["macrophages", "CELL", 29, 40], ["NK cells", "CELL", 42, 50], ["CTLs", "CELL", 56, 60], ["patients", "ORGANISM", 64, 72], ["cells", "CELL", 134, 139], ["macrophages", "CELL_TYPE", 29, 40], ["NK cells", "CELL_TYPE", 42, 50], ["CTLs", "CELL_TYPE", 56, 60], ["cytokine", "PROTEIN", 101, 109], ["cytokine", "PROTEIN", 160, 168], ["patients", "SPECIES", 64, 72], ["The persistent activation of macrophages", "PROBLEM", 0, 40], ["NK cells", "PROBLEM", 42, 50], ["CTLs", "PROBLEM", 56, 60], ["HLH", "PROBLEM", 78, 81], ["excessive cytokine production", "PROBLEM", 91, 120], ["multiorgan failure", "PROBLEM", 213, 231], ["this syndrome", "PROBLEM", 258, 271], ["persistent", "OBSERVATION_MODIFIER", 4, 14], ["activation of macrophages", "OBSERVATION", 15, 40], ["NK cells", "OBSERVATION", 42, 50], ["cytokine storm", "OBSERVATION", 160, 174], ["thought to be responsible for", "UNCERTAINTY", 183, 212], ["failure", "OBSERVATION", 224, 231], ["high", "OBSERVATION_MODIFIER", 240, 244]]], ["Cytokines found at extremely high levels in the plasma of patients with HLH include, besides (IFN- \u03b3), tumor necrosis factor alpha (TNF\u03b1); interleukins (IL) such as IL-6, IL-10, and IL-12; and the soluble IL-2 receptor (CD25) [9, 10, 11].DiscussionOne interesting feature of the disease is the hemophagocytosis, which refers to the engulfment (literally \"eating\") of host blood cells by macrophages.", [["plasma", "ANATOMY", 48, 54], ["blood cells", "ANATOMY", 372, 383], ["macrophages", "ANATOMY", 387, 398], ["HLH", "DISEASE", 72, 75], ["tumor", "DISEASE", 103, 108], ["hemophagocytosis", "DISEASE", 294, 310], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["patients", "ORGANISM", 58, 66], ["IFN- \u03b3", "GENE_OR_GENE_PRODUCT", 94, 100], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 103, 130], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 132, 136], ["interleukins", "GENE_OR_GENE_PRODUCT", 139, 151], ["IL", "GENE_OR_GENE_PRODUCT", 153, 155], ["IL-6", "GENE_OR_GENE_PRODUCT", 165, 169], ["IL-10", "GENE_OR_GENE_PRODUCT", 171, 176], ["IL-12", "GENE_OR_GENE_PRODUCT", 182, 187], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 205, 218], ["CD25", "GENE_OR_GENE_PRODUCT", 220, 224], ["host blood cells", "CELL", 367, 383], ["macrophages", "CELL", 387, 398], ["Cytokines", "PROTEIN", 0, 9], ["IFN", "PROTEIN", 94, 97], ["\u03b3", "PROTEIN", 99, 100], ["tumor necrosis factor alpha", "PROTEIN", 103, 130], ["TNF\u03b1", "PROTEIN", 132, 136], ["interleukins", "PROTEIN", 139, 151], ["IL", "PROTEIN", 153, 155], ["IL-6", "PROTEIN", 165, 169], ["IL", "PROTEIN", 171, 173], ["IL-12", "PROTEIN", 182, 187], ["soluble IL-2 receptor", "PROTEIN", 197, 218], ["CD25", "PROTEIN", 220, 224], ["host blood cells", "CELL_TYPE", 367, 383], ["macrophages", "CELL_TYPE", 387, 398], ["patients", "SPECIES", 58, 66], ["Cytokines", "TEST", 0, 9], ["HLH", "PROBLEM", 72, 75], ["IFN", "TEST", 94, 97], ["tumor necrosis", "PROBLEM", 103, 117], ["alpha (TNF\u03b1", "TEST", 125, 136], ["interleukins (IL)", "TREATMENT", 139, 156], ["IL", "TEST", 165, 167], ["IL", "TEST", 171, 173], ["IL", "TEST", 182, 184], ["the soluble IL", "TREATMENT", 193, 207], ["the disease", "PROBLEM", 275, 286], ["the hemophagocytosis", "PROBLEM", 290, 310], ["HLH", "OBSERVATION", 72, 75], ["tumor", "OBSERVATION_MODIFIER", 103, 108], ["necrosis", "OBSERVATION", 109, 117], ["disease", "OBSERVATION", 279, 286], ["hemophagocytosis", "OBSERVATION", 294, 310]]], ["Hemophagocytosis is characterized by the presence of red blood cells, platelets, or white blood cells (or fragments of these cells) within the cytoplasm of macrophages, and it can be observed in the biopsies of immune tissues (lymph nodes, spleen, liver) or bone marrow aspirates/biopsies.DiscussionPrompt treatment is critical, but the greatest barrier to a successful outcome is often a delay in diagnosis due to the rarity of this syndrome, variable clinical presentation, and lack of specificity of the clinical and laboratory findings.DiscussionHLH initially presents as a febrile illness associated with multiple organ involvement.", [["red blood cells", "ANATOMY", 53, 68], ["platelets", "ANATOMY", 70, 79], ["white blood cells", "ANATOMY", 84, 101], ["fragments", "ANATOMY", 106, 115], ["cells", "ANATOMY", 125, 130], ["cytoplasm", "ANATOMY", 143, 152], ["macrophages", "ANATOMY", 156, 167], ["biopsies", "ANATOMY", 199, 207], ["immune tissues", "ANATOMY", 211, 225], ["lymph nodes", "ANATOMY", 227, 238], ["spleen", "ANATOMY", 240, 246], ["liver", "ANATOMY", 248, 253], ["bone marrow aspirates", "ANATOMY", 258, 279], ["biopsies", "ANATOMY", 280, 288], ["organ", "ANATOMY", 619, 624], ["Hemophagocytosis", "DISEASE", 0, 16], ["febrile illness", "DISEASE", 578, 593], ["red blood cells", "CELL", 53, 68], ["platelets", "CELL", 70, 79], ["white blood cells", "CELL", 84, 101], ["cells", "CELL", 125, 130], ["cytoplasm", "ORGANISM_SUBSTANCE", 143, 152], ["macrophages", "CELL", 156, 167], ["biopsies", "TISSUE", 199, 207], ["immune tissues", "TISSUE", 211, 225], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 227, 238], ["spleen", "ORGAN", 240, 246], ["liver", "ORGAN", 248, 253], ["bone marrow aspirates", "MULTI-TISSUE_STRUCTURE", 258, 279], ["biopsies", "TISSUE", 280, 288], ["organ", "ORGAN", 619, 624], ["red blood cells", "CELL_TYPE", 53, 68], ["platelets", "CELL_TYPE", 70, 79], ["white blood cells", "CELL_TYPE", 84, 101], ["macrophages", "CELL_TYPE", 156, 167], ["Hemophagocytosis", "PROBLEM", 0, 16], ["red blood cells", "PROBLEM", 53, 68], ["platelets", "TEST", 70, 79], ["white blood cells", "PROBLEM", 84, 101], ["fragments of these cells", "PROBLEM", 106, 130], ["the biopsies", "TEST", 195, 207], ["immune tissues", "PROBLEM", 211, 225], ["lymph nodes", "TEST", 227, 238], ["bone marrow aspirates", "PROBLEM", 258, 279], ["biopsies", "TEST", 280, 288], ["this syndrome", "PROBLEM", 429, 442], ["a febrile illness", "PROBLEM", 576, 593], ["multiple organ involvement", "PROBLEM", 610, 636], ["red blood cells", "OBSERVATION", 53, 68], ["cytoplasm", "OBSERVATION_MODIFIER", 143, 152], ["macrophages", "OBSERVATION", 156, 167], ["immune tissues", "OBSERVATION", 211, 225], ["lymph nodes", "OBSERVATION", 227, 238], ["spleen", "ANATOMY", 240, 246], ["liver", "ANATOMY", 248, 253], ["bone", "ANATOMY", 258, 262], ["marrow aspirates", "OBSERVATION", 263, 279], ["organ", "ANATOMY", 619, 624], ["involvement", "OBSERVATION", 625, 636]]], ["Thus, the initial signs and symptoms of HLH can mimic common infections, fever of unknown origin, hepatitis, or encephalitis.", [["HLH", "DISEASE", 40, 43], ["infections", "DISEASE", 61, 71], ["fever", "DISEASE", 73, 78], ["hepatitis", "DISEASE", 98, 107], ["encephalitis", "DISEASE", 112, 124], ["the initial signs and symptoms", "PROBLEM", 6, 36], ["HLH", "PROBLEM", 40, 43], ["common infections", "PROBLEM", 54, 71], ["fever", "PROBLEM", 73, 78], ["hepatitis", "PROBLEM", 98, 107], ["encephalitis", "PROBLEM", 112, 124], ["infections", "OBSERVATION", 61, 71], ["hepatitis", "OBSERVATION", 98, 107], ["encephalitis", "OBSERVATION", 112, 124]]], ["With few exceptions, the clinical features are similar regardless of whether an underlying genetic defect has been identified.DiscussionThe HLH-2004 study, which included 369 patients, reported the following clinical findings and, therefore, were considered as diagnostic criteria [12]:\u2022Fever \u226538.5\u00b0C (95%);\u2022Splenomegaly (89%);\u2022Peripheral blood cytopenia, with at least two of the following: hemoglobin <9 g/dL (for infants <4 weeks, hemoglobin <10 g/dL); platelets <100,000/microL; absolute neutrophil count <1000/microL (92%);\u2022Hypertriglyceridemia (fasting triglycerides >265 mg/dL) and/or hypofibrinogenemia (fibrinogen <150 mg/dL) (90%);\u2022Hemophagocytosis in bone marrow, spleen, lymph node, or liver (82%);\u2022Low or absent NK cell activity (71%);\u2022Ferritin >500 ng/mL (94%)\u2022Elevated soluble CD25 (soluble IL-2 receptor alpha [sIL-2R]) two standard deviations above age-adjusted laboratory-specific norms (97%).", [["Peripheral blood", "ANATOMY", 328, 344], ["platelets", "ANATOMY", 456, 465], ["neutrophil", "ANATOMY", 492, 502], ["bone marrow", "ANATOMY", 662, 673], ["spleen", "ANATOMY", 675, 681], ["lymph node", "ANATOMY", 683, 693], ["liver", "ANATOMY", 698, 703], ["NK cell", "ANATOMY", 725, 732], ["Fever", "DISEASE", 287, 292], ["Splenomegaly", "DISEASE", 308, 320], ["Peripheral blood cytopenia", "DISEASE", 328, 354], ["Hypertriglyceridemia", "DISEASE", 529, 549], ["hypofibrinogenemia", "DISEASE", 592, 610], ["triglycerides", "CHEMICAL", 559, 572], ["patients", "ORGANISM", 175, 183], ["blood", "ORGANISM_SUBSTANCE", 339, 344], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 392, 402], ["infants", "ORGANISM", 416, 423], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 434, 444], ["platelets", "CELL", 456, 465], ["neutrophil", "CELL", 492, 502], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 612, 622], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 662, 673], ["spleen", "ORGAN", 675, 681], ["lymph node", "MULTI-TISSUE_STRUCTURE", 683, 693], ["liver", "ORGAN", 698, 703], ["NK cell", "CELL", 725, 732], ["Ferritin", "GENE_OR_GENE_PRODUCT", 749, 757], ["CD25", "GENE_OR_GENE_PRODUCT", 792, 796], ["IL-2 receptor alpha", "GENE_OR_GENE_PRODUCT", 806, 825], ["sIL-2R", "GENE_OR_GENE_PRODUCT", 827, 833], ["hemoglobin", "PROTEIN", 392, 402], ["hemoglobin", "PROTEIN", 434, 444], ["platelets", "CELL_TYPE", 456, 465], ["fibrinogen", "PROTEIN", 612, 622], ["Ferritin", "PROTEIN", 749, 757], ["CD25", "PROTEIN", 792, 796], ["soluble IL-2 receptor alpha", "PROTEIN", 798, 825], ["sIL", "PROTEIN", 827, 830], ["patients", "SPECIES", 175, 183], ["infants", "SPECIES", 416, 423], ["an underlying genetic defect", "PROBLEM", 77, 105], ["Fever", "PROBLEM", 287, 292], ["\u00b0C", "TEST", 298, 300], ["\u2022Splenomegaly", "PROBLEM", 307, 320], ["Peripheral blood cytopenia", "PROBLEM", 328, 354], ["hemoglobin", "TEST", 392, 402], ["infants", "TEST", 416, 423], ["hemoglobin", "TEST", 434, 444], ["dL", "TEST", 451, 453], ["platelets", "TEST", 456, 465], ["microL", "TEST", 475, 481], ["absolute neutrophil count", "TEST", 483, 508], ["microL", "TEST", 515, 521], ["Hypertriglyceridemia", "TEST", 529, 549], ["fasting triglycerides", "TEST", 551, 572], ["hypofibrinogenemia", "PROBLEM", 592, 610], ["fibrinogen", "TEST", 612, 622], ["Hemophagocytosis in bone marrow", "PROBLEM", 642, 673], ["lymph node", "TEST", 683, 693], ["Low or absent NK cell activity", "PROBLEM", 711, 741], ["Ferritin", "TEST", 749, 757], ["Elevated soluble CD25 (soluble IL", "TREATMENT", 775, 808], ["receptor alpha [sIL-2R])", "TREATMENT", 811, 835], ["few", "OBSERVATION_MODIFIER", 5, 8], ["genetic", "OBSERVATION_MODIFIER", 91, 98], ["defect", "OBSERVATION", 99, 105], ["Splenomegaly", "OBSERVATION", 308, 320], ["Peripheral", "ANATOMY_MODIFIER", 328, 338], ["blood", "ANATOMY", 339, 344], ["cytopenia", "OBSERVATION", 345, 354], ["Hypertriglyceridemia", "OBSERVATION", 529, 549], ["hypofibrinogenemia", "OBSERVATION", 592, 610], ["Hemophagocytosis", "OBSERVATION", 642, 658], ["bone marrow", "ANATOMY", 662, 673], ["spleen", "ANATOMY", 675, 681], ["lymph node", "OBSERVATION", 683, 693], ["liver", "ANATOMY", 698, 703], ["NK cell activity", "OBSERVATION", 725, 741], ["soluble CD25", "OBSERVATION", 784, 796]]]], "fdbcd88d8040655aa840b609660db03ed1008512": [["INTRODUCTIONThe interaction between allergens and IgE antibodies is at the core of the allergic response.", [["allergic", "DISEASE", 87, 95], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 50, 64], ["allergens", "PROTEIN", 36, 45], ["IgE antibodies", "PROTEIN", 50, 64], ["IgE antibodies", "TEST", 50, 64], ["the allergic response", "PROBLEM", 83, 104], ["allergic response", "OBSERVATION", 87, 104]]], ["Epitopes could potentially be located on any part of the allergen surface.", [["surface", "ANATOMY", 66, 73], ["allergen surface", "CELLULAR_COMPONENT", 57, 73], ["Epitopes", "TREATMENT", 0, 8], ["could potentially be", "UNCERTAINTY", 9, 29], ["allergen surface", "OBSERVATION", 57, 73]]], ["However, evidence shows that antibodies are very specific about the epitopes that they recognize and certain areas on the allergen seem to be preferential for antibody binding.", [["antibodies", "PROTEIN", 29, 39], ["epitopes", "PROTEIN", 68, 76], ["antibodies", "PROBLEM", 29, 39], ["antibody binding", "PROBLEM", 159, 175]]], ["The identification of epitopes recognized by IgE is valuable for the design of hypoallergens or other therapeutics.", [["IgE", "GENE_OR_GENE_PRODUCT", 45, 48], ["epitopes", "PROTEIN", 22, 30], ["IgE", "PROTEIN", 45, 48], ["epitopes", "PROBLEM", 22, 30], ["hypoallergens", "TREATMENT", 79, 92], ["other therapeutics", "TREATMENT", 96, 114]]], ["This review will discuss various methods to probe epitopes and the knowledge that has been gained from available studies on allergens.HISTORICAL PERSPECTIVE TO IgE EPITOPE MAPPINGSince the 1980s, efforts to identify antigenic determinants on allergens have been pursued, but progress in the area has been slow due to technical limitations.", [["epitopes", "PROTEIN", 50, 58], ["IgE", "PROTEIN", 160, 163], ["various methods", "TREATMENT", 25, 40]]], ["Original epitope mapping studies were based on the synthesis of overlapping peptides covering the full sequence of the allergen, and the selection of the peptides that bound IgE (1, 2) .", [["IgE", "GENE_OR_GENE_PRODUCT", 174, 177], ["IgE", "PROTEIN", 174, 177], ["Original epitope mapping studies", "TEST", 0, 32], ["overlapping peptides", "TREATMENT", 64, 84]]], ["This approach led to the identification of linear epitopes that comprise a sequential or continuous set of amino acids.", [["amino acids", "CHEMICAL", 107, 118], ["amino acids", "CHEMICAL", 107, 118], ["amino acids", "AMINO_ACID", 107, 118], ["linear epitopes", "PROTEIN", 43, 58], ["linear epitopes", "PROBLEM", 43, 58], ["amino acids", "TREATMENT", 107, 118]]], ["However, allergens are proteins or glycoproteins with a defined three-dimensional structure that determines the molecular surface and epitopes recognized by antibodies.", [["surface", "ANATOMY", 122, 129], ["surface", "CELLULAR_COMPONENT", 122, 129], ["glycoproteins", "PROTEIN", 35, 48], ["epitopes", "PROTEIN", 134, 142], ["antibodies", "PROTEIN", 157, 167], ["allergens", "PROBLEM", 9, 18], ["proteins or glycoproteins", "PROBLEM", 23, 48], ["surface", "OBSERVATION_MODIFIER", 122, 129]]], ["Therefore, most allergenic epitopes are conformational, involving amino acids that are close in space due to the protein folding, but non-contiguous in the allergen sequence (3) .", [["amino acids", "CHEMICAL", 66, 77], ["amino acids", "CHEMICAL", 66, 77], ["amino acids", "AMINO_ACID", 66, 77], ["allergenic epitopes", "PROTEIN", 16, 35], ["most allergenic epitopes", "PROBLEM", 11, 35], ["amino acids", "TREATMENT", 66, 77], ["the protein folding", "PROBLEM", 109, 128], ["allergenic epitopes", "OBSERVATION", 16, 35], ["protein folding", "OBSERVATION", 113, 128]]], ["Technologies that consider the threedimensional structure of the allergens were necessary to analyze conformational epitopes.HISTORICAL PERSPECTIVE TO IgE EPITOPE MAPPINGIn the absence of complete structural information, most of the original approaches to epitope mapping were indirect, based on the reduction of IgE antibody binding to modified allergen molecules in dot blots or enzyme-linked immunosorbent assays (ELISA) (4) .", [["IgE antibody", "GENE_OR_GENE_PRODUCT", 313, 325], ["conformational epitopes", "PROTEIN", 101, 124], ["IgE", "PROTEIN", 151, 154], ["IgE antibody", "PROTEIN", 313, 325], ["allergen molecules", "PROTEIN", 346, 364], ["the allergens", "PROBLEM", 61, 74], ["conformational epitopes", "PROBLEM", 101, 124], ["epitope mapping", "TEST", 256, 271], ["IgE antibody binding", "PROBLEM", 313, 333], ["modified allergen molecules", "PROBLEM", 337, 364], ["dot blots", "TEST", 368, 377], ["enzyme", "TEST", 381, 387], ["immunosorbent assays", "TEST", 395, 415], ["IgE antibody", "OBSERVATION", 313, 325]]], ["They were possible thanks to peptide synthesis or to the development of recombinant technology, with in vitro expression of either allergen fragments, mutants, or allergen chimeras, and their subsequent testing for IgE antibody binding.", [["IgE antibody", "GENE_OR_GENE_PRODUCT", 215, 227], ["allergen fragments", "PROTEIN", 131, 149], ["allergen chimeras", "PROTEIN", 163, 180], ["IgE antibody", "PROTEIN", 215, 227], ["allergen fragments", "PROBLEM", 131, 149], ["allergen chimeras", "PROBLEM", 163, 180], ["their subsequent testing", "TEST", 186, 210], ["IgE antibody binding", "PROBLEM", 215, 235], ["allergen fragments", "OBSERVATION", 131, 149]]], ["The development of microarrays or bead-based epitope assays facilitated the investigation of the relevance of linear epitopes, using large sets of linear peptides (5, 6) .", [["linear epitopes", "PROTEIN", 110, 125], ["bead-based epitope assays", "PROBLEM", 34, 59], ["linear epitopes", "PROBLEM", 110, 125], ["large sets of linear peptides", "TREATMENT", 133, 162], ["linear", "OBSERVATION_MODIFIER", 110, 116], ["epitopes", "OBSERVATION", 117, 125], ["large", "OBSERVATION_MODIFIER", 133, 138], ["linear", "OBSERVATION_MODIFIER", 147, 153]]], ["Microarrays have been especially useful for food allergens because they have mainly linear epitopes due to food processing and/or digestion (6) (7) (8) (9) .", [["Microarrays", "TEST", 0, 11]]], ["Several IgE/IgG4-binding peptide epitopes were suggested as biomarkers for predicting clinical reactivity and severity to certain foods (10, 11) .", [["IgE", "GENE_OR_GENE_PRODUCT", 8, 11], ["IgG4", "GENE_OR_GENE_PRODUCT", 12, 16], ["IgE", "PROTEIN", 8, 11], ["IgG4", "PROTEIN", 12, 16], ["Several IgE/IgG4-binding peptide epitopes", "TEST", 0, 41], ["biomarkers", "TEST", 60, 70]]], ["Another approach uses information from the allergen structure, and hybrid or chimeric allergens are designed by combining the sequences of homologous allergens from different species (12) (13) (14) .", [["chimeric allergens", "PROTEIN", 77, 95], ["hybrid or chimeric allergens", "PROBLEM", 67, 95], ["homologous allergens", "PROBLEM", 139, 159]]], ["Patches on the allergen surface associated with binding of IgE (from sera of subjects allergic to one of the allergens in the chimera) indicate the presence of epitopes (most likely conformational) on those regions.", [["surface", "ANATOMY", 24, 31], ["sera", "ANATOMY", 69, 73], ["allergic", "DISEASE", 86, 94], ["IgE", "GENE_OR_GENE_PRODUCT", 59, 62], ["sera", "ORGANISM_SUBSTANCE", 69, 73], ["IgE", "PROTEIN", 59, 62], ["chimera", "PROTEIN", 126, 133], ["epitopes", "PROTEIN", 160, 168], ["Patches on the allergen surface", "PROBLEM", 0, 31], ["binding of IgE", "PROBLEM", 48, 62], ["subjects allergic", "PROBLEM", 77, 94], ["epitopes", "PROBLEM", 160, 168], ["allergen surface", "OBSERVATION", 15, 31], ["epitopes", "OBSERVATION", 160, 168], ["most likely", "UNCERTAINTY", 170, 181]]], ["Another approach to epitope mapping is the identification of mimotopes, which mimic the structure of an epitope (15) .", [["epitope mapping", "TREATMENT", 20, 35], ["mimotopes", "PROBLEM", 61, 70]]], ["It is based on the use of phage display libraries for the selection of peptides that, in combination with a computational algorithm, allow the identification of patches on the allergen surface that mimic conformational epitopes (16, 17) .", [["surface", "ANATOMY", 185, 192], ["conformational epitopes", "PROTEIN", 204, 227], ["phage display libraries", "TREATMENT", 26, 49], ["the selection of peptides", "TREATMENT", 54, 79], ["a computational algorithm", "TEST", 106, 131], ["patches on the allergen surface", "TREATMENT", 161, 192]]], ["A knowledge of the allergen structure is needed, but the mimotope resulting from the analysis is not necessarily the same as the real epitope.", [["the allergen structure", "PROBLEM", 15, 37], ["the analysis", "TEST", 81, 93]]], ["Each of these technologies has provided valuable information on epitope mapping.", [["epitope mapping", "TREATMENT", 64, 79]]], ["X-ray crystallography and nuclear magnetic resonance have determined the three-dimensional structure of many allergens, which helps immensely in interpreting epitopes.", [["epitopes", "PROTEIN", 158, 166], ["X-ray crystallography", "TEST", 0, 21], ["nuclear magnetic resonance", "TEST", 26, 52], ["many allergens", "PROBLEM", 104, 118], ["many", "OBSERVATION_MODIFIER", 104, 108], ["allergens", "OBSERVATION", 109, 118]]], ["Allergens have a wide variety of three-dimensional structures, despite belonging to a limited number of protein families (18) (19) (20) .", [["wide", "OBSERVATION_MODIFIER", 17, 21], ["variety", "OBSERVATION_MODIFIER", 22, 29]]], ["Only 1.3% of the total Pfam domains are present in allergens (http:// www.meduniwien.ac.at/allfam/).", [["Pfam domains", "PROTEIN", 23, 35], ["the total Pfam domains", "TEST", 13, 35]]], ["Once the allergen molecular surface is defined, certain amino acids can be selected for sitedirected mutagenesis to analyze allergen-antibody interactions (21) .", [["surface", "ANATOMY", 28, 35], ["amino acids", "CHEMICAL", 56, 67], ["amino acids", "CHEMICAL", 56, 67], ["surface", "CELLULAR_COMPONENT", 28, 35], ["amino acids", "AMINO_ACID", 56, 67], ["certain amino acids", "TREATMENT", 48, 67], ["sitedirected mutagenesis", "TREATMENT", 88, 112]]], ["Experimental IgE binding and cross-reactivity data can be compared for homologous allergens in conjunction with the molecular structure to understand the approximate location of IgE-binding epitopes (22, 23) .", [["IgE", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgE", "GENE_OR_GENE_PRODUCT", 178, 181], ["IgE", "PROTEIN", 13, 16], ["IgE", "PROTEIN", 178, 181], ["binding epitopes", "PROTEIN", 182, 198], ["Experimental IgE binding and cross-reactivity data", "PROBLEM", 0, 50], ["homologous allergens", "PROBLEM", 71, 91], ["IgE-binding epitopes", "PROBLEM", 178, 198], ["IgE binding", "OBSERVATION", 13, 24]]], ["Ultimately, the structures of allergen-antibody complexes provide the most detailed information of the epitope-paratope interaction.", [["paratope", "SIMPLE_CHEMICAL", 111, 119], ["allergen-antibody complexes", "PROTEIN", 30, 57], ["allergen-antibody complexes", "TREATMENT", 30, 57]]], ["This review primarily covers X-ray crystallography and NMR approaches to epitope mapping ( Table 1) .", [["ray crystallography", "TEST", 31, 50], ["epitope mapping", "TEST", 73, 88]]], ["Additional technologies that also consider the three-dimensional structure of proteins for epitope mapping are cryo-electron microscopy (cryo-EM) and chemical protection assays combined with mass spectrometry (MS).", [["epitope mapping", "TREATMENT", 91, 106], ["cryo-electron microscopy", "TEST", 111, 135], ["chemical protection assays", "TEST", 150, 176], ["mass spectrometry", "PROBLEM", 191, 208]]], ["These will also be briefly discussed.X-Ray CrystallographyOver 88% of experimental models of macromolecules that are deposited in the Protein Data Bank (PDB) were determined using X-ray crystallography ( Table 1) .", [["Protein Data Bank", "PROTEIN", 134, 151], ["Ray CrystallographyOver", "TEST", 39, 62], ["experimental models of macromolecules", "PROBLEM", 70, 107], ["X-ray crystallography", "TEST", 180, 201]]], ["This technique is often used to generate experimental models of antigen-antibody complexes, and allows for a detailed description of epitopes, paratopes and their chemical interactions.", [["antigen-antibody", "GENE_OR_GENE_PRODUCT", 64, 80], ["antigen-antibody complexes", "PROTEIN", 64, 90], ["epitopes", "PROTEIN", 133, 141], ["This technique", "TREATMENT", 0, 14]]], ["Structural analysis by X-ray crystallography provides the most detailed description of interactions between allergens and antibodies, but is not always easy to perform (24, 25) .", [["allergens", "PROTEIN", 108, 117], ["antibodies", "PROTEIN", 122, 132], ["Structural analysis", "TEST", 0, 19], ["X-ray crystallography", "TEST", 23, 44]]], ["This approach requires the generation of: (1) significant quantities (mg amounts) of pure and homogeneous protein preparations, specifically the allergenantibody complex, and (2) a well-diffracting crystal to perform an X-ray diffraction experiment.", [["allergenantibody complex", "PROTEIN", 145, 169], ["significant quantities (mg amounts) of pure and homogeneous protein preparations", "PROBLEM", 46, 126], ["an X-ray diffraction experiment", "TREATMENT", 217, 248]]], ["An additional difficulty in studying epitopes is that highly flexible molecules, like antibodies, are typically recalcitrant to the process of crystallization.", [["epitopes", "PROTEIN", 37, 45], ["antibodies", "PROTEIN", 86, 96], ["An additional difficulty in studying epitopes", "PROBLEM", 0, 45], ["highly flexible molecules, like antibodies", "PROBLEM", 54, 96], ["flexible molecules", "OBSERVATION", 61, 79]]], ["To our knowledge, there is not currently a single structure of an antigen in complex with an intact antibody.", [["intact antibody", "PROTEIN", 93, 108], ["intact antibody", "OBSERVATION", 93, 108]]], ["Fragments derived from monoclonal antibodies (Fab, Fab \u2032 ) or antibody constructs (single-chain variable fragment -scFv-, scFab, rFab) are used for crystallization because they have significantly reduced conformational flexibility in comparison with intact immunoglobulins.", [["Fab", "GENE_OR_GENE_PRODUCT", 46, 49], ["Fab", "GENE_OR_GENE_PRODUCT", 51, 54], ["scFab", "SIMPLE_CHEMICAL", 122, 127], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 257, 272], ["monoclonal antibodies", "PROTEIN", 23, 44], ["Fab", "PROTEIN", 46, 49], ["Fab \u2032", "PROTEIN", 51, 56], ["antibody constructs", "DNA", 62, 81], ["single-chain variable fragment", "PROTEIN", 83, 113], ["scFv-", "PROTEIN", 115, 120], ["scFab", "PROTEIN", 122, 127], ["rFab", "PROTEIN", 129, 133], ["immunoglobulins", "PROTEIN", 257, 272], ["Fragments", "PROBLEM", 0, 9], ["monoclonal antibodies", "TEST", 23, 44], ["Fab, Fab \u2032", "TEST", 46, 56], ["antibody constructs", "PROBLEM", 62, 81], ["single-chain variable fragment", "TREATMENT", 83, 113], ["crystallization", "TREATMENT", 148, 163], ["significantly reduced conformational flexibility", "PROBLEM", 182, 230], ["intact immunoglobulins", "TREATMENT", 250, 272], ["monoclonal antibodies", "OBSERVATION", 23, 44], ["reduced", "OBSERVATION_MODIFIER", 196, 203], ["conformational flexibility", "OBSERVATION", 204, 230]]], ["Success in obtaining well-diffracting crystals is not guaranteed, even when sufficient quantities of pure and homogeneous allergen-antibody complexes are available.", [["allergen-antibody complexes", "PROTEIN", 122, 149], ["homogeneous allergen-antibody complexes", "TEST", 110, 149]]], ["As crystallization conditions cannot be predicted, hundreds or thousands of trials using different solvent conditions are tested, as well as modifications to the allergen and antibody (26) .", [["crystallization conditions", "PROBLEM", 3, 29], ["trials", "TREATMENT", 76, 82], ["different solvent conditions", "TREATMENT", 89, 117], ["the allergen and antibody", "TEST", 158, 183]]], ["Once a well-diffracting crystal is obtained, the process of 1 | Comparison of four epitope mapping techniques that consider the three-dimensional structure of the allergen: X-ray crystallography, NMR, cryo-EM and mass spectrometry.X-ray crystallographyNuclear magnetic resonanceX-ray crystallography\u2022 Crystalline state, however, the crystals contain \u223c30-70% of disordered solvent \u2022 Solution conditions (requires weeks of stability for data collection).X-ray crystallography\u2022 Theoretically no structure size limit \u2022 Proteins purified from natural sources can be usedX-ray crystallography\u2022 High resolution structures up to \u223c30 kDa.X-ray crystallography\u2022 Expression with isotope is typically not required for proteins or DNA.", [["DNA", "CELLULAR_COMPONENT", 718, 721], ["four epitope mapping techniques", "TREATMENT", 78, 109], ["X-ray crystallography", "TEST", 173, 194], ["NMR", "TEST", 196, 199], ["mass spectrometry", "PROBLEM", 213, 230], ["X-ray crystallography", "TEST", 231, 252], ["Nuclear magnetic resonanceX", "TEST", 252, 279], ["ray crystallography", "TEST", 280, 299], ["the crystals", "TEST", 329, 341], ["disordered solvent \u2022 Solution conditions", "TREATMENT", 361, 401], ["data collection", "TEST", 435, 450], ["X-ray crystallography", "TEST", 452, 473], ["ray crystallography", "TEST", 567, 586], ["X-ray crystallography", "TEST", 629, 650], ["proteins", "PROBLEM", 706, 714], ["DNA", "PROBLEM", 718, 721], ["mass spectrometry", "OBSERVATION", 213, 230], ["size", "OBSERVATION_MODIFIER", 502, 506]]], ["Sometimes selenomethionine is incorporated instead of Met.X-ray crystallography\u2022 Protein/DNA samples usually require 13 C and 15 N labeling (stable isotopes).", [["samples", "ANATOMY", 93, 100], ["selenomethionine", "CHEMICAL", 10, 26], ["Met", "CHEMICAL", 54, 57], ["selenomethionine", "CHEMICAL", 10, 26], ["Met", "CHEMICAL", 54, 57], ["N", "CHEMICAL", 129, 130], ["selenomethionine", "SIMPLE_CHEMICAL", 10, 26], ["Met", "GENE_OR_GENE_PRODUCT", 54, 57], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["Met", "PROTEIN", 54, 57], ["selenomethionine", "TREATMENT", 10, 26], ["X-ray crystallography", "TEST", 58, 79], ["Protein/DNA samples", "TEST", 81, 100], ["15 N labeling", "TREATMENT", 126, 139]]], ["Cost of expression is prohibitive except in prokaryotes.X-ray crystallography\u2022 X-rays diffraction data are recorded, and the diffraction patterns are used to calculate initial electron density maps.", [["electron", "SIMPLE_CHEMICAL", 176, 184], ["X-ray crystallography", "TEST", 56, 77], ["X-rays diffraction data", "TEST", 79, 102], ["prohibitive", "OBSERVATION", 22, 33]]], ["The maps are used to trace a model of the macromolecule, that is later refined and validatedX-ray crystallography\u2022 Data is nuclear resonance frequencies of primarily 1 H, 13 C, and 15 N. Distances between 1 H atoms are used to build ensembles of possible structures.X-ray crystallography\u2022 Highly flexible/disordered regions of proteins cannot be modeled and are absent in the final modelsX-ray crystallography\u2022 Motion and disorder can be directly measured on many time scales.X-ray crystallographyMass spectrometry Cryo-electron microscopy \u2022 Typically used in protection assays for epitope mapping. \u2022 High sensitivity/low sample requirements. \u2022 Atomic resolution identifies specific residues for protection from modification. \u2022 Residues that are convenient to modify in protection assays are not always useful for epitope mapping. \u2022 Chemistry of modification procedures can have off target effects.X-ray crystallography\u2022 Can determine atomic resolution structures frozen from solution in vitreous ice. \u2022 Low sample requirements.X-ray crystallography\u2022 Resolution occasionally as good as X-ray crystallography.X-ray crystallography\u2022 Performs better on very large samples with high symmetry, typically 100's of kDa, so it is currently not easily or generally applicable to allergen epitope mapping.X-ray crystallographystructure determination can be very fast, as currently available software allows to determine initial models very quickly after collection of diffraction data.", [["nuclear", "ANATOMY", 123, 130], ["sample", "ANATOMY", 1008, 1014], ["samples", "ANATOMY", 1161, 1168], ["disorder", "DISEASE", 422, 430], ["H", "CHEMICAL", 168, 169], ["H", "CHEMICAL", 207, 208], ["samples", "CANCER", 1161, 1168], ["The maps", "TEST", 0, 8], ["validatedX-ray crystallography", "TEST", 83, 113], ["nuclear resonance frequencies", "TEST", 123, 152], ["X-ray crystallography", "TEST", 266, 287], ["Highly flexible/disordered regions of proteins", "PROBLEM", 289, 335], ["Motion and disorder", "PROBLEM", 411, 430], ["X-ray crystallography", "TEST", 476, 497], ["Mass spectrometry", "TEST", 497, 514], ["Cryo-electron microscopy", "TEST", 515, 539], ["epitope mapping", "TREATMENT", 582, 597], ["High sensitivity", "PROBLEM", 601, 617], ["low sample requirements", "PROBLEM", 618, 641], ["protection assays", "TEST", 770, 787], ["epitope mapping", "TREATMENT", 814, 829], ["modification procedures", "TREATMENT", 846, 869], ["X-ray crystallography", "TEST", 898, 919], ["vitreous ice", "TREATMENT", 988, 1000], ["Low sample requirements", "PROBLEM", 1004, 1027], ["X-ray crystallography", "TEST", 1028, 1049], ["X-ray crystallography", "TEST", 1086, 1107], ["X-ray crystallography", "TEST", 1108, 1129], ["high symmetry", "PROBLEM", 1174, 1187], ["allergen epitope mapping", "TREATMENT", 1270, 1294], ["X-ray crystallographystructure determination", "TEST", 1295, 1339], ["collection of diffraction data", "TEST", 1444, 1474], ["flexible", "OBSERVATION", 296, 304], ["cannot be", "UNCERTAINTY", 336, 345], ["low sample requirements", "OBSERVATION_MODIFIER", 618, 641], ["resolution", "OBSERVATION_MODIFIER", 652, 662], ["specific residues", "OBSERVATION", 674, 691], ["sample requirements", "OBSERVATION", 1008, 1027], ["good", "OBSERVATION_MODIFIER", 1078, 1082], ["high symmetry", "OBSERVATION_MODIFIER", 1174, 1187]]], ["Therefore, taking into account the many advances in molecular biology, instrumentation, and software development, it is not surprising that the number of experimental structures deposited to the PDB and determined by X-ray crystallography continuously increases.", [["instrumentation", "TREATMENT", 71, 86], ["X-ray crystallography", "TEST", 217, 238], ["PDB", "ANATOMY", 195, 198]]], ["Currently, 145,000 models have been determined using this technique.", [["this technique", "TREATMENT", 53, 67]]], ["However, very few are structures of allergen-antibody complexes (see section Structures of Allergen-Antibody Complexes by X-Ray Crystallography).Nuclear Magnetic Resonance (NMR)NMR approaches to observe antibody complexes utilize molecules in solution as opposed to crystallization that attempts to coax molecules out of solution and into a crystal lattice.", [["allergen-antibody complexes", "PROTEIN", 36, 63], ["Allergen", "PROTEIN", 91, 99], ["Antibody Complexes", "PROTEIN", 100, 118], ["X", "PROTEIN", 122, 123], ["antibody complexes", "PROTEIN", 203, 221], ["coax molecules", "PROTEIN", 299, 313], ["allergen-antibody complexes", "PROBLEM", 36, 63], ["Allergen", "TEST", 91, 99], ["Nuclear Magnetic Resonance", "TEST", 145, 171], ["antibody complexes", "PROBLEM", 203, 221], ["molecules in solution", "TREATMENT", 230, 251], ["crystallization", "TREATMENT", 266, 281], ["a crystal lattice", "TREATMENT", 339, 356], ["very", "OBSERVATION_MODIFIER", 9, 13], ["few", "OBSERVATION_MODIFIER", 14, 17]]], ["NMR detects the resonant frequencies of atoms in a magnetic field.", [["NMR", "TEST", 0, 3], ["resonant frequencies", "OBSERVATION", 16, 36]]], ["These frequencies are primarily influenced by the type of atom ( 1 H, 13 C, or 15 N) and secondarily by the chemical environment of particular atoms.", [["H", "CHEMICAL", 67, 68]]], ["An additional difficulty in observing macromolecules is that the signals become exponentially more difficult to observe as molecular weight increases.", [["An additional difficulty in observing macromolecules", "PROBLEM", 0, 52], ["additional", "OBSERVATION_MODIFIER", 3, 13], ["difficulty", "OBSERVATION", 14, 24]]], ["NMR methods can determine macromolecular structures but are typically limited to molecules of <20 kDa for high resolution structures.", [["NMR methods", "TEST", 0, 11], ["high resolution", "OBSERVATION_MODIFIER", 106, 121]]], ["All of the atoms in small allergens (approximately <20 kDa) can be readily observed, while much larger complexes (such as IgE, 190 kDa, combined with two allergens) require specific labeling of certain chemical groups that provide high sensitivity.", [["IgE", "GENE_OR_GENE_PRODUCT", 122, 125], ["IgE", "PROTEIN", 122, 125], ["190 kDa", "PROTEIN", 127, 134], ["small allergens", "PROBLEM", 20, 35], ["high sensitivity", "PROBLEM", 231, 247], ["small", "OBSERVATION_MODIFIER", 20, 25], ["allergens", "OBSERVATION", 26, 35]]], ["It is important to realize that, in contrast to crystallography that directly determines the structure of the complex, the NMR data on epitopes requires a careful comparison of the atomic frequencies or intensities in the allergen before and after complexation.", [["epitopes", "PROTEIN", 135, 143], ["the NMR data", "TEST", 119, 131]]], ["Therefore, the NMR results are potentially subject to interpretation in the context of previously known structures or epitope mapping data.Cryo-Electron Microscopy (Cryo-EM)Another emerging methodology that may become applicable to epitope mapping is cryo-electron microscopy (Cryo-EM) ( Table 1) .", [["the NMR", "TEST", 11, 18], ["epitope mapping data", "TEST", 118, 138], ["epitope mapping", "TEST", 232, 247], ["cryo-electron microscopy", "TEST", 251, 275]]], ["Due to technical improvements in the detectors, and secondarily computational methods, cryo-EM has demonstrated the ability to determine macromolecular structures at resolutions occasionally as good as X-ray crystallography, but frequently reasonable for epitope mapping (27) .", [["X-ray crystallography", "TEST", 202, 223], ["epitope mapping", "TEST", 255, 270]]], ["In July 2020 there were 63 Cryo-EM structures with <2 \u00c5 reconstruction resolution out of more than 5,000 reported in the PDB.", [["2 \u00c5 reconstruction resolution", "TREATMENT", 52, 81], ["PDB", "ANATOMY", 121, 124]]], ["Some attractive advantages of Cryo-EM include that samples are flash frozen, so they don't require crystallization and much less sample is typically required, frequently less than a mg.", [["samples", "ANATOMY", 51, 58], ["Cryo-EM", "SIMPLE_CHEMICAL", 30, 37], ["Cryo", "TREATMENT", 30, 34], ["flash frozen", "PROBLEM", 63, 75], ["crystallization", "TREATMENT", 99, 114]]], ["However, in the sample, the molecules still need to be relatively homogeneous in purity and conformation so the inherent flexibility of antibodies may preclude high resolution analysis.", [["antibodies", "PROTEIN", 136, 146], ["high resolution analysis", "TEST", 160, 184], ["relatively", "OBSERVATION_MODIFIER", 55, 65], ["homogeneous", "OBSERVATION_MODIFIER", 66, 77]]], ["Although smaller antibody constructs such as Fv or scFv are presently too small for structural analysis by Cryo-EM, this technique may improve to facilitate the use of smaller proteins (28, 29) .Cryo-Electron Microscopy (Cryo-EM)There have been several papers on epitopes mapped by Cryo-EM, which are worth noting.", [["Fv", "GENE_OR_GENE_PRODUCT", 45, 47], ["scFv", "GENE_OR_GENE_PRODUCT", 51, 55], ["antibody constructs", "DNA", 17, 36], ["Fv", "PROTEIN", 45, 47], ["scFv", "PROTEIN", 51, 55], ["epitopes", "PROTEIN", 263, 271], ["smaller antibody constructs", "PROBLEM", 9, 36], ["scFv", "PROBLEM", 51, 55], ["structural analysis", "TEST", 84, 103], ["this technique", "TREATMENT", 116, 130], ["Electron Microscopy", "TEST", 200, 219], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["antibody constructs", "OBSERVATION", 17, 36]]], ["For example, Fab fragments from monoclonal antibodies were localized on the spike protein of SARS-CoV-2, and on Zika virus particles (30, 31) .", [["Fab", "GENE_OR_GENE_PRODUCT", 13, 16], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 93, 103], ["Zika virus", "ORGANISM", 112, 122], ["Fab fragments", "PROTEIN", 13, 26], ["monoclonal antibodies", "PROTEIN", 32, 53], ["spike protein", "PROTEIN", 76, 89], ["SARS-CoV", "SPECIES", 93, 101], ["Zika virus", "SPECIES", 112, 122], ["Fab fragments", "PROBLEM", 13, 26], ["monoclonal antibodies", "TEST", 32, 53], ["the spike protein", "TEST", 72, 89], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["Zika virus particles", "PROBLEM", 112, 132], ["Fab fragments", "OBSERVATION", 13, 26], ["monoclonal antibodies", "OBSERVATION", 32, 53]]], ["More intriguing was the characterization of multiple epitopes simultaneously using polyclonal Fab from sera in a study of neutralizing antibodies of the HIV envelope trimer (32) .", [["sera", "ANATOMY", 103, 107], ["Fab", "GENE_OR_GENE_PRODUCT", 94, 97], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["epitopes", "PROTEIN", 53, 61], ["polyclonal Fab", "PROTEIN", 83, 97], ["neutralizing antibodies", "PROTEIN", 122, 145], ["HIV envelope trimer", "PROTEIN", 153, 172], ["HIV", "SPECIES", 153, 156], ["HIV", "SPECIES", 153, 156], ["multiple epitopes", "PROBLEM", 44, 61], ["polyclonal Fab", "TREATMENT", 83, 97], ["a study", "TEST", 111, 118], ["neutralizing antibodies", "TREATMENT", 122, 145], ["the HIV envelope trimer", "TREATMENT", 149, 172]]], ["The study was able to characterize several epitope sites from a small blood volume derived from an immunized animal.", [["blood", "ANATOMY", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["The study", "TEST", 0, 9], ["several epitope sites", "PROBLEM", 35, 56], ["a small blood volume", "PROBLEM", 62, 82], ["small", "OBSERVATION_MODIFIER", 64, 69], ["blood volume", "OBSERVATION", 70, 82]]], ["Notice that the antigens in all three cases were very large proteins or particles, which is favorable for Cryo-EM characterization but is not typical of allergens which are usually small proteins.", [["antigens", "PROTEIN", 16, 24], ["allergens", "PROTEIN", 153, 162], ["very large proteins or particles", "PROBLEM", 49, 81], ["Cryo-EM characterization", "TEST", 106, 130], ["allergens", "PROBLEM", 153, 162], ["small proteins", "PROBLEM", 181, 195], ["large", "OBSERVATION_MODIFIER", 54, 59], ["proteins", "OBSERVATION", 60, 68], ["particles", "OBSERVATION_MODIFIER", 72, 81], ["not typical of", "UNCERTAINTY", 138, 152], ["allergens", "OBSERVATION", 153, 162]]], ["However, in this rapidly developing field, studies like these may be feasible in the future for allergens.Protection Assays Combined With Mass Spectrometry (MS)Alternative methods for epitope mapping that rely on mass spectrometry are described in this section ( Table 1) .", [["allergens", "PROBLEM", 96, 105], ["Protection Assays", "TREATMENT", 106, 123], ["Mass Spectrometry (MS)", "TREATMENT", 138, 160], ["Alternative methods", "TREATMENT", 160, 179], ["epitope mapping", "TREATMENT", 184, 199], ["mass spectrometry", "PROBLEM", 213, 230]]], ["One of the MS approaches is called paratope or epitope \"excision\" (33) .", [["epitope \"excision", "TREATMENT", 47, 64]]], ["The excision procedure includes enzymatic proteolysis that allows for generation of peptides forming epitopes or paratopes, which later are identified using, for example, a combination of MALDI (matrix-assisted laser desorption/ionization) and ESI (electrospray ionization) mass spectrometry (33) (34) (35) .", [["epitopes", "PROTEIN", 101, 109], ["The excision procedure", "TREATMENT", 0, 22], ["enzymatic proteolysis", "PROBLEM", 32, 53], ["peptides forming epitopes or paratopes", "PROBLEM", 84, 122], ["MALDI (matrix-assisted laser desorption/ionization)", "TREATMENT", 188, 239], ["ESI (electrospray ionization", "TREATMENT", 244, 272], ["mass spectrometry", "TEST", 274, 291], ["excision", "OBSERVATION", 4, 12], ["enzymatic proteolysis", "OBSERVATION", 32, 53]]], ["This approach requires a small sample that does not need to be labeled.", [["a small sample", "TREATMENT", 23, 37], ["small", "OBSERVATION_MODIFIER", 25, 30]]], ["However, as most often the epitopes of interest are discontinuous/conformational in nature, excision is usually combined with chemical modification of the studied complexes.", [["epitopes", "PROTEIN", 27, 35], ["excision", "TREATMENT", 92, 100]]], ["The most common method of the chemical modification involves hydrogen-deuterium exchange (HDX).", [["hydrogen-deuterium", "CHEMICAL", 61, 79], ["hydrogen", "CHEMICAL", 61, 69], ["deuterium", "CHEMICAL", 70, 79], ["hydrogen-deuterium", "SIMPLE_CHEMICAL", 61, 79], ["the chemical modification", "TREATMENT", 26, 51], ["hydrogen-deuterium exchange", "TREATMENT", 61, 88], ["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["During this modification the antigen-antibody complex is placed in heavy water and protein backbone amide hydrogen atoms ( 1 H) can be exchanged for deuterium ( 2 H).", [["1 H", "CHEMICAL", 123, 126], ["amide", "CHEMICAL", 100, 105], ["hydrogen", "CHEMICAL", 106, 114], ["deuterium", "CHEMICAL", 149, 158], ["amide hydrogen atoms", "SIMPLE_CHEMICAL", 100, 120], ["antigen-antibody complex", "PROTEIN", 29, 53], ["this modification the antigen-antibody complex", "TREATMENT", 7, 53], ["heavy water and protein backbone amide hydrogen atoms", "TREATMENT", 67, 120]]], ["The rate of the 1 H-2 H exchange (HDX) depends on solvent accessibility and dynamics of a particular protein fragment.", [["H-2 H", "CHEMICAL", 18, 23], ["H-2 H", "CHEMICAL", 18, 23], ["H-2 H", "SIMPLE_CHEMICAL", 18, 23], ["protein fragment", "PROTEIN", 101, 117], ["a particular protein fragment", "PROBLEM", 88, 117], ["protein fragment", "OBSERVATION", 101, 117]]], ["Generally, hydrogens that are buried within the protein core or shielded from the solvent, such as hydrogens buried in an antigen-antibody interface will have a low rate of 1 H-2 H exchange.", [["H-2 H", "CHEMICAL", 175, 180], ["hydrogens", "CHEMICAL", 11, 20], ["H-2 H", "CHEMICAL", 175, 180], ["hydrogens", "SIMPLE_CHEMICAL", 11, 20], ["H-2 H", "SIMPLE_CHEMICAL", 175, 180], ["an antigen", "TEST", 119, 129], ["hydrogens", "OBSERVATION", 11, 20], ["antibody interface", "OBSERVATION", 130, 148]]], ["After the incubation in heavy water the complex undergoes enzymatic cleavage and the resulting peptides are identified by the change in mass, using MS. It is expected that surface residues forming epitopes and paratopes will have a relatively low level of incorporated 2 H. This information combined with the molecular models of the antigen and the antibody allows for mapping of the interacting molecular surfaces.", [["surface", "ANATOMY", 172, 179], ["epitopes", "PROTEIN", 197, 205], ["the incubation", "TREATMENT", 6, 20], ["enzymatic cleavage", "TREATMENT", 58, 76], ["the resulting peptides", "PROBLEM", 81, 103], ["the change in mass", "PROBLEM", 122, 140], ["surface residues forming epitopes and paratopes", "PROBLEM", 172, 219], ["the antigen", "TEST", 329, 340], ["the antibody", "TEST", 345, 357], ["enzymatic cleavage", "OBSERVATION", 58, 76], ["change", "OBSERVATION_MODIFIER", 126, 132], ["mass", "OBSERVATION", 136, 140], ["surface", "OBSERVATION_MODIFIER", 172, 179], ["molecular surfaces", "OBSERVATION", 396, 414]]], ["Therefore, HDX-MS became a very successful technique that not only has found application in analysis of antigen-antibody complexes, but also in mapping of other protein-ligand interactions (36, 37) .", [["HDX", "CHEMICAL", 11, 14], ["HDX", "SIMPLE_CHEMICAL", 11, 14], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 104, 120], ["antigen-antibody complexes", "PROTEIN", 104, 130], ["HDX", "TEST", 11, 14], ["MS", "PROBLEM", 15, 17], ["antigen-antibody complexes", "TEST", 104, 130]]], ["Moreover, HDX-MS can be used for studies of protein conformational dynamics, and was successfully used in characterization of the dynamic behavior of antibodies (38, 39) .", [["HDX", "CHEMICAL", 10, 13], ["antibodies", "PROTEIN", 150, 160], ["HDX", "TEST", 10, 13], ["MS", "PROBLEM", 14, 16], ["protein conformational dynamics", "TEST", 44, 75]]], ["1 H-2 H exchange is not the only chemical modification that can be applied in protection assays combined with mass spectrometry.", [["H-2 H", "CHEMICAL", 2, 7], ["1 H-2 H", "CHEMICAL", 0, 7], ["H-2 H", "SIMPLE_CHEMICAL", 2, 7], ["mass spectrometry", "PROBLEM", 110, 127]]], ["For example, various surface exposed amino acids can be oxidized by H 2 O 2 or modified by photochemically induced reactions (40, 41) .", [["surface", "ANATOMY", 21, 28], ["amino acids", "CHEMICAL", 37, 48], ["H 2 O", "CHEMICAL", 68, 73], ["amino acids", "CHEMICAL", 37, 48], ["H 2 O 2", "CHEMICAL", 68, 75], ["amino acids", "AMINO_ACID", 37, 48], ["H 2 O 2", "SIMPLE_CHEMICAL", 68, 75], ["various surface exposed amino acids", "TREATMENT", 13, 48], ["amino acids", "OBSERVATION", 37, 48]]], ["The modifications to the allergen before and after complexation with the antibody can be compared for epitope information.STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYThe X-ray crystallographic structures of allergen-antibody complexes were first determined for egg lysozyme with fragments of murine IgG monoclonal antibodies (mAb) (42) (43) (44) (45) (46) (47) .", [["egg lysozyme", "ORGANISM_SUBSTANCE", 283, 295], ["murine", "ORGANISM", 314, 320], ["IgG", "GENE_OR_GENE_PRODUCT", 321, 324], ["allergen-antibody complexes", "PROTEIN", 229, 256], ["egg lysozyme", "PROTEIN", 283, 295], ["murine IgG monoclonal antibodies", "PROTEIN", 314, 346], ["mAb", "PROTEIN", 348, 351], ["murine", "SPECIES", 314, 320], ["the antibody", "TREATMENT", 69, 81], ["ALLERGEN-ANTIBODY COMPLEXES", "TEST", 136, 163], ["X-RAY CRYSTALLOGRAPHYThe X-ray", "TEST", 167, 197], ["crystallographic structures of allergen-antibody complexes", "TEST", 198, 256], ["egg lysozyme", "TEST", 283, 295], ["fragments of murine IgG monoclonal antibodies", "TEST", 301, 346], ["mAb", "TEST", 348, 351]]], ["Subsequently, other structures were reported for other allergens, where murine IgG mAb were selected as surrogates for human IgE, due to their capacity to inhibit binding of human IgE antibody to the allergen ( Table 2 ) (48-53, 56, 58, 60-64) .", [["murine", "ORGANISM", 72, 78], ["IgG mAb", "GENE_OR_GENE_PRODUCT", 79, 86], ["human", "ORGANISM", 119, 124], ["IgE", "GENE_OR_GENE_PRODUCT", 125, 128], ["human", "ORGANISM", 174, 179], ["IgE antibody", "GENE_OR_GENE_PRODUCT", 180, 192], ["murine IgG mAb", "PROTEIN", 72, 86], ["human IgE", "PROTEIN", 119, 128], ["human IgE antibody", "PROTEIN", 174, 192], ["murine", "SPECIES", 72, 78], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 119, 124], ["human", "SPECIES", 174, 179], ["other allergens", "PROBLEM", 49, 64], ["murine IgG mAb", "TREATMENT", 72, 86], ["human IgE", "TEST", 119, 128], ["their capacity", "PROBLEM", 137, 151], ["human IgE antibody", "TEST", 174, 192]]], ["These studies involved the purification of an allergen either from the natural source or from in vitro cultures expressing recombinant allergens.", [["in vitro cultures", "CELL_LINE", 94, 111], ["recombinant allergens", "PROTEIN", 123, 144], ["These studies", "TEST", 0, 13], ["an allergen", "PROBLEM", 43, 54], ["vitro cultures", "TEST", 97, 111], ["recombinant allergens", "PROBLEM", 123, 144]]], ["The IgG mAb were cleaved using pepsin or papain, which resulted in F(ab \u2032 ) 2 -that was reduced to F(ab \u2032 )-or Fab, respectively.", [["IgG mAb", "GENE_OR_GENE_PRODUCT", 4, 11], ["pepsin", "GENE_OR_GENE_PRODUCT", 31, 37], ["papain", "GENE_OR_GENE_PRODUCT", 41, 47], ["Fab", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgG mAb", "PROTEIN", 4, 11], ["pepsin", "PROTEIN", 31, 37], ["Fab", "PROTEIN", 111, 114], ["The IgG mAb", "TREATMENT", 0, 11], ["pepsin", "TREATMENT", 31, 37], ["papain", "TREATMENT", 41, 47], ["F(ab \u2032 )", "TEST", 67, 75], ["Fab", "TEST", 111, 114]]], ["These antibody fragments contain the paratope and were purified and combined with the allergen to form a complex, which was purified for crystallography.STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYAlthough there are <20 different allergens that have their structures determined in complexes with antibodies ( Table 2) their analysis provides interesting insights into epitopes and paratopes.", [["fragments", "ANATOMY", 15, 24], ["antibodies", "PROTEIN", 318, 328], ["epitopes", "PROTEIN", 390, 398], ["These antibody fragments", "PROBLEM", 0, 24], ["crystallography", "TEST", 137, 152], ["X-RAY CRYSTALLOGRAPHYAlthough", "TEST", 198, 227], ["20 different allergens", "PROBLEM", 239, 261], ["their analysis", "TEST", 340, 354], ["antibody fragments", "OBSERVATION", 6, 24]]], ["Chicken lysozyme (Gal d 4) is often used as a test molecule and there is a vast amount of literature on the use of this protein to study interactions with antibodies.", [["Gal d 4", "CHEMICAL", 18, 25], ["Chicken", "ORGANISM", 0, 7], ["lysozyme", "GENE_OR_GENE_PRODUCT", 8, 16], ["Gal d 4", "GENE_OR_GENE_PRODUCT", 18, 25], ["Chicken lysozyme", "PROTEIN", 0, 16], ["Gal d 4", "PROTEIN", 18, 25], ["antibodies", "PROTEIN", 155, 165], ["Chicken", "SPECIES", 0, 7], ["Chicken", "SPECIES", 0, 7], ["Chicken lysozyme (Gal d 4", "TREATMENT", 0, 25], ["a test molecule", "TEST", 44, 59], ["this protein", "TREATMENT", 115, 127]]], ["Therefore, to avoid bias that a large number of lysozyme-antibody complex may cause we selected for analyses only some representative structures.", [["lysozyme", "GENE_OR_GENE_PRODUCT", 48, 56], ["lysozyme", "PROTEIN", 48, 56], ["antibody complex", "PROTEIN", 57, 73], ["lysozyme-antibody complex", "TREATMENT", 48, 73], ["large", "OBSERVATION_MODIFIER", 32, 37]]], ["While allergens have a wide variety of structures, antibodies of the same isotype have the same structure, formed by immunoglobulin-fold domains of about 100 amino acids.", [["amino acids", "CHEMICAL", 158, 169], ["amino acids", "CHEMICAL", 158, 169], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 117, 131], ["amino acids", "AMINO_ACID", 158, 169], ["antibodies", "PROTEIN", 51, 61], ["immunoglobulin-fold domains", "PROTEIN", 117, 144], ["a wide variety of structures", "PROBLEM", 21, 49], ["immunoglobulin", "TEST", 117, 131], ["amino acids", "TREATMENT", 158, 169]]], ["Light chains have an N-terminal variable domain (V L ) followed by a constant domain.", [["N", "CHEMICAL", 21, 22], ["N-terminal variable domain", "PROTEIN", 21, 47], ["V L", "PROTEIN", 49, 52], ["Light chains", "TEST", 0, 12], ["terminal variable domain (V L )", "TREATMENT", 23, 54]]], ["Similarly, heavy chains have a variable N-terminal domain (V H ), but it is followed by either 3 (in IgG) or 4 (in IgE) constant domains.", [["N", "CHEMICAL", 40, 41], ["IgG", "GENE_OR_GENE_PRODUCT", 101, 104], ["heavy chains", "PROTEIN", 11, 23], ["N-terminal domain", "PROTEIN", 40, 57], ["V H", "PROTEIN", 59, 62], ["IgG", "PROTEIN", 101, 104], ["IgE", "PROTEIN", 115, 118], ["heavy", "OBSERVATION_MODIFIER", 11, 16], ["chains", "OBSERVATION_MODIFIER", 17, 23], ["variable", "OBSERVATION_MODIFIER", 31, 39]]], ["The central part of these domains is made of anti-parallel \u03b2-sheets, in which \u03b2-strands are linked to form the so-called Greek-key motifs.", [["anti-parallel \u03b2-sheets", "PROTEIN", 45, 67], ["Greek-key motifs", "PROTEIN", 121, 137], ["anti-parallel \u03b2-sheets", "TREATMENT", 45, 67], ["central", "ANATOMY_MODIFIER", 4, 11]]], ["For example, IgG V H domain is made of anti-parallel \u03b2-sheets composed of nine \u03b2-strands that are linked by eight loops (Figure 1 ) (65) .", [["IgG V H", "GENE_OR_GENE_PRODUCT", 13, 20], ["IgG V H domain", "PROTEIN", 13, 27], ["anti-parallel \u03b2-sheets", "PROTEIN", 39, 61], ["\u03b2-strands", "PROTEIN", 79, 88], ["anti-parallel \u03b2-sheets", "TREATMENT", 39, 61], ["nine \u03b2-strands", "TREATMENT", 74, 88], ["loops", "OBSERVATION_MODIFIER", 114, 119]]], ["Of the four apical loops, only loops 1, 2, and 4 interact with the antigen, and contain the complementary determining regions (CDRs): CDR1, CDR2, and CDR3, respectively.", [["apical loops", "ANATOMY", 12, 24], ["2", "GENE_OR_GENE_PRODUCT", 40, 41], ["4", "GENE_OR_GENE_PRODUCT", 47, 48], ["CDR1", "GENE_OR_GENE_PRODUCT", 134, 138], ["CDR2", "GENE_OR_GENE_PRODUCT", 140, 144], ["CDR3", "GENE_OR_GENE_PRODUCT", 150, 154], ["loops 1, 2, and 4", "PROTEIN", 31, 48], ["complementary determining regions", "PROTEIN", 92, 125], ["CDRs", "PROTEIN", 127, 131], ["CDR1", "DNA", 134, 138], ["CDR2", "DNA", 140, 144], ["CDR3", "DNA", 150, 154], ["CDR2", "TEST", 140, 144], ["four", "ANATOMY_MODIFIER", 7, 11], ["apical", "ANATOMY_MODIFIER", 12, 18], ["loops", "ANATOMY_MODIFIER", 19, 24], ["loops", "ANATOMY_MODIFIER", 31, 36]]], ["The loops 1, 2, and 4 are between beta-sheets B-C, C \u2032 -C \u2032\u2032 , and F-G, respectively (Figure 1) .", [["beta-sheets B-C", "SIMPLE_CHEMICAL", 34, 49], ["C \u2032 -C \u2032\u2032", "SIMPLE_CHEMICAL", 51, 60], ["F-G", "SIMPLE_CHEMICAL", 67, 70], ["loops 1, 2, and 4", "DNA", 4, 21], ["beta", "PROTEIN", 34, 38], ["B", "PROTEIN", 46, 47], ["C", "PROTEIN", 48, 49], ["The loops", "TEST", 0, 9], ["beta", "TEST", 34, 38], ["C", "TEST", 51, 52], ["loops", "ANATOMY_MODIFIER", 4, 9]]], ["A similar \u03b2-sheet configuration occurs in the light chain.", [["light chain", "PROTEIN", 46, 57], ["light", "OBSERVATION_MODIFIER", 46, 51], ["chain", "OBSERVATION_MODIFIER", 52, 57]]], ["The 6 loops involved in paratope formation form the following CDRs: H CDR1, H CDR2, H CDR3 in the heavy chain, and L CDR1, L CDR2, and L CDR3 in the light chain.", [["paratope", "SIMPLE_CHEMICAL", 24, 32], ["H CDR1", "GENE_OR_GENE_PRODUCT", 68, 74], ["H CDR2", "GENE_OR_GENE_PRODUCT", 76, 82], ["H CDR3", "GENE_OR_GENE_PRODUCT", 84, 90], ["L CDR1", "GENE_OR_GENE_PRODUCT", 115, 121], ["L CDR2", "GENE_OR_GENE_PRODUCT", 123, 129], ["L CDR3", "GENE_OR_GENE_PRODUCT", 135, 141], ["H CDR1", "PROTEIN", 68, 74], ["H CDR2", "PROTEIN", 76, 82], ["H CDR3", "PROTEIN", 84, 90], ["heavy chain", "PROTEIN", 98, 109], ["L CDR1", "PROTEIN", 115, 121], ["L CDR2", "PROTEIN", 123, 129], ["L CDR3", "PROTEIN", 135, 141], ["light chain", "PROTEIN", 149, 160], ["H CDR2", "TEST", 76, 82], ["H CDR3", "TEST", 84, 90], ["heavy chain", "ANATOMY", 98, 109], ["L", "ANATOMY_MODIFIER", 115, 116], ["CDR1", "ANATOMY", 117, 121], ["L", "ANATOMY_MODIFIER", 123, 124], ["CDR2", "ANATOMY", 125, 129], ["L", "ANATOMY_MODIFIER", 135, 136], ["CDR3", "ANATOMY", 137, 141], ["light", "ANATOMY_MODIFIER", 149, 154], ["chain", "ANATOMY_MODIFIER", 155, 160]]], ["The CDRs contain the amino acids that form the paratope.", [["amino acids", "CHEMICAL", 21, 32], ["amino acids", "CHEMICAL", 21, 32], ["amino acids", "AMINO_ACID", 21, 32], ["CDRs", "PROTEIN", 4, 8], ["the amino acids", "TREATMENT", 17, 32], ["amino acids", "OBSERVATION", 21, 32]]], ["The H CDR3 is sufficient for most antibody specificities (66), although exceptions have been found (67) .", [["H CDR3", "GENE_OR_GENE_PRODUCT", 4, 10], ["H CDR3", "PROTEIN", 4, 10], ["The H CDR3", "TEST", 0, 10], ["most antibody specificities", "TEST", 29, 56]]], ["In a few cases, additional residues outside the CDR, located in the \"framework\" of the antibody, can also contribute to antibody binding.", [["CDR", "PROTEIN", 48, 51], ["antibody binding", "PROBLEM", 120, 136]]], ["While epitopes can be located on different parts of the allergen surface, paratopes are always at the apical region of the variable domain of the antibody, formed by the 6 CDRs.", [["surface", "ANATOMY", 65, 72], ["apical region", "ANATOMY", 102, 115], ["allergen surface", "CELLULAR_COMPONENT", 56, 72], ["apical region", "CELLULAR_COMPONENT", 102, 115], ["epitopes", "PROTEIN", 6, 14], ["variable domain", "PROTEIN", 123, 138], ["antibody", "PROTEIN", 146, 154], ["CDRs", "PROTEIN", 172, 176], ["allergen surface", "OBSERVATION", 56, 72], ["apical", "ANATOMY_MODIFIER", 102, 108], ["region", "ANATOMY_MODIFIER", 109, 115], ["variable", "OBSERVATION_MODIFIER", 123, 131], ["domain", "OBSERVATION_MODIFIER", 132, 138], ["antibody", "ANATOMY", 146, 154]]], ["The CDR boundaries have been historically defined in different ways (68) (69) (70) , and currently the ImmunoGenetics website (www.imgt.org) utilizes a consensus for their estimation.", [["their estimation", "TEST", 166, 182]]], ["A significant fraction of the available allergen-antibody structures corresponds to complexes of Group 1-the best studied-and Group 2 house dust mite allergens, and the cockroach allergen Bla g 2 (Figure 2) .", [["the cockroach allergen", "TREATMENT", 165, 187], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["fraction", "OBSERVATION", 14, 22]]], ["A major allergen is one to which >50% of subjects allergic to the allergen source are sensitized.", [["allergic", "DISEASE", 50, 58], ["A major allergen", "PROBLEM", 0, 16], ["subjects allergic", "PROBLEM", 41, 58], ["major", "OBSERVATION_MODIFIER", 2, 7], ["allergen", "OBSERVATION", 8, 16]]], ["Group 1 includes Der p 1, Der f 1, Blo t 1, and others, and are cysteine proteases.", [["cysteine", "CHEMICAL", 64, 72], ["Der p 1", "GENE_OR_GENE_PRODUCT", 17, 24], ["Der f 1", "GENE_OR_GENE_PRODUCT", 26, 33], ["Blo t 1", "GENE_OR_GENE_PRODUCT", 35, 42], ["Der f 1", "PROTEIN", 26, 33], ["cysteine proteases", "PROTEIN", 64, 82]]], ["Group 2 includes Der p 2, Der f 2, Blo t 2, and others with an MD-2-related lipid-recognition (ML) domain (www.allergen.org).", [["lipid-recognition (ML) domain", "PROTEIN", 76, 105], ["www.allergen.org", "PROTEIN", 107, 123]]], ["Three X-ray crystal structures of Der p 1 have been determined in complexes with three different murine IgG mAb (4C1, 5H8, and 10B9), from which mAb 4C1 is a cross-reacting antibody that also binds to Der f 1 (53, 56) .", [["Der p 1", "GENE_OR_GENE_PRODUCT", 34, 41], ["murine", "ORGANISM", 97, 103], ["IgG mAb", "GENE_OR_GENE_PRODUCT", 104, 111], ["5H8", "GENE_OR_GENE_PRODUCT", 118, 121], ["4C1", "GENE_OR_GENE_PRODUCT", 149, 152], ["Der f 1", "GENE_OR_GENE_PRODUCT", 201, 208], ["Der p 1", "PROTEIN", 34, 41], ["murine IgG mAb", "PROTEIN", 97, 111], ["4C1", "PROTEIN", 113, 116], ["5H8", "PROTEIN", 118, 121], ["10B9", "PROTEIN", 127, 131], ["mAb 4C1", "PROTEIN", 145, 152], ["cross-reacting antibody", "PROTEIN", 158, 181], ["Der f 1", "PROTEIN", 201, 208], ["murine", "SPECIES", 97, 103], ["a cross-reacting antibody", "PROBLEM", 156, 181], ["IgG mAb", "OBSERVATION", 104, 111]]], ["Comparison of Der f 1 and Der p 1 structures with 4C1 revealed that the cross-reactive mAb binds to a conserved surface patch that is present on both allergens (53) .", [["surface", "ANATOMY", 112, 119], ["Der f 1", "GENE_OR_GENE_PRODUCT", 14, 21], ["Der p 1", "GENE_OR_GENE_PRODUCT", 26, 33], ["mAb", "GENE_OR_GENE_PRODUCT", 87, 90], ["Der f 1", "PROTEIN", 14, 21], ["Der p 1 structures", "PROTEIN", 26, 44], ["4C1", "PROTEIN", 50, 53], ["cross-reactive mAb", "PROTEIN", 72, 90], ["Der f 1 and Der p 1 structures", "TEST", 14, 44], ["the cross-reactive mAb binds", "PROBLEM", 68, 96], ["a conserved surface patch", "TREATMENT", 100, 125], ["surface", "OBSERVATION_MODIFIER", 112, 119]]], ["Unexpectedly, this patch is not a part of the largest conserved surface area in common for both Der f 1 and Der p 1, and which includes the active site of the enzymes.", [["surface area", "ANATOMY", 64, 76], ["Der f 1", "GENE_OR_GENE_PRODUCT", 96, 103], ["Der p 1", "GENE_OR_GENE_PRODUCT", 108, 115], ["Der f 1", "PROTEIN", 96, 103], ["Der p 1", "PROTEIN", 108, 115], ["enzymes", "PROTEIN", 159, 166], ["this patch", "TREATMENT", 14, 24], ["the enzymes", "TEST", 155, 166], ["surface", "OBSERVATION_MODIFIER", 64, 71], ["active", "OBSERVATION", 140, 146]]], ["The majority of the amino acids forming the central part of the epitope are conserved, and in very similar conformations.", [["amino acids", "CHEMICAL", 20, 31], ["amino acids", "CHEMICAL", 20, 31], ["amino acids", "AMINO_ACID", 20, 31], ["epitope", "PROTEIN", 64, 71], ["the amino acids", "TEST", 16, 31], ["amino acids", "OBSERVATION", 20, 31], ["central", "OBSERVATION_MODIFIER", 44, 51], ["epitope", "OBSERVATION", 64, 71]]], ["Interestingly, the epitopes for 10B9 and 4C1 partially overlap, but 10B9 is Structures of complexes with antibodies were superposed to compare location of epitopes.", [["10B9", "GENE_OR_GENE_PRODUCT", 32, 36], ["4C1", "GENE_OR_GENE_PRODUCT", 41, 44], ["epitopes", "PROTEIN", 19, 27], ["10B9", "PROTEIN", 32, 36], ["4C1", "PROTEIN", 41, 44], ["10B9", "PROTEIN", 68, 72], ["antibodies", "PROTEIN", 105, 115], ["epitopes", "PROTEIN", 155, 163], ["partially overlap", "PROBLEM", 45, 62], ["antibodies", "PROBLEM", 105, 115], ["epitopes", "PROBLEM", 155, 163]]], ["Epitopes on Der p 1 for mAb 4C1 and 10B9 partially overlap, but they both are far from the epitope recognized by 5H8.", [["Der p 1", "GENE_OR_GENE_PRODUCT", 12, 19], ["mAb", "GENE_OR_GENE_PRODUCT", 24, 27], ["10B9", "GENE_OR_GENE_PRODUCT", 36, 40], ["Der p 1", "PROTEIN", 12, 19], ["mAb 4C1", "PROTEIN", 24, 31], ["10B9", "PROTEIN", 36, 40], ["5H8", "PROTEIN", 113, 116], ["mAb", "TEST", 24, 27], ["overlap", "OBSERVATION", 51, 58]]], ["Epitope on Bla g 2 that is recognized by antibody 4C3 included a carbohydrate (shown here as orange spheres).", [["carbohydrate", "CHEMICAL", 65, 77], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 11, 18], ["Bla g 2", "PROTEIN", 11, 18], ["antibody 4C3", "PROTEIN", 41, 53], ["Epitope on Bla g", "TREATMENT", 0, 16], ["a carbohydrate", "TREATMENT", 63, 77]]], ["Fab fragments of the antibodies are shown in space-filling models, and allergens are shown using ribbon representations.", [["Fab", "GENE_OR_GENE_PRODUCT", 0, 3], ["antibodies", "PROTEIN", 21, 31], ["Fab fragments of the antibodies", "TEST", 0, 31], ["allergens", "PROBLEM", 71, 80], ["filling models", "OBSERVATION", 51, 65]]], ["Light chains are marked using lighter colors.STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYnot able to bind to Der f 1.", [["Der f 1", "GENE_OR_GENE_PRODUCT", 131, 138], ["Der f 1", "PROTEIN", 131, 138], ["Light chains", "PROBLEM", 0, 12], ["chains", "OBSERVATION_MODIFIER", 6, 12], ["marked", "OBSERVATION_MODIFIER", 17, 23]]], ["The epitope for 4C1 is \"rotated counterclockwise\" by \u223c90 \u2022 in relation to the position of the 10B9 epitope on Der p 1.", [["Der p 1", "GENE_OR_GENE_PRODUCT", 110, 117], ["4C1", "PROTEIN", 16, 19], ["10B9 epitope", "PROTEIN", 94, 106], ["Der p 1", "PROTEIN", 110, 117]]], ["On the other hand, the 5H8 binding epitope is located at a significant distance from both 4C1 and 10B9 epitopes.", [["5H8 binding epitope", "PROTEIN", 23, 42], ["4C1", "PROTEIN", 90, 93], ["10B9 epitopes", "PROTEIN", 98, 111], ["significant", "OBSERVATION_MODIFIER", 59, 70]]], ["The image of the structure of three Der p 1antibody complexes clearly illustrates that mAb 5H8 and 4C1 or 10B9 can simultaneously bind to the same allergen molecule (Figure 2 ) (56) .", [["mAb 5H8", "SIMPLE_CHEMICAL", 87, 94], ["4C1", "SIMPLE_CHEMICAL", 99, 102], ["10B9", "SIMPLE_CHEMICAL", 106, 110], ["Der p 1antibody complexes", "PROTEIN", 36, 61], ["mAb 5H8", "PROTEIN", 87, 94], ["4C1", "PROTEIN", 99, 102], ["10B9", "PROTEIN", 106, 110], ["allergen molecule", "PROTEIN", 147, 164], ["mAb", "TEST", 87, 90]]], ["Bla g 2 has a bilobal structure typical of aspartic proteases, but it is enzymatically inactive due to substitutions in the catalytic site (71, 72) .", [["Bla g 2", "GENE_OR_GENE_PRODUCT", 0, 7], ["Bla g 2", "PROTEIN", 0, 7], ["aspartic proteases", "PROTEIN", 43, 61], ["catalytic site", "PROTEIN", 124, 138], ["aspartic proteases", "PROBLEM", 43, 61], ["substitutions in the catalytic site", "PROBLEM", 103, 138], ["bilobal structure", "OBSERVATION", 14, 31], ["aspartic proteases", "OBSERVATION", 43, 61], ["inactive", "OBSERVATION", 87, 95], ["substitutions", "OBSERVATION", 103, 116]]], ["Two structures of Bla g 2 with mAb 7C11 and 4C3 have been determined, showing their binding to opposite lobes of the molecule (50, 52) .", [["Bla g 2", "GENE_OR_GENE_PRODUCT", 18, 25], ["mAb 7C11", "GENE_OR_GENE_PRODUCT", 31, 39], ["4C3", "GENE_OR_GENE_PRODUCT", 44, 47], ["Bla g 2", "PROTEIN", 18, 25], ["mAb 7C11", "PROTEIN", 31, 39], ["4C3", "PROTEIN", 44, 47], ["mAb", "TEST", 31, 34], ["lobes", "ANATOMY_MODIFIER", 104, 109], ["molecule", "ANATOMY_MODIFIER", 117, 125]]], ["The complex with mAb 4C3 was unique because it showed that carbohydrates contributed to the interactions with Bla g 2 (Figure 2) .", [["carbohydrates", "CHEMICAL", 59, 72], ["mAb 4C3", "SIMPLE_CHEMICAL", 17, 24], ["carbohydrates", "SIMPLE_CHEMICAL", 59, 72], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 110, 117], ["mAb 4C3", "PROTEIN", 17, 24], ["Bla g 2", "PROTEIN", 110, 117], ["mAb", "TREATMENT", 17, 20]]], ["The murine IgG mAbs used in these crystallographic studies were chosen as surrogate IgE antibodies, because they inhibit binding of IgE to the allergen.", [["murine", "ORGANISM", 4, 10], ["IgG mAbs", "GENE_OR_GENE_PRODUCT", 11, 19], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 84, 98], ["IgE", "GENE_OR_GENE_PRODUCT", 132, 135], ["murine IgG mAbs", "PROTEIN", 4, 19], ["IgE antibodies", "PROTEIN", 84, 98], ["IgE", "PROTEIN", 132, 135], ["murine", "SPECIES", 4, 10], ["The murine IgG mAbs", "TREATMENT", 0, 19], ["these crystallographic studies", "TEST", 28, 58], ["surrogate IgE antibodies", "TEST", 74, 98]]], ["Once the IgG epitope was identified, site-directed mutagenesis of the allergen residues involved in antibody recognition was performed, followed by IgE antibody binding analysis of the mutants, to identify IgE antibody binding sites.", [["IgG", "GENE_OR_GENE_PRODUCT", 9, 12], ["IgE antibody", "GENE_OR_GENE_PRODUCT", 148, 160], ["IgE antibody", "GENE_OR_GENE_PRODUCT", 206, 218], ["IgG epitope", "PROTEIN", 9, 20], ["IgE antibody", "PROTEIN", 148, 160], ["IgE antibody binding sites", "DNA", 206, 232], ["the IgG epitope", "TREATMENT", 5, 20], ["the allergen residues", "TREATMENT", 66, 87], ["antibody recognition", "TEST", 100, 120], ["IgE antibody binding analysis", "TEST", 148, 177], ["the mutants", "PROBLEM", 181, 192], ["IgE antibody binding sites", "PROBLEM", 206, 232], ["allergen residues", "OBSERVATION", 70, 87]]], ["This approach resulted in the design and production of allergen mutants with decreased capacity to bind IgE, which are being investigated as future candidates for immunotherapy (51, 58, 67, 73) .STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYThe antibodies in the majority of allergen-antibody complexes that have their structures determined are IgG1.", [["IgE", "GENE_OR_GENE_PRODUCT", 104, 107], ["IgG1", "GENE_OR_GENE_PRODUCT", 365, 369], ["IgE", "PROTEIN", 104, 107], ["allergen-antibody complexes", "PROTEIN", 295, 322], ["IgG1", "PROTEIN", 365, 369], ["allergen mutants", "PROBLEM", 55, 71], ["decreased capacity", "PROBLEM", 77, 95], ["immunotherapy", "TREATMENT", 163, 176], ["STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES", "TEST", 195, 236], ["X-RAY CRYSTALLOGRAPHYThe antibodies", "TEST", 240, 275], ["allergen-antibody complexes", "TEST", 295, 322]]], ["However, three of the structures reported in Table 2 are different from the IgG1 isotype: 1) IgG4 (in complex with Fel d 1), 2) an IgG1 construct engineered to combine the constant domains of human IgG1 heavy and kappa light chains with variable regions of a human IgE construct derived from an scFv combinatorial library (in complex with Bos d 5), or 3) an Fab isolated from a combinatorial library, which is a hybrid of the variable domain of the IgE Fab and the constant domain of human IgG1 (in complex with Phl p 2) (60, 63, 64).", [["IgG1", "GENE_OR_GENE_PRODUCT", 76, 80], ["IgG4", "GENE_OR_GENE_PRODUCT", 93, 97], ["Fel d 1", "GENE_OR_GENE_PRODUCT", 115, 122], ["IgG1", "GENE_OR_GENE_PRODUCT", 131, 135], ["human", "ORGANISM", 192, 197], ["IgG1 heavy and kappa light chains", "GENE_OR_GENE_PRODUCT", 198, 231], ["human", "ORGANISM", 259, 264], ["IgE", "GENE_OR_GENE_PRODUCT", 265, 268], ["Bos d 5", "ORGANISM", 339, 346], ["Fab", "GENE_OR_GENE_PRODUCT", 358, 361], ["IgE Fab", "GENE_OR_GENE_PRODUCT", 449, 456], ["human", "ORGANISM", 484, 489], ["IgG1", "GENE_OR_GENE_PRODUCT", 490, 494], ["Phl p 2", "GENE_OR_GENE_PRODUCT", 512, 519], ["IgG1 isotype", "PROTEIN", 76, 88], ["IgG4", "PROTEIN", 93, 97], ["Fel d 1", "PROTEIN", 115, 122], ["IgG1", "PROTEIN", 131, 135], ["human IgG1 heavy and kappa light chains", "PROTEIN", 192, 231], ["human IgE construct", "DNA", 259, 278], ["scFv combinatorial library", "DNA", 295, 321], ["Bos d 5", "PROTEIN", 339, 346], ["Fab", "PROTEIN", 358, 361], ["variable domain", "PROTEIN", 426, 441], ["IgE Fab", "PROTEIN", 449, 456], ["constant domain", "PROTEIN", 465, 480], ["human IgG1", "PROTEIN", 484, 494], ["Phl p 2", "PROTEIN", 512, 519], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 259, 264], ["human", "SPECIES", 484, 489], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 259, 264], ["human", "SPECIES", 484, 489], ["an IgG1 construct", "TREATMENT", 128, 145], ["kappa light chains", "TREATMENT", 213, 231], ["a human IgE construct", "TREATMENT", 257, 278], ["an scFv combinatorial library", "TREATMENT", 292, 321], ["an Fab", "TEST", 355, 361], ["the IgE Fab", "TREATMENT", 445, 456], ["the constant domain of human IgG1", "TREATMENT", 461, 494]]], ["The IgG4 (REGN1909) binding Fel d 1 is a fully humanized antibody that was derived from mice immunized with recombinant dimeric Fel d 1 (60) .", [["IgG4", "GENE_OR_GENE_PRODUCT", 4, 8], ["REGN1909", "SIMPLE_CHEMICAL", 10, 18], ["Fel d 1", "GENE_OR_GENE_PRODUCT", 28, 35], ["mice", "ORGANISM", 88, 92], ["IgG4 (REGN1909) binding Fel d 1", "PROTEIN", 4, 35], ["humanized antibody", "PROTEIN", 47, 65], ["recombinant dimeric Fel d 1", "PROTEIN", 108, 135], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["The IgG4", "TEST", 0, 8], ["a fully humanized antibody", "PROBLEM", 39, 65]]], ["REGN1909 is able to partially block IgE binding to natural Fel d 1, with a maximum inhibition of 51%.", [["REGN1909", "CHEMICAL", 0, 8], ["REGN1909", "CHEMICAL", 0, 8], ["REGN1909", "SIMPLE_CHEMICAL", 0, 8], ["IgE", "GENE_OR_GENE_PRODUCT", 36, 39], ["IgE", "PROTEIN", 36, 39], ["partially block IgE binding", "PROBLEM", 20, 47], ["a maximum inhibition", "TEST", 73, 93]]], ["REGN1909 together with another IgG4 (REGN1908), which binds to a different nonoverlapping epitope, was able to block up to 83% of IgE binding to natural Fel d 1.", [["REGN1909", "CHEMICAL", 0, 8], ["REGN1909", "CHEMICAL", 0, 8], ["REGN1909", "SIMPLE_CHEMICAL", 0, 8], ["IgG4", "GENE_OR_GENE_PRODUCT", 31, 35], ["REGN1908", "GENE_OR_GENE_PRODUCT", 37, 45], ["IgE", "GENE_OR_GENE_PRODUCT", 130, 133], ["Fel d 1", "GENE_OR_GENE_PRODUCT", 153, 160], ["IgG4", "PROTEIN", 31, 35], ["REGN1908", "PROTEIN", 37, 45], ["IgE", "PROTEIN", 130, 133], ["natural Fel d 1", "PROTEIN", 145, 160]]], ["A combination of X-ray crystallography and HDX-MS was used to elucidate information on the antibody binding epitopes for REGN1908 and REGN1909.", [["REGN1909", "CHEMICAL", 134, 142], ["REGN1909", "CHEMICAL", 134, 142], ["REGN1908", "SIMPLE_CHEMICAL", 121, 129], ["REGN1909", "SIMPLE_CHEMICAL", 134, 142], ["antibody binding epitopes", "PROTEIN", 91, 116], ["X-ray crystallography", "TEST", 17, 38], ["HDX", "TEST", 43, 46], ["MS", "PROBLEM", 47, 49], ["the antibody binding epitopes", "PROBLEM", 87, 116]]], ["Only the crystal structure of Fel d 1 in complex with REGN1908 was obtained (60) .STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYWhile most often the antibodies that are used in studies of allergens are composed of light and heavy chains with six total CDRs, there are also examples of heavy chain only antibodies.", [["REGN1908", "CHEMICAL", 54, 62], ["Fel d 1", "GENE_OR_GENE_PRODUCT", 30, 37], ["REGN1908", "SIMPLE_CHEMICAL", 54, 62], ["Fel d 1", "PROTEIN", 30, 37], ["REGN1908", "PROTEIN", 54, 62], ["antibodies", "PROTEIN", 169, 179], ["CDRs", "PROTEIN", 272, 276], ["heavy chain only antibodies", "PROTEIN", 305, 332], ["STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES", "TEST", 82, 123], ["X-RAY CRYSTALLOGRAPHYWhile", "TEST", 127, 153], ["the antibodies", "TEST", 165, 179], ["allergens", "PROBLEM", 208, 217], ["six total CDRs", "TREATMENT", 262, 276], ["heavy chain only antibodies", "PROBLEM", 305, 332], ["crystal", "OBSERVATION_MODIFIER", 9, 16]]], ["These can contain two heavy chains only (and therefore have 3CDRs for recognition per chain) or single domain antibodies, which have a single antigen binding domain (74) (75) (76) .", [["heavy chains", "PROTEIN", 22, 34], ["3CDRs", "PROTEIN", 60, 65], ["recognition per chain", "PROTEIN", 70, 91], ["single domain antibodies", "PROTEIN", 96, 120], ["antigen binding domain", "PROTEIN", 142, 164], ["single domain antibodies", "TEST", 96, 120], ["two", "OBSERVATION_MODIFIER", 18, 21], ["heavy", "OBSERVATION_MODIFIER", 22, 27], ["chains", "OBSERVATION_MODIFIER", 28, 34]]], ["Heavy chain only antibodies are present in nature and are produced by camelids and sharks.", [["antibodies", "PROTEIN", 17, 27], ["Heavy chain only antibodies", "PROBLEM", 0, 27], ["chain", "OBSERVATION_MODIFIER", 6, 11], ["antibodies", "OBSERVATION", 17, 27]]], ["The paratopes formed by the single chain antibodies have a very similar amino acid composition to that observed in conventional antibodies (77, 78) .", [["amino acid", "CHEMICAL", 72, 82], ["amino acid", "CHEMICAL", 72, 82], ["amino acid", "AMINO_ACID", 72, 82], ["single chain antibodies", "PROTEIN", 28, 51], ["antibodies", "PROTEIN", 128, 138], ["the single chain antibodies", "TEST", 24, 51], ["a very similar amino acid composition", "PROBLEM", 57, 94]]], ["The heavy chain only antibodies, and especially their V H domains, are relatively easy to produce and their biophysical, as well as structural properties, allow for easy application in biotechnology and therapeutics (77, 79) .", [["heavy chain", "PROTEIN", 4, 15], ["antibodies", "PROTEIN", 21, 31], ["V H domains", "PROTEIN", 54, 65], ["heavy", "OBSERVATION_MODIFIER", 4, 9], ["chain", "OBSERVATION_MODIFIER", 10, 15]]], ["Single domain antibodies (specific for lysozyme) were isolated years before discovery of heavy chain antibodies in camelids (76) , and were proposed as alternative to conventional monoclonal antibodies.", [["lysozyme", "GENE_OR_GENE_PRODUCT", 39, 47], ["Single domain antibodies", "PROTEIN", 0, 24], ["lysozyme", "PROTEIN", 39, 47], ["heavy chain antibodies", "PROTEIN", 89, 111], ["monoclonal antibodies", "PROTEIN", 180, 201], ["Single domain antibodies", "TEST", 0, 24], ["lysozyme", "TEST", 39, 47], ["heavy chain antibodies in camelids", "PROBLEM", 89, 123], ["conventional monoclonal antibodies", "TEST", 167, 201]]], ["Later on, camelids' V H domains also became a model for the generation of their human equivalents.", [["V H", "GENE_OR_GENE_PRODUCT", 20, 23], ["human", "ORGANISM", 80, 85], ["V H domains", "PROTEIN", 20, 31], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85]]], ["Fully human V H single domains were used to generate complexes with Gal d 4 ( Table 2 ) (61) .STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYA new type of allergen-antibody interaction was recently reported thanks to the determination of a Phl p 7-antibody crystal structure (Figure 3 ) (62) .", [["human", "ORGANISM", 6, 11], ["Gal d 4", "GENE_OR_GENE_PRODUCT", 68, 75], ["human V H single domains", "DNA", 6, 30], ["Gal d 4", "PROTEIN", 68, 75], ["Phl p 7", "PROTEIN", 259, 266], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["Fully human V H single domains", "TREATMENT", 0, 30], ["Gal d", "TREATMENT", 68, 73], ["STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES", "TEST", 94, 135], ["X-RAY", "TEST", 139, 144], ["allergen-antibody interaction", "PROBLEM", 174, 203], ["a Phl p 7-antibody crystal structure", "TEST", 257, 293]]], ["An IgG4 originally generated from single B cell cloning was converted into an IgG1 for structure determination of the allergen-antibody complex.", [["B cell", "ANATOMY", 41, 47], ["IgG4", "GENE_OR_GENE_PRODUCT", 3, 7], ["B cell", "CELL", 41, 47], ["IgG1", "GENE_OR_GENE_PRODUCT", 78, 82], ["IgG4", "PROTEIN", 3, 7], ["IgG1", "PROTEIN", 78, 82], ["allergen-antibody complex", "PROTEIN", 118, 143], ["An IgG4", "TEST", 0, 7], ["single B cell cloning", "TREATMENT", 34, 55], ["the allergen-antibody complex", "TREATMENT", 114, 143]]], ["The structure revealed that two antibodies bind simultaneously to Phl p 7 in two different ways: (1) the classical mode that involves both heavy and light chains of the antibody, and (2) an unusual non-standard way, involving only binding of the light chain to the allergen to a separate Phl p 7.", [["Phl p 7", "GENE_OR_GENE_PRODUCT", 66, 73], ["antibodies", "PROTEIN", 32, 42], ["Phl p 7", "PROTEIN", 66, 73], ["heavy and light chains", "PROTEIN", 139, 161], ["antibody", "PROTEIN", 169, 177], ["light chain", "PROTEIN", 246, 257], ["Phl p 7", "PROTEIN", 288, 295], ["two antibodies bind", "PROBLEM", 28, 47], ["the antibody", "TEST", 165, 177]]], ["This resulted in trapping two monomeric allergen molecules between two molecules of the same antibody (62) .", [["monomeric allergen molecules", "PROTEIN", 30, 58], ["trapping two monomeric allergen molecules", "PROBLEM", 17, 58], ["allergen molecules", "OBSERVATION", 40, 58]]], ["While Phl p 7 was not a dimer, the stoichiometry of the complex still required two Phl p 7 molecules.", [["Phl p 7", "GENE_OR_GENE_PRODUCT", 6, 13], ["Phl p 7", "PROTEIN", 6, 13], ["dimer", "PROTEIN", 24, 29], ["Phl p 7 molecules", "PROTEIN", 83, 100]]], ["Therefore, this Phl p 7-antibody structure has changed the prior view that one antibody is able to recognize only a single epitope on an allergen/antigen.STRUCTURES OF ALLERGEN-ANTIBODY COMPLEXES BY X-RAY CRYSTALLOGRAPHYThe allergens that we have described are proteins, and their interactions with antibodies are the same as for other proteinaceous antigens.", [["Phl p 7", "GENE_OR_GENE_PRODUCT", 16, 23], ["Phl p 7", "PROTEIN", 16, 23], ["allergen/antigen", "PROTEIN", 137, 153], ["antibodies", "PROTEIN", 299, 309], ["proteinaceous antigens", "PROTEIN", 336, 358], ["this Phl p 7-antibody structure", "TEST", 11, 42], ["an allergen/antigen", "TREATMENT", 134, 153], ["X-RAY CRYSTALLOGRAPHY", "TEST", 199, 220], ["The allergens", "PROBLEM", 220, 233], ["antibodies", "TREATMENT", 299, 309], ["other proteinaceous antigens", "PROBLEM", 330, 358]]], ["It also has to be stressed that Xray crystallography provides generally a static picture of the interacting molecules.", [["interacting molecules", "PROTEIN", 96, 117], ["Xray crystallography", "TEST", 32, 52], ["interacting molecules", "OBSERVATION", 96, 117]]], ["However, both antigens and specifically antibodies display a great level of conformational flexibility (80, 81) .", [["antigens", "PROTEIN", 14, 22], ["antibodies", "PROTEIN", 40, 50], ["antibodies", "TEST", 40, 50]]], ["It was shown that conformational flexibility and local structural dynamics of antibodies play a very important role in recognition and binding (82, 83) .", [["antibodies", "PROTEIN", 78, 88], ["conformational flexibility", "PROBLEM", 18, 44]]], ["A higher level of conformational flexibility usually is attributed to antibodies that are not matured, and the flexibility allows them to recognize more antigens and/or altered antigens (84) .", [["antibodies", "PROTEIN", 70, 80], ["antigens", "PROTEIN", 153, 161], ["A higher level of conformational flexibility", "PROBLEM", 0, 44], ["antibodies", "PROBLEM", 70, 80], ["altered antigens", "PROBLEM", 169, 185], ["higher", "OBSERVATION_MODIFIER", 2, 8]]], ["During an antibody's maturation the increase of specificity is often achieved at the cost of the conformational flexibility, and a more rigid antibody binds better to one antigen (85, 86) .", [["an antibody", "TEST", 7, 18], ["a more rigid antibody binds", "PROBLEM", 129, 156], ["increase", "OBSERVATION_MODIFIER", 36, 44]]], ["Therefore, studies of the CDR conformations are critical for understanding the process of recognition and binding of antigens by antibodies (87) (88) (89) (90) , and these studies are most often performed using NMR, HDX-MS and various computational methods.LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYAn analysis of 16 allergen-antibody structures selected from Table 2 revealed a detailed description of the interface formed by epitopes and paratopes (45-50, 52, 53, 56, 58, 60-64) .", [["antigens", "PROTEIN", 117, 125], ["epitopes", "PROTEIN", 465, 473], ["antibodies", "TEST", 129, 139], ["these studies", "TEST", 166, 179], ["NMR", "TEST", 211, 214], ["HDX", "TEST", 216, 219], ["MS", "PROBLEM", 220, 222], ["X-RAY CRYSTALLOGRAPHYAn analysis", "TEST", 316, 348], ["16 allergen-antibody structures", "TEST", 352, 383], ["paratopes", "TEST", 478, 487]]], ["Typically, the interface area falls in the 650-920 \u00c5 2 range (an average of 813 \u00c5 2 ; Figure 4A ) (91) .", [["interface", "OBSERVATION_MODIFIER", 15, 24], ["area", "OBSERVATION_MODIFIER", 25, 29]]], ["In the complex with Phl p 7 mentioned above, the interface area is larger, and can be divided between a \"classic\" interface (\u223c820 \u00c5 2 ) with one antibody, and an additional interface (\u223c380 \u00c5 2 ) responsible for the non-standard interaction with the light chain from the second antibody (62) .", [["Phl p 7", "GENE_OR_GENE_PRODUCT", 20, 27], ["Phl p 7", "PROTEIN", 20, 27], ["light chain", "PROTEIN", 249, 260], ["one antibody", "TEST", 141, 153], ["the second antibody", "TEST", 266, 285], ["interface", "OBSERVATION_MODIFIER", 49, 58], ["area", "OBSERVATION_MODIFIER", 59, 63], ["larger", "OBSERVATION_MODIFIER", 67, 73]]], ["In most cases, the antibody heavy chain provides the largest contribution toward the total area of the interface, but this contribution is not always significantly bigger than the light chain share (Figure 4A) .", [["antibody heavy chain", "PROTEIN", 19, 39], ["light chain", "PROTEIN", 180, 191], ["largest", "OBSERVATION_MODIFIER", 53, 60], ["total", "OBSERVATION_MODIFIER", 85, 90], ["area", "OBSERVATION_MODIFIER", 91, 95], ["interface", "OBSERVATION", 103, 112], ["not always", "UNCERTAINTY", 139, 149], ["significantly", "OBSERVATION_MODIFIER", 150, 163], ["bigger", "OBSERVATION", 164, 170]]], ["The light chain provides between 23 and 53% of the interface area.", [["light chain", "PROTEIN", 4, 15], ["light chain", "OBSERVATION_MODIFIER", 4, 15]]], ["In the Api m 2 and Bla g 2 (2NR6) complexes, the light and heavy chains contribute almost equally to the interface area (48, 50) .", [["Bla g 2 (2NR6) complexes", "PROTEIN", 19, 43], ["light and heavy chains", "PROTEIN", 49, 71]]], ["However, it is worthwhile to note that in two complexes of antibody V H domains with Gal d 4 (PDB codes: 4PGJ and 4U3X), the allergen-antibody interface areas are quite large (810 and 826 \u00c5 2 , respectively), perhaps to compensate that the paratope is formed only by the heavy chain.LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYAnalysis of the allergen-antibody interfaces at the amino acid level shows that paratopes are formed by 18-28 residues that interact with epitopes composed of a similar number of amino acids (12-25 in the set of 16 complexes analyzed here) ( Figure 4B, Table 2 ) (45-50, 52, 53, 56, 58, 60-64) .", [["amino acid", "CHEMICAL", 415, 425], ["amino acids", "CHEMICAL", 542, 553], ["amino acid", "CHEMICAL", 415, 425], ["amino acids", "CHEMICAL", 542, 553], ["antibody V H", "GENE_OR_GENE_PRODUCT", 59, 71], ["Gal d 4", "GENE_OR_GENE_PRODUCT", 85, 92], ["4U3X", "GENE_OR_GENE_PRODUCT", 114, 118], ["amino acid", "AMINO_ACID", 415, 425], ["amino acids", "AMINO_ACID", 542, 553], ["antibody V H domains", "PROTEIN", 59, 79], ["Gal d 4", "PROTEIN", 85, 92], ["PDB codes", "PROTEIN", 94, 103], ["4PGJ", "PROTEIN", 105, 109], ["4U3X", "PROTEIN", 114, 118], ["allergen", "PROTEIN", 125, 133], ["heavy chain", "PROTEIN", 271, 282], ["epitopes", "PROTEIN", 501, 509], ["16 complexes", "PROTEIN", 575, 587], ["Gal d", "TREATMENT", 85, 90], ["the allergen-antibody interface areas", "TEST", 121, 158], ["X-RAY CRYSTALLOGRAPHYAnalysis", "TEST", 342, 371], ["the allergen-antibody interfaces", "TEST", 375, 407], ["the amino acid level", "TEST", 411, 431], ["amino acids", "TEST", 542, 553], ["antibody interface", "OBSERVATION", 134, 152], ["large", "OBSERVATION_MODIFIER", 169, 174]]], ["In addition, it is possible to examine the distribution of various amino acids in the epitope and paratope areas.", [["amino acids", "CHEMICAL", 67, 78], ["amino acids", "CHEMICAL", 67, 78], ["amino acids", "AMINO_ACID", 67, 78], ["various amino acids in the epitope and paratope areas", "PROBLEM", 59, 112], ["amino acids", "OBSERVATION", 67, 78]]], ["While the amino acid composition of epitopes is barely different from the overall composition of the allergen surface residues (93), there is a significant bias in amino acid composition of paratopes (Figures 5-7) .", [["surface", "ANATOMY", 110, 117], ["amino acid", "CHEMICAL", 10, 20], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "CHEMICAL", 10, 20], ["amino acid", "CHEMICAL", 164, 174], ["amino acid", "AMINO_ACID", 10, 20], ["amino acid", "AMINO_ACID", 164, 174], ["epitopes", "PROTEIN", 36, 44], ["the amino acid composition of epitopes", "TREATMENT", 6, 44], ["a significant bias in amino acid composition of paratopes", "PROBLEM", 142, 199], ["barely different", "OBSERVATION_MODIFIER", 48, 64], ["significant", "OBSERVATION_MODIFIER", 144, 155], ["bias", "OBSERVATION", 156, 160], ["amino acid", "OBSERVATION", 164, 174]]], ["Namely, the paratopes have a very high content of tyrosine, serine, and glycine residues, with relatively low content of isoleucine, leucine, lysine, methionine, and proline (94) (95) (96) (97) .", [["tyrosine", "CHEMICAL", 50, 58], ["serine", "CHEMICAL", 60, 66], ["glycine", "CHEMICAL", 72, 79], ["isoleucine", "CHEMICAL", 121, 131], ["leucine", "CHEMICAL", 133, 140], ["lysine", "CHEMICAL", 142, 148], ["methionine", "CHEMICAL", 150, 160], ["proline", "CHEMICAL", 166, 173], ["tyrosine", "CHEMICAL", 50, 58], ["serine", "CHEMICAL", 60, 66], ["glycine", "CHEMICAL", 72, 79], ["isoleucine", "CHEMICAL", 121, 131], ["leucine", "CHEMICAL", 133, 140], ["lysine", "CHEMICAL", 142, 148], ["methionine", "CHEMICAL", 150, 160], ["proline", "CHEMICAL", 166, 173], ["tyrosine", "AMINO_ACID", 50, 58], ["serine", "AMINO_ACID", 60, 66], ["glycine", "AMINO_ACID", 72, 79], ["isoleucine", "AMINO_ACID", 121, 131], ["leucine", "AMINO_ACID", 133, 140], ["lysine", "AMINO_ACID", 142, 148], ["methionine", "SIMPLE_CHEMICAL", 150, 160], ["proline (94)", "SIMPLE_CHEMICAL", 166, 178], ["tyrosine", "TREATMENT", 50, 58], ["glycine residues", "TREATMENT", 72, 88], ["isoleucine", "TREATMENT", 121, 131], ["leucine, lysine", "TREATMENT", 133, 148], ["methionine", "TREATMENT", 150, 160], ["very", "OBSERVATION_MODIFIER", 29, 33], ["high content", "OBSERVATION_MODIFIER", 34, 46]]], ["The paratopes also tend to have a relatively high content of aromatic residues (Tyr, Trp, Phe, and His).", [["Phe", "CHEMICAL", 90, 93], ["Tyr", "CHEMICAL", 80, 83], ["Trp", "CHEMICAL", 85, 88], ["Phe", "CHEMICAL", 90, 93], ["His", "CHEMICAL", 99, 102], ["Tyr", "AMINO_ACID", 80, 83], ["Trp", "AMINO_ACID", 85, 88], ["Phe", "AMINO_ACID", 90, 93], ["aromatic residues", "PROBLEM", 61, 78], ["Trp", "TEST", 85, 88], ["Phe", "TEST", 90, 93], ["relatively", "OBSERVATION_MODIFIER", 34, 44], ["high content", "OBSERVATION_MODIFIER", 45, 57], ["aromatic residues", "OBSERVATION", 61, 78]]], ["Unfortunately, the relatively small number of determined structures of allergenantibody complexes does not allow for generalizations on the compositional bias of allergen epitopes, especially when among the 16 structures analyzed here, three contain Der p 1, three contain Gal d 4, and two contain Bla g 2.", [["Gal d 4", "GENE_OR_GENE_PRODUCT", 273, 280], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 298, 305], ["allergenantibody complexes", "PROTEIN", 71, 97], ["allergen epitopes", "PROTEIN", 162, 179], ["Der p 1", "PROTEIN", 250, 257], ["Gal d 4", "PROTEIN", 273, 280], ["Bla g 2", "PROTEIN", 298, 305], ["allergenantibody complexes", "PROBLEM", 71, 97], ["allergen epitopes", "PROBLEM", 162, 179], ["Gal d 4", "TREATMENT", 273, 280], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["small", "OBSERVATION_MODIFIER", 30, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["allergen epitopes", "OBSERVATION", 162, 179]]], ["However, in large datasets of protein-protein interactions, aromatic residues are also generally favored (98, 99) .", [["aromatic residues", "PROBLEM", 60, 77], ["large", "OBSERVATION_MODIFIER", 12, 17], ["aromatic residues", "OBSERVATION", 60, 77]]], ["No obvious differences were observed between allergen-antibody interactions and the antibody recognition of other non-allergen proteins.LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYThe chemical interactions that drive allergen-antibody formation include covalent (H-bonds) as well as non-covalent binding interactions (e.g., hydrophobic, van der Waals, charge-charge, and cation-\u03c0 interactions).", [["H", "CHEMICAL", 299, 300], ["cation-\u03c0", "SIMPLE_CHEMICAL", 407, 415], ["non-allergen proteins", "PROTEIN", 114, 135], ["obvious differences", "PROBLEM", 3, 22], ["antibody interactions", "PROBLEM", 54, 75], ["the antibody recognition", "TEST", 80, 104], ["other non-allergen proteins", "PROBLEM", 108, 135], ["X-RAY CRYSTALLOGRAPHYThe chemical interactions", "TREATMENT", 195, 241], ["drive allergen", "TREATMENT", 247, 261], ["antibody formation", "PROBLEM", 262, 280], ["non-covalent binding interactions", "PROBLEM", 319, 352], ["hydrophobic, van der Waals, charge-charge", "TREATMENT", 360, 401]]], ["Hydrophobic and electrostatic interactions are most important for a primary contact between antigens and antibodies (100).", [["antigens", "PROTEIN", 92, 100], ["antibodies", "PROTEIN", 105, 115], ["Hydrophobic and electrostatic interactions", "PROBLEM", 0, 42], ["electrostatic interactions", "OBSERVATION", 16, 42]]], ["However, once the distance between antigen and antibody is shortened, van der Waals interactions and H-bonds start to play a significant role.", [["H", "CHEMICAL", 101, 102], ["H", "CHEMICAL", 101, 102], ["antigen", "GENE_OR_GENE_PRODUCT", 35, 42], ["antibody", "PROTEIN", 47, 55]]], ["H-bonds are especially important, as they quite often are associated with specificity of the binding.", [["H", "CHEMICAL", 0, 1], ["H", "CHEMICAL", 0, 1]]], ["The analysis of 16 structures in Table 2 indicates that there are between 7 and 16 H-bonds that mediate contacts within the epitopeparatope interface (Figure 8) .", [["H", "CHEMICAL", 83, 84], ["The analysis", "TEST", 0, 12]]], ["Heavy chains of the antibodies are responsible for the majority of the hydrogen bonds that are formed.", [["hydrogen", "CHEMICAL", 71, 79], ["antibodies", "PROTEIN", 20, 30], ["Heavy chains of the antibodies", "PROBLEM", 0, 30], ["the hydrogen bonds", "PROBLEM", 67, 85], ["chains", "OBSERVATION_MODIFIER", 6, 12], ["hydrogen bonds", "OBSERVATION", 71, 85]]], ["While most often atoms that are hydrogen donors or acceptors in the H-bonds belong to the side chains of amino acids forming paratopes or epitopes, there are also hydrogen bonds formed by main chain atoms (Figure 8) .LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYAmino acids with charged side chains also play an important role in mediation of epitope-paratope interactions (101) .", [["H", "CHEMICAL", 68, 69], ["amino acids", "CHEMICAL", 105, 116], ["hydrogen", "CHEMICAL", 32, 40], ["H", "CHEMICAL", 68, 69], ["amino acids", "CHEMICAL", 105, 116], ["hydrogen", "CHEMICAL", 163, 171], ["H-bonds", "SIMPLE_CHEMICAL", 68, 75], ["amino acids", "AMINO_ACID", 105, 116], ["paratopes", "SIMPLE_CHEMICAL", 125, 134], ["paratopes", "PROTEIN", 125, 134], ["epitopes", "PROTEIN", 138, 146], ["hydrogen donors", "TREATMENT", 32, 47], ["acceptors", "TREATMENT", 51, 60], ["amino acids forming paratopes", "PROBLEM", 105, 134], ["epitopes", "PROBLEM", 138, 146], ["hydrogen bonds", "PROBLEM", 163, 177], ["X-RAY CRYSTALLOGRAPHYAmino acids", "TREATMENT", 276, 308], ["charged side chains", "TREATMENT", 314, 333], ["epitope-paratope interactions", "TREATMENT", 378, 407], ["amino acids", "OBSERVATION", 105, 116], ["hydrogen bonds", "OBSERVATION", 163, 177], ["main", "OBSERVATION_MODIFIER", 188, 192], ["chain atoms", "OBSERVATION", 193, 204]]], ["For example, salt bridges in the interfaces are formed between positively charged amino acids (Arg or Lys) and negatively charged side chains of Asp or Glu.", [["amino acids", "CHEMICAL", 82, 93], ["Arg", "CHEMICAL", 95, 98], ["Lys", "CHEMICAL", 102, 105], ["Asp", "CHEMICAL", 145, 148], ["Glu", "CHEMICAL", 152, 155], ["amino acids", "CHEMICAL", 82, 93], ["Arg", "CHEMICAL", 95, 98], ["Lys", "CHEMICAL", 102, 105], ["Asp", "CHEMICAL", 145, 148], ["Glu", "CHEMICAL", 152, 155], ["salt bridges", "SIMPLE_CHEMICAL", 13, 25], ["amino acids", "AMINO_ACID", 82, 93], ["Arg", "AMINO_ACID", 95, 98], ["Lys", "AMINO_ACID", 102, 105], ["Asp", "AMINO_ACID", 145, 148], ["Glu", "AMINO_ACID", 152, 155], ["salt bridges in the interfaces", "PROBLEM", 13, 43], ["charged amino acids", "TREATMENT", 74, 93], ["Asp or Glu", "PROBLEM", 145, 155], ["salt bridges", "OBSERVATION", 13, 25]]], ["Enrichment of epitopes in such amino acids is illustrated in Figures 5-7 .", [["amino acids", "CHEMICAL", 31, 42], ["amino acids", "CHEMICAL", 31, 42], ["amino acids", "AMINO_ACID", 31, 42], ["epitopes", "PROTEIN", 14, 22], ["epitopes in such amino acids", "TREATMENT", 14, 42]]], ["It has been shown that electrostatic interactions increase the binding specificity between antigens and antibodies (102, 103) .", [["antigens", "PROTEIN", 91, 99], ["antibodies", "PROTEIN", 104, 114], ["electrostatic interactions", "PROBLEM", 23, 49], ["antibodies", "TEST", 104, 114], ["electrostatic", "OBSERVATION_MODIFIER", 23, 36]]], ["In addition, positively charged side chains may participate in cation-\u03c0 interactions (50, 104, 105) .", [["cation-\u03c0", "SIMPLE_CHEMICAL", 63, 71]]], ["This type of interaction is relatively common in antigen-antibody interfaces, as it is formed by aromatic residues (e.g., Phe, Tyr, Trp) and side chains of Arg or Lys, which are over-represented in epitopes and paratopes.", [["Phe, Tyr, Trp", "CHEMICAL", 122, 135], ["Phe", "CHEMICAL", 122, 125], ["Tyr", "CHEMICAL", 127, 130], ["Trp", "CHEMICAL", 132, 135], ["Arg", "CHEMICAL", 156, 159], ["Lys", "CHEMICAL", 163, 166], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 49, 65], ["Phe", "AMINO_ACID", 122, 125], ["Tyr", "AMINO_ACID", 127, 130], ["Trp", "AMINO_ACID", 132, 135], ["Arg", "AMINO_ACID", 156, 159], ["Lys", "AMINO_ACID", 163, 166], ["epitopes", "PROTEIN", 198, 206], ["paratopes", "PROTEIN", 211, 220], ["aromatic residues", "PROBLEM", 97, 114], ["Phe", "TEST", 122, 125], ["Trp", "TEST", 132, 135], ["side chains of Arg or Lys", "PROBLEM", 141, 166], ["antibody interfaces", "OBSERVATION", 57, 76], ["aromatic residues", "OBSERVATION", 97, 114]]], ["For example, cation\u03c0 interactions were observed in interfaces formed between Bla g 2 and mAb 7C11, Der p 1 and 5H8, as well as between Der p 2 and mAb 7A1 (50, 56, 58) .", [["cation\u03c0", "SIMPLE_CHEMICAL", 13, 20], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 77, 84], ["mAb 7C11", "GENE_OR_GENE_PRODUCT", 89, 97], ["Der p 1", "GENE_OR_GENE_PRODUCT", 99, 106], ["5H8", "GENE_OR_GENE_PRODUCT", 111, 114], ["Der p 2", "GENE_OR_GENE_PRODUCT", 135, 142], ["mAb 7A1", "GENE_OR_GENE_PRODUCT", 147, 154], ["Bla g 2", "PROTEIN", 77, 84], ["mAb 7C11", "PROTEIN", 89, 97], ["Der p 1", "PROTEIN", 99, 106], ["5H8", "PROTEIN", 111, 114], ["Der p 2", "PROTEIN", 135, 142], ["mAb 7A1", "PROTEIN", 147, 154], ["cation\u03c0 interactions", "PROBLEM", 13, 33], ["Bla g", "TEST", 77, 82], ["mAb", "TEST", 147, 150]]], ["Side chains of aromatic residues may be also involved in various \u03c0-\u03c0 interactions (56, 105) .LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYBesides protein-protein contacts at the allergen-antibody interface, other chemical moieties can form contacts between the two molecules.", [["aromatic residues", "PROBLEM", 15, 32], ["X-RAY CRYSTALLOGRAPHYBesides protein", "TEST", 152, 188], ["aromatic residues", "OBSERVATION", 15, 32]]], ["One of them is carbohydrates.", [["carbohydrates", "CHEMICAL", 15, 28], ["carbohydrates", "SIMPLE_CHEMICAL", 15, 28], ["carbohydrates", "OBSERVATION", 15, 28]]], ["An epitope on Bla g 2 that is recognized by mAb 4C3 includes a glycan (Figure 2) (52) .", [["Bla g 2", "GENE_OR_GENE_PRODUCT", 14, 21], ["Bla g 2", "PROTEIN", 14, 21], ["mAb 4C3", "PROTEIN", 44, 51], ["An epitope on Bla g 2", "TREATMENT", 0, 21], ["epitope", "OBSERVATION", 3, 10]]], ["The role of this glycan as part of the epitope has also been demonstrated in relation to IgE binding and basophil histamine release (106) .", [["basophil", "ANATOMY", 105, 113], ["histamine", "CHEMICAL", 114, 123], ["histamine", "CHEMICAL", 114, 123], ["IgE", "GENE_OR_GENE_PRODUCT", 89, 92], ["basophil histamine", "GENE_OR_GENE_PRODUCT", 105, 123], ["IgE", "PROTEIN", 89, 92], ["this glycan", "TREATMENT", 12, 23], ["the epitope", "TREATMENT", 35, 46], ["IgE binding", "TREATMENT", 89, 100], ["basophil histamine release", "TREATMENT", 105, 131]]], ["This observation stresses the potential importance of post-translational modifications of the allergens for their interactions with antibodies (107, 108) .", [["antibodies", "PROTEIN", 132, 142], ["the allergens", "TREATMENT", 90, 103]]], ["Production of recombinant proteins in some systems, such as E. coli, which do not add carbohydrates to expressed proteins, may lead to a lack of proper recognition by antibodies from allergic individuals raised against the glycosylated natural allergen.", [["allergic", "DISEASE", 183, 191], ["carbohydrates", "CHEMICAL", 86, 99], ["E. coli", "ORGANISM", 60, 67], ["recombinant proteins", "PROTEIN", 14, 34], ["antibodies", "PROTEIN", 167, 177], ["E. coli", "SPECIES", 60, 67], ["E. coli", "SPECIES", 60, 67], ["recombinant proteins in some systems", "PROBLEM", 14, 50], ["E. coli", "PROBLEM", 60, 67], ["allergic individuals", "PROBLEM", 183, 203], ["the glycosylated natural allergen", "PROBLEM", 219, 252], ["recombinant proteins", "OBSERVATION", 14, 34]]], ["Nevertheless, the allergen recognition might still occur, if the antibody recognizes the protein part of the epitope.LESSONS LEARNED ABOUT ALLERGEN-ANTIBODY INTERACTIONS USING X-RAY CRYSTALLOGRAPHYDuring the process of antigen-antibody recognition many water molecules that were on the surface of the interreacting molecules are displaced.", [["surface", "ANATOMY", 286, 293], ["antigen-antibody", "GENE_OR_GENE_PRODUCT", 219, 235], ["surface", "CELLULAR_COMPONENT", 286, 293], ["epitope", "PROTEIN", 109, 116], ["interreacting molecules", "PROTEIN", 301, 324], ["the allergen recognition", "TEST", 14, 38], ["the antibody", "TEST", 61, 73], ["antigen", "TEST", 219, 226], ["interreacting molecules", "OBSERVATION", 301, 324], ["displaced", "OBSERVATION_MODIFIER", 329, 338]]], ["However, this process does not always lead to their complete displacement.", [["their complete displacement", "PROBLEM", 46, 73], ["complete", "OBSERVATION_MODIFIER", 52, 60], ["displacement", "OBSERVATION", 61, 73]]], ["In fact, water molecules can play an important role in allergen-antibody interactions, in purely protein-protein complexes, and the aforementioned protein-carbohydrate complex (52) .", [["carbohydrate", "CHEMICAL", 155, 167], ["protein-protein complexes", "PROTEIN", 97, 122], ["carbohydrate complex", "PROTEIN", 155, 175], ["antibody interactions", "PROBLEM", 64, 85], ["water molecules", "OBSERVATION", 9, 24]]], ["Very often, the water molecules are buried between the allergen and the antibody and mediate the contact between the macromolecules through hydrogen bonds (52, 58, 109) .", [["hydrogen", "CHEMICAL", 140, 148], ["antibody", "PROTEIN", 72, 80], ["the water molecules", "PROBLEM", 12, 31], ["hydrogen bonds", "TEST", 140, 154], ["hydrogen bonds", "OBSERVATION", 140, 154]]], ["In some cases, the presence of buried water molecules significantly improves the fit between allergen and antibody surfaces, allowing for stronger binding (75) .IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESThe most interesting complexes for allergy research are with human IgE, but they are also the most challenging to obtain.", [["allergy", "DISEASE", 243, 250], ["human", "ORGANISM", 269, 274], ["IgE", "GENE_OR_GENE_PRODUCT", 275, 278], ["IgE", "PROTEIN", 179, 182], ["human IgE", "PROTEIN", 269, 278], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["buried water molecules", "PROBLEM", 31, 53], ["allergen and antibody surfaces", "TREATMENT", 93, 123], ["IgE ANTIBODY", "OBSERVATION", 179, 191]]], ["One of the main limitations to defining epitopes for human IgE has been the difficulty of obtaining human IgE monoclonal antibodies in the amounts required for crystallography or NMR.", [["human", "ORGANISM", 53, 58], ["IgE", "GENE_OR_GENE_PRODUCT", 59, 62], ["human", "ORGANISM", 100, 105], ["IgE monoclonal antibodies", "GENE_OR_GENE_PRODUCT", 106, 131], ["epitopes", "PROTEIN", 40, 48], ["human IgE", "PROTEIN", 53, 62], ["human IgE monoclonal antibodies", "PROTEIN", 100, 131], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 100, 105], ["human IgE", "PROBLEM", 53, 62], ["human IgE monoclonal antibodies", "TREATMENT", 100, 131], ["crystallography", "TEST", 160, 175], ["NMR", "TEST", 179, 182], ["main", "OBSERVATION_MODIFIER", 11, 15]]], ["IgE is polyclonal and present in low concentrations in blood (ng/mL).", [["blood", "ANATOMY", 55, 60], ["IgE", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["IgE", "PROTEIN", 0, 3], ["low concentrations", "OBSERVATION_MODIFIER", 33, 51]]], ["B cells expressing IgE circulate in low frequency in peripheral blood (3 \u00d7 10 \u22127 to 7 \u00d7 10 \u22126 ) (110), which makes it difficult to isolate and grow them in primary cultures.", [["B cells", "ANATOMY", 0, 7], ["peripheral blood", "ANATOMY", 53, 69], ["primary cultures", "ANATOMY", 156, 172], ["B cells", "CELL", 0, 7], ["IgE", "GENE_OR_GENE_PRODUCT", 19, 22], ["peripheral blood", "ORGANISM_SUBSTANCE", 53, 69], ["B cells", "CELL_TYPE", 0, 7], ["IgE", "PROTEIN", 19, 22], ["primary cultures", "CELL_LINE", 156, 172], ["B cells", "TEST", 0, 7], ["IgE circulate", "TEST", 19, 32], ["peripheral blood", "TEST", 53, 69], ["primary cultures", "TEST", 156, 172], ["IgE circulate", "OBSERVATION", 19, 32], ["low frequency", "OBSERVATION_MODIFIER", 36, 49], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["blood", "ANATOMY", 64, 69]]], ["Historically, several alternative methods were developed.IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESOne approach to study the human IgE repertoire is to isolate IgE antibody constructs from phage display combinatorial libraries prepared using peripheral blood mononuclear cells (PBMC) of allergic subjects (111) (112) (113) .", [["peripheral blood mononuclear cells", "ANATOMY", 247, 281], ["PBMC", "ANATOMY", 283, 287], ["allergic", "DISEASE", 292, 300], ["human", "ORGANISM", 130, 135], ["IgE", "GENE_OR_GENE_PRODUCT", 136, 139], ["IgE", "GENE_OR_GENE_PRODUCT", 165, 168], ["peripheral blood mononuclear cells", "CELL", 247, 281], ["PBMC", "CELL", 283, 287], ["IgE", "PROTEIN", 75, 78], ["human IgE repertoire", "PROTEIN", 130, 150], ["IgE antibody constructs", "DNA", 165, 188], ["peripheral blood mononuclear cells", "CELL_TYPE", 247, 281], ["PBMC", "CELL_TYPE", 283, 287], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["several alternative methods", "TREATMENT", 14, 41], ["the human IgE repertoire", "TREATMENT", 126, 150], ["IgE antibody constructs", "TEST", 165, 188], ["combinatorial libraries", "PROBLEM", 208, 231], ["peripheral blood mononuclear cells", "TREATMENT", 247, 281], ["allergic subjects", "PROBLEM", 292, 309], ["IgE ANTIBODY", "OBSERVATION", 75, 87], ["mononuclear cells", "OBSERVATION", 264, 281]]], ["Basically, antibody heavy chains are combined with light chains from the same or a different subject, to form IgE antibody constructs that are displayed by phagemids.", [["antibody heavy chains", "GENE_OR_GENE_PRODUCT", 11, 32], ["IgE", "GENE_OR_GENE_PRODUCT", 110, 113], ["antibody heavy chains", "PROTEIN", 11, 32], ["light chains", "PROTEIN", 51, 63], ["IgE antibody constructs", "DNA", 110, 133], ["antibody heavy chains", "PROBLEM", 11, 32], ["light chains", "PROBLEM", 51, 63], ["IgE antibody constructs", "TREATMENT", 110, 133], ["antibody", "OBSERVATION", 11, 19], ["heavy chains", "OBSERVATION", 20, 32]]], ["Such technology relies on the fact that antibody specificity largely resides in the heavy chain variable domain and its third hypervariable loop (H CDR3) (66) .", [["heavy chain variable domain", "PROTEIN", 84, 111], ["third hypervariable loop", "PROTEIN", 120, 144], ["antibody specificity", "TEST", 40, 60], ["third", "OBSERVATION_MODIFIER", 120, 125], ["hypervariable loop", "OBSERVATION", 126, 144]]], ["Phage display technology led to the isolation of IgG1 antibody constructs with IgE variable domains against Bos d 5 from cow and Phl p 2 from timothy grass pollen, and the allergen-antibody Fab complexes were determined by X-ray crystallography ( Table 2 ) (63, 64) .", [["pollen", "ANATOMY", 156, 162], ["IgG1", "GENE_OR_GENE_PRODUCT", 49, 53], ["Bos d 5", "ORGANISM", 108, 115], ["cow", "ORGANISM", 121, 124], ["Phl p 2", "GENE_OR_GENE_PRODUCT", 129, 136], ["timothy", "ORGANISM", 142, 149], ["IgG1 antibody constructs", "DNA", 49, 73], ["IgE variable domains", "PROTEIN", 79, 99], ["Bos d 5", "PROTEIN", 108, 115], ["Phl p 2", "PROTEIN", 129, 136], ["allergen-antibody Fab complexes", "PROTEIN", 172, 203], ["cow", "SPECIES", 121, 124], ["cow", "SPECIES", 121, 124], ["the isolation of IgG1 antibody constructs", "TREATMENT", 32, 73], ["IgE variable domains", "PROBLEM", 79, 99], ["Bos d 5", "PROBLEM", 108, 115], ["the allergen-antibody Fab complexes", "TEST", 168, 203], ["X-ray crystallography", "TEST", 223, 244]]], ["Since the antibodies were isolated using IgE combinatorial libraries, it is not known whether light and heavy chain pairing corresponds to that observed in antibodies produced by allergic individuals.", [["allergic", "DISEASE", 179, 187], ["antibodies", "PROTEIN", 10, 20], ["IgE", "PROTEIN", 41, 44], ["antibodies", "PROTEIN", 156, 166], ["the antibodies", "TEST", 6, 20], ["IgE combinatorial libraries", "TREATMENT", 41, 68], ["light and heavy chain pairing", "PROBLEM", 94, 123], ["allergic individuals", "PROBLEM", 179, 199], ["allergic individuals", "OBSERVATION", 179, 199]]], ["Both structures are useful, as they currently provide the closest picture of the interactions between allergens and IgE that take place in humans.IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESThe structure of the Bos d 5-antibody complex illustrates an additional important phenomenon, namely the importance of the oligomerization state or quaternary structure of the allergen.", [["IgE", "GENE_OR_GENE_PRODUCT", 116, 119], ["humans", "ORGANISM", 139, 145], ["Bos d 5", "ORGANISM", 214, 221], ["allergens", "PROTEIN", 102, 111], ["IgE", "PROTEIN", 116, 119], ["IgE", "PROTEIN", 164, 167], ["Bos d 5-antibody complex", "PROTEIN", 214, 238], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["IgE", "TREATMENT", 116, 119], ["the Bos d 5-antibody complex", "TREATMENT", 210, 238], ["IgE ANTIBODY", "OBSERVATION", 164, 176]]], ["Bos d 5 is a dimer in the reported structure (114) .", [["Bos d 5", "ORGANISM", 0, 7]]], ["Dimerization of an allergen allows for cross-linking of IgE receptors with the same antibody.", [["IgE receptors", "GENE_OR_GENE_PRODUCT", 56, 69], ["IgE receptors", "PROTEIN", 56, 69], ["an allergen", "TREATMENT", 16, 27], ["cross-linking of IgE receptors", "TREATMENT", 39, 69]]], ["Localization of IgE epitopes clearly illustrates why, for allergens forming homo-oligomers, only one epitope per protein chain is sufficient for the allergic reaction to be triggered (115, 116) .", [["allergic reaction", "DISEASE", 149, 166], ["IgE", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgE epitopes", "PROTEIN", 16, 28], ["homo-oligomers", "PROTEIN", 76, 90], ["protein chain", "PROTEIN", 113, 126], ["allergens", "PROBLEM", 58, 67], ["the allergic reaction", "PROBLEM", 145, 166], ["IgE epitopes", "OBSERVATION", 16, 28]]], ["For example, a cockroach Bla g 2 mutant with amino acid substitutions that prevented dimerization induced less \u03b2-hexosaminidase release from mast cells than the dimeric wild-type Bla g 2, suggesting a functional role of dimerization in allergenicity (50) .", [["mast cells", "ANATOMY", 141, 151], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "CHEMICAL", 45, 55], ["cockroach", "ORGANISM", 15, 24], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 25, 32], ["amino acid", "AMINO_ACID", 45, 55], ["\u03b2-hexosaminidase", "GENE_OR_GENE_PRODUCT", 111, 127], ["mast cells", "CELL", 141, 151], ["Bla g 2", "GENE_OR_GENE_PRODUCT", 179, 186], ["cockroach Bla g 2 mutant", "PROTEIN", 15, 39], ["\u03b2-hexosaminidase", "PROTEIN", 111, 127], ["mast cells", "CELL_TYPE", 141, 151], ["dimeric wild-type Bla g 2", "PROTEIN", 161, 186], ["a cockroach Bla g", "TREATMENT", 13, 30], ["amino acid substitutions", "TREATMENT", 45, 69], ["mast cells", "PROBLEM", 141, 151], ["mast cells", "OBSERVATION", 141, 151]]], ["Dimerization of an allergen also provides an opportunity to use a single mAb binding for capture and detection in a \"sandwich\" ELISA (115, 117) .IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESOther studies addressed allergen epitope mapping using indirect approaches.", [["mAb", "PROTEIN", 73, 76], ["IgE", "PROTEIN", 163, 166], ["a single mAb binding", "TREATMENT", 64, 84], ["EPITOPESOther studies", "TEST", 184, 205], ["allergen epitope mapping", "TREATMENT", 216, 240], ["indirect approaches", "TREATMENT", 247, 266], ["IgE ANTIBODY", "OBSERVATION", 163, 175]]], ["A cluster of several IgE antibody binding epitopes was located on the C-terminal domain of Phl p 1 using human IgE obtained by phage display technology.", [["C", "CHEMICAL", 70, 71], ["IgE", "GENE_OR_GENE_PRODUCT", 21, 24], ["Phl p 1", "GENE_OR_GENE_PRODUCT", 91, 98], ["human", "ORGANISM", 105, 110], ["IgE", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgE antibody binding epitopes", "PROTEIN", 21, 50], ["C-terminal domain", "PROTEIN", 70, 87], ["Phl p 1", "PROTEIN", 91, 98], ["human IgE", "PROTEIN", 105, 114], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["several IgE antibody binding epitopes", "PROBLEM", 13, 50], ["human IgE", "TEST", 105, 114], ["cluster", "OBSERVATION_MODIFIER", 2, 9], ["several", "OBSERVATION_MODIFIER", 13, 20], ["IgE antibody", "OBSERVATION", 21, 33]]], ["In combination with site-directed mutagenesis, the authors designed a hypoallergenic group 1 grass pollen allergen fragment (118) .", [["site-directed mutagenesis", "TREATMENT", 20, 45], ["a hypoallergenic group 1 grass pollen allergen fragment", "PROBLEM", 68, 123], ["allergen fragment", "OBSERVATION", 106, 123]]], ["Two other studies used IgE constructs from phage display libraries to map epitopes on Phl p 5 and Bet v 1 (119, 120) .", [["IgE", "GENE_OR_GENE_PRODUCT", 23, 26], ["Bet v 1", "GENE_OR_GENE_PRODUCT", 98, 105], ["IgE constructs", "DNA", 23, 37], ["Phl p 5", "PROTEIN", 86, 93], ["Bet v 1", "PROTEIN", 98, 105], ["Two other studies", "TEST", 0, 17], ["IgE constructs", "TREATMENT", 23, 37], ["map epitopes", "TEST", 70, 82], ["Phl p", "TEST", 86, 91], ["Bet v", "TEST", 98, 103]]], ["Four independent epitope clusters on Phl p 5.0101 and two on Phl p 5.0201 were identified (119) .", [["Phl p 5.0101", "DNA", 37, 49], ["Phl p 5.0201", "PROTEIN", 61, 73], ["Phl p", "TEST", 37, 42], ["Phl p", "TEST", 61, 66], ["epitope clusters", "OBSERVATION", 17, 33]]], ["Four Bet v 1-specific IgE (for one of which the structure was determined) were identified that targeted two non-overlapping epitopes in Bet v 1, as assessed by immunological assays (120) .IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESRecently, a house dust mite Der p 2-specific IgG mAb overlapping with IgE was mapped by X-ray crystallography and site-directed mutagenesis analysis.", [["Bet v 1", "GENE_OR_GENE_PRODUCT", 5, 12], ["IgE", "GENE_OR_GENE_PRODUCT", 22, 25], ["Bet v 1", "GENE_OR_GENE_PRODUCT", 136, 143], ["Der p 2", "GENE_OR_GENE_PRODUCT", 263, 270], ["IgE", "GENE_OR_GENE_PRODUCT", 305, 308], ["Bet v 1", "PROTEIN", 5, 12], ["IgE", "PROTEIN", 22, 25], ["epitopes", "PROTEIN", 124, 132], ["Bet v 1", "PROTEIN", 136, 143], ["IgE", "PROTEIN", 206, 209], ["house dust mite Der p 2", "PROTEIN", 247, 270], ["IgG mAb", "PROTEIN", 280, 287], ["IgE", "PROTEIN", 305, 308], ["immunological assays", "TEST", 160, 180], ["IgE ANTIBODY BINDING EPITOPESRecently", "PROBLEM", 206, 243], ["specific IgG mAb", "TREATMENT", 271, 287], ["IgE", "TREATMENT", 305, 308], ["X-ray crystallography", "TEST", 323, 344], ["site-directed mutagenesis analysis", "TEST", 349, 383], ["IgE ANTIBODY", "OBSERVATION", 206, 218]]], ["A Der p 2-specific IgE construct isolated from a single-chain variable fragment (scFv)encoding phagemid library recognized the same main residues as the IgG, further confirming the relevance of this epitope to human health (58) .", [["Der p 2", "GENE_OR_GENE_PRODUCT", 2, 9], ["IgE", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 153, 156], ["human", "ORGANISM", 210, 215], ["Der p 2-specific IgE construct", "DNA", 2, 32], ["single-chain variable fragment", "DNA", 49, 79], ["scFv", "PROTEIN", 81, 85], ["IgG", "PROTEIN", 153, 156], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["A Der p 2-specific IgE construct", "TREATMENT", 0, 32], ["a single-chain variable fragment (scFv)encoding phagemid library", "TREATMENT", 47, 111], ["the IgG", "TEST", 149, 156], ["fragment", "OBSERVATION", 71, 79]]], ["These studies underline the utility of using constructs derived from phage display technology to investigate the antigenic determinants relevant to allergy.IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESAlternative approaches to isolate antibodies are based on sorting single B cells for amplification of mRNA that encodes for the antibody.", [["B cells", "ANATOMY", 276, 283], ["allergy", "DISEASE", 148, 155], ["single B cells", "CELL", 269, 283], ["IgE", "PROTEIN", 174, 177], ["sorting single B cells", "CELL_TYPE", 261, 283], ["mRNA", "RNA", 305, 309], ["These studies", "TEST", 0, 13], ["allergy", "PROBLEM", 148, 155], ["IgE ANTIBODY BINDING EPITOPESAlternative approaches", "TREATMENT", 174, 225], ["isolate antibodies", "TEST", 229, 247], ["sorting single B cells", "TREATMENT", 261, 283], ["the antibody", "TEST", 327, 339], ["IgE ANTIBODY", "OBSERVATION", 174, 186]]], ["They have proven effective for identifying the exact pairing of IgG heavy and light chains, but not for B cells expressing IgE due to their low frequency in blood (121) .", [["B cells", "ANATOMY", 104, 111], ["blood", "ANATOMY", 157, 162], ["IgG heavy and light chains", "GENE_OR_GENE_PRODUCT", 64, 90], ["B cells", "CELL", 104, 111], ["IgE", "GENE_OR_GENE_PRODUCT", 123, 126], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["IgG heavy and light chains", "PROTEIN", 64, 90], ["B cells", "CELL_TYPE", 104, 111], ["IgE", "PROTEIN", 123, 126], ["IgG heavy and light chains", "PROBLEM", 64, 90], ["B cells", "PROBLEM", 104, 111], ["their low frequency in blood", "PROBLEM", 134, 162]]], ["A study used single B cell RT-PCR to obtain allergen-specific IgG antibody pairings (122) .", [["B cell", "ANATOMY", 20, 26], ["B cell", "CELL", 20, 26], ["IgG", "ORGANISM", 62, 65], ["IgG antibody", "PROTEIN", 62, 74], ["A study", "TEST", 0, 7], ["single B cell RT", "TREATMENT", 13, 29], ["PCR", "TEST", 30, 33], ["allergen", "TEST", 44, 52]]], ["In addition, heavy chain variable gene sequences of IgE antibodies were obtained by deep sequencing PBMCs, but this study did not lead to the production of allergenspecific native pairs for IgE.", [["PBMCs", "ANATOMY", 100, 105], ["IgE antibodies", "GENE_OR_GENE_PRODUCT", 52, 66], ["PBMCs", "CELL", 100, 105], ["IgE", "GENE_OR_GENE_PRODUCT", 190, 193], ["heavy chain variable gene sequences", "DNA", 13, 48], ["IgE antibodies", "PROTEIN", 52, 66], ["PBMCs", "CELL_TYPE", 100, 105], ["IgE", "PROTEIN", 190, 193], ["heavy chain variable gene sequences of IgE antibodies", "TEST", 13, 66], ["deep sequencing PBMCs", "TEST", 84, 105], ["this study", "TEST", 111, 121]]], ["One recent publication reports single B cell sorting combined with RNAseq as an approach to obtain human IgE mAb against peanut allergens (123) .", [["B cell", "ANATOMY", 38, 44], ["B cell", "CELL", 38, 44], ["human", "ORGANISM", 99, 104], ["IgE mAb", "GENE_OR_GENE_PRODUCT", 105, 112], ["peanut", "ORGANISM", 121, 127], ["human IgE mAb", "PROTEIN", 99, 112], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["single B cell sorting", "TREATMENT", 31, 52], ["RNAseq", "TREATMENT", 67, 73], ["human IgE mAb", "TREATMENT", 99, 112], ["publication", "OBSERVATION", 11, 22]]], ["However, large amounts of sequencing (currently at very high cost) would be required to obtain sequences of the full IgE repertoire using this technology.IDENTIFICATION OF IgE ANTIBODY BINDING EPITOPESA new approach to isolate human IgE monoclonal antibodies has emerged using hybridoma technology (124) .", [["IgE", "GENE_OR_GENE_PRODUCT", 117, 120], ["human", "ORGANISM", 227, 232], ["IgE", "GENE_OR_GENE_PRODUCT", 233, 236], ["IgE repertoire", "PROTEIN", 117, 131], ["IgE", "PROTEIN", 172, 175], ["human IgE monoclonal antibodies", "PROTEIN", 227, 258], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 227, 232], ["large amounts of sequencing", "PROBLEM", 9, 36], ["this technology", "TREATMENT", 138, 153], ["IgE ANTIBODY BINDING", "PROBLEM", 172, 192], ["new approach", "TREATMENT", 203, 215], ["isolate human IgE monoclonal antibodies", "TREATMENT", 219, 258], ["hybridoma technology", "TREATMENT", 277, 297], ["large", "OBSERVATION_MODIFIER", 9, 14], ["amounts", "OBSERVATION_MODIFIER", 15, 22], ["IgE ANTIBODY", "OBSERVATION", 172, 184]]], ["Individuals are selected according to their specific IgE sensitization, and their B cells are screened for allergen-specific IgE reactivity before fusion with myeloma cells to create hybridomas.", [["B cells", "ANATOMY", 82, 89], ["myeloma cells", "ANATOMY", 159, 172], ["hybridomas", "ANATOMY", 183, 193], ["myeloma", "DISEASE", 159, 166], ["IgE", "GENE_OR_GENE_PRODUCT", 53, 56], ["B cells", "CELL", 82, 89], ["IgE", "GENE_OR_GENE_PRODUCT", 125, 128], ["myeloma cells", "CELL", 159, 172], ["hybridomas", "CELL", 183, 193], ["IgE", "PROTEIN", 53, 56], ["B cells", "CELL_TYPE", 82, 89], ["IgE", "PROTEIN", 125, 128], ["myeloma cells", "CELL_LINE", 159, 172], ["hybridomas", "CELL_LINE", 183, 193], ["their specific IgE sensitization", "TEST", 38, 70], ["their B cells", "TEST", 76, 89], ["allergen", "PROBLEM", 107, 115], ["myeloma cells", "PROBLEM", 159, 172], ["hybridomas", "PROBLEM", 183, 193], ["myeloma cells", "OBSERVATION", 159, 172]]], ["This is an advantage versus the RT-PCR approach, in which the allergen-specificity is not known until recombinant antibodies are expressed based on the sequences obtained.", [["recombinant antibodies", "PROTEIN", 102, 124], ["the RT-PCR approach", "TREATMENT", 28, 47], ["recombinant antibodies", "PROBLEM", 102, 124], ["the sequences", "TEST", 148, 161]]], ["Using this technology, several allergenspecific antibodies were isolated and are being used for IgE epitope mapping by X-ray crystallography and NMR (125) (126) (127) .", [["allergenspecific antibodies", "PROTEIN", 31, 58], ["IgE", "PROTEIN", 96, 99], ["this technology", "TREATMENT", 6, 21], ["several allergenspecific antibodies", "TREATMENT", 23, 58], ["IgE epitope mapping", "TREATMENT", 96, 115], ["X-ray crystallography", "TEST", 119, 140], ["NMR", "TEST", 145, 148]]], ["It should be noted that this method is still labor intensive, but compared to the other approaches, the clones contain the natural pairing of the heavy and light chains increasing the relevance of this technology.EPITOPES DEFINED BY NUCLEAR MAGNETIC RESONANCE (NMR)Because of the limitations in the size of proteins for which NMR can determine structures, NMR experiments to determine allergen epitopes necessarily involve clever experimental design and accurate interpretation.", [["clones", "CELL", 104, 110], ["heavy and light chains", "PROTEIN", 146, 168], ["allergen epitopes", "PROTEIN", 385, 402], ["still labor", "PROBLEM", 39, 50], ["the clones", "PROBLEM", 100, 110], ["this technology", "TREATMENT", 197, 212], ["NMR experiments", "TEST", 356, 371]]], ["In well-designed experiments, the data provides atom-specific information on the epitope region, which can be readily understood in the context of the allergen structure.", [["epitope region", "PROTEIN", 81, 95], ["allergen structure", "OBSERVATION", 151, 169]]], ["The following section describes the design and range of applicability of various NMR designed experiments.NMR Protection AssaysThe earliest NMR epitope mapping experiments designed by Yvonne Paterson and co-workers were protection assays that measured the exchange rate of amide protons for deuterons in an antigen with and without the antibody present, similar to the HDX-MS (128) .", [["amide", "CHEMICAL", 273, 278], ["amide protons", "SIMPLE_CHEMICAL", 273, 286], ["deuterons", "SIMPLE_CHEMICAL", 291, 300], ["NMR Protection", "TREATMENT", 106, 120], ["the exchange rate of amide protons", "TREATMENT", 252, 286], ["deuterons in an antigen", "PROBLEM", 291, 314], ["the antibody", "TEST", 332, 344], ["the HDX", "TEST", 365, 372], ["MS", "TEST", 373, 375]]], ["Instead of measuring a change in mass, the approach takes advantage of the fact that protons and deuterons resonate at very different frequencies.", [["protons", "SIMPLE_CHEMICAL", 85, 92], ["deuterons", "SIMPLE_CHEMICAL", 97, 106], ["a change in mass", "PROBLEM", 21, 37], ["protons and deuterons", "TREATMENT", 85, 106], ["change", "OBSERVATION_MODIFIER", 23, 29], ["mass", "OBSERVATION", 33, 37]]], ["The exchange of protons for deuterons leads to a disappearance of observable 1 H frequencies in the antigen.", [["deuterons", "CHEMICAL", 28, 37], ["deuterons", "CHEMICAL", 28, 37], ["H", "CHEMICAL", 79, 80], ["protons", "SIMPLE_CHEMICAL", 16, 23], ["deuterons", "SIMPLE_CHEMICAL", 28, 37], ["The exchange of protons for deuterons", "TREATMENT", 0, 37]]], ["In the Paterson design, the antibody was covalently linked to beads to make an affinity column.", [["the antibody", "TREATMENT", 24, 36], ["affinity column", "OBSERVATION", 79, 94]]], ["Subsequently, the antigen in solution was added to the column and allowed to bind the antibody.", [["the antigen in solution", "TREATMENT", 14, 37]]], ["The buffer was then easily changed from 1 H 2 O to 2 H 2 O, so the 1 H-amide protons on the antigen surface could be exchanged for deuterons, except in the epitope that was protected by the antibody.", [["surface", "ANATOMY", 100, 107], ["H", "CHEMICAL", 69, 70], ["H 2 O", "CHEMICAL", 42, 47], ["H 2 O", "CHEMICAL", 53, 58], ["H", "CHEMICAL", 69, 70], ["2 H 2 O", "SIMPLE_CHEMICAL", 51, 58], ["1 H-amide protons", "SIMPLE_CHEMICAL", 67, 84], ["deuterons", "SIMPLE_CHEMICAL", 131, 140], ["The buffer", "TREATMENT", 0, 10], ["the 1 H-amide protons", "TREATMENT", 63, 84], ["the antigen surface", "TREATMENT", 88, 107]]], ["Finally, the antigen was eluted at low pH to quench or stop further amide exchange.", [["amide", "CHEMICAL", 68, 73], ["amide", "SIMPLE_CHEMICAL", 68, 73], ["the antigen", "TEST", 9, 20], ["further amide exchange", "TREATMENT", 60, 82]]], ["The cleverness of this design is that the antigen (smaller than the antibody, and therefore with better NMR properties) retains information about the protection.", [["antibody", "PROTEIN", 68, 76], ["the antigen", "PROBLEM", 38, 49], ["the antibody", "TEST", 64, 76]]], ["Paterson applied this method to the model antigen cytochrome c, and it was subsequently adapted for the allergens hen-egg lysozyme (Gal d 4) and Der p 2 (59, 129) .NMR Protection AssaysEach of these protection studies provided useful epitope mapping information for the antibodies analyzed.", [["cytochrome c", "GENE_OR_GENE_PRODUCT", 50, 62], ["Gal d 4", "GENE_OR_GENE_PRODUCT", 132, 139], ["antigen cytochrome c", "PROTEIN", 42, 62], ["antibodies", "PROTEIN", 270, 280], ["hen", "SPECIES", 114, 117], ["Paterson", "TREATMENT", 0, 8], ["the model antigen cytochrome c", "TREATMENT", 32, 62], ["the allergens", "TREATMENT", 100, 113], ["egg lysozyme", "TREATMENT", 118, 130], ["NMR Protection", "TREATMENT", 164, 178], ["these protection studies", "TEST", 193, 217], ["epitope mapping", "TREATMENT", 234, 249], ["the antibodies", "TEST", 266, 280]]], ["Paterson showed that one antibody protected from amide exchange 11 residues that were derived from 3 discontinuous peptides (128) .", [["amide", "CHEMICAL", 49, 54], ["amide exchange", "TREATMENT", 49, 63]]], ["The 3 peptides were all in close proximity on the crystal structure.", [["The 3 peptides", "TREATMENT", 0, 14], ["crystal structure", "OBSERVATION", 50, 67]]], ["The Der p 2 studies probed the epitopes of 3 murine mAb, one of which (epitope for mAb 7A1) was recently corroborated with a crystal structure, and further NMR data (see below) (58) .", [["murine", "ORGANISM", 45, 51], ["mAb", "GENE_OR_GENE_PRODUCT", 52, 55], ["Der p 2", "PROTEIN", 4, 11], ["epitopes", "PROTEIN", 31, 39], ["murine mAb", "PROTEIN", 45, 55], ["epitope", "PROTEIN", 71, 78], ["mAb 7A1", "PROTEIN", 83, 90], ["murine", "SPECIES", 45, 51], ["The Der p 2 studies", "TEST", 0, 19], ["3 murine mAb", "TREATMENT", 43, 55], ["further NMR data", "TEST", 148, 164]]], ["However, only the protection assays for mAb 7A1 gave discontinuous epitope information.", [["mAb 7A1", "GENE_OR_GENE_PRODUCT", 40, 47], ["mAb 7A1", "PROTEIN", 40, 47], ["the protection assays", "TEST", 14, 35], ["discontinuous epitope information", "TREATMENT", 53, 86]]], ["The absence of protection information for the other two antibodies does not imply that the other epitopes are linear.", [["antibodies", "PROTEIN", 56, 66], ["epitopes", "PROTEIN", 97, 105], ["the other two antibodies", "PROBLEM", 42, 66], ["linear", "OBSERVATION_MODIFIER", 110, 116]]], ["Instead, it was probably due to unfortunate circumstances where the exchange rate for protected versus non-protected was too fast to measure using the antibody column technology.NMR Protection AssaysAdditionally, in the lysozyme studies, it became apparent that not only could amides in the epitope be protected from exchange, but more distal atoms could show differences in exchange rate (129) .", [["amides", "CHEMICAL", 277, 283], ["lysozyme", "PROTEIN", 220, 228], ["the exchange rate", "TEST", 64, 81], ["the antibody column technology", "TREATMENT", 147, 177], ["the lysozyme studies", "TEST", 216, 236], ["exchange rate", "TEST", 375, 388], ["probably due to", "UNCERTAINTY", 16, 31], ["distal", "ANATOMY_MODIFIER", 336, 342]]], ["This is understood to be due to conformational changes in the antigen, or changes in the folding-unfolding rate of the protein due to the formation of the complex with the antibody, which was also noticed by Paterson et al. (130) .", [["antibody", "PROTEIN", 172, 180], ["conformational changes in the antigen", "PROBLEM", 32, 69], ["changes in the folding", "PROBLEM", 74, 96], ["unfolding rate", "PROBLEM", 97, 111], ["the protein", "PROBLEM", 115, 126]]], ["Interestingly, similar distal changes in exchange rate were observed for binding of the Fv fragment of the lysozyme antibody and the mAb 7A1 (58, 131) .", [["Fv fragment", "PROTEIN", 88, 99], ["lysozyme antibody", "PROTEIN", 107, 124], ["mAb 7A1", "PROTEIN", 133, 140], ["exchange rate", "TEST", 41, 54], ["the lysozyme antibody", "TEST", 103, 124], ["the mAb", "TEST", 129, 136], ["similar", "OBSERVATION_MODIFIER", 15, 22], ["distal", "OBSERVATION_MODIFIER", 23, 29], ["changes", "OBSERVATION", 30, 37], ["exchange rate", "OBSERVATION", 41, 54], ["Fv fragment", "OBSERVATION", 88, 99]]], ["This is an important lesson for all NMR studies: proximal and distal changes in antigen conformation upon antibody binding can similarly influence the data, and it might be difficult to differentiate a priori which changes occur within the epitope.", [["all NMR studies", "TEST", 32, 47], ["proximal and distal changes in antigen conformation", "PROBLEM", 49, 100], ["antibody binding", "PROBLEM", 106, 122], ["proximal", "OBSERVATION_MODIFIER", 49, 57], ["distal", "OBSERVATION_MODIFIER", 62, 68]]], ["Therefore, it is frequently important to support the observed changes in the NMR data with additional information.", [["the NMR data", "TEST", 73, 85]]], ["This additional data could be proximity in the structure of atoms that experience NMR spectral changes, or data from mutant proteins and complimentary immunoassays to prove or disprove antibody binding.NMR Protection AssaysThe HDX-NMR protection assays were successful but have fallen out of favor for several reasons.", [["HDX", "SIMPLE_CHEMICAL", 227, 230], ["mutant proteins", "PROTEIN", 117, 132], ["NMR spectral changes", "PROBLEM", 82, 102], ["mutant proteins", "PROBLEM", 117, 132], ["complimentary immunoassays", "TEST", 137, 163], ["antibody binding", "PROBLEM", 185, 201], ["NMR Protection", "TEST", 202, 216], ["The HDX", "TEST", 223, 230], ["NMR protection assays", "TEST", 231, 252]]], ["First, creating an antibody column with enough capacity for an NMR experiment, typically 5-10 mg of antibody, can be cost prohibitive.", [["an antibody column", "TEST", 16, 34], ["an NMR experiment", "TEST", 60, 77], ["antibody", "TEST", 100, 108], ["antibody column", "OBSERVATION", 19, 34]]], ["Second, not all antigens survive the low pH required to quench the exchange.", [["antigens", "PROTEIN", 16, 24], ["the low pH", "PROBLEM", 33, 43]]], ["Third, NMR instrumentation improved and labeling techniques (132) with newer experiments [called TROSY (133, 134) ] were developed to better observe larger complexes directly, obviating the need of using the antibody column and the measurement of exchange rates.NMR Direct Observation of ComplexesThe \"antibody\"-allergen complex can now be directly observed with careful choices of the labeling scheme.", [["allergen complex", "PROTEIN", 312, 328], ["NMR instrumentation", "TREATMENT", 7, 26], ["labeling techniques", "TEST", 40, 59], ["the antibody column", "TREATMENT", 204, 223], ["exchange rates", "TREATMENT", 247, 261], ["allergen complex", "PROBLEM", 312, 328], ["instrumentation", "OBSERVATION", 11, 26]]], ["Complete 15 N backbone labeling of the allergen or antibody fragment such as Fab (\u223c50 kDa) or scFv (\u223c25 kDa) is sometimes possible.", [["Fab", "GENE_OR_GENE_PRODUCT", 77, 80], ["scFv", "GENE_OR_GENE_PRODUCT", 94, 98], ["allergen", "PROTEIN", 39, 47], ["antibody fragment", "PROTEIN", 51, 68], ["Fab", "PROTEIN", 77, 80], ["\u223c50 kDa", "PROTEIN", 82, 89], ["scFv", "PROTEIN", 94, 98], ["\u223c25 kDa", "PROTEIN", 100, 107], ["Complete 15 N backbone labeling", "TREATMENT", 0, 31], ["the allergen", "TREATMENT", 35, 47], ["antibody fragment", "PROBLEM", 51, 68], ["Fab", "TEST", 77, 80], ["scFv (\u223c25 kDa", "TREATMENT", 94, 107]]], ["These amide detection techniques using antibody fragments have been successfully applied to the allergen Blo t 5 in complex with a Fab.", [["amide", "CHEMICAL", 6, 11], ["Fab", "GENE_OR_GENE_PRODUCT", 131, 134], ["allergen Blo t 5", "PROTEIN", 96, 112], ["Fab", "PROTEIN", 131, 134], ["These amide detection techniques", "TREATMENT", 0, 32], ["antibody fragments", "TREATMENT", 39, 57], ["a Fab", "TREATMENT", 129, 134]]], ["A discontinuous epitope was identified by comparing the 1 H-15 N chemical shift perturbations of the bound and free allergen (135, 136) .", [["H-15 N", "CHEMICAL", 58, 64], ["A discontinuous epitope", "TREATMENT", 0, 23], ["discontinuous", "OBSERVATION_MODIFIER", 2, 15], ["epitope", "OBSERVATION", 16, 23]]], ["This epitope was shown to overlap with binding sites of patient polyclonal IgE.", [["patient", "ORGANISM", 56, 63], ["IgE", "GENE_OR_GENE_PRODUCT", 75, 78], ["patient polyclonal IgE", "PROTEIN", 56, 78], ["patient", "SPECIES", 56, 63], ["This epitope", "TREATMENT", 0, 12], ["polyclonal IgE", "OBSERVATION", 64, 78]]], ["However, in our experience, the use of smaller forms of the whole antibody, such as Fab or scFv, in an attempt to increase NMR signals, has not always been successful.", [["Fab", "GENE_OR_GENE_PRODUCT", 84, 87], ["scFv", "GENE_OR_GENE_PRODUCT", 91, 95], ["whole antibody", "PROTEIN", 60, 74], ["Fab", "PROTEIN", 84, 87], ["scFv", "PROTEIN", 91, 95], ["the whole antibody", "TEST", 56, 74], ["Fab or scFv", "TREATMENT", 84, 95], ["NMR signals", "TEST", 123, 134]]], ["Some of these smaller antibody constructs are hard to produce, and surprisingly, do not always maintain the high affinity of the full antibody for the antigen.", [["antibody constructs", "DNA", 22, 41], ["these smaller antibody constructs", "PROBLEM", 8, 41], ["smaller", "OBSERVATION_MODIFIER", 14, 21], ["antibody constructs", "OBSERVATION", 22, 41]]], ["Therefore, other techniques such as those below have been explored for NMR detection of allergen-antibody complexes.NMR Direct Observation of ComplexesA similar labeling scheme, but in a subtly different experiment, was used to map the Der f 2 epitopes of two full length murine IgG (150 kDa) (137) .", [["murine", "ORGANISM", 272, 278], ["IgG", "GENE_OR_GENE_PRODUCT", 279, 282], ["allergen-antibody complexes", "PROTEIN", 88, 115], ["Der f 2 epitopes", "PROTEIN", 236, 252], ["full length murine IgG", "PROTEIN", 260, 282], ["150 kDa", "PROTEIN", 284, 291], ["murine", "SPECIES", 272, 278], ["NMR detection", "TEST", 71, 84], ["allergen-antibody complexes", "PROBLEM", 88, 115], ["ComplexesA similar labeling scheme", "PROBLEM", 142, 176]]], ["The authors again utilized 1 H-15 N labeled allergen, which would typically not be detectable at this large size when bound to antibody, assuming tight binding to the IgG.", [["1 H-15 N", "CHEMICAL", 27, 35], ["H-15 N", "SIMPLE_CHEMICAL", 29, 35], ["IgG", "GENE_OR_GENE_PRODUCT", 167, 170], ["IgG", "PROTEIN", 167, 170], ["size", "OBSERVATION_MODIFIER", 108, 112]]], ["In this case, detergent was added to the sample to reduce the antibody affinity.", [["sample", "ANATOMY", 41, 47], ["the antibody affinity", "PROBLEM", 58, 79]]], ["As a result, in the NMR experiment the researchers were observing the allergen 1 H-15 N chemical shift perturbations between bound and free, with the smaller molecule in the free state being the one that was detected.", [["H-15 N", "CHEMICAL", 81, 87]]], ["The ratio of bound to free was tuned with the concentration of detergent so that there was a differential reduction or broadening in the NMR signals of those residues in proximity to the antibody compared to the free protein.", [["detergent", "TREATMENT", 63, 72], ["a differential reduction", "PROBLEM", 91, 115], ["those residues", "PROBLEM", 152, 166], ["the antibody", "TEST", 183, 195], ["differential", "OBSERVATION_MODIFIER", 93, 105], ["reduction", "OBSERVATION_MODIFIER", 106, 115], ["broadening", "OBSERVATION_MODIFIER", 119, 129]]], ["The broadening is due to increased relaxation of the NMR signal due to the large fully 1 H labeled antibody binding to the antigen (138) .", [["H", "CHEMICAL", 89, 90], ["H", "CHEMICAL", 89, 90], ["1 H labeled antibody", "PROTEIN", 87, 107], ["increased relaxation", "PROBLEM", 25, 45], ["the NMR signal", "TEST", 49, 63], ["the large fully 1 H labeled antibody binding", "PROBLEM", 71, 115], ["the antigen", "TEST", 119, 130], ["due to", "UNCERTAINTY", 18, 24], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["relaxation", "OBSERVATION", 35, 45], ["large", "OBSERVATION_MODIFIER", 75, 80]]], ["In the Der f 2 study, the differential exchange broadening data provided results that mapped the epitopes to two disparate regions of the protein, consistent with the simultaneous binding of the two antibodies.", [["epitopes", "PROTEIN", 97, 105], ["antibodies", "PROTEIN", 199, 209], ["the protein", "TEST", 134, 145], ["the simultaneous binding of the two antibodies", "PROBLEM", 163, 209], ["consistent with", "UNCERTAINTY", 147, 162]]], ["A potential disadvantage of this technique is that it requires empirical tuning of the solvent conditions, which may or may not be applicable to all systems.NMR Direct Observation of ComplexesInstead of looking at fragments of the antibody-allergen complex, or the free allergen in exchange with complex, it is also possible to utilize whole antibodies, but this requires another compromise in the labeling scheme.", [["antibody-allergen complex", "PROTEIN", 231, 256], ["whole antibodies", "PROTEIN", 336, 352], ["this technique", "TREATMENT", 28, 42], ["the solvent conditions", "TREATMENT", 83, 105], ["allergen complex", "PROBLEM", 240, 256], ["whole antibodies", "TEST", 336, 352]]], ["At the very high molecular weights of allergen-antibody complexes, usually only methyl groups are still observable in a background of otherwise 2 H labeled proteins (132) .", [["methyl", "CHEMICAL", 80, 86], ["methyl", "CHEMICAL", 80, 86], ["2 H", "CHEMICAL", 144, 147], ["methyl groups", "SIMPLE_CHEMICAL", 80, 93], ["allergen-antibody complexes", "PROTEIN", 38, 65], ["H labeled proteins", "PROTEIN", 146, 164]]], ["Focusing on only labeling methyl groups in the allergen restricts the number of probes available for epitope mapping to the methyl groups of Val, Leu and Ile.", [["methyl", "CHEMICAL", 26, 32], ["methyl", "CHEMICAL", 124, 130], ["methyl", "CHEMICAL", 26, 32], ["methyl", "CHEMICAL", 124, 130], ["Val", "CHEMICAL", 141, 144], ["Leu", "CHEMICAL", 146, 149], ["Ile", "CHEMICAL", 154, 157], ["methyl", "SIMPLE_CHEMICAL", 26, 32], ["methyl", "SIMPLE_CHEMICAL", 124, 130], ["Val", "AMINO_ACID", 141, 144], ["Leu", "AMINO_ACID", 146, 149], ["Ile", "AMINO_ACID", 154, 157], ["labeling methyl groups", "TREATMENT", 17, 39], ["epitope mapping", "TREATMENT", 101, 116]]], ["The effectiveness of this was demonstrated for [U-2 H, 1 H, 13 Cmethyl Val, Leu, Ile] Der p 2 bound to an scFv fragment of mAb 7A1 (58) .", [["U-2 H, 1 H, 13 Cmethyl Val, Leu, Ile", "CHEMICAL", 48, 84], ["[U-2 H, 1 H, 13 Cmethyl Val", "CHEMICAL", 47, 74], ["Leu", "CHEMICAL", 76, 79], ["Ile", "CHEMICAL", 81, 84], ["[U-2 H, 1 H, 13 Cmethyl Val, Leu", "SIMPLE_CHEMICAL", 47, 79], ["mAb 7A1", "PROTEIN", 123, 130], ["U", "TEST", 48, 49], ["an scFv fragment", "TEST", 103, 119]]], ["The data showed relaxation broadening for Ile-97 in the allergen, which was directly in contact with the scFv, and chemical shift perturbations for V63 and L61, which were adjacent to the epitope as described in a crystal structure (Figure 9 ).", [["Ile-97", "CHEMICAL", 42, 48], ["Ile-97", "CHEMICAL", 42, 48], ["Ile-97", "SIMPLE_CHEMICAL", 42, 48], ["scFv", "GENE_OR_GENE_PRODUCT", 105, 109], ["L61", "GENE_OR_GENE_PRODUCT", 156, 159], ["scFv", "PROTEIN", 105, 109], ["V63", "PROTEIN", 148, 151], ["L61", "PROTEIN", 156, 159], ["epitope", "PROTEIN", 188, 195], ["The data", "TEST", 0, 8], ["relaxation broadening", "PROBLEM", 16, 37], ["Ile", "TEST", 42, 45], ["the scFv", "TREATMENT", 101, 109], ["chemical shift perturbations", "TREATMENT", 115, 143], ["V63 and L61", "PROBLEM", 148, 159], ["the epitope", "PROBLEM", 184, 195], ["broadening", "OBSERVATION_MODIFIER", 27, 37], ["scFv", "ANATOMY", 105, 109], ["epitope", "OBSERVATION", 188, 195]]], ["This is again consistent with previous observations that close proximity to the 1 H antibody causes broadening or a disappearance of signal, and distal residues can also experience chemical shift perturbations (138) .NMR Direct Observation of ComplexesMethyl labeled Der p 2 as described above was successfully applied to study 4 human IgE mAb epitopes and 3 murine IgG mAb epitopes (127) .", [["Methyl", "CHEMICAL", 252, 258], ["Methyl", "CHEMICAL", 252, 258], ["1 H antibody", "GENE_OR_GENE_PRODUCT", 80, 92], ["Der p 2", "GENE_OR_GENE_PRODUCT", 267, 274], ["human", "ORGANISM", 330, 335], ["IgE", "GENE_OR_GENE_PRODUCT", 336, 339], ["murine", "ORGANISM", 359, 365], ["1 H antibody", "PROTEIN", 80, 92], ["Der p 2", "PROTEIN", 267, 274], ["human IgE mAb epitopes", "PROTEIN", 330, 352], ["murine IgG mAb epitopes", "PROTEIN", 359, 382], ["human", "SPECIES", 330, 335], ["murine", "SPECIES", 359, 365], ["human", "SPECIES", 330, 335], ["a disappearance of signal, and distal residues", "PROBLEM", 114, 160], ["ComplexesMethyl labeled Der p 2", "TREATMENT", 243, 274], ["study", "TEST", 322, 327], ["human IgE mAb epitopes", "TREATMENT", 330, 352], ["3 murine IgG mAb epitopes", "TREATMENT", 357, 382], ["consistent with", "UNCERTAINTY", 14, 29], ["broadening", "OBSERVATION_MODIFIER", 100, 110], ["distal residues", "OBSERVATION", 145, 160]]], ["Similar data observations of broadening and chemical shift perturbations were analyzed to map the epitope regions.", [["epitope regions", "PROTEIN", 98, 113], ["chemical shift perturbations", "TREATMENT", 44, 72], ["broadening", "OBSERVATION_MODIFIER", 29, 39]]], ["Since the epitope data is sparse, being only derived from a few methyl probes, it needs to be interpreted with caution.", [["methyl", "CHEMICAL", 64, 70], ["the epitope data", "TEST", 6, 22], ["a few methyl probes", "TREATMENT", 58, 77]]], ["For each antibody, the data indicated that few residues in close proximity were broadened or perturbed, and this was consistent with previous mutagenesis studies or data from Der p 2 isoforms.", [["Der p 2", "GENE_OR_GENE_PRODUCT", 175, 182], ["Der p 2 isoforms", "PROTEIN", 175, 191], ["each antibody", "TEST", 4, 17], ["the data", "TEST", 19, 27], ["few residues", "PROBLEM", 43, 55], ["previous mutagenesis studies", "TEST", 133, 161]]], ["The NMR data were in agreement with the relative epitope FIGURE 9 | Residues both near and far from the epitope can be affected by antibody binding.", [["epitope", "PROTEIN", 104, 111], ["The NMR data", "TEST", 0, 12], ["antibody binding", "PROBLEM", 131, 147]]], ["The crystal structure of Der p 2 in complex with the murine IgG mAb 7A1 is shown with Der p 2 rendered in green with specific methyl residues highlighted in orange.", [["methyl", "CHEMICAL", 126, 132], ["methyl", "CHEMICAL", 126, 132], ["Der p 2", "GENE_OR_GENE_PRODUCT", 25, 32], ["murine", "ORGANISM", 53, 59], ["IgG mAb 7A1", "GENE_OR_GENE_PRODUCT", 60, 71], ["Der p 2", "GENE_OR_GENE_PRODUCT", 86, 93], ["Der p 2", "PROTEIN", 25, 32], ["murine IgG mAb 7A1", "PROTEIN", 53, 71], ["Der p 2", "PROTEIN", 86, 93], ["murine", "SPECIES", 53, 59], ["the murine IgG mAb", "TEST", 49, 67], ["specific methyl residues", "TREATMENT", 117, 141], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["methyl residues", "OBSERVATION", 126, 141]]], ["The mAb 7A1 heavy and light chains are rendered as blue and lavender surfaces, respectively.", [["mAb 7A1 heavy and light chains", "PROTEIN", 4, 34], ["The mAb", "TREATMENT", 0, 7]]], ["The shift of methyl resonances of the orange residues upon complex formation were measured by NMR.", [["methyl", "CHEMICAL", 13, 19], ["methyl", "CHEMICAL", 13, 19], ["methyl", "SIMPLE_CHEMICAL", 13, 19], ["the orange residues", "PROBLEM", 34, 53], ["shift", "OBSERVATION_MODIFIER", 4, 9], ["methyl resonances", "OBSERVATION", 13, 30], ["orange residues", "OBSERVATION", 38, 53]]], ["The figure shows that residues proximal and distal from the epitope can be affected by binding to an antibody. mapping obtained using competitive and direct antibody binding immunoassays, which demonstrated which epitopes did or did not overlap.NMR Direct Observation of ComplexesWhile these data are an impressive first mapping of human IgE epitopes, three important drawbacks of the technique need to be mentioned.", [["human", "ORGANISM", 332, 337], ["IgE", "GENE_OR_GENE_PRODUCT", 338, 341], ["epitope", "PROTEIN", 60, 67], ["epitopes", "PROTEIN", 213, 221], ["human IgE epitopes", "PROTEIN", 332, 350], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 332, 337], ["residues proximal and distal from the epitope", "PROBLEM", 22, 67], ["mapping", "TEST", 111, 118], ["direct antibody binding immunoassays", "TEST", 150, 186], ["human IgE epitopes", "TREATMENT", 332, 350], ["the technique", "TREATMENT", 381, 394], ["residues", "OBSERVATION_MODIFIER", 22, 30], ["proximal", "OBSERVATION_MODIFIER", 31, 39], ["distal", "OBSERVATION_MODIFIER", 44, 50]]], ["First, it requires monoclonal antibodies, of which human IgE are very difficult to clone from patients.", [["human", "ORGANISM", 51, 56], ["IgE", "GENE_OR_GENE_PRODUCT", 57, 60], ["clone", "CELL", 83, 88], ["patients", "ORGANISM", 94, 102], ["monoclonal antibodies", "PROTEIN", 19, 40], ["human IgE", "PROTEIN", 51, 60], ["human", "SPECIES", 51, 56], ["patients", "SPECIES", 94, 102], ["human", "SPECIES", 51, 56], ["monoclonal antibodies", "TREATMENT", 19, 40], ["monoclonal antibodies", "OBSERVATION", 19, 40]]], ["Although this technique may be applicable to polyclonal antibodies, its effectiveness remains to be demonstrated in this case.", [["polyclonal antibodies", "PROTEIN", 45, 66], ["this technique", "TREATMENT", 9, 23], ["polyclonal antibodies", "TEST", 45, 66]]], ["1 H-15 N labeling of Art v 1 and Bet v 1 was combined with either pooled allergic sera, or individual allergic sera, respectively, but the NMR results were nebulous (139) (140) (141) .", [["sera", "ANATOMY", 82, 86], ["sera", "ANATOMY", 111, 115], ["allergic", "DISEASE", 73, 81], ["allergic sera", "DISEASE", 102, 115], ["1 H-15 N", "CHEMICAL", 0, 8], ["Art v 1", "GENE_OR_GENE_PRODUCT", 21, 28], ["Bet v 1", "GENE_OR_GENE_PRODUCT", 33, 40], ["sera", "ORGANISM_SUBSTANCE", 82, 86], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["Bet v 1", "PROTEIN", 33, 40], ["Art v", "TREATMENT", 21, 26], ["Bet v", "TEST", 33, 38], ["pooled allergic sera", "PROBLEM", 66, 86], ["individual allergic sera", "PROBLEM", 91, 115], ["the NMR", "TEST", 135, 142]]], ["Second, the methyl labeling is expensive, typically $1,000 per liter of bacterial expression culture.", [["methyl", "CHEMICAL", 12, 18], ["methyl", "CHEMICAL", 12, 18], ["methyl", "SIMPLE_CHEMICAL", 12, 18], ["the methyl labeling", "TREATMENT", 8, 27], ["bacterial expression culture", "TEST", 72, 100]]], ["Thus, high expression levels of the protein are needed to be cost effective.", [["high expression levels of the protein", "PROBLEM", 6, 43]]], ["And third, as mentioned above, the distribution of sparse methyl groups may not be ideal for all allergens to get good epitope data.", [["methyl", "CHEMICAL", 58, 64], ["methyl", "CHEMICAL", 58, 64], ["methyl", "SIMPLE_CHEMICAL", 58, 64], ["sparse methyl groups", "PROBLEM", 51, 71]]], ["Hence, the epitopes proposed from these NMR data likely include more residues than the ones that are directly observed contacting the antibody in a crystal structure and should be further tested for functional importance.NMR Direct Observation of ComplexesIn summary, a variety of NMR techniques and labeling schemes have been applied for allergen epitope mapping.", [["epitopes", "PROTEIN", 11, 19], ["these NMR data", "TEST", 34, 48], ["NMR techniques", "TREATMENT", 281, 295], ["labeling schemes", "TREATMENT", 300, 316], ["allergen epitope mapping", "TREATMENT", 339, 363]]], ["In each case, atoms or residues specific to the epitope were successfully identified.FUTURE DIRECTIONSExperimental epitope mapping of IgE antibodies on allergens originated \u223c30 years ago with the identification of mostly linear epitopes.", [["IgE antibodies", "GENE_OR_GENE_PRODUCT", 134, 148], ["epitope", "PROTEIN", 48, 55], ["IgE antibodies", "PROTEIN", 134, 148], ["the epitope", "PROBLEM", 44, 55], ["FUTURE DIRECTIONSExperimental epitope mapping", "TREATMENT", 85, 130], ["IgE antibodies", "PROBLEM", 134, 148], ["allergens", "PROBLEM", 152, 161], ["mostly linear epitopes", "PROBLEM", 214, 236], ["IgE antibodies", "OBSERVATION", 134, 148], ["linear", "OBSERVATION_MODIFIER", 221, 227], ["epitopes", "OBSERVATION", 228, 236]]], ["Several breakthroughs have allowed the identification of conformational epitopes.", [["conformational epitopes", "PROTEIN", 57, 80], ["conformational epitopes", "PROBLEM", 57, 80]]], ["These epitopes are the most common on allergens, especially on allergens for which exposure occurs by inhalation.", [["epitopes", "PROTEIN", 6, 14]]], ["Techniques such as recombinant technology, X-ray crystallography and nuclear magnetic resonance were developed and used for the determination of structures of allergen-antibody complexes.", [["allergen-antibody complexes", "PROTEIN", 159, 186], ["X-ray crystallography", "TEST", 43, 64], ["nuclear magnetic resonance", "TEST", 69, 95], ["allergen-antibody complexes", "TREATMENT", 159, 186], ["antibody complexes", "OBSERVATION", 168, 186]]], ["These advances required preparation of pure and homogeneous allergens and monoclonal antibodies.", [["monoclonal antibodies", "PROTEIN", 74, 95], ["pure and homogeneous allergens", "PROBLEM", 39, 69], ["monoclonal antibodies", "TEST", 74, 95], ["monoclonal antibodies", "OBSERVATION", 74, 95]]], ["Initially, mostly IgG antibodies that inhibit IgE antibody binding were used as surrogates of IgE and fragmented for epitope mapping.", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 18, 32], ["IgE antibody", "GENE_OR_GENE_PRODUCT", 46, 58], ["IgE", "GENE_OR_GENE_PRODUCT", 94, 97], ["IgG antibodies", "PROTEIN", 18, 32], ["IgE antibody", "PROTEIN", 46, 58], ["IgE", "PROTEIN", 94, 97], ["mostly IgG antibodies", "PROBLEM", 11, 32], ["IgE antibody binding", "PROBLEM", 46, 66], ["IgE", "PROBLEM", 94, 97], ["epitope mapping", "TREATMENT", 117, 132], ["IgG antibodies", "OBSERVATION", 18, 32]]], ["Another approach led to the isolation of IgE antibody constructs using phage display technology.", [["IgE", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgE antibody constructs", "DNA", 41, 64], ["the isolation of IgE antibody constructs", "TREATMENT", 24, 64]]], ["Only more recently, single cell antibody sequencing and human hybridoma technology are opening a new era of epitope mapping that will allow direct visualization of allergen-IgE antibody interactions in detail.", [["cell", "ANATOMY", 27, 31], ["cell", "CELL", 27, 31], ["human", "ORGANISM", 56, 61], ["allergen-IgE", "GENE_OR_GENE_PRODUCT", 164, 176], ["IgE antibody", "PROTEIN", 173, 185], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["single cell antibody sequencing", "TEST", 20, 51], ["human hybridoma technology", "TREATMENT", 56, 82], ["epitope mapping", "TREATMENT", 108, 123]]], ["Other technologies such as cryo-electron microscopy and labeling with mass spectrometry will also contribute to epitope mapping with less demanding protein amounts.", [["cryo-electron microscopy", "TEST", 27, 51], ["mass spectrometry", "PROBLEM", 70, 87], ["epitope mapping", "TREATMENT", 112, 127]]], ["Moreover, the experimental results allow for a significant development of many computational approaches to identify and/or analyze paratopes and epitopes (142) .", [["paratopes", "PROTEIN", 131, 140], ["epitopes", "PROTEIN", 145, 153]]], ["For example, approaches used in image recognition, like Zernike moments, were shown to be very promising in predicting B-cell epitopes (143) (144) (145) .", [["B-cell", "ANATOMY", 119, 125], ["B-cell", "CELL", 119, 125], ["image recognition", "TEST", 32, 49]]], ["Therefore, we expect that computational methods will start to play a more important role in studies of interactions between antibodies and allergens.", [["antibodies", "PROTEIN", 124, 134], ["allergens", "PROTEIN", 139, 148], ["computational methods", "TREATMENT", 26, 47]]], ["Ultimately, identification of IgE antibody binding epitopes associated with the human IgE repertoire will contribute to understanding the immune response to allergens and will lead to the design of modified recombinant allergens for safer and more effective immunotherapy.AUTHOR CONTRIBUTIONSAP designed, wrote, and edited the review.", [["IgE antibody", "GENE_OR_GENE_PRODUCT", 30, 42], ["human", "ORGANISM", 80, 85], ["IgE", "GENE_OR_GENE_PRODUCT", 86, 89], ["IgE antibody binding epitopes", "PROTEIN", 30, 59], ["human IgE repertoire", "PROTEIN", 80, 100], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["IgE antibody binding epitopes", "PROBLEM", 30, 59], ["the human IgE repertoire", "TREATMENT", 76, 100], ["modified recombinant allergens", "TREATMENT", 198, 228], ["effective immunotherapy", "TREATMENT", 248, 271], ["IgE antibody", "OBSERVATION", 30, 42]]], ["She especially wrote the sections about IgE epitope mapping.", [["sections", "ANATOMY", 25, 33], ["IgE", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgE epitope", "PROTEIN", 40, 51], ["IgE epitope mapping", "TREATMENT", 40, 59]]], ["GM wrote the sections associated with NMR and cryo-EM.", [["sections", "ANATOMY", 13, 21], ["GM", "CHEMICAL", 0, 2], ["NMR", "TEST", 38, 41], ["cryo-EM", "TEST", 46, 53]]], ["MC analyzed crystal structures of allergen-antibody complexes and wrote sections about X-ray crystallography and mass spectrometry.AUTHOR CONTRIBUTIONSGM and MC also contributed to editing the manuscript.", [["sections", "ANATOMY", 72, 80], ["allergen-antibody complexes", "PROTEIN", 34, 61], ["X-ray crystallography", "TEST", 87, 108], ["mass spectrometry", "PROBLEM", 113, 130], ["mass spectrometry", "OBSERVATION", 113, 130]]], ["All authors contributed to the article and approved the submitted version.FUNDINGResearch reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI077653 (to AP-contact PI-, MC).", [["Infectious Diseases", "DISEASE", 174, 193], ["Infectious", "OBSERVATION_MODIFIER", 174, 184]]], ["This research was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (Z01-ES102906, GM).", [["Z01-ES102906", "CHEMICAL", 131, 143], ["GM", "CHEMICAL", 145, 147]]]], "PMC6607295": [["IntroductionUrbanization and population growth lead to increased and inhomogeneous consumption of water resources.", [["IntroductionUrbanization", "TREATMENT", 0, 24], ["population growth lead", "PROBLEM", 29, 51], ["water resources", "TREATMENT", 98, 113], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["inhomogeneous", "OBSERVATION_MODIFIER", 69, 82]]], ["This is why access to safe drinking water and sanitation is among the UN's Sustainable Development Goals, i.e., Agenda 2030.1 In low\u2010income countries, when a centralized water supply is not available or the quantity is limited, poor households have to rely on water obtained from rivers, rain, or shallow wells.2 The lack of safe water is a part of a vicious cycle, where poverty and poor healthcare feed each other.", [["a centralized water supply", "TREATMENT", 156, 182]]], ["Water safety is also an important issue in high\u2010income countries with centralized water supply since water\u2010borne outbreaks continue to occur3, 4, 5, 6, 7, 8, 9, 10 and many more incidents are expected, especially among susceptible population groups, including increasing elderly population above the age of 65, children below the age of 5, chronically ill patients, recipients of immunosuppressive therapies, and pregnant women.11 Globalization of commerce, expansion of food supply sources from regions with unimproved irrigation, people migration from areas with poor hygiene, and natural sporadic mutations contribute to the spread of water\u2010borne diseases.11", [["chronically ill", "DISEASE", 340, 355], ["water\u2010borne diseases", "DISEASE", 638, 658], ["children", "ORGANISM", 311, 319], ["patients", "ORGANISM", 356, 364], ["women", "ORGANISM", 422, 427], ["children", "SPECIES", 311, 319], ["patients", "SPECIES", 356, 364], ["women", "SPECIES", 422, 427], ["people", "SPECIES", 532, 538], ["immunosuppressive therapies", "TREATMENT", 380, 407], ["unimproved irrigation", "TREATMENT", 509, 530], ["people migration", "TREATMENT", 532, 548], ["natural sporadic mutations", "PROBLEM", 583, 609], ["water\u2010borne diseases", "PROBLEM", 638, 658], ["expansion", "OBSERVATION_MODIFIER", 458, 467], ["unimproved", "OBSERVATION_MODIFIER", 509, 519], ["irrigation", "OBSERVATION", 520, 530], ["migration", "OBSERVATION_MODIFIER", 539, 548], ["areas", "OBSERVATION_MODIFIER", 554, 559], ["poor hygiene", "OBSERVATION", 565, 577]]]], "3c83a45d3f3e227de8b5e0e88022352385dd78e8": [["This program has universal coverage, including pharmaceuticals, ambulatory care, inpatient care, traditional Chinese medicine, dental services, child delivery, rehabilitation, home nursing care and chronic psychiatric rehabilitation.", [["psychiatric", "DISEASE", 206, 217], ["universal coverage", "TREATMENT", 17, 35], ["pharmaceuticals", "TREATMENT", 47, 62], ["ambulatory care", "TREATMENT", 64, 79], ["inpatient care", "TREATMENT", 81, 95], ["child delivery", "TREATMENT", 144, 158], ["rehabilitation", "TREATMENT", 160, 174], ["home nursing care", "TREATMENT", 176, 193], ["chronic psychiatric rehabilitation", "TREATMENT", 198, 232]]], ["Currently, it covers more than 99% of the population (approximately 23 million people) [1] .BackgroundThe three main components of the NHI system are the BNHI, the insured and the BNHI-contracted health care providers.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["three", "OBSERVATION_MODIFIER", 106, 111], ["main", "OBSERVATION_MODIFIER", 112, 116], ["components", "OBSERVATION_MODIFIER", 117, 127]]], ["The BNHI issues insurance cards to the insured and pays the health care providers according to the services they provide, including prescriptions listed in the Pharmaceutical Benefit scheme (PBS).", [["prescriptions", "TREATMENT", 132, 145]]], ["When the insured receive medical services from BNHI-contracted health care providers, they only pay the provider a registration fee as well as any co-payment for outpatient services, inpatient services and drugs [1] .BackgroundThe BNHI established the PBS in 1996.", [["a registration fee", "TREATMENT", 113, 131]]], ["It contains the reimbursement principles, and a list of the reimbursed products with a brand-specific reimbursement price for each product.", [["the reimbursed products", "TREATMENT", 56, 79]]], ["However, physicians can purchase medications from pharmaceutical companies at the market trading price with a discount on the PBS reimbursement price.", [["medications", "TREATMENT", 33, 44], ["the PBS reimbursement price", "TREATMENT", 122, 149]]], ["Annual pharmaceutical expenditures have doubled from 62.2 billion New Taiwan Dollars (NT$; at an exchange rate of NT$30.39 to US$1 on June 30, 2008) in 1996 to NT.", [["an exchange rate of NT", "TREATMENT", 94, 116]]], ["The utilization of and expenditures on ACEIs and ARBs were expressed in months to show longitudinal changes over time.Drug utilization, expenditures and price adjustment policySeven drug price adjustments were examined, including one based on the market price and volume survey imple-Statistical analysesMultivariate logistic regression was used to explore the differences between ACEI users, ARB users and both drugs users.", [["ACEI", "CHEMICAL", 381, 385], ["ARB", "CHEMICAL", 393, 396], ["ACEIs", "SIMPLE_CHEMICAL", 39, 44], ["ARBs", "SIMPLE_CHEMICAL", 49, 53], ["ACEIs", "TREATMENT", 39, 44], ["ARBs", "TREATMENT", 49, 53], ["longitudinal changes", "PROBLEM", 87, 107], ["Seven drug price adjustments", "TREATMENT", 176, 204], ["volume survey", "TEST", 264, 277], ["Multivariate logistic regression", "PROBLEM", 304, 336], ["ACEI users", "TREATMENT", 381, 391], ["ARB users", "TREATMENT", 393, 402]]], ["Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated.Statistical analysesBox-Tiao intervention analysis [12, 13] was applied to determine whether each price adjustment was associated with significant changes in utilization of and expenditures on ACEIs, ARBs and overall renin-angiotensin drugs, after controlling for potential confounding factors.", [["angiotensin", "CHEMICAL", 294, 305], ["ACEIs", "SIMPLE_CHEMICAL", 264, 269], ["ARBs", "SIMPLE_CHEMICAL", 271, 275], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 288, 305], ["renin", "PROTEIN", 288, 293], ["Statistical analysesBox-Tiao intervention analysis", "TEST", 71, 121], ["ACEIs", "TREATMENT", 264, 269], ["ARBs", "TREATMENT", 271, 275], ["overall renin-angiotensin drugs", "TREATMENT", 280, 311], ["potential confounding factors", "PROBLEM", 335, 364]]], ["In the intervention analysis, we fitted the independent variables first and then applied the autoregressive integrated movingaverage (ARIMA) modeling identification process to the residuals.Statistical analysesTherefore, we considered the following model [13, 14] ,Statistical analyseswhere y t is the dependent variable (i.e., response series), t is the baseline trend, denoting months in numerical order, from 1 to T (T is the sample size), and n is the number of price adjustments in this study.", [["the intervention analysis", "TEST", 3, 28], ["the autoregressive integrated movingaverage (ARIMA)", "TREATMENT", 89, 140], ["this study", "TEST", 487, 497]]], ["PA it is a level indicator function to indicate whether the level changed as the ith price adjustment occurred.", [["PA", "GENE_OR_GENE_PRODUCT", 0, 2], ["the ith price adjustment", "TREATMENT", 77, 101]]], ["TPA it is a trend variable to indicate whether the trend changed as the ith price adjustment occurred, that is, let TPA it be 0 for t < t 0 , and t \u00c0 t 0 +1, for t\u2265t 0 . \u03b2 0 is the constant term that describes the baseline level of the dependent variable. \u03b2 1 describes the baseline trend before the first intervention occurred. \u03b2 2i depicts the level change immediately after the ith price adjustment and \u03b2 2i+1 depicts the trend change after the ith price adjustment (i.e., it compares the monthly trend after the ith price adjustment with the monthly trend before the ith price adjustment).", [["TPA", "CHEMICAL", 0, 3], ["TPA", "SIMPLE_CHEMICAL", 0, 3], ["TPA", "SIMPLE_CHEMICAL", 116, 119], ["\u03b2 1", "GENE_OR_GENE_PRODUCT", 256, 259], ["\u03b2 2i", "GENE_OR_GENE_PRODUCT", 329, 333], ["\u03b2 1", "PROTEIN", 256, 259], ["\u03b2 2i", "PROTEIN", 329, 333], ["TPA", "TREATMENT", 0, 3], ["the ith price adjustment", "TREATMENT", 68, 92], ["the first intervention", "TREATMENT", 296, 318], ["the ith price adjustment", "TREATMENT", 377, 401], ["the ith price adjustment", "TREATMENT", 444, 468], ["the ith price adjustment", "TREATMENT", 512, 536], ["the ith price adjustment", "TREATMENT", 567, 591], ["trend", "OBSERVATION_MODIFIER", 425, 430], ["change", "OBSERVATION_MODIFIER", 431, 437]]], ["B is the backshift operator (i.e., B i X t \u00bc X t\u00c0i ). \u03d5 B \u00f0 \u00de \u00bc 1 \u00c0 \u03d5 1 B \u00c0 \u22ef \u00c0 \u03d5 p B p is the autoregressive polynomial of the model, and \u03b8 B \u00f0 \u00de \u00bc 1 \u00c0 \u03b8 1 B \u00c0 \u22ef \u00c0 \u03b8 q B q is the moving average polynomial. a t is the white noise with mean 0 and variance \u03c3 2 .Statistical analysesDependent variables in primary analyses were the monthly utilization of and expenditures on ACEIs, ARBs and overall renin-angiotensin drugs.", [["\u03d5", "CHEMICAL", 54, 55], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["ACEIs", "SIMPLE_CHEMICAL", 372, 377], ["ARBs", "SIMPLE_CHEMICAL", 379, 383], ["renin-angiotensin drugs", "GENE_OR_GENE_PRODUCT", 396, 419], ["backshift operator", "DNA", 9, 27], ["X t\u00c0i", "DNA", 45, 50], ["\u03d5", "PROTEIN", 80, 81], ["\u03b8 B", "PROTEIN", 139, 142], ["\u03b8", "PROTEIN", 165, 166], ["B q", "PROTEIN", 169, 172], ["renin", "PROTEIN", 396, 401], ["model", "TEST", 128, 133], ["\u03b8", "TEST", 153, 154], ["B", "TEST", 157, 158], ["\u00c0", "TEST", 159, 160], ["\u22ef", "TEST", 161, 162], ["\u00c0", "TEST", 163, 164], ["the moving average polynomial", "PROBLEM", 176, 205], ["the white noise", "TEST", 214, 229], ["Statistical analyses", "TEST", 260, 280], ["primary analyses", "TEST", 303, 319], ["ACEIs", "TREATMENT", 372, 377], ["ARBs", "TREATMENT", 379, 383], ["overall renin-angiotensin drugs", "TREATMENT", 388, 419]]], ["In subgroup analyses, the monthly utilization of and expenditures on ACEIs were categorized into patented drugs (benazepril, cilazapril, imidapril, perindopril and ramipril) and off-patent drugs (captopril, off-patent from PA2003; enalapril, fosinopril, lisinopril and quinapril, off-patent from PA2006).", [["benazepril", "CHEMICAL", 113, 123], ["cilazapril", "CHEMICAL", 125, 135], ["imidapril", "CHEMICAL", 137, 146], ["perindopril", "CHEMICAL", 148, 159], ["ramipril", "CHEMICAL", 164, 172], ["captopril", "CHEMICAL", 196, 205], ["PA2003", "CHEMICAL", 223, 229], ["enalapril", "CHEMICAL", 231, 240], ["fosinopril", "CHEMICAL", 242, 252], ["lisinopril", "CHEMICAL", 254, 264], ["quinapril", "CHEMICAL", 269, 278], ["PA2006", "CHEMICAL", 296, 302], ["benazepril", "CHEMICAL", 113, 123], ["cilazapril", "CHEMICAL", 125, 135], ["imidapril", "CHEMICAL", 137, 146], ["perindopril", "CHEMICAL", 148, 159], ["ramipril", "CHEMICAL", 164, 172], ["captopril", "CHEMICAL", 196, 205], ["PA2003", "CHEMICAL", 223, 229], ["enalapril", "CHEMICAL", 231, 240], ["fosinopril", "CHEMICAL", 242, 252], ["lisinopril", "CHEMICAL", 254, 264], ["quinapril", "CHEMICAL", 269, 278], ["PA2006", "CHEMICAL", 296, 302], ["ACEIs", "SIMPLE_CHEMICAL", 69, 74], ["benazepril", "SIMPLE_CHEMICAL", 113, 123], ["cilazapril", "SIMPLE_CHEMICAL", 125, 135], ["imidapril", "SIMPLE_CHEMICAL", 137, 146], ["perindopril", "SIMPLE_CHEMICAL", 148, 159], ["ramipril", "SIMPLE_CHEMICAL", 164, 172], ["captopril", "SIMPLE_CHEMICAL", 196, 205], ["PA2003", "SIMPLE_CHEMICAL", 223, 229], ["enalapril", "SIMPLE_CHEMICAL", 231, 240], ["fosinopril", "SIMPLE_CHEMICAL", 242, 252], ["lisinopril", "SIMPLE_CHEMICAL", 254, 264], ["quinapril", "SIMPLE_CHEMICAL", 269, 278], ["PA2006", "SIMPLE_CHEMICAL", 296, 302], ["ACEIs", "TREATMENT", 69, 74], ["patented drugs", "TREATMENT", 97, 111], ["benazepril", "TREATMENT", 113, 123], ["cilazapril", "TREATMENT", 125, 135], ["imidapril", "TREATMENT", 137, 146], ["perindopril", "TREATMENT", 148, 159], ["ramipril", "TREATMENT", 164, 172], ["patent drugs", "TREATMENT", 182, 194], ["captopril", "TREATMENT", 196, 205], ["PA2003", "TREATMENT", 223, 229], ["enalapril", "TREATMENT", 231, 240], ["fosinopril", "TREATMENT", 242, 252], ["lisinopril", "TREATMENT", 254, 264], ["quinapril", "TREATMENT", 269, 278], ["patent", "OBSERVATION", 182, 188], ["patent", "OBSERVATION", 211, 217], ["patent", "OBSERVATION", 284, 290]]], ["The offpatent ACEIs were further categorized into original branded and generic versions.", [["The offpatent ACEIs", "TREATMENT", 0, 19]]], ["Potential independent variables included a constant (baseline level); a baseline trend; two indicator variables for each price adjustment, namely level change (the immediate effect) and trend change (the long-term effect or changes over time) [14] ; and three confounding factors.", [["Potential independent variables", "PROBLEM", 0, 31], ["a constant (baseline level)", "PROBLEM", 41, 68], ["a baseline trend", "PROBLEM", 70, 86], ["each price adjustment", "TREATMENT", 116, 137], ["trend change", "PROBLEM", 186, 198], ["the long-term effect", "TREATMENT", 200, 220], ["long-term effect", "OBSERVATION_MODIFIER", 204, 220]]], ["One of the three confounding factors was the global budget system implemented in Taiwan's hospitals on July 1, 2002 (GB2002) that increased outpatient use of anti-diabetic and anti-hypertensive agents [15] , and increased expenditures on all PBS listed drugs [5] .", [["anti-diabetic", "TREATMENT", 158, 171], ["anti-hypertensive agents", "TREATMENT", 176, 200], ["all PBS listed drugs", "TREATMENT", 238, 258]]], ["The other two confounding factors were the Chinese New Year (CNY) [5, 16] and the outbreak of severe acute respiratory syndrome (SARS) in 2003 [5] , both of which decreased expenditures on all PBS listed drugs.", [["acute respiratory syndrome", "DISEASE", 101, 127], ["SARS", "DISEASE", 129, 133], ["severe acute respiratory syndrome", "PROBLEM", 94, 127], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["When modeling each dependent variable, we removed a number of potential independent variables representing the cut-points of price adjustments, and only selected some of them to incorporate into the model (a so-called parsimonious model).", [["price adjustments", "TREATMENT", 125, 142]]], ["These independent variables were initially selected using a backward elimination procedure.", [["a backward elimination procedure", "TREATMENT", 58, 90]]], ["Collinearity diagnostics were subsequently performed to remove variables until the condition index was less than 30 [13, 17] .", [["Collinearity diagnostics", "TEST", 0, 24], ["the condition index", "TEST", 79, 98]]], ["The Ljung-Box chisquare statistic revealed insignificant autocorrelation for the residuals [13] .", [["Ljung-Box chisquare statistic", "DNA", 4, 33], ["The Ljung-Box chisquare statistic", "TEST", 0, 33], ["the residuals", "TEST", 77, 90], ["insignificant", "OBSERVATION_MODIFIER", 43, 56]]], ["All statistical analyses were performed using SAS 9.1 (SAS, Cary, NC) with a p-value of 0.05 considered significant.PatientsOf the 147 157 patients who met the inclusion criteria, 64 710, 22 317and 60 130 were identified as ACEI users, ARB users and both drugs users, respectively (Table 1) .", [["ACEI", "CHEMICAL", 224, 228], ["ARB", "CHEMICAL", 236, 239], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["All statistical analyses", "TEST", 0, 24], ["SAS", "TEST", 46, 49], ["SAS", "TEST", 55, 58], ["a p-value", "TEST", 75, 84], ["ACEI", "TREATMENT", 224, 228], ["ARB users", "TREATMENT", 236, 245]]], ["Among these patients, those aged under 60 years were less likely to be ARB users and both drugs users than ACEI users.", [["ARB", "CHEMICAL", 71, 74], ["ACEI", "CHEMICAL", 107, 111], ["patients", "ORGANISM", 12, 20], ["ARB", "SIMPLE_CHEMICAL", 71, 74], ["patients", "SPECIES", 12, 20], ["ACEI users", "TREATMENT", 107, 117]]], ["Male patients were more likely to be ARB users than ACEI users (OR = 1.08, 95% CI: 1.04-1.11), but they were less likely to be both drugs users than ACEI users (OR = 0.91, 95% CI: 0.89-0.93).", [["ARB", "CHEMICAL", 37, 40], ["ACEI", "CHEMICAL", 52, 56], ["ACEI", "CHEMICAL", 149, 153], ["patients", "ORGANISM", 5, 13], ["ARB", "SIMPLE_CHEMICAL", 37, 40], ["patients", "SPECIES", 5, 13], ["ACEI", "TREATMENT", 52, 56], ["CI", "TEST", 79, 81], ["ACEI", "TREATMENT", 149, 153], ["CI", "TEST", 176, 178]]], ["Patients with hyperlipidemia (OR = 1.70, 95% CI: 1.64-1.77) were more likely to take ARBs than ACEIs.", [["hyperlipidemia", "DISEASE", 14, 28], ["Patients", "ORGANISM", 0, 8], ["ACEIs", "SIMPLE_CHEMICAL", 95, 100], ["Patients", "SPECIES", 0, 8], ["hyperlipidemia", "PROBLEM", 14, 28], ["CI", "TEST", 45, 47], ["ARBs", "TREATMENT", 85, 89], ["ACEIs", "TREATMENT", 95, 100], ["hyperlipidemia", "OBSERVATION", 14, 28]]], ["Patients at risk of CVD (OR = 6.14, 95% CI: 5.54-6.81), diabetes (OR = 2.04, 95% CI: 1.98-2.10), kidney disease (OR = 2.96, 95% CI: 2.83-3.10), and hyperlipidemia (OR = 2.63, 95% CI: 2.56-2.71) revealed a higher likelihood of being prescribed both drugs rather than just ACEIs.", [["kidney", "ANATOMY", 97, 103], ["CVD", "DISEASE", 20, 23], ["diabetes", "DISEASE", 56, 64], ["kidney disease", "DISEASE", 97, 111], ["hyperlipidemia", "DISEASE", 148, 162], ["Patients", "ORGANISM", 0, 8], ["kidney", "ORGAN", 97, 103], ["Patients", "SPECIES", 0, 8], ["CVD", "PROBLEM", 20, 23], ["CI", "TEST", 40, 42], ["diabetes", "PROBLEM", 56, 64], ["CI", "TEST", 81, 83], ["kidney disease", "PROBLEM", 97, 111], ["CI", "TEST", 128, 130], ["hyperlipidemia", "PROBLEM", 148, 162], ["CI", "TEST", 179, 181], ["both drugs", "TREATMENT", 243, 253], ["ACEIs", "TREATMENT", 271, 276], ["kidney", "ANATOMY", 97, 103], ["disease", "OBSERVATION", 104, 111], ["hyperlipidemia", "OBSERVATION", 148, 162]]], ["(Figure 2b) , and the number of cumulative incident ARB users (from 1998 to a given year) was always less than the number of prevalent ARB users in each year, with the former only being 60 to 80% of the latter (Figure 2d ).", [["ARB", "CHEMICAL", 52, 55], ["ARB", "CHEMICAL", 135, 138]]], ["This indicates that annual prevalent ARB users were not only from the category of cumulative incident ARB users, but also included users who initially used ACEIs, or both drugs, in preceding years and switched to ARBs thereafter.Drug utilizationThe baseline level of utilization of ACEIs was 232 380 DDD and increased by 5 531 DDD (p < 0.0001) per month from January 1997.", [["ARB", "CHEMICAL", 37, 40], ["ARB", "CHEMICAL", 102, 105], ["ACEIs", "CHEMICAL", 156, 161], ["ACEIs", "CHEMICAL", 282, 287], ["ARB", "SIMPLE_CHEMICAL", 102, 105], ["ACEIs", "TREATMENT", 156, 161], ["drugs", "TREATMENT", 171, 176], ["ARBs", "TREATMENT", 213, 217], ["Drug utilization", "TREATMENT", 229, 245], ["ACEIs", "TEST", 282, 287], ["DDD", "TEST", 300, 303], ["DDD", "TEST", 327, 330]]], ["There was an immediate decrease of 48 286 DDD (level change: -20.8%, p < 0.0001) when PA2000 was implemented, but an immediate increase of 28 987 DDD (level change: 15.7%, p = 0.0073) following PA2004.", [["PA2000", "CHEMICAL", 86, 92], ["PA2004", "CHEMICAL", 194, 200], ["PA2000", "CHEMICAL", 86, 92], ["PA2004", "CHEMICAL", 194, 200], ["level change", "TEST", 47, 59], ["DDD (level change", "TEST", 146, 163], ["p", "TEST", 172, 173], ["immediate", "OBSERVATION_MODIFIER", 13, 22], ["decrease", "OBSERVATION_MODIFIER", 23, 31]]], ["ACEIs long-term increasing trend decreased to 671 DDD per month after the implementation of PA2004 (trend change: -87.9%, p < 0.0001) and turned to a long-term decreasing trend of 2 858 DDD per month after the implementation of PA2006 (trend change: -525.9%, p = 0.0002), diminishing to 691 742 DDD in December 2008 ( Figure 3a and Table 2 ).", [["PA2004", "CHEMICAL", 92, 98], ["PA2006", "CHEMICAL", 228, 234], ["PA2006", "CHEMICAL", 228, 234], ["ACEIs", "TREATMENT", 0, 5]]], ["In subgroup analyses, we observed that the utilization of off-patent ACEIs showed a similar trend to that of ACEIs, but the baseline increasing trend turned to a downward trend even earlier following PA2004.", [["ACEIs", "CHEMICAL", 109, 114], ["PA2004", "CHEMICAL", 200, 206], ["PA2004", "CHEMICAL", 200, 206], ["ACEIs", "SIMPLE_CHEMICAL", 109, 114], ["PA2004", "SIMPLE_CHEMICAL", 200, 206], ["patent ACEIs", "TREATMENT", 62, 74], ["ACEIs", "TREATMENT", 109, 114], ["ACEIs", "OBSERVATION", 109, 114]]], ["On the other hand, the utilization of patented ACEIs showed an increasing trend throughout the study period ( Figure 3b and Table 2 ).", [["patented ACEIs", "TEST", 38, 52], ["the study", "TEST", 91, 100], ["increasing", "OBSERVATION_MODIFIER", 63, 73], ["trend", "OBSERVATION_MODIFIER", 74, 79]]], ["When off-patent ACEIs were further categorized into original branded and generic versions, we found that the baseline increasing trend for the utilization of original branded version turned to a decreasing trend after the implementation of PA2004.", [["PA2004", "CHEMICAL", 240, 246], ["PA2004", "CHEMICAL", 240, 246], ["PA2004", "SIMPLE_CHEMICAL", 240, 246], ["patent ACEIs", "TREATMENT", 9, 21], ["increasing", "OBSERVATION_MODIFIER", 118, 128], ["decreasing", "OBSERVATION_MODIFIER", 195, 205]]], ["Generic versions still showed an upward trend at PA2004 and only turned to a downward trend afterward when PA2005 was implemented ( Figure 3c and Table 2 ).Drug utilizationUnlike ACEIs, a long-term increasing trend in the utilization of ARBs and overall renin-angiotensin drugs was observed from 1998 to 2008 and from 1997 to 2008, Age is defined at the earliest date of ACEIs or ARBs prescription.{The clinical conditions were represented by ICD9-CM codes. } The adjusted odds ratios were estimated in multivariate logistic regression with the reference group defined as patients who were treated only with ACEIs during the study period.", [["PA2004", "CHEMICAL", 49, 55], ["PA2005", "CHEMICAL", 107, 113], ["ARBs", "CHEMICAL", 237, 241], ["ARBs", "CHEMICAL", 380, 384], ["CM", "DISEASE", 448, 450], ["PA2004", "CHEMICAL", 49, 55], ["PA2005", "CHEMICAL", 107, 113], ["PA2004", "SIMPLE_CHEMICAL", 49, 55], ["PA2005", "SIMPLE_CHEMICAL", 107, 113], ["ACEIs", "SIMPLE_CHEMICAL", 179, 184], ["ARBs", "SIMPLE_CHEMICAL", 237, 241], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 254, 271], ["patients", "ORGANISM", 572, 580], ["renin", "PROTEIN", 254, 259], ["patients", "SPECIES", 572, 580], ["Generic versions", "TEST", 0, 16], ["an upward trend", "PROBLEM", 30, 45], ["Drug utilization", "TREATMENT", 156, 172], ["ACEIs", "TREATMENT", 179, 184], ["ARBs", "TREATMENT", 237, 241], ["overall renin-angiotensin drugs", "TREATMENT", 246, 277], ["ACEIs", "TREATMENT", 371, 376], ["ARBs prescription", "TREATMENT", 380, 397], ["The adjusted odds ratios", "TEST", 460, 484], ["ACEIs", "TREATMENT", 608, 613], ["the study", "TEST", 621, 630], ["upward", "OBSERVATION_MODIFIER", 33, 39], ["ACEIs", "OBSERVATION", 179, 184], ["long-term", "OBSERVATION_MODIFIER", 188, 197], ["increasing", "OBSERVATION_MODIFIER", 198, 208]]], ["Patients who were treated only with ARBs were defined as ARB users.", [["ARB", "CHEMICAL", 57, 60], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ARBs", "TREATMENT", 36, 40]]], ["Patients who were treated with at least one ACEI and one ARB during the study period were defined as both drug users. } Significance is represented as: p < 0.01, # p < 0.0001.", [["ACEI", "CHEMICAL", 44, 48], ["ARB", "CHEMICAL", 57, 60], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ACEI", "TREATMENT", 44, 48], ["one ARB", "TREATMENT", 53, 60], ["the study", "TEST", 68, 77]]], ["ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; OR, odds ratio; SD, standard deviation.{respectively.", [["ACEI", "CHEMICAL", 0, 4], ["angiotensin", "CHEMICAL", 6, 17], ["ARB", "CHEMICAL", 47, 50], ["angiotensin", "CHEMICAL", 52, 63], ["ACEI", "SIMPLE_CHEMICAL", 0, 4], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 6, 35], ["ARB", "SIMPLE_CHEMICAL", 47, 50], ["angiotensin receptor blocker", "SIMPLE_CHEMICAL", 52, 80], ["ACEI", "TREATMENT", 0, 4], ["angiotensin", "TREATMENT", 6, 17], ["enzyme inhibitor", "TREATMENT", 29, 45], ["ARB", "TREATMENT", 47, 50], ["angiotensin receptor blocker", "TREATMENT", 52, 80], ["SD", "PROBLEM", 98, 100]]], ["The baseline level of the utilization of ARBs was zero and increased by 5 044 DDD (p < 0.0001) per month from February 1998.", [["ARBs", "TEST", 41, 45]]], ["Following PA2003, the longterm increasing trend of the use of ARBs further increased to 10 058 DDD per month (trend change: 99.4%, p < 0.0001).", [["PA2003", "CHEMICAL", 10, 16], ["ARBs", "CHEMICAL", 62, 66], ["PA2003", "CHEMICAL", 10, 16], ["ARBs", "TREATMENT", 62, 66]]], ["When PA2007 was implemented, ARBs longterm increasing trend further increased to 18 041 DDD per month (trend change: 85.3%, p = 0.0003), reaching 1 157 724 DDD in December 2008.", [["PA2007", "CHEMICAL", 5, 11], ["PA2007", "CHEMICAL", 5, 11], ["PA2007", "SIMPLE_CHEMICAL", 5, 11], ["ARBs", "TREATMENT", 29, 33], ["p", "TEST", 124, 125]]], ["The baseline level of the utilization of overall renin-angiotensin drugs was 135 289 DDD, and utilization showed a long-term increasing trend of 12 027 DDD (p < 0.0001) per month from January 1997.", [["angiotensin", "CHEMICAL", 55, 66], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 49, 66], ["renin", "PROTEIN", 49, 54], ["overall renin", "TEST", 41, 54], ["angiotensin drugs", "TREATMENT", 55, 72], ["DDD", "TEST", 85, 88], ["a long-term increasing trend", "PROBLEM", 113, 141], ["DDD", "TEST", 152, 155]]], ["When PA2000 was implemented, overall usage experienced an immediate decrease of 73 794 DDD (level change: -54.5%, p = 0.0053).", [["PA2000", "CHEMICAL", 5, 11], ["PA2000", "CHEMICAL", 5, 11], ["PA2000", "SIMPLE_CHEMICAL", 5, 11], ["DDD (level change", "TEST", 87, 104], ["p", "TEST", 114, 115], ["decrease", "OBSERVATION_MODIFIER", 68, 76]]], ["However, throughout the study period, the long-term increasing trend in the utilization of overall renin-angiotensin drugs was not influenced by any price adjustment, reaching 1 817 084 DDD in December 2008 (Figure 3a and Table 2 ).{With regard to the three confounding factors, only CNY significantly resulted in immediate decreases in the utilization of ACEIs (including in subgroup analyses), ARBs and overall renin-angiotensin drugs ( Table 2 ).Drug expendituresThe baseline level of expenditures on ACEIs was 4 509 908 NT$ and increased by 66 568 NT$ (p < 0.0001) per month from January 1997.", [["angiotensin", "CHEMICAL", 105, 116], ["CNY", "CHEMICAL", 284, 287], ["angiotensin", "CHEMICAL", 419, 430], ["ACEIs", "CHEMICAL", 504, 509], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 99, 116], ["CNY", "SIMPLE_CHEMICAL", 284, 287], ["ACEIs", "SIMPLE_CHEMICAL", 356, 361], ["renin-angiotensin drugs", "GENE_OR_GENE_PRODUCT", 413, 436], ["renin", "PROTEIN", 99, 104], ["renin", "PROTEIN", 413, 418], ["the study", "TEST", 20, 29], ["the long-term increasing trend", "PROBLEM", 38, 68], ["overall renin-angiotensin drugs", "TREATMENT", 91, 122], ["ACEIs", "TREATMENT", 356, 361], ["subgroup analyses", "TEST", 376, 393], ["ARBs", "TREATMENT", 396, 400], ["overall renin-angiotensin drugs", "TREATMENT", 405, 436], ["Drug expenditures", "PROBLEM", 449, 466], ["ACEIs", "TEST", 504, 509], ["decreases", "OBSERVATION_MODIFIER", 324, 333]]], ["The expenditures on ACEIs experienced an immediate decrease of 592 252 NT$ (level change: -13.1%, p = 0.0151) and 1 255 287 NT$ (level change: -32.0%, p < 0.0001), respectively, following PA2000 and PA2003.", [["ACEIs", "CHEMICAL", 20, 25], ["PA2000", "CHEMICAL", 188, 194], ["PA2003", "CHEMICAL", 199, 205], ["PA2000", "CHEMICAL", 188, 194], ["PA2003", "CHEMICAL", 199, 205], ["ACEIs", "TREATMENT", 20, 25], ["level change", "TEST", 76, 88], ["p", "TEST", 98, 99], ["NT", "TEST", 124, 126], ["level change", "TEST", 129, 141], ["p", "TEST", 151, 152], ["decrease", "OBSERVATION_MODIFIER", 51, 59]]], ["The long-term increasing trend in ACEI expenditures turned to a downward trend of 30 014 NT$ per month after the implementation of PA2004 (trend change: -145.1%, p < 0.0001).", [["ACEI", "CHEMICAL", 34, 38], ["PA2004", "CHEMICAL", 131, 137], ["PA2004", "CHEMICAL", 131, 137], ["ACEI", "SIMPLE_CHEMICAL", 34, 38], ["The long-term increasing trend", "PROBLEM", 0, 30], ["ACEI expenditures", "TREATMENT", 34, 51], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["increasing", "OBSERVATION_MODIFIER", 14, 24]]], ["When PA2006 was implemented, ACEI expenditures showed an immediate decrease of 1 545 767 NT$ (level change: -58.1%, p < 0.0001).", [["PA2006", "CHEMICAL", 5, 11], ["ACEI", "CHEMICAL", 29, 33], ["PA2006", "CHEMICAL", 5, 11], ["PA2006", "SIMPLE_CHEMICAL", 5, 11], ["ACEI expenditures", "TEST", 29, 46], ["level change", "TEST", 94, 106], ["decrease", "OBSERVATION_MODIFIER", 67, 75]]], ["After PA2006, it maintained the long-term Table 3 ).", [["PA2006", "CHEMICAL", 6, 12], ["PA2006", "CHEMICAL", 6, 12]]], ["In subgroup analyses, we observed that expenditures on off-patent ACEIs showed a similar trend to that of ACEIs overall.", [["ACEIs", "CHEMICAL", 106, 111], ["ACEIs", "SIMPLE_CHEMICAL", 106, 111], ["subgroup analyses", "TEST", 3, 20], ["patent ACEIs", "TEST", 59, 71], ["ACEIs", "TEST", 106, 111]]], ["The baseline increasing trend also turned to a decreasing trend following PA2004, but experienced an additional level reduction following PA2007.", [["PA2004", "CHEMICAL", 74, 80], ["PA2007", "CHEMICAL", 138, 144], ["PA2004", "CHEMICAL", 74, 80], ["PA2007", "CHEMICAL", 138, 144], ["PA2004", "SIMPLE_CHEMICAL", 74, 80], ["PA2007", "SIMPLE_CHEMICAL", 138, 144], ["an additional level reduction", "TREATMENT", 98, 127], ["increasing", "OBSERVATION_MODIFIER", 13, 23]]], ["On the other hand, expenditures on patented ACEIs showed an increasing trend throughout the study period (Figure 4b and Table 3 ).", [["patented ACEIs", "TEST", 35, 49], ["the study", "TEST", 88, 97], ["increasing", "OBSERVATION_MODIFIER", 60, 70], ["trend", "OBSERVATION_MODIFIER", 71, 76]]], ["When off-patent ACEIs were further categorized into original branded and generic versions, we found that expenditures on off-patent original branded ACEIs showed a similar trend to off-patent ACEIs.", [["ACEIs", "SIMPLE_CHEMICAL", 16, 21], ["ACEIs", "SIMPLE_CHEMICAL", 149, 154], ["patent ACEIs", "TREATMENT", 9, 21], ["ACEIs", "TEST", 149, 154], ["patent ACEIs", "TREATMENT", 185, 197], ["patent", "OBSERVATION", 185, 191], ["ACEIs", "OBSERVATION", 192, 197]]], ["Expenditures on off-patent generic ACEIs only showed an immediate decrease when PA2003, PA2006 and PA2007 were implemented, but was not influenced by any price adjustment in the long term (Figure 4c and Table 3 ).Drug expendituresUnlike ACEIs, expenditures on ARBs revealed a longterm increasing trend from 1998 to 2008.", [["PA2003", "CHEMICAL", 80, 86], ["PA2006", "CHEMICAL", 88, 94], ["PA2007", "CHEMICAL", 99, 105], ["PA2003", "CHEMICAL", 80, 86], ["PA2006", "CHEMICAL", 88, 94], ["PA2007", "CHEMICAL", 99, 105], ["PA2003", "SIMPLE_CHEMICAL", 80, 86], ["PA2006", "SIMPLE_CHEMICAL", 88, 94], ["PA2007", "SIMPLE_CHEMICAL", 99, 105], ["Expenditures", "TEST", 0, 12], ["Drug expendituresUnlike ACEIs", "PROBLEM", 213, 242], ["ARBs", "TEST", 260, 264], ["ACEIs", "OBSERVATION", 35, 40], ["immediate", "OBSERVATION_MODIFIER", 56, 65], ["decrease", "OBSERVATION_MODIFIER", 66, 74], ["ACEIs", "OBSERVATION", 237, 242]]], ["The baseline level of expenditures on ARBs was zero and increased by a trend of 92 537 NT$ (p < 0.0001) per month from February 1998.", [["ARBs", "TEST", 38, 42]]], ["Following PA2001, the long-term increasing trend of expenditures on ARBs increased to 253 009 NT$ per month (trend change: 173.4%, p < 0.0001).", [["PA2001", "CHEMICAL", 10, 16], ["ARBs", "CHEMICAL", 68, 72], ["ARBs", "TEST", 68, 72]]], ["When PA2004 was implemented, the long-term increasing trend decreased to 132 671 NT$ per month (trend change: -47.6%, p = 0.0003), but following PA2007, the long-term upward trend further increased to 326 714 NT$ (trend change: 146.3%, p < 0.0001), reaching 24 228 254 NT$ in December 2008.", [["PA2004", "CHEMICAL", 5, 11], ["PA2004", "CHEMICAL", 5, 11], ["PA2004", "SIMPLE_CHEMICAL", 5, 11], ["trend change", "TEST", 214, 226]]], ["The baseline level of expenditures on overall renin-angiotensin drugs was 3 753 898 NT$ and increased with a trend of 152 800 NT$ (p < 0.0001) per month from January 1997.", [["angiotensin", "CHEMICAL", 52, 63], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 46, 63], ["renin", "PROTEIN", 46, 51], ["overall renin", "TEST", 38, 51], ["angiotensin drugs", "TREATMENT", 52, 69]]], ["When PA2001 was implemented, the long-term increasing trend increased to 263 059 NT$ per month (trend change: 72.2%, p < 0.0001), 0 500,000 1,000,000 1,500,000 2,000,000 (Figure 4a and Table 3 ).", [["PA2001", "CHEMICAL", 5, 11], ["PA2001", "CHEMICAL", 5, 11]]], ["With regard to the three confounding factors, only CNY significantly resulted in immediate decreases in the expenditures on ACEIs (except for off-patent generic ACEIs), ARBs and overall renin-angiotensin drugs ( Table 3) .", [["CNY", "CHEMICAL", 51, 54], ["angiotensin", "CHEMICAL", 192, 203], ["CNY", "SIMPLE_CHEMICAL", 51, 54], ["ACEIs", "SIMPLE_CHEMICAL", 124, 129], ["ARBs", "SIMPLE_CHEMICAL", 169, 173], ["renin-angiotensin drugs", "GENE_OR_GENE_PRODUCT", 186, 209], ["renin", "PROTEIN", 186, 191], ["ACEIs", "TREATMENT", 124, 129], ["patent generic ACEIs", "TREATMENT", 146, 166], ["ARBs", "TREATMENT", 169, 173], ["overall renin-angiotensin drugs", "TREATMENT", 178, 209], ["immediate", "OBSERVATION_MODIFIER", 81, 90], ["decreases", "OBSERVATION_MODIFIER", 91, 100]]], ["Table 2 Impact of price adjustments on monthly utilization of ACEIs, ARBs and overall renin-angiotensin drugs (Continued) * Factored ARIMA model is represented by p, d, q: p, auto-regressive order; d, differencing order; q, moving-average order; seasonal order is represented by p = (12), d = (12) or q = (12) .", [["ACEIs", "CHEMICAL", 62, 67], ["angiotensin", "CHEMICAL", 92, 103], ["ACEIs", "SIMPLE_CHEMICAL", 62, 67], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 86, 103], ["renin", "PROTEIN", 86, 91], ["price adjustments", "TREATMENT", 18, 35], ["ACEIs", "TREATMENT", 62, 67], ["ARBs", "TREATMENT", 69, 73], ["overall renin-angiotensin drugs", "TREATMENT", 78, 109]]], ["Take ACEIs as an example.", [["ACEIs", "TREATMENT", 5, 10]]], ["The moving-average operator represented by q = (6)(12) means(1-\u03b8 6 B 6 ) (1-\u03b8 12 B 12 ). \u2020 Parsimonious models were adopted, and therefore, only significant independent variables were incorporated into the model.DiscussionThere are two major findings in our study.", [["means", "TEST", 55, 60], ["our study", "TEST", 254, 263]]], ["One is that the increase in prevalent ARB users is associated with switching from being an ACEI user.", [["ARB", "CHEMICAL", 38, 41], ["ARB", "SIMPLE_CHEMICAL", 38, 41], ["an ACEI user", "TREATMENT", 88, 100], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["This result is consistent with the long-term trend increases in utilization of ARBs, but a long-term trend decrease in utilization of ACEIs.", [["ACEIs", "SIMPLE_CHEMICAL", 134, 139], ["ARBs", "TREATMENT", 79, 83], ["ACEIs", "TREATMENT", 134, 139], ["consistent with", "UNCERTAINTY", 15, 30], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["ACEIs", "OBSERVATION", 134, 139]]], ["The other is that the increase in expenditures on renin-angiotensin drugs throughout this study primarily resulted from increases in the number of incident ARB users and potential switching from ACEIs to ARBs, but not from changes in the use of overall renin-angiotensin drugs.", [["angiotensin", "CHEMICAL", 56, 67], ["ARB", "CHEMICAL", 156, 159], ["angiotensin", "CHEMICAL", 259, 270], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 50, 67], ["ARB", "SIMPLE_CHEMICAL", 156, 159], ["ARBs", "SIMPLE_CHEMICAL", 204, 208], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 253, 270], ["renin", "PROTEIN", 50, 55], ["renin", "PROTEIN", 253, 258], ["the increase in expenditures", "PROBLEM", 18, 46], ["renin-angiotensin drugs", "TREATMENT", 50, 73], ["this study", "TEST", 85, 95], ["ARB users", "TREATMENT", 156, 165], ["ACEIs", "TREATMENT", 195, 200], ["ARBs", "TREATMENT", 204, 208], ["overall renin", "TREATMENT", 245, 258], ["angiotensin drugs", "TREATMENT", 259, 276], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["increases", "OBSERVATION_MODIFIER", 120, 129]]], ["Ultimately, cost savings have not been achieved in overall use of renin-angiotensin drugs.", [["renin-angiotensin drugs", "GENE_OR_GENE_PRODUCT", 66, 89], ["renin", "PROTEIN", 66, 71], ["renin-angiotensin drugs", "TREATMENT", 66, 89]]], ["Our findings differ from those of previous studies that showed cost savings in pharmaceutical expenditures for all PBS listed drugs [5] and generic substitution driven by the financial incentive for physicians [6] after price adjustments.", [["previous studies", "TEST", 34, 50], ["cost savings in pharmaceutical expenditures", "PROBLEM", 63, 106], ["all PBS listed drugs", "TREATMENT", 111, 131], ["generic substitution", "TREATMENT", 140, 160]]], ["As mentioned, a feature of Taiwan's health care system is that physicians both prescribe and dispense drugs because they are permitted by Taiwan's Department of Health to hire pharmacists to work at their on-site pharmacies [2] .", [["drugs", "TREATMENT", 102, 107]]], ["In 2009, Liu et al. [6] conducted a study in Taiwan to investigate prescribing preferences between original branded and generic drugs in relation to this potential profit margin, and found that prescribing of generics increased as the reimbursement price decreased.", [["a study", "TEST", 34, 41], ["generic drugs", "TREATMENT", 120, 133], ["generics", "TREATMENT", 209, 217]]], ["Our results were only consistent with these findings when we examined the change in utilization of off-patent ACEIs.", [["ACEIs", "SIMPLE_CHEMICAL", 110, 115], ["patent ACEIs", "TREATMENT", 103, 115], ["consistent with", "UNCERTAINTY", 22, 37], ["patent", "OBSERVATION_MODIFIER", 103, 109], ["ACEIs", "OBSERVATION", 110, 115]]], ["We observed that the utilization of off-patent original branded ACEIs was lower than that of off-patent generic ACEIs since 2001.", [["ACEIs", "CHEMICAL", 64, 69], ["ACEIs", "SIMPLE_CHEMICAL", 64, 69], ["patent original branded ACEIs", "TREATMENT", 40, 69], ["patent generic ACEIs", "TREATMENT", 97, 117], ["patent", "OBSERVATION", 97, 103], ["ACEIs", "OBSERVATION", 112, 117]]], ["Although the initial upward trend in the use of off-patent generic ACEIs turned to a decreasing trend after the implementation of PA2005, the use of these drugs is still higher than that of off-patent original branded drugs.", [["PA2005", "CHEMICAL", 130, 136], ["PA2005", "CHEMICAL", 130, 136], ["PA2005", "SIMPLE_CHEMICAL", 130, 136], ["patent generic ACEIs", "TREATMENT", 52, 72], ["these drugs", "TREATMENT", 149, 160], ["upward", "OBSERVATION_MODIFIER", 21, 27], ["trend", "OBSERVATION_MODIFIER", 28, 33], ["decreasing", "OBSERVATION_MODIFIER", 85, 95]]], ["However, our findings differ to those of Liu et al. when looking at both ACEIs and ARBs.", [["ARBs", "SIMPLE_CHEMICAL", 83, 87], ["ARBs", "TEST", 83, 87]]], ["Since these two classes of drugs work through the same renin-angiotensin pathway and have a similar effect in cardiovascular disease and renal protection [7] , physicians make a prescribing decision between ACEIs and ARBs when the patient needs a renin-angiotensin drugs.", [["cardiovascular", "ANATOMY", 110, 124], ["renal", "ANATOMY", 137, 142], ["cardiovascular disease", "DISEASE", 110, 132], ["angiotensin", "CHEMICAL", 253, 264], ["renin", "GENE_OR_GENE_PRODUCT", 55, 60], ["cardiovascular", "ANATOMICAL_SYSTEM", 110, 124], ["renal", "ORGAN", 137, 142], ["ACEIs", "SIMPLE_CHEMICAL", 207, 212], ["ARBs", "SIMPLE_CHEMICAL", 217, 221], ["patient", "ORGANISM", 231, 238], ["renin-angiotensin drugs", "SIMPLE_CHEMICAL", 247, 270], ["renin", "PROTEIN", 55, 60], ["renin", "PROTEIN", 247, 252], ["patient", "SPECIES", 231, 238], ["drugs", "TREATMENT", 27, 32], ["the same renin-angiotensin pathway", "TREATMENT", 46, 80], ["cardiovascular disease", "PROBLEM", 110, 132], ["renal protection", "TREATMENT", 137, 153], ["ACEIs", "TREATMENT", 207, 212], ["ARBs", "TREATMENT", 217, 221], ["a renin-angiotensin drugs", "TREATMENT", 245, 270], ["cardiovascular disease", "OBSERVATION", 110, 132], ["renal", "ANATOMY", 137, 142]]], ["We observed that, following PA2006, the initial rising trend of the use of ACEIs turned to a decreasing trend, primarily due to the decreases in the use of off-patent ACEIs.", [["PA2006", "CHEMICAL", 28, 34], ["ACEIs", "CHEMICAL", 75, 80], ["PA2006", "CHEMICAL", 28, 34], ["ACEIs", "SIMPLE_CHEMICAL", 75, 80], ["ACEIs", "SIMPLE_CHEMICAL", 167, 172], ["ACEIs", "TREATMENT", 75, 80], ["patent ACEIs", "TREATMENT", 160, 172], ["decreasing", "OBSERVATION_MODIFIER", 93, 103], ["decreases", "OBSERVATION_MODIFIER", 132, 141], ["ACEIs", "OBSERVATION", 167, 172]]], ["The initial rising trend of the use of ARBs further increased following PA2003 and PA2007, and the use of ARBs exceeded that of ACEIs from 2007.", [["ARBs", "CHEMICAL", 39, 43], ["PA2003", "CHEMICAL", 72, 78], ["PA2007", "CHEMICAL", 83, 89], ["ARBs", "CHEMICAL", 106, 110], ["PA2003", "CHEMICAL", 72, 78], ["PA2007", "CHEMICAL", 83, 89], ["PA2003", "SIMPLE_CHEMICAL", 72, 78], ["PA2007", "SIMPLE_CHEMICAL", 83, 89], ["ARBs", "SIMPLE_CHEMICAL", 106, 110], ["ARBs", "TREATMENT", 39, 43], ["ARBs", "TREATMENT", 106, 110], ["ACEIs", "TREATMENT", 128, 133], ["rising", "OBSERVATION_MODIFIER", 12, 18], ["trend", "OBSERVATION_MODIFIER", 19, 24], ["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["In fact, the profit margin from patented and off-patent drugs varies over time, depending on when a drug turned from patented (applying WAP adjustment) to off-patent (applying GWAP adjustment) as well as the value of the r-zone (the accessible profit margin for physicians) imposed by the BNHI.", [["WAP", "PROTEIN", 136, 139], ["WAP adjustment", "TREATMENT", 136, 150], ["GWAP adjustment", "TREATMENT", 176, 191], ["margin", "OBSERVATION_MODIFIER", 20, 26], ["patent", "OBSERVATION", 49, 55], ["patent", "OBSERVATION", 159, 165]]], ["Because the extent of WAP adjustment for patented drugs is smaller than that of the GWAP adjustment for off-patent drugs, and because the r-zone is larger for patented drugs than for offpatent drugs, patented drugs offer higher financial incentive to physicians through stepwise price adjustments.DiscussionAnother study conducted by Lee et al. [5] addressed the issue of Taiwan's cost containment strategies on pharmaceutical expenditures.", [["WAP", "GENE_OR_GENE_PRODUCT", 22, 25], ["WAP", "PROTEIN", 22, 25], ["WAP adjustment", "TREATMENT", 22, 36], ["patented drugs", "TREATMENT", 41, 55], ["the GWAP adjustment", "TREATMENT", 80, 99], ["patent drugs", "TREATMENT", 108, 120], ["patented drugs", "TREATMENT", 159, 173], ["offpatent drugs", "TREATMENT", 183, 198], ["patented drugs", "TREATMENT", 200, 214], ["stepwise price adjustments", "TREATMENT", 270, 296], ["Another study", "TEST", 307, 320], ["Taiwan's cost containment strategies", "TREATMENT", 372, 408], ["pharmaceutical expenditures", "TREATMENT", 412, 439], ["smaller", "OBSERVATION_MODIFIER", 59, 66], ["larger", "OBSERVATION_MODIFIER", 148, 154]]], ["The authors of that study also applied Box-Tiao intervention analysis to examine the level change (the immediate effect) after the implementation of drug price adjustments.", [["that study", "TEST", 15, 25], ["Box-Tiao intervention analysis", "TEST", 39, 69], ["drug price adjustments", "TREATMENT", 149, 171]]], ["They found that pharmaceutical expenditures on all PBS listed drugs significantly decreased after the introduction of price adjustments based on generic grouping (PA2001 and PA2003).", [["pharmaceutical expenditures", "PROBLEM", 16, 43], ["all PBS listed drugs", "TREATMENT", 47, 67], ["price adjustments", "TREATMENT", 118, 135], ["pharmaceutical", "OBSERVATION_MODIFIER", 16, 30], ["expenditures", "OBSERVATION", 31, 43]]], ["Our study included a time trend variable in the model, which enabled us to investigate the long-term effects of price adjustments.", [["Our study", "TEST", 0, 9], ["price adjustments", "TREATMENT", 112, 129], ["long-term", "OBSERVATION_MODIFIER", 91, 100]]], ["In fact, we found that the long-term trend in expenditures on overall renin-angiotensin drugs increased after PA2001 and PA2007.DiscussionExploring increases in expenditures on overall renin-angiotensin drugs, we found that annual incident renin-angiotensin drug users declined over time, and no significant trend increases were found in the utilization of renin-angiotensin drugs over the study period.", [["angiotensin", "CHEMICAL", 76, 87], ["PA2001", "CHEMICAL", 110, 116], ["PA2007", "CHEMICAL", 121, 127], ["angiotensin", "CHEMICAL", 246, 257], ["angiotensin", "CHEMICAL", 363, 374], ["PA2001", "CHEMICAL", 110, 116], ["PA2007", "CHEMICAL", 121, 127], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 70, 87], ["PA2001", "SIMPLE_CHEMICAL", 110, 116], ["PA2007", "SIMPLE_CHEMICAL", 121, 127], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 185, 202], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 240, 257], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 357, 374], ["renin", "PROTEIN", 70, 75], ["renin", "PROTEIN", 185, 190], ["renin", "PROTEIN", 240, 245], ["renin", "PROTEIN", 357, 362], ["the long-term trend", "PROBLEM", 23, 42], ["overall renin", "TEST", 62, 75], ["angiotensin drugs", "TREATMENT", 76, 93], ["overall renin-angiotensin drugs", "TREATMENT", 177, 208], ["renin", "TEST", 240, 245], ["renin-angiotensin drugs", "TREATMENT", 357, 380], ["no", "UNCERTAINTY", 293, 295], ["significant", "OBSERVATION_MODIFIER", 296, 307], ["trend", "OBSERVATION_MODIFIER", 308, 313], ["increases", "OBSERVATION_MODIFIER", 314, 323]]], ["We also found that annual incident ARB users and annual prevalent ARB users increased over time.", [["ARB", "CHEMICAL", 35, 38], ["ARB", "CHEMICAL", 66, 69], ["ARB users", "TREATMENT", 35, 44], ["annual prevalent ARB users", "TREATMENT", 49, 75]]], ["In particular, the annual prevalent ARB users always exceeded the number of cumulative incident ARB users, indicating that annual prevalent ARB users were not only from the category of cumulative incident ARB users, but also patients who were ever treated with ACEIs.", [["ARB", "CHEMICAL", 36, 39], ["ARB", "CHEMICAL", 96, 99], ["ARB", "CHEMICAL", 140, 143], ["ARB", "CHEMICAL", 205, 208], ["ARB", "SIMPLE_CHEMICAL", 205, 208], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233], ["ACEIs", "TREATMENT", 261, 266]]], ["These findings suggest that the increase in expenditures on reninangiotensin drugs throughout this study primarily resulted from increases in the number of incident ARB users and potential switching from ACEIs to ARBs, but not from changes in the use of overall renin-angiotensin drugs.DiscussionAlthough the health care systems in Canada and European countries are different from that in Taiwan, and the reference pricing (RP) scheme [18] adopted in these countries control cost from the demand side (patients) but not from the providers (physicians) side, some of the studies conducted reveal that the RP scheme did not have any long-term effects.", [["reninangiotensin", "CHEMICAL", 60, 76], ["ARB", "CHEMICAL", 165, 168], ["reninangiotensin", "SIMPLE_CHEMICAL", 60, 76], ["ARBs", "SIMPLE_CHEMICAL", 213, 217], ["renin-angiotensin drugs", "GENE_OR_GENE_PRODUCT", 262, 285], ["patients", "ORGANISM", 502, 510], ["renin", "PROTEIN", 262, 267], ["patients", "SPECIES", 502, 510], ["the increase in expenditures", "PROBLEM", 28, 56], ["reninangiotensin drugs", "TREATMENT", 60, 82], ["this study", "TEST", 94, 104], ["ARB users", "TREATMENT", 165, 174], ["ACEIs", "TREATMENT", 204, 209], ["ARBs", "TREATMENT", 213, 217], ["overall renin-angiotensin drugs", "TREATMENT", 254, 285], ["the studies", "TEST", 566, 577], ["any long-term effects", "PROBLEM", 627, 648], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["increases", "OBSERVATION_MODIFIER", 129, 138]]], ["Evidence from the Netherlands showed that, after the implementation of the RP scheme, the cost of drugs covered by the RP scheme increased less than predicted, but the cost of drugs outside of the RP scheme has increased annually [19] .", [["the RP scheme", "TREATMENT", 71, 84], ["drugs", "TREATMENT", 98, 103], ["the RP scheme", "PROBLEM", 115, 128], ["drugs", "TREATMENT", 176, 181], ["the RP scheme", "TREATMENT", 193, 206], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["increased", "OBSERVATION_MODIFIER", 211, 220]]], ["In addition, evidence from Germany and Hungary showed that pharmaceutical expenditures are still not well controlled because of volume growth that occurred after the implementation of the RP scheme [20, 21] .DiscussionPrevious studies have reported that the use of cheaper, generic drugs may lead to cost savings, but clinical concerns regarding patient safety and therapeutic effectiveness related to treatment discontinuation have also been raised [22] [23] [24] [25] .", [["patient", "ORGANISM", 346, 353], ["[22] [23] [24] [25]", "SIMPLE_CHEMICAL", 450, 469], ["patient", "SPECIES", 346, 353], ["pharmaceutical expenditures", "PROBLEM", 59, 86], ["volume growth", "PROBLEM", 128, 141], ["the RP scheme", "TEST", 184, 197], ["DiscussionPrevious studies", "TEST", 208, 234], ["cheaper", "TREATMENT", 265, 272], ["generic drugs", "TREATMENT", 274, 287], ["cost savings", "PROBLEM", 300, 312], ["therapeutic effectiveness", "TREATMENT", 365, 390], ["treatment discontinuation", "TREATMENT", 402, 427], ["volume growth", "OBSERVATION", 128, 141]]], ["Our study demonstrated that prescription switching was from cheaper drugs to more expensive agents, and our patients, with a complexity of clinical conditions, were more likely to be treated with both drugs (subsequent or concurrent use of ACEI and ARB) than ACEIs alone.", [["ACEI", "CHEMICAL", 240, 244], ["ARB", "CHEMICAL", 249, 252], ["ACEIs", "CHEMICAL", 259, 264], ["patients", "ORGANISM", 108, 116], ["ACEI", "SIMPLE_CHEMICAL", 240, 244], ["ARB", "SIMPLE_CHEMICAL", 249, 252], ["ACEIs", "SIMPLE_CHEMICAL", 259, 264], ["patients", "SPECIES", 108, 116], ["Our study", "TEST", 0, 9], ["cheaper drugs", "TREATMENT", 60, 73], ["more expensive agents", "TREATMENT", 77, 98], ["both drugs", "TREATMENT", 196, 206], ["ACEI", "TREATMENT", 240, 244], ["ARB", "TREATMENT", 249, 252], ["ACEIs", "TREATMENT", 259, 264]]], ["It is noteworthy that a difference between ARBs and ACEIs may be the persistent coughing caused by ACEIs.", [["ARBs", "CHEMICAL", 43, 47], ["ACEIs", "CHEMICAL", 52, 57], ["coughing", "DISEASE", 80, 88], ["ARBs", "SIMPLE_CHEMICAL", 43, 47], ["ACEIs", "SIMPLE_CHEMICAL", 52, 57], ["ACEIs", "SIMPLE_CHEMICAL", 99, 104], ["ARBs", "TREATMENT", 43, 47], ["ACEIs", "TREATMENT", 52, 57], ["the persistent coughing", "PROBLEM", 65, 88], ["ACEIs", "TEST", 99, 104], ["persistent", "OBSERVATION_MODIFIER", 69, 79], ["coughing", "OBSERVATION", 80, 88]]], ["Patients who cannot tolerate ACEIs often switch to ARBs.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ACEIs", "TREATMENT", 29, 34], ["ARBs", "TREATMENT", 51, 55]]], ["No differences in the clinical recommendations for ARBs and ACEIs were noted during the study period [7] .", [["ARBs", "SIMPLE_CHEMICAL", 51, 55], ["ACEIs", "SIMPLE_CHEMICAL", 60, 65], ["ARBs", "TREATMENT", 51, 55], ["ACEIs", "TREATMENT", 60, 65]]], ["Further analyses are warranted to compare the effectiveness and economic outcome for patients treated with ACEIs, those treated with ARBs, and those who switched from ACEIs to ARBs.DiscussionThis study had several limitations.", [["ACEIs", "CHEMICAL", 107, 112], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Further analyses", "TEST", 0, 16], ["ACEIs", "TREATMENT", 107, 112], ["ARBs", "TREATMENT", 133, 137], ["ACEIs", "TREATMENT", 167, 172], ["ARBs", "TREATMENT", 176, 180], ["This study", "TEST", 191, 201]]], ["First, the baseline disease severity which led to initiation of treatment with ACEIs or ARBs was not compared, and we were unable to distinguish the clinical appropriateness of stopping or switching drugs for individual patients.", [["ACEIs", "CHEMICAL", 79, 84], ["ACEIs", "SIMPLE_CHEMICAL", 79, 84], ["ARBs", "SIMPLE_CHEMICAL", 88, 92], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["the baseline disease severity", "PROBLEM", 7, 36], ["treatment", "TREATMENT", 64, 73], ["ACEIs", "TREATMENT", 79, 84], ["ARBs", "TREATMENT", 88, 92], ["switching drugs", "TREATMENT", 189, 204], ["disease", "OBSERVATION", 20, 27]]], ["The assessment of clinical conditions using ICD9-CM codes is likely to minimize most, but not all, of the potential bias.", [["CM", "DISEASE", 49, 51], ["The assessment", "TEST", 0, 14], ["clinical conditions", "PROBLEM", 18, 37], ["ICD9-CM codes", "TREATMENT", 44, 57]]], ["Second, there was no control group in this study, because price adjustments were implemented nationwide concurrently.", [["this study", "TEST", 38, 48], ["no", "UNCERTAINTY", 18, 20]]], ["However, the time points in the pre-intervention period served as a control group for the post-intervention period in the intervention analysis.", [["the intervention analysis", "TEST", 118, 143]]], ["Finally, because the time period between price adjustments is quite short, incorporating each price adjustment's level change and trend change into the intervention model would show severe multicollinearity, and it would be difficult to achieve significance for the collinearity parameters.", [["price adjustments", "TREATMENT", 41, 58], ["the intervention model", "TEST", 148, 170], ["severe multicollinearity", "PROBLEM", 182, 206], ["the collinearity parameters", "TEST", 262, 289], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["multicollinearity", "OBSERVATION", 189, 206]]], ["That is why some previous studies only examined the level change, but not the trend change.", [["some previous studies", "TEST", 12, 33]]], ["However, since the trend change represents the long-term effect of policy interventions, its implication is greater than what the level change can explain and so it cannot be ignored.", [["policy interventions", "TREATMENT", 67, 87], ["long-term effect", "OBSERVATION_MODIFIER", 47, 63], ["greater", "OBSERVATION_MODIFIER", 108, 115]]], ["Therefore, we adopted a parsimonious model instead of a full model [14] , keeping only the significant predictors selected by a backward elimination procedure and collinearity diagnostics.", [["a backward elimination procedure", "TREATMENT", 126, 158], ["collinearity diagnostics", "TEST", 163, 187]]], ["In this way, the long-term effect of the price adjustments can be examined and the multicollinearity problem can be avoided.ConclusionsThe implementation of Taiwan's stepwise price adjustments, with different adjustment strategies applied to patented and off-patent drugs, has achieved cost savings for off-patent ACEIs, but not for patented ACEI, ARBs and overall renin-angiotensin drugs in the long term.", [["ACEI", "CHEMICAL", 342, 346], ["angiotensin", "CHEMICAL", 371, 382], ["ACEIs", "SIMPLE_CHEMICAL", 314, 319], ["ACEI", "SIMPLE_CHEMICAL", 342, 346], ["ARBs", "SIMPLE_CHEMICAL", 348, 352], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 365, 382], ["renin", "PROTEIN", 365, 370], ["the price adjustments", "TREATMENT", 37, 58], ["the multicollinearity problem", "PROBLEM", 79, 108], ["Taiwan's stepwise price adjustments", "TREATMENT", 157, 192], ["different adjustment strategies", "TREATMENT", 199, 230], ["cost savings", "TREATMENT", 286, 298], ["patent ACEIs", "TREATMENT", 307, 319], ["ACEI", "TREATMENT", 342, 346], ["ARBs", "TREATMENT", 348, 352], ["overall renin", "TREATMENT", 357, 370], ["angiotensin drugs", "TREATMENT", 371, 388], ["long-term effect", "OBSERVATION_MODIFIER", 17, 33], ["patent", "OBSERVATION", 259, 265]]], ["Increases in incident ARB users and possible switching from ACEIs to ARBs have emerged.", [["ARB", "CHEMICAL", 22, 25], ["ACEIs", "CHEMICAL", 60, 65], ["ARBs", "CHEMICAL", 69, 73], ["ARB", "SIMPLE_CHEMICAL", 22, 25], ["ARBs", "SIMPLE_CHEMICAL", 69, 73], ["ARB users", "TREATMENT", 22, 31], ["ACEIs", "TREATMENT", 60, 65], ["ARBs", "TREATMENT", 69, 73]]], ["These results indicate that policy makers in Taiwan should reconsider the appropriateness of the current adjustment strategies applied to patented and off-patent products, since they result in a difference in the profit margin that physicians obtain from these two classes of drugs and affect physicians' prescribing decisions.Additional filesAdditional file 1: The principles of Taiwan's price adjustments based on the market price and volume surveys, as well as generic grouping.", [["the current adjustment strategies", "TREATMENT", 93, 126], ["drugs", "TREATMENT", 276, 281], ["Taiwan's price adjustments", "TREATMENT", 380, 406], ["the market price", "TREATMENT", 416, 432], ["volume surveys", "TEST", 437, 451], ["patent", "OBSERVATION", 155, 161]]], ["This file describes the background of Taiwan's pharmaceutical benefit scheme (PBS) and delineates in detail the process of stepwise price adjustment.", [["stepwise price adjustment", "TREATMENT", 123, 148]]]], "adeaaa8cf4aa51586721b4ac4e4c8547030b395c": [["SummaryBackground To investigate the impact of goggles on their health and clinical practice during management of patients with COVID-19.SummaryMethods 231 nurse practitioners were enrolled who worked in isolation region in designated hospitals to admit patients with COVID-19 in China.", [["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 254, 262], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 254, 262], ["COVID", "TEST", 128, 133], ["COVID", "TEST", 268, 273]]], ["Demographic data, goggle-associated symptoms and underlying reasons, incidence of medical errors or exposures, the effects of fog in goggles on practice were all collected.", [["Demographic data", "TEST", 0, 16], ["associated symptoms", "PROBLEM", 25, 44], ["medical errors", "PROBLEM", 82, 96]]], ["Risk factors of goggle-associated medical errors were analyzed by multivariable logistical regression analysis.SummaryFindings Goggle-associated symptoms and foggy goggles widely presented in nurses.", [["goggle-associated medical errors", "PROBLEM", 16, 48], ["multivariable logistical regression analysis", "TEST", 66, 110], ["associated symptoms", "PROBLEM", 134, 153], ["foggy goggles", "PROBLEM", 158, 171]]], ["The most common symptoms were headache, skin pressure injury and dizziness.", [["skin", "ANATOMY", 40, 44], ["headache", "DISEASE", 30, 38], ["skin pressure injury", "DISEASE", 40, 60], ["dizziness", "DISEASE", 65, 74], ["skin", "ORGAN", 40, 44], ["The most common symptoms", "PROBLEM", 0, 24], ["headache", "PROBLEM", 30, 38], ["skin pressure injury", "PROBLEM", 40, 60], ["dizziness", "PROBLEM", 65, 74], ["skin", "ANATOMY", 40, 44], ["pressure injury", "OBSERVATION", 45, 60]]], ["Headache, vomit and nausea were significantly fewer reported in nurses with longer working experience while rash occurred higher in this group.", [["Headache", "DISEASE", 0, 8], ["vomit", "DISEASE", 10, 15], ["nausea", "DISEASE", 20, 26], ["rash", "DISEASE", 108, 112], ["Headache", "PROBLEM", 0, 8], ["vomit", "PROBLEM", 10, 15], ["nausea", "PROBLEM", 20, 26], ["rash", "PROBLEM", 108, 112]]], ["The underlying reasons included tightness of goggles, unsuitable design and uncomfortable materials.", [["tightness of goggles", "PROBLEM", 32, 52], ["unsuitable design and uncomfortable materials", "PROBLEM", 54, 99]]], ["The working status of nurses with more working experience Introduction Over 2.4 million people have been diagnosed with coronavirus disease 2019 (COVID-19) till now.SummaryWith the global outbreak of COVID-19 in recent three months, medial resources, including personal protective equipment (PPE) and human resources, are insufficient to cope with rapid growth of diagnosed patients.", [["coronavirus disease", "DISEASE", 120, 139], ["people", "ORGANISM", 88, 94], ["human", "ORGANISM", 301, 306], ["patients", "ORGANISM", 374, 382], ["people", "SPECIES", 88, 94], ["human", "SPECIES", 301, 306], ["patients", "SPECIES", 374, 382], ["human", "SPECIES", 301, 306], ["coronavirus disease", "PROBLEM", 120, 139], ["COVID", "TEST", 146, 151], ["COVID", "TEST", 200, 205], ["personal protective equipment", "TREATMENT", 261, 290], ["coronavirus disease", "OBSERVATION", 120, 139], ["global", "OBSERVATION_MODIFIER", 181, 187], ["outbreak", "OBSERVATION_MODIFIER", 188, 196]]], ["Recently, the health status of healthcare professionals involved in management of patients with COVID-19 was concerned [1] [2] [3] [4] [5] .", [["COVID-19", "CHEMICAL", 96, 104], ["COVID-19", "CHEMICAL", 96, 104], ["patients", "ORGANISM", 82, 90], ["[1] [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 119, 138], ["patients", "SPECIES", 82, 90], ["COVID", "TEST", 96, 101]]], ["A number of physicians realized and called on the potential risks on health of healthcare professionals due to the shortage of PPE [4] [5] [6] [7] [8] [9] .SummaryOn the other hand, donning of the PPE often associates with uncomfortable and cumbersome.", [["PPE [4] [5", "CHEMICAL", 127, 137], ["PPE [4] [5] [6] [7] [8] [9]", "CHEMICAL", 127, 154], ["PPE [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 127, 154], ["hand", "ORGANISM_SUBDIVISION", 176, 180], ["uncomfortable and cumbersome", "PROBLEM", 223, 251]]], ["It was reported that PPE can cause headache and difficulty breathing, indicating PPE itself may potentially harm to healthcare professionals in some situations [10] , thus PPE-associated harms can not be neglected during COVID-19 pandemic.SummaryA special situation that should be considered is many healthcare professionals whose specialties are not respiratory or infective diseases involve in the management of patients with COVID-19 due to the sudden outbreak of COVID-19 worldwide.", [["respiratory", "ANATOMY", 351, 362], ["PPE", "CHEMICAL", 21, 24], ["headache", "DISEASE", 35, 43], ["respiratory or infective diseases", "DISEASE", 351, 384], ["COVID-19", "CHEMICAL", 467, 475], ["patients", "ORGANISM", 414, 422], ["patients", "SPECIES", 414, 422], ["headache", "PROBLEM", 35, 43], ["difficulty breathing", "PROBLEM", 48, 68], ["PPE", "PROBLEM", 81, 84], ["PPE", "PROBLEM", 172, 175], ["COVID", "TEST", 221, 226], ["pandemic", "PROBLEM", 230, 238], ["respiratory or infective diseases", "PROBLEM", 351, 384], ["COVID", "TEST", 428, 433], ["COVID", "TEST", 467, 472], ["infective", "OBSERVATION", 366, 375]]], ["Under the emergent situation, a number of them got limited training on wearing PPE and had little time to adapt to working in PPE before going to frontline.", [["wearing PPE", "TREATMENT", 71, 82]]], ["It is reasonable that insufficient experience with working in PPE combined with the states of fearing exposure may enhance the discomfortableness.", [["discomfortableness", "DISEASE", 127, 145], ["working in PPE", "TREATMENT", 51, 65], ["the discomfortableness", "PROBLEM", 123, 145]]], ["These discomforts may negatively impact the working status and the accuracy of procedures.", [["discomforts", "DISEASE", 6, 17], ["These discomforts", "PROBLEM", 0, 17], ["procedures", "TEST", 79, 89]]], ["However, whether and to what extent the negative effects of PPE on both healthcare professionals and patients were rarely reported in studies on COVID-19.SummaryComparing with physicians, nurses have more chances to directly contacts with patients in daily practice.", [["PPE", "CHEMICAL", 60, 63], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 239, 247], ["COVID", "TEST", 145, 150], ["negative", "OBSERVATION", 40, 48]]], ["The possibility of occurring medical exposures during clinical practice may be increased.SummaryAlthough nurses who involved in management of this pandemic received training on use of PPE and psychological education before they went to frontline [11] , high proportion of nurses that engaged in the management of epidemic still complained about discomforts associated with PPE, of which goggles were mostly mentioned in all kinds of PPE.", [["discomforts", "DISEASE", 345, 356], ["clinical practice", "TREATMENT", 54, 71], ["PPE", "TREATMENT", 184, 187], ["psychological education", "TREATMENT", 192, 215], ["discomforts", "PROBLEM", 345, 356], ["PPE", "PROBLEM", 373, 376], ["PPE", "PROBLEM", 433, 436], ["possibility of", "UNCERTAINTY", 4, 18], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["Nurses indicated that goggles may cause serious somatic symptoms that remarkedly impacted their working status.", [["serious somatic symptoms", "PROBLEM", 40, 64]]], ["Meanwhile, fogging in goggles was likely unavoidable during clinical work and their vision was interfered which impacted their clinical practice.", [["likely", "UNCERTAINTY", 34, 40], ["unavoidable", "OBSERVATION_MODIFIER", 41, 52]]], ["Considering the universality and necessities of wearing goggles during this pandemic, it is essential to investigate the epidemiologic features of goggle-associated discomforts and to what extent the goggles impact the working status of nurses.SummaryIn this questionnaire-based retrospective study, we analyzed 231 questionnaires getting from nurse practitioners.", [["goggles", "TREATMENT", 56, 63], ["goggle-associated discomforts", "PROBLEM", 147, 176], ["retrospective study", "TEST", 279, 298]]], ["All of participants worked in isolation region for management of patients with COVID-19.", [["COVID-19", "CHEMICAL", 79, 87], ["patients", "ORGANISM", 65, 73], ["participants", "SPECIES", 7, 19], ["patients", "SPECIES", 65, 73], ["management", "TREATMENT", 51, 61], ["COVID", "TEST", 79, 84]]], ["We detailly interpreted the prevalence and distribution of goggle-associated complications and interpreted the underlying reasons through stratified age or working experience.", [["goggle-associated complications", "PROBLEM", 59, 90]]], ["Furthermore, the risk factors associated with medical errors were analyzed.", [["the risk factors", "PROBLEM", 13, 29]]], ["On the other hand, the negative effects of fog in goggles on working status of nurses were studied.", [["negative", "OBSERVATION", 23, 31]]], ["We still introduced some improving measures that can reduce the goggle-associated discomforts.", [["the goggle-associated discomforts", "PROBLEM", 60, 93], ["some", "OBSERVATION_MODIFIER", 20, 24], ["improving", "OBSERVATION_MODIFIER", 25, 34]]], ["Our findings specifically emphases the health problems caused by goggles during management of patients with COVID-19.", [["COVID-19", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["COVID", "TEST", 108, 113], ["goggles", "OBSERVATION", 65, 72]]], ["In addition, we would like to arouse the concerns from authorities and PPE manufactures on the harms caused by PPE to both healthcare professionals and patients during the management of COVID-19.Study design and participantsThis study was approved by the Ethical Committee at General hospital of Western TheaterStudy design and participantsCommand.", [["patients", "ORGANISM", 152, 160], ["participants", "ORGANISM", 212, 224], ["patients", "SPECIES", 152, 160], ["participants", "SPECIES", 212, 224], ["participants", "SPECIES", 328, 340], ["PPE manufactures", "TREATMENT", 71, 87], ["COVID", "TEST", 186, 191], ["This study", "TEST", 224, 234]]], ["This questionnaire-based retrospective study was done at several designated hospitals to treat patients with COVID-19 in Wuhan and Chongqing, China.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["This questionnaire", "TEST", 0, 18], ["based retrospective study", "TEST", 19, 44], ["COVID", "TEST", 109, 114]]], ["All participants were nurse practitioners, who worked in isolation region (also called red zone) from late January to late March and participated in the direct management of patients with COVID-19.", [["patients", "ORGANISM", 174, 182], ["participants", "SPECIES", 4, 16], ["patients", "SPECIES", 174, 182], ["COVID", "TEST", 188, 193]]], ["The survey was performed anonymously, the data collected were presented in an aggregated form.Definitions and data collectionMedical errors in this study are defined as unsuccessful clinical procedures, such as unsuccessful venipuncture, or medication errors on patients and harms to healthcare professionals.", [["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["the data", "TEST", 38, 46], ["this study", "TEST", 143, 153], ["clinical procedures", "TREATMENT", 182, 201], ["unsuccessful venipuncture", "TREATMENT", 211, 236], ["medication errors", "PROBLEM", 241, 258]]], ["Medical exposure specifically indicated the situation that healthcare professionals were exposed to the environment that could be infected due to some unexpected reasons, such as needle-stick injuries, damage of PPE, etc. Skin medical device-related pressure injury ( SMDRPI)means localized skin injury as a result of sustained pressure from medical device, it can be divided into 4 stages as defined in previous study: Stage 1, whole skin with erythema that does not whiten; Stage 2, loss of skin in its partial thickness with dermis exposure; Stage 3, loss of skin in its overall thickness;Definitions and data collectionStage 4, loss of skin in its total thickness and tissue loss [12] .Definitions and data collectionData were collected and evaluated using own-designed questionnaires.", [["Skin", "ANATOMY", 222, 226], ["skin", "ANATOMY", 291, 295], ["skin", "ANATOMY", 435, 439], ["skin", "ANATOMY", 493, 497], ["dermis", "ANATOMY", 528, 534], ["skin", "ANATOMY", 562, 566], ["skin", "ANATOMY", 640, 644], ["tissue", "ANATOMY", 672, 678], ["injuries", "DISEASE", 192, 200], ["pressure injury", "DISEASE", 250, 265], ["SMDRPI", "DISEASE", 268, 274], ["skin injury", "DISEASE", 291, 302], ["erythema", "DISEASE", 445, 453], ["Skin", "ORGAN", 222, 226], ["skin", "ORGAN", 291, 295], ["skin", "ORGAN", 435, 439], ["skin", "ORGAN", 493, 497], ["dermis", "TISSUE", 528, 534], ["skin", "ORGAN", 562, 566], ["skin", "ORGAN", 640, 644], ["tissue", "TISSUE", 672, 678], ["needle-stick injuries", "PROBLEM", 179, 200], ["damage of PPE", "PROBLEM", 202, 215], ["Skin medical device", "TREATMENT", 222, 241], ["pressure injury", "PROBLEM", 250, 265], ["localized skin injury", "PROBLEM", 281, 302], ["sustained pressure from medical device", "TREATMENT", 318, 356], ["previous study", "TEST", 404, 418], ["Stage 1", "PROBLEM", 420, 427], ["whole skin with erythema", "PROBLEM", 429, 453], ["Stage 2", "PROBLEM", 476, 483], ["loss of skin", "PROBLEM", 485, 497], ["dermis exposure", "PROBLEM", 528, 543], ["Stage 3", "PROBLEM", 545, 552], ["loss of skin in its overall thickness", "PROBLEM", 554, 591], ["data collection", "TEST", 608, 623], ["Stage 4", "PROBLEM", 623, 630], ["loss of skin", "PROBLEM", 632, 644], ["tissue loss", "PROBLEM", 672, 683], ["data collectionData", "TEST", 706, 725], ["pressure", "OBSERVATION_MODIFIER", 250, 258], ["injury", "OBSERVATION", 259, 265], ["skin", "ANATOMY", 291, 295], ["injury", "OBSERVATION", 296, 302], ["pressure", "OBSERVATION_MODIFIER", 328, 336], ["skin", "ANATOMY", 435, 439], ["erythema", "OBSERVATION", 445, 453], ["skin", "ANATOMY", 493, 497], ["partial thickness", "OBSERVATION_MODIFIER", 505, 522], ["dermis", "ANATOMY", 528, 534], ["exposure", "OBSERVATION", 535, 543], ["Stage 3", "OBSERVATION_MODIFIER", 545, 552], ["loss", "OBSERVATION_MODIFIER", 554, 558], ["skin", "ANATOMY", 562, 566], ["overall thickness", "OBSERVATION_MODIFIER", 574, 591], ["loss", "OBSERVATION_MODIFIER", 632, 636], ["skin", "ANATOMY", 640, 644], ["total thickness", "OBSERVATION_MODIFIER", 652, 667], ["tissue loss", "OBSERVATION", 672, 683]]], ["We primarily concentrated on two aspects: discomforts caused by goggles and the effects of fog in goggles on clinical practice.", [["discomforts", "DISEASE", 42, 53], ["discomforts", "PROBLEM", 42, 53], ["goggles", "OBSERVATION", 64, 71]]], ["Considering ages and practice experience may be two critical impact factors to influence metal stress, working status and tolerance for symptoms, critical information was further analyzed stratified by age groups and practice durations.Definitions and data collectionData on age, sex, specialty, duration of practice, experience of wearing goggles, mental stress in clinical practice, goggles associated symptoms (claustrophobia, irritability, vomit, headache, dizziness, nausea, eczema, skin pressure injury), effects of fog in goggles on medical exposure, measures relieving discomfort and fog, were collected and evaluated.Statistical analysisContinuous variables were expressed as median and interquartile range (IQR), comparisons between two groups or multiple groups were done with Mann-whitney U or kruskal-wallis H test, respectively.", [["skin", "ANATOMY", 488, 492], ["claustrophobia", "DISEASE", 414, 428], ["irritability", "DISEASE", 430, 442], ["vomit", "DISEASE", 444, 449], ["headache", "DISEASE", 451, 459], ["dizziness", "DISEASE", 461, 470], ["nausea", "DISEASE", 472, 478], ["eczema", "DISEASE", 480, 486], ["skin pressure injury", "DISEASE", 488, 508], ["skin", "ORGAN", 488, 492], ["metal stress", "PROBLEM", 89, 101], ["symptoms", "PROBLEM", 136, 144], ["wearing goggles", "PROBLEM", 332, 347], ["mental stress in clinical practice", "PROBLEM", 349, 383], ["goggles associated symptoms", "PROBLEM", 385, 412], ["claustrophobia", "PROBLEM", 414, 428], ["irritability", "PROBLEM", 430, 442], ["vomit", "PROBLEM", 444, 449], ["headache", "PROBLEM", 451, 459], ["dizziness", "PROBLEM", 461, 470], ["nausea", "PROBLEM", 472, 478], ["eczema", "PROBLEM", 480, 486], ["skin pressure injury", "PROBLEM", 488, 508], ["medical exposure", "TREATMENT", 540, 556], ["relieving discomfort", "PROBLEM", 567, 587], ["fog", "PROBLEM", 592, 595], ["Statistical analysisContinuous variables", "PROBLEM", 626, 666], ["kruskal-wallis H test", "TEST", 806, 827], ["skin", "ANATOMY", 488, 492]]], ["Categorical variables were presented as number (%) and differences among groups were compared with Chi-square or Fisher's exact test where appropriate.", [["Categorical variables", "TEST", 0, 21], ["Fisher's exact test", "TEST", 113, 132]]], ["The relationships between level of tightness of goggles and level of mental stress and between age and practice duration were assessed by Spearman's rank correlation coefficient, respectively.", [["tightness of goggles", "PROBLEM", 35, 55], ["mental stress", "PROBLEM", 69, 82], ["tightness", "OBSERVATION", 35, 44], ["goggles", "OBSERVATION", 48, 55]]], ["The potential factors associated with medical errors were investigated using univariate and multivariate binary logistic regression models.", [["medical errors", "PROBLEM", 38, 52], ["multivariate binary logistic regression models", "TREATMENT", 92, 138]]], ["Statistical analyses in this study were down with SPSS, version 18.0 (SPSS statistics for windows, Inc., Chicago, Ill., USA).", [["Statistical analyses", "TEST", 0, 20], ["this study", "TEST", 24, 34], ["SPSS", "TEST", 50, 54], ["version", "TEST", 56, 63]]], ["All tests were bilateral and p values less than 0.05 were considered significant.Most nurses had insufficient experience to work in PPETotal 231 questionnaires were eligible for subsequent analysis.", [["All tests", "TEST", 0, 9], ["p values", "TEST", 29, 37], ["subsequent analysis", "TEST", 178, 197], ["bilateral", "ANATOMY_MODIFIER", 15, 24]]], ["The median age was 32.0 (IQR 28.0-37.0) years old.", [["IQR", "TEST", 25, 28]]], ["The median practice duration was 11.0 (IQR 6.5-16.0) years.", [["IQR", "TEST", 39, 42]]], ["96.1% (222) participants were female, the ratio of male and female showed no significance when stratified by age range or practice duration ( Table 1 ).", [["participants", "ORGANISM", 12, 24], ["participants", "SPECIES", 12, 24]]], ["The specialties of participants included neurology, outpatient department, infectious disease, orthopedics, oncology, emergency, gastrointestinal surgery, respiratory, intensive critical care, ear-nose-throat (ENT), anesthesiology, obstetrics and gynecology (OG), pediatrics, minimally invasive surgery, rehabilitation, geriatrics, nephrology, cardiology, operating room, endocrine, thoracic surgery, urinary surgery, physiotherapy, burns, maxillofacial surgery and hepatology, approximately 9.1% of participants worked in department of infectious diseases or department of respirator before this pandemic.", [["gastrointestinal", "ANATOMY", 129, 145], ["respiratory", "ANATOMY", 155, 166], ["ear", "ANATOMY", 193, 196], ["endocrine", "ANATOMY", 372, 381], ["thoracic", "ANATOMY", 383, 391], ["urinary", "ANATOMY", 401, 408], ["maxillofacial", "ANATOMY", 440, 453], ["infectious disease", "DISEASE", 75, 93], ["burns", "DISEASE", 433, 438], ["infectious diseases", "DISEASE", 537, 556], ["gastrointestinal", "ORGAN", 129, 145], ["ear", "ORGAN", 193, 196], ["thoracic", "MULTI-TISSUE_STRUCTURE", 383, 391], ["urinary", "ORGANISM_SUBDIVISION", 401, 408], ["participants", "SPECIES", 19, 31], ["participants", "SPECIES", 500, 512], ["gastrointestinal surgery", "TREATMENT", 129, 153], ["minimally invasive surgery", "TREATMENT", 276, 302], ["thoracic surgery", "TREATMENT", 383, 399], ["urinary surgery", "TREATMENT", 401, 416], ["physiotherapy", "TREATMENT", 418, 431], ["maxillofacial surgery", "TREATMENT", 440, 461], ["respirator", "TREATMENT", 574, 584], ["gastrointestinal", "ANATOMY", 129, 145], ["ear", "ANATOMY", 193, 196], ["nose", "ANATOMY", 197, 201], ["throat", "ANATOMY", 202, 208], ["thoracic", "ANATOMY", 383, 391], ["urinary", "ANATOMY", 401, 408], ["maxillofacial", "ANATOMY", 440, 453], ["infectious", "OBSERVATION", 537, 547]]], ["Meanwhile, only 10.0% (23) participants had the experience of wearing PPE in clinical practice and there was no significance among each group stratified by age or practice duration ( Table 1 ).", [["participants", "ORGANISM", 27, 39], ["participants", "SPECIES", 27, 39]]], ["All of participants received training for wearing PPE and psychological education before going to frontline, the training hours were similar among each group, the median time for training and education in total participants was 7.0 (IQR 2.0-10.0) days ( Table 1 ).", [["participants", "ORGANISM", 7, 19], ["participants", "SPECIES", 7, 19], ["participants", "SPECIES", 211, 223], ["wearing PPE", "TREATMENT", 42, 53], ["psychological education", "TREATMENT", 58, 81]]], ["All of participants worked for average 4 (IQR 4 -5) hours in isolation region per day.", [["participants", "SPECIES", 7, 19]]], ["To evaluate the level of mental stress on fearing exposure, participants were asked to select a point from an \"1-10\" scale (1 = Not at all, 10 = Extremely), the median point was 5.0 (IQR 3.0-8.0).", [["participants", "SPECIES", 60, 72], ["mental stress", "PROBLEM", 25, 38], ["IQR", "TEST", 183, 186]]], ["Comparing with other two age groups, this rating was significantly lower in nurses with age \u2265 40 years (4.0, 1.0-6.5, p = 0.032) ( Table 1) .Most nurses had insufficient experience to work in PPEThese baseline characteristics indicated most of nurses who involved in first line of management of COVID-19 had little experience in working in PPE before this pandemic.", [["management of COVID", "TREATMENT", 281, 300]]], ["Due to the urgent situation, there was limited time for training on wearing PPE and receiving psychological education.Most nurses had insufficient experience to work in PPEGoggle-associated symptoms were highly prevalent in nurses who involving in management ofCOVID-19To investigate to what extent goggles impacted nurses, we analyzed the symptoms caused by wearing goggles that were reported by nurses.", [["PPEGoggle", "CHEMICAL", 169, 178], ["wearing PPE", "TREATMENT", 68, 79], ["psychological education", "TREATMENT", 94, 117], ["associated symptoms", "PROBLEM", 179, 198], ["the symptoms", "PROBLEM", 336, 348]]], ["The occurred symptoms, the initial symptoms and All rights reserved.", [["The occurred symptoms", "PROBLEM", 0, 21], ["the initial symptoms", "PROBLEM", 23, 43]]], ["No reuse allowed without permission.COVID-19(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.COVID-19The copyright holder for this preprint this version posted May 15, 2020. . the most frequently occurred symptoms were collected and analyzed, respectively.COVID-19In our report, the three most reported occurred symptoms were headache (79.1%), skin pressure injury (I -IV stages) (66.2%) and dizziness (49.4%), all of symptoms showed no significant differences among age groups (Table 2) .", [["skin", "ANATOMY", 430, 434], ["headache", "DISEASE", 412, 420], ["skin pressure injury", "DISEASE", 430, 450], ["dizziness", "DISEASE", 478, 487], ["skin", "ORGAN", 430, 434], ["COVID", "TEST", 179, 184], ["The copyright holder", "TREATMENT", 187, 207], ["symptoms", "PROBLEM", 291, 299], ["symptoms", "PROBLEM", 398, 406], ["headache", "PROBLEM", 412, 420], ["skin pressure injury", "PROBLEM", 430, 450], ["dizziness", "PROBLEM", 478, 487], ["all of symptoms", "PROBLEM", 497, 512], ["med", "ANATOMY", 123, 126], ["skin", "ANATOMY", 430, 434], ["pressure", "OBSERVATION_MODIFIER", 435, 443], ["injury", "OBSERVATION", 444, 450], ["no", "UNCERTAINTY", 520, 522]]], ["When stratified by practice duration, the incidence of headache and vomit was similar between nurses with 0-10 years working experience and 11-20 years working experience, but much higher than the incidence in group with \u2265 21 years working experience.", [["headache", "DISEASE", 55, 63], ["headache", "PROBLEM", 55, 63], ["vomit", "PROBLEM", 68, 73]]], ["On the contrary, the incidence of rash was highest in nurses with \u2265 21 years working experience comparing with other two groups ( Table 2) .", [["rash", "DISEASE", 34, 38], ["rash", "PROBLEM", 34, 38], ["rash", "OBSERVATION", 34, 38]]], ["On the other hand, headache, skin pressure injury, nausea and dizziness were the symptoms with highest incidence in each age group or practice duration group (Fig 1a and 1d ).COVID-19When asked the earliest occurred symptoms, headache was also mostly reported (64.3%) and the proportion was much higher than other symptoms.", [["skin", "ANATOMY", 29, 33], ["headache", "DISEASE", 19, 27], ["pressure injury", "DISEASE", 34, 49], ["nausea", "DISEASE", 51, 57], ["dizziness", "DISEASE", 62, 71], ["headache", "DISEASE", 226, 234], ["skin", "ORGAN", 29, 33], ["COVID-19When", "DNA", 175, 187], ["headache", "PROBLEM", 19, 27], ["skin pressure injury", "PROBLEM", 29, 49], ["nausea", "PROBLEM", 51, 57], ["dizziness", "PROBLEM", 62, 71], ["the symptoms", "PROBLEM", 77, 89], ["symptoms", "PROBLEM", 216, 224], ["headache", "PROBLEM", 226, 234], ["other symptoms", "PROBLEM", 308, 322], ["headache", "OBSERVATION", 19, 27], ["skin", "ANATOMY", 29, 33], ["pressure", "OBSERVATION_MODIFIER", 34, 42], ["injury", "OBSERVATION", 43, 49]]], ["In addition, the proportion of initial symptom as headache in nurses with \u2265 21 years working experience was much lower than other two groups (42.1%, p=0.012).", [["headache", "DISEASE", 50, 58], ["initial symptom", "PROBLEM", 31, 46], ["headache", "PROBLEM", 50, 58]]], ["The second mostly reported initial symptom was skin pressure injury (I -IV stages) and the third one was dizziness.", [["skin", "ANATOMY", 47, 51], ["skin pressure injury", "DISEASE", 47, 67], ["dizziness", "DISEASE", 105, 114], ["skin", "ORGAN", 47, 51], ["initial symptom", "PROBLEM", 27, 42], ["skin pressure injury", "PROBLEM", 47, 67], ["dizziness", "PROBLEM", 105, 114], ["skin", "ANATOMY", 47, 51], ["pressure", "OBSERVATION_MODIFIER", 52, 60], ["injury", "OBSERVATION", 61, 67], ["dizziness", "OBSERVATION", 105, 114]]], ["Besides to headache and claustrophobia, no significance was observed in each symptom when stratified by age or practice duration ( Table 2) .", [["headache", "DISEASE", 11, 19], ["claustrophobia", "DISEASE", 24, 38], ["headache", "PROBLEM", 11, 19], ["claustrophobia", "PROBLEM", 24, 38]]], ["When analyzing the distribution of each symptoms in age group or practice duration group, the percentages of headache and skin pressure injury were much higher than other symptoms (Fig 1b and 1e ).COVID-19Next, we further investigated the most frequent occurred symptoms.", [["skin", "ANATOMY", 122, 126], ["headache", "DISEASE", 109, 117], ["pressure injury", "DISEASE", 127, 142], ["skin", "ORGAN", 122, 126], ["each symptoms", "PROBLEM", 35, 48], ["headache", "PROBLEM", 109, 117], ["skin pressure injury", "PROBLEM", 122, 142], ["other symptoms", "PROBLEM", 165, 179], ["the most frequent occurred symptoms", "PROBLEM", 235, 270], ["skin", "ANATOMY", 122, 126], ["pressure injury", "OBSERVATION", 127, 142]]], ["Headache was also reported as the symptom on rank 1 that was most frequently occurred (47.0%).", [["Headache", "DISEASE", 0, 8], ["Headache", "PROBLEM", 0, 8]]], ["The second was skin pressure injury and the third symptom was dizziness.", [["skin", "ANATOMY", 15, 19], ["pressure injury", "DISEASE", 20, 35], ["dizziness", "DISEASE", 62, 71], ["skin", "ORGAN", 15, 19], ["skin pressure injury", "PROBLEM", 15, 35], ["the third symptom", "PROBLEM", 40, 57], ["dizziness", "PROBLEM", 62, 71], ["skin", "ANATOMY", 15, 19], ["pressure injury", "OBSERVATION", 20, 35]]], ["In addition, the proportion of headache was nearly 20% higher than the proportion of skin pressure injury.", [["skin", "ANATOMY", 85, 89], ["headache", "DISEASE", 31, 39], ["pressure injury", "DISEASE", 90, 105], ["skin", "ORGAN", 85, 89], ["headache", "PROBLEM", 31, 39], ["skin pressure injury", "PROBLEM", 85, 105], ["headache", "OBSERVATION", 31, 39], ["skin", "ANATOMY", 85, 89], ["pressure injury", "OBSERVATION", 90, 105]]], ["Furthermore, the proportion of all symptoms showed no significant differences in each group (Table 2) .", [["all symptoms", "PROBLEM", 31, 43], ["no", "UNCERTAINTY", 51, 53], ["significant", "OBSERVATION_MODIFIER", 54, 65]]], ["Similar with the distributions in occurred symptoms and initial symptoms, headache and skin pressure injury were the top 2 symptoms with highest proportions in each age group and practice duration group (Fig 1c and 1f ).COVID-19Taking together, these results showed goggle-associated discomforts extensively presented in nurses with a high proportion.", [["skin", "ANATOMY", 87, 91], ["headache", "DISEASE", 74, 82], ["pressure injury", "DISEASE", 92, 107], ["skin", "ORGAN", 87, 91], ["occurred symptoms", "PROBLEM", 34, 51], ["initial symptoms", "PROBLEM", 56, 72], ["headache", "PROBLEM", 74, 82], ["skin pressure injury", "PROBLEM", 87, 107], ["the top 2 symptoms", "PROBLEM", 113, 131], ["goggle-associated discomforts", "PROBLEM", 266, 295], ["distributions", "OBSERVATION_MODIFIER", 17, 30], ["skin", "ANATOMY", 87, 91], ["pressure", "OBSERVATION_MODIFIER", 92, 100], ["injury", "OBSERVATION", 101, 107]]], ["Notably, headache and skin pressure injury should be noticed with special caution while rash, vomit and nausea were also common symptoms in different groups.COVID-19Moreover, vomit and headache were likely to occur in nurses with shorter working experience and rash was more likely to occur in nurses with longer working experience, indicating precautions for goggle-associated symptoms should be prepared differentially.Goggle-associated symptoms negatively impacted the working statusOur results showed the onset of goggle-associated discomforts occurred mostly in the first day after wearing goggles.", [["skin", "ANATOMY", 22, 26], ["headache", "DISEASE", 9, 17], ["pressure injury", "DISEASE", 27, 42], ["rash", "DISEASE", 88, 92], ["vomit", "DISEASE", 94, 99], ["nausea", "DISEASE", 104, 110], ["vomit", "DISEASE", 175, 180], ["headache", "DISEASE", 185, 193], ["rash", "DISEASE", 261, 265], ["discomforts", "DISEASE", 536, 547], ["skin", "ORGAN", 22, 26], ["headache", "PROBLEM", 9, 17], ["skin pressure injury", "PROBLEM", 22, 42], ["rash", "PROBLEM", 88, 92], ["vomit", "PROBLEM", 94, 99], ["nausea", "PROBLEM", 104, 110], ["common symptoms in different groups", "PROBLEM", 121, 156], ["COVID", "TEST", 157, 162], ["vomit", "PROBLEM", 175, 180], ["headache", "PROBLEM", 185, 193], ["rash", "PROBLEM", 261, 265], ["precautions", "TREATMENT", 344, 355], ["goggle-associated symptoms", "PROBLEM", 360, 386], ["associated symptoms", "PROBLEM", 428, 447], ["goggle-associated discomforts", "PROBLEM", 518, 547], ["headache", "OBSERVATION", 9, 17], ["skin", "ANATOMY", 22, 26], ["pressure", "OBSERVATION_MODIFIER", 27, 35], ["injury", "OBSERVATION", 36, 42], ["discomforts", "OBSERVATION", 536, 547]]], ["In addition, only wearing goggles for average 3.0 (IQR 2.0-10.75) days, the nurses can begin to endure the goggle-associated discomforts (Table 3) .", [["discomforts", "DISEASE", 125, 136], ["the goggle-associated discomforts", "PROBLEM", 103, 136]]], ["These results showed no obvious differences among each age or practice duration group.", [["obvious differences", "PROBLEM", 24, 43], ["no obvious", "UNCERTAINTY", 21, 31]]], ["No reuse allowed without permission.Goggle-associated symptoms negatively impacted the working status(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Goggle-associated symptoms negatively impacted the working statusThe copyright holder for this preprint this version posted May 15, 2020. . participants never adapted to these discomforts (Data not shown).Goggle-associated symptoms negatively impacted the working statusConsidering the rapid onset of discomforts and the relative long time before tolerance, we concerned whether it would impact the working status in clinical practice.", [["discomforts", "DISEASE", 537, 548], ["participants", "SPECIES", 376, 388], ["associated symptoms", "PROBLEM", 43, 62], ["Goggle-associated symptoms", "PROBLEM", 236, 262], ["The copyright holder", "TREATMENT", 301, 321], ["these discomforts", "PROBLEM", 406, 423], ["associated symptoms", "PROBLEM", 448, 467], ["discomforts", "PROBLEM", 537, 548], ["med", "ANATOMY", 180, 183]]], ["As expected, total 82.7% (191) participants thought goggle-associated discomforts remarkedly impacted the working status, of which 89.1% (115) participants in 30-39 years old group thought their work was negatively influenced by goggle-associated symptoms while only 65.5% (19) participants in group of age\u226540 years agreed with this viewpoint (p=0.004).", [["discomforts", "DISEASE", 70, 81], ["participants", "ORGANISM", 31, 43], ["participants", "SPECIES", 31, 43], ["participants", "SPECIES", 143, 155], ["participants", "SPECIES", 278, 290], ["associated discomforts", "PROBLEM", 59, 81], ["associated symptoms", "PROBLEM", 236, 255]]], ["Interestingly, nurses with \u2265 20 years working experience (57.9%) thought they were less impacted by these discomforts comparing with other two groups (p=0.006).", [["these discomforts", "PROBLEM", 100, 117]]], ["Interestingly, among the three age groups, the proportion that acknowledging goggle-associated discomforts would increase medical exposure was lowest in nurses with age \u2265 40 years (p=0.030).", [["goggle", "CHEMICAL", 77, 83], ["discomforts", "DISEASE", 95, 106], ["associated discomforts", "PROBLEM", 84, 106]]], ["Furthermore, 68.4% (158) nurses discontinued or wanted to discontinued work due to goggle-associated discomforts and this proportion showed no significant differences when stratified by age or practice duration (Table 3) .", [["goggle-associated discomforts", "PROBLEM", 83, 112]]], ["Moreover, the total times for discontinuing work were 202 (range from 1 to 10), 4.3% (10) participants discontinued working for more than 5 times.Goggle-associated symptoms negatively impacted the working statusWe further explored the underlying reasons that causing goggle-associated symptoms.", [["participants", "SPECIES", 90, 102], ["Goggle-associated symptoms", "PROBLEM", 146, 172], ["goggle-associated symptoms", "PROBLEM", 267, 293]]], ["Tightness of goggles (69.3%) was the most important reason that caused goggle-associated symptoms.", [["Tightness of goggles", "PROBLEM", 0, 20], ["goggle-associated symptoms", "PROBLEM", 71, 97]]], ["Meanwhile, unsuitable design for Chinese face shape (24.2%) and uncomfortable materials, such as too stiff (22.9%) were the second reason and the third reason, respectively (Table 3) .Goggle-associated symptoms negatively impacted the working statusSince it was reasonable that mental stress may make nurses wearing the goggles too tight, especially in the situation that most nurses had insufficient experience with working in PPE as well as managing infectious disease, we next explored how mental stress influenced on wearing the goggles too tight.", [["infectious disease", "DISEASE", 452, 470], ["Chinese face shape", "TEST", 33, 51], ["uncomfortable materials", "PROBLEM", 64, 87], ["associated symptoms", "PROBLEM", 191, 210], ["mental stress", "PROBLEM", 278, 291], ["managing infectious disease", "PROBLEM", 443, 470], ["mental stress", "PROBLEM", 493, 506]]], ["The correlation between the two scales, \"Mental stress on fearing exposure\"Risk factors for discomfort-associated medical errorsIt is reasonable that working status was likely to be influenced by discomforts and inferior working status may associate with increased possibility of medical errors, thus we collected the proportion of nurses that occurred medical errors, total 11.3% (26) nurses occurred medical exposures in clinical practice.", [["Mental stress", "PROBLEM", 41, 54], ["Risk factors", "PROBLEM", 75, 87], ["discomfort", "PROBLEM", 92, 102], ["medical errors", "PROBLEM", 114, 128], ["discomforts", "PROBLEM", 196, 207], ["medical errors", "PROBLEM", 280, 294]]], ["19.5% (45) nurses made medial errors on patients.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["medial", "OBSERVATION_MODIFIER", 23, 29]]], ["The incidence showed no significant differences between each group when stratified by age or working experience ( Table 3) .Risk factors for discomfort-associated medical errorsAll rights reserved.", [["Risk factors", "PROBLEM", 124, 136], ["discomfort", "PROBLEM", 141, 151], ["associated medical errors", "PROBLEM", 152, 177], ["no", "UNCERTAINTY", 21, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["differences", "OBSERVATION", 36, 47]]], ["No reuse allowed without permission.Risk factors for discomfort-associated medical errors(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Risk factors for discomfort-associated medical errorsThe copyright holder for this preprint this version posted May 15, 2020. .", [["Risk factors", "PROBLEM", 36, 48], ["discomfort", "PROBLEM", 53, 63], ["Risk factors", "PROBLEM", 224, 236], ["discomfort", "PROBLEM", 241, 251], ["associated medical errors", "PROBLEM", 252, 277], ["The copyright holder", "TREATMENT", 277, 297], ["med", "ANATOMY", 168, 171]]], ["We next explored the risk factors for medical errors in management of COVID-19.", [["medical errors", "PROBLEM", 38, 52], ["COVID", "TEST", 70, 75]]], ["Multivariable logistical regression analysis showed \"Days before enduring goggle-associated discomforts\" (OR, 2.73; 95% CI, 1.43-5.22), \"Adjusting goggles\" (OR, 2.56; 95% CI, 1.28-5.14) and \"Headache\" (OR, 5.50; 95% CI, 1.82-16.58) were identified as three risk factors contributing to medical errors, of which the possibility of occurring medical errors in nurses occurred headache enhanced 5.5 folders comparing with nurses without headache (Table 4 ).Risk factors for discomfort-associated medical errorsThese findings demonstrated that negative effects of goggles did not only impact the healthcare professionals' physical and mental health, but also directly impact the practice and increase the exposure risk as well as harms to patients.", [["discomforts", "DISEASE", 92, 103], ["Headache", "DISEASE", 191, 199], ["headache", "DISEASE", 374, 382], ["headache", "DISEASE", 434, 442], ["patients", "ORGANISM", 735, 743], ["patients", "SPECIES", 735, 743], ["Multivariable logistical regression analysis", "TEST", 0, 44], ["associated discomforts", "PROBLEM", 81, 103], ["CI", "TEST", 120, 122], ["CI", "TEST", 171, 173], ["Headache", "PROBLEM", 191, 199], ["CI", "TEST", 216, 218], ["medical errors", "PROBLEM", 286, 300], ["headache", "PROBLEM", 374, 382], ["headache", "PROBLEM", 434, 442], ["Risk factors", "PROBLEM", 454, 466], ["discomfort", "PROBLEM", 471, 481], ["associated medical errors", "PROBLEM", 482, 507], ["the exposure risk", "TREATMENT", 697, 714]]], ["In addition, the time to tolerate the discomforts, adjusting goggles and headache significantly increased the risk occurring medical errors, which should be prevented before and during management of patients with COVID-19.Fog in goggles may contribute to medical exposures during the management of COVID-19Foggy goggles were reported frequently in our survey, 97.0% (224) (Table 5) .Fog in goggles may contribute to medical exposures during the management of COVID-19Interfered vision during practice caused by fog may lead to clinical exposure or medical errors, when we asked healthcare professionals or patients were more likely to be affected due to vision interfering, most participants tented to selecting patients but not healthcare professionals, and this selection showed no statistic differences among all groups when stratified by age or practice experience.", [["discomforts", "DISEASE", 38, 49], ["headache", "DISEASE", 73, 81], ["COVID-19", "CHEMICAL", 213, 221], ["patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 606, 614], ["patients", "ORGANISM", 712, 720], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 606, 614], ["participants", "SPECIES", 679, 691], ["patients", "SPECIES", 712, 720], ["the discomforts", "PROBLEM", 34, 49], ["adjusting goggles", "PROBLEM", 51, 68], ["headache", "PROBLEM", 73, 81], ["COVID", "TEST", 213, 218], ["Fog in goggles", "PROBLEM", 222, 236], ["medical exposures", "PROBLEM", 255, 272], ["COVID-19Foggy goggles", "TREATMENT", 298, 319], ["Fog in goggles", "PROBLEM", 383, 397], ["medical exposures", "PROBLEM", 416, 433], ["COVID", "TREATMENT", 459, 464], ["medical errors", "PROBLEM", 548, 562], ["vision interfering", "PROBLEM", 654, 672], ["this selection", "TEST", 759, 773], ["statistic differences", "PROBLEM", 784, 805]]], ["Notably, 10.4% (24) participants reported they exposed during clinical practice due to fog (Table 5 ).Fog in goggles may contribute to medical exposures during the management of COVID-19These results indicating that fog frequently occurred in clinical practice when managing patients with COVID-19.", [["COVID-19", "CHEMICAL", 289, 297], ["participants", "ORGANISM", 20, 32], ["patients", "ORGANISM", 275, 283], ["participants", "SPECIES", 20, 32], ["patients", "SPECIES", 275, 283], ["Fog in goggles", "PROBLEM", 102, 116], ["medical exposures", "PROBLEM", 135, 152], ["COVID", "TEST", 178, 183], ["COVID", "TEST", 289, 294]]], ["In addition, it was widely accepted by nurses in all groups that inferior vision caused by fog largely impacted the routine work and contributed to noticeable medical exposure.Fog in goggles may contribute to medical exposures during the management of COVID-19Tips for attenuating goggle-associated discomforts and relieving fog during wearing PPE Total 83.8% (193) participants took actions to deal with fogs and this ratio showed no significant differences when stratified in age or practice experience.", [["inferior vision", "DISEASE", 65, 80], ["COVID-19Tips", "CHEMICAL", 252, 264], ["goggle", "CHEMICAL", 281, 287], ["discomforts", "DISEASE", 299, 310], ["COVID-19Tips", "SIMPLE_CHEMICAL", 252, 264], ["participants", "SPECIES", 366, 378], ["inferior vision", "PROBLEM", 65, 80], ["noticeable medical exposure", "PROBLEM", 148, 175], ["Fog in goggles", "PROBLEM", 176, 190], ["medical exposures", "PROBLEM", 209, 226], ["the management", "TREATMENT", 234, 248], ["COVID", "TEST", 252, 257], ["attenuating goggle", "PROBLEM", 269, 287], ["associated discomforts", "PROBLEM", 288, 310], ["relieving fog", "PROBLEM", 315, 328], ["this ratio", "TEST", 414, 424]]], ["Varieties of reagents were utilized to smear on eyeglass, including iodine, liquid soap or soap, antifoggant, hydrogel, bath foam (Supplement Fig 3) .", [["eyeglass", "ANATOMY", 48, 56], ["iodine", "CHEMICAL", 68, 74], ["iodine", "CHEMICAL", 68, 74], ["eyeglass", "SIMPLE_CHEMICAL", 48, 56], ["iodine", "SIMPLE_CHEMICAL", 68, 74], ["antifoggant", "SIMPLE_CHEMICAL", 97, 108], ["reagents", "TREATMENT", 13, 21], ["smear", "TEST", 39, 44], ["eyeglass", "TREATMENT", 48, 56], ["iodine", "TREATMENT", 68, 74], ["liquid soap", "TREATMENT", 76, 87], ["soap", "TREATMENT", 91, 95], ["antifoggant", "TREATMENT", 97, 108], ["hydrogel, bath foam (Supplement Fig", "TREATMENT", 110, 145]]], ["Self-rating on the efficiency of these methods was 6 (IQR 3.75-8), interestingly, the rating in nurses under 30 years was lowest in all groups (Table 5) .Fog in goggles may contribute to medical exposures during the management of COVID-19There were few ways to relieve goggle-associated discomforts, most nurses directly loosed band a bit intermittently.", [["COVID-19", "CHEMICAL", 230, 238], ["discomforts", "DISEASE", 287, 298], ["COVID-19", "CHEMICAL", 230, 238], ["Fog in goggles", "PROBLEM", 154, 168], ["medical exposures", "PROBLEM", 187, 204], ["COVID", "TEST", 230, 235], ["goggle-associated discomforts", "PROBLEM", 269, 298]]], ["Other methods included selecting goggles with wider or softer bands and using All rights reserved.", [["selecting goggles", "TREATMENT", 23, 40], ["wider or softer bands", "TREATMENT", 46, 67], ["All rights", "TREATMENT", 78, 88]]], ["No reuse allowed without permission.Fog in goggles may contribute to medical exposures during the management of COVID-19(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Fog in goggles may contribute to medical exposures during the management of COVID-19The copyright holder for this preprint this version posted May 15, 2020. . anti-stress trips to relieve the pressure of bands on skin, however, exposure possibility should be concerned when using these methods.DiscussionDue to high infectivity of SARS-CoV-2 virus, precautions on protection of healthcare professionals were frequently mentioned recently [13, 14] .", [["skin", "ANATOMY", 468, 472], ["COVID", "DISEASE", 112, 117], ["COVID-19", "CHEMICAL", 331, 339], ["SARS", "DISEASE", 586, 590], ["COVID-19", "CHEMICAL", 331, 339], ["skin", "ORGAN", 468, 472], ["SARS-CoV-2 virus", "ORGANISM", 586, 602], ["CoV-2 virus", "SPECIES", 591, 602], ["SARS-CoV-2 virus", "SPECIES", 586, 602], ["Fog in goggles", "PROBLEM", 36, 50], ["medical exposures", "PROBLEM", 69, 86], ["Fog in goggles", "PROBLEM", 255, 269], ["medical exposures", "PROBLEM", 288, 305], ["COVID", "TEST", 331, 336], ["The copyright holder", "TREATMENT", 339, 359], ["anti-stress trips", "TREATMENT", 414, 431], ["the pressure of bands on skin", "PROBLEM", 443, 472], ["SARS", "PROBLEM", 586, 590], ["CoV", "TEST", 591, 594], ["med", "ANATOMY", 199, 202], ["pressure", "OBSERVATION_MODIFIER", 447, 455], ["skin", "ANATOMY", 468, 472]]], ["In China, best efforts were performed to prevent possible medical errors and relieve mental stress.", [["medical errors", "PROBLEM", 58, 72], ["mental stress", "PROBLEM", 85, 98]]], ["Nurses who involved in first line treatment of patients with COVID-19 received education and training on use of PPE and personal emotion management in some hospitals [11] .", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["first line treatment", "TREATMENT", 23, 43], ["COVID", "TREATMENT", 61, 66], ["education", "TREATMENT", 79, 88], ["PPE", "TREATMENT", 112, 115], ["personal emotion management", "TREATMENT", 120, 147]]], ["Meanwhile, the daily working time was restricted to avoid PPE-associated complications, such as dehydration, as described by us and the other study [11] .", [["dehydration", "DISEASE", 96, 107], ["PPE", "PROBLEM", 58, 61], ["associated complications", "PROBLEM", 62, 86], ["dehydration", "PROBLEM", 96, 107], ["the other study", "TEST", 132, 147], ["complications", "OBSERVATION", 73, 86]]], ["However, as described in this study, due to shortage of nurses in this pandemic, the proportion of nurses who had no experience to work in PPE before this pandemic in frontline of treating COVID-19 was higher than expected.", [["this study", "TEST", 25, 35], ["COVID", "TEST", 189, 194]]], ["In addition, we also identified most of them did not work in department of respiratory or infective disease, implying they may have insufficient experience on fulminating infectious disease in their previous clinical practice.", [["respiratory", "ANATOMY", 75, 86], ["respiratory or infective disease", "DISEASE", 75, 107], ["infectious disease", "DISEASE", 171, 189], ["respiratory or infective disease", "PROBLEM", 75, 107], ["fulminating infectious disease", "PROBLEM", 159, 189], ["respiratory", "ANATOMY", 75, 86], ["infective", "OBSERVATION", 90, 99]]], ["Although it is reasonable that training and education may benefit to reduce negative effects caused by goggles and have been emphasized in previous studies [11] , however, our findings showed short-term education and training on wearing PPE has limited effectiveness on easing mental stress and discomforts and cannot substantially avoid the occurrence of medical errors.", [["discomforts", "DISEASE", 295, 306], ["previous studies", "TEST", 139, 155], ["wearing PPE", "TREATMENT", 229, 240], ["mental stress", "PROBLEM", 277, 290], ["discomforts", "PROBLEM", 295, 306], ["medical errors", "PROBLEM", 356, 370]]], ["A large number of nurses in all groups occurred goggle-associated discomforts and had experiences of discontinuation from work at some time.DiscussionAlthough goggle-associated symptoms widely presented in all of nurses, we found nurses with \u2265 40 years or \u2265 21 years working experience showed a more optimistic attitude to the impact of mental stress, discomforts or fog on working status and the occurrence of medical errors.", [["discomforts", "DISEASE", 66, 77], ["discomforts", "DISEASE", 352, 363], ["associated discomforts", "PROBLEM", 55, 77], ["associated symptoms", "PROBLEM", 166, 185], ["mental stress", "PROBLEM", 337, 350], ["discomforts", "PROBLEM", 352, 363], ["fog on working status", "PROBLEM", 367, 388], ["medical errors", "PROBLEM", 411, 425], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["In addition, the proportions of headache and vomit were also significant lower in nurses with \u2265 21 years working experience.", [["headache", "DISEASE", 32, 40], ["vomit", "DISEASE", 45, 50], ["headache", "PROBLEM", 32, 40], ["vomit", "PROBLEM", 45, 50], ["headache", "OBSERVATION", 32, 40], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["lower", "OBSERVATION_MODIFIER", 73, 78]]], ["Because both of two groups represent more mature mentality and more abundant working experience, furthermore, age and practice duration were highly correlated with each other in our study (r = 0.94, p < 0.001, Supplement Fig 2) .", [["our study", "TEST", 178, 187], ["Supplement Fig", "TREATMENT", 210, 224], ["more", "OBSERVATION_MODIFIER", 37, 41], ["mature", "OBSERVATION_MODIFIER", 42, 48], ["mentality", "OBSERVATION", 49, 58]]], ["The findings revealed that training on psychological enduring capacity and enhancing proficiency may be useful to overcome some symptoms that can be induced by stress and can be more quickly adapting to new situations in a shorter time.", [["psychological enduring capacity", "PROBLEM", 39, 70], ["some symptoms", "PROBLEM", 123, 136]]], ["Considering training is the only way to increase the experience in short time, though short-term training was found to have limited effects on improving mental stress, we strongly suggest longer and earlier training and education should be performed to help the accumulation of experience with working in PPE more rapidly, especially in younger nurses.DiscussionHeadache was mostly mentioned in PPE-associated symptoms in previous study [10] .", [["Headache", "DISEASE", 362, 370], ["improving mental stress", "PROBLEM", 143, 166], ["Headache", "PROBLEM", 362, 370], ["PPE", "PROBLEM", 395, 398], ["associated symptoms", "PROBLEM", 399, 418], ["previous study", "TEST", 422, 436]]], ["Our results supported that headache could be the most prevalent symptom caused by goggles.", [["headache", "DISEASE", 27, 35], ["headache", "PROBLEM", 27, 35], ["goggles", "OBSERVATION", 82, 89]]], ["Moreover, dizziness, nausea, skin pressure injury, vomit and dysphoria were also broadly present in nurses during practice in management of COVID-19.", [["skin", "ANATOMY", 29, 33], ["dizziness", "DISEASE", 10, 19], ["nausea", "DISEASE", 21, 27], ["pressure injury", "DISEASE", 34, 49], ["vomit", "DISEASE", 51, 56], ["dysphoria", "DISEASE", 61, 70], ["skin", "ORGAN", 29, 33], ["dizziness", "PROBLEM", 10, 19], ["nausea", "PROBLEM", 21, 27], ["skin pressure injury", "PROBLEM", 29, 49], ["vomit", "PROBLEM", 51, 56], ["dysphoria", "PROBLEM", 61, 70], ["COVID", "TEST", 140, 145], ["skin", "ANATOMY", 29, 33], ["pressure", "OBSERVATION_MODIFIER", 34, 42], ["injury", "OBSERVATION", 43, 49]]], ["Interestingly, unlike the distribution of most symptoms in this study, the incidence of rash was much higher in nurses with \u2265 21 years working All rights reserved.", [["rash", "DISEASE", 88, 92], ["most symptoms", "PROBLEM", 42, 55], ["this study", "TEST", 59, 69], ["rash", "PROBLEM", 88, 92], ["rash", "OBSERVATION", 88, 92]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 15, 2020. . experience, the possible reason is the skin was aging in this group and was more susceptive to the hostile environment, indicating the prevention of symptoms should be performed discretely on nurses in different age range.DiscussionGoggle-associated discomforts occurred in early stage and these discomforts seriously impacted their clinical practice during management of patients with COVID-19 and contributed to medical errors.", [["skin", "ANATOMY", 305, 309], ["discomforts", "DISEASE", 516, 527], ["skin", "ORGAN", 305, 309], ["patients", "ORGANISM", 638, 646], ["patients", "SPECIES", 638, 646], ["symptoms", "PROBLEM", 415, 423], ["associated discomforts", "PROBLEM", 505, 527], ["these discomforts", "PROBLEM", 556, 573], ["COVID", "TEST", 652, 657], ["medical errors", "PROBLEM", 680, 694], ["med", "ANATOMY", 125, 128], ["skin", "ANATOMY", 305, 309]]], ["Our data demonstrated that discomforts are not only harmful to the health but also lead to inferior quality of clinical works, thus relief of these discomforts is essential to protect healthcare professionals and patients.", [["discomforts", "DISEASE", 27, 38], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["Our data", "TEST", 0, 8], ["discomforts", "PROBLEM", 27, 38], ["these discomforts", "PROBLEM", 142, 159]]], ["For the underlying reasons to cause these discomforts, tightness of goggles was complained mostly.DiscussionWearing too tight can be impacted by subjective reasons and objective reasons.", [["these discomforts", "PROBLEM", 36, 53], ["tightness of goggles", "PROBLEM", 55, 75]]], ["As we described previously, mental stress on fearing exposure partly made nurses to wear goggles more tight than ordinary time.", [["mental stress on fearing exposure", "PROBLEM", 28, 61]]], ["On the other hand, some nurses also attenuated discomforts through selecting softer band or wider band and using anti-stress trips to reduce the pressure, indicating materials and designs may also be useful to improve the user experience on tightness.", [["discomforts", "DISEASE", 47, 58], ["attenuated discomforts", "PROBLEM", 36, 58], ["selecting softer band", "TREATMENT", 67, 88], ["wider band", "TREATMENT", 92, 102], ["anti-stress trips", "TREATMENT", 113, 130], ["the pressure", "TEST", 141, 153], ["tightness", "PROBLEM", 241, 250]]], ["In addition, besides to tightness feeling, we also identified the unsuitable face shape and hard materials used for producing goggles were also two important reasons to induce the discomforts.", [["face", "ANATOMY", 77, 81], ["discomforts", "DISEASE", 180, 191], ["the discomforts", "PROBLEM", 176, 191]]], ["Consistent with previous conclusion, adequate psychological training is essential to help resolving mental stress-associated discomforts.", [["discomforts", "DISEASE", 125, 136], ["adequate psychological training", "TREATMENT", 37, 68], ["mental stress", "PROBLEM", 100, 113], ["associated discomforts", "PROBLEM", 114, 136]]], ["Moreover, the design and materials can be substantially improved, a customized goggle for different races with softer band or wider band may be more popular in nurses.DiscussionMedical errors can potentially cause serious problems during clinical practice.", [["softer band or wider band", "TREATMENT", 111, 136], ["serious problems", "PROBLEM", 214, 230], ["softer band", "OBSERVATION_MODIFIER", 111, 122]]], ["Unfortunately, our study found goggle is associated with increased medical errors and this cannot be changed significantly by more abundant working experience.", [["our study", "TEST", 15, 24], ["increased medical errors", "PROBLEM", 57, 81], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["medical errors", "OBSERVATION", 67, 81]]], ["Among the risk factors, the longer time before tolerating discomforts and headache meant the nurses' focus on practice would be interrupted and more frequent adjusting goggles can increase the chances of occurring medical errors.", [["discomforts", "DISEASE", 58, 69], ["headache", "DISEASE", 74, 82], ["discomforts", "PROBLEM", 58, 69], ["headache", "PROBLEM", 74, 82]]], ["Because these three risk factors all associated with mental stress and design of goggles, modified goggles and psychological education should be seriously considered.DiscussionFog is another refractory problem of goggles.", [["mental stress", "PROBLEM", 53, 66], ["goggles", "PROBLEM", 81, 88], ["modified goggles", "TREATMENT", 90, 106], ["psychological education", "TREATMENT", 111, 134], ["goggles", "PROBLEM", 213, 220], ["goggles", "OBSERVATION", 213, 220]]], ["In this study, the median time to arising fog in goggles was only 1 hour after wearing PPE, indicating nurses had to work with blurred vision for a long time.", [["blurred vision", "DISEASE", 127, 141], ["this study", "TEST", 3, 13], ["blurred vision", "PROBLEM", 127, 141]]], ["Although we did not compare the incidence of exposures caused by fog in management of COVID-19 with the incidence in ordinary times, the exposure incidence of 10.4% cannot be neglected.", [["COVID", "TEST", 86, 91]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted May 15, 2020. .DiscussionThere are some limits in this study: First, the sample size was a bit small.", [["the sample size", "TEST", 319, 334], ["med", "ANATOMY", 125, 128], ["size", "OBSERVATION_MODIFIER", 330, 334], ["bit small", "OBSERVATION_MODIFIER", 341, 350]]], ["However, all of age groups and working experience were covered in this study and our results can reflect the overall condition.", [["this study", "TEST", 66, 76]]], ["Second, this survey was performed after mission completed and the participants have rested for several days, this may cause potential bias on rating.", [["participants", "SPECIES", 66, 78]]], ["The negative effects and the level of nervous may be underestimated.", [["nervous", "ANATOMY", 38, 45], ["nervous", "ANATOMICAL_SYSTEM", 38, 45], ["negative effects", "OBSERVATION", 4, 20]]], ["Third, this retrospective study performs a preliminary assessment, goggle-associated symptoms and negative effects of fog in goggles were primary analyzed, the effects of other PPE on health and working status of healthcare professionals should be further investigated.DiscussionTaking together, goggle-associated symptoms and fog are two major problems that impact the clinical practice.", [["this retrospective study", "TEST", 7, 31], ["a preliminary assessment", "TEST", 41, 65], ["associated symptoms", "PROBLEM", 74, 93], ["fog in goggles", "PROBLEM", 118, 132], ["healthcare professionals", "TREATMENT", 213, 237], ["associated symptoms", "PROBLEM", 303, 322], ["fog", "PROBLEM", 327, 330]]], ["Goggle-associated symptoms are highly prevalent in nurses involving in management of patients with COVID-19.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Goggle-associated symptoms", "PROBLEM", 0, 26], ["COVID", "TEST", 99, 104]]], ["These discomforts significantly impacted working status and potentially lead to medical errors.", [["These discomforts", "PROBLEM", 0, 17]]], ["Headache, adjusting goggles and time before adapting goggles are three risk factors of medical errors.", [["Headache", "DISEASE", 0, 8], ["Headache", "PROBLEM", 0, 8], ["medical errors", "PROBLEM", 87, 101]]], ["Improvement of design and materials of goggles during productive process is promising way to reduce the incidence of symptoms and fog and may benefit to working status and the occurrence of medical errors.", [["goggles", "TREATMENT", 39, 46], ["symptoms", "PROBLEM", 117, 125], ["fog", "PROBLEM", 130, 133], ["medical errors", "PROBLEM", 190, 204]]], ["In addition, longer training time and psychological education may help to reduce the mental stress through increasing the psychological quality and proficiency.Competing interests:The authors declare that they have no competing interests.", [["psychological education", "TREATMENT", 38, 61], ["the mental stress", "PROBLEM", 81, 98]]], ["Infect Control Hosp Epidemiol, 2020, 1-4, doi:10.1017/ice.2020.148.Competing interests:[4] Dorr, R. Protecting patients and healthcare personnel from COVID-19: considerations for practice and outpatient care in cardiology [J] .", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["Herz, 2020, Stage IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) 0 (0%) NA Initial symptoms (%)Competing interests:All rights reserved.", [["Herz", "TEST", 0, 4], ["Stage IV", "TEST", 12, 20], ["NA", "TEST", 49, 51], ["NA Initial symptoms", "TEST", 73, 92]]], ["No reuse allowed without permission.Competing interests:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 135, 138]]]], "d9f9b1c0b86910498dd02926485c7abadadedcc3": [["ABSTRACT:Objective:ABSTRACT:To describe the implementation of technological support important for optimizing clinical management of the COVID-19 pandemic.Materials and Methods:Our health system has confirmed prior and current cases of COVID-19.", [["COVID-19", "CHEMICAL", 235, 243], ["technological support", "TREATMENT", 62, 83], ["optimizing clinical management", "TREATMENT", 98, 128], ["the COVID", "TEST", 132, 141], ["pandemic", "PROBLEM", 145, 153], ["COVID", "TEST", 235, 240]]], ["An Incident CommandMaterials and Methods:Center was established early in the crisis and helped identify electronic health record (EHR) based tools to support clinical care.Results:We outline the design and implementation of EHR based rapid screening processes, laboratory testing, clinical decision support, reporting tools, and patient-facing technology related to COVID-19.Discussion:The EHR is a useful tool to enable rapid deployment of standardized processes.", [["patient", "ORGANISM", 329, 336], ["COVID-19", "DNA", 366, 374], ["patient", "SPECIES", 329, 336], ["clinical care", "TREATMENT", 158, 171], ["laboratory testing", "TEST", 261, 279], ["COVID", "TEST", 366, 371]]], ["UC San Diego Health built multiple COVID-19-specific tools to support outbreak management, including scripted triaging, electronic check-in, standard ordering and documentation, secure messaging, real-time data analytics, and telemedicine capabilities.", [["multiple COVID", "TEST", 26, 40], ["outbreak management", "TREATMENT", 70, 89], ["scripted triaging", "TEST", 101, 118], ["electronic check", "TEST", 120, 136]]], ["Challenges included the need to frequently adjust build to meet rapidly evolving requirements, communication and adoption, and coordinating the needs of multiple stakeholders while maintaining high-quality, pre-pandemic medical care.ConclusionThe EHR is an essential tool in supporting the clinical needs of a health system managing the COVID-19 pandemic.BACKGROUND AND SIGNIFICANCE:The novel coronavirus COVID-19 was initially identified in December 2019 as a case of pneumonia in Wuhan, China and has since become a global pandemic, affecting greater than 150 countries around the world.[1-6] The World Health Organization declared the outbreak a pandemic on March 11, 2020 and called for coordinated mechanisms to support preparedness and response to the infection across health sectors.", [["pneumonia", "DISEASE", 469, 478], ["infection", "DISEASE", 758, 767], ["coronavirus COVID-19", "ORGANISM", 393, 413], ["coronavirus COVID-19", "SPECIES", 393, 413], ["pre-pandemic medical care", "TREATMENT", 207, 232], ["the COVID", "TEST", 333, 342], ["pandemic", "PROBLEM", 346, 354], ["The novel coronavirus COVID", "TEST", 383, 410], ["pneumonia", "PROBLEM", 469, 478], ["a global pandemic", "PROBLEM", 516, 533], ["the infection across health sectors", "PROBLEM", 754, 789], ["essential", "OBSERVATION_MODIFIER", 257, 266], ["pneumonia", "OBSERVATION", 469, 478], ["global", "OBSERVATION_MODIFIER", 518, 524], ["pandemic", "OBSERVATION", 525, 533], ["infection", "OBSERVATION", 758, 767]]], ["[8] While the incidence of COVID-19 continues to rise, healthcare systems are rapidly preparing and adapting to increasing clinical demands.", [["COVID-19", "CHEMICAL", 27, 35], ["COVID", "TEST", 27, 32], ["increasing clinical demands", "PROBLEM", 112, 139]]], ["[9] [10] Inherent to the operational management of a pandemic in the era of modern medicine is leveraging the capabilities of the electronic health record (EHR), which can be useful for developing tools to support standard management of patients.", [["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["standard management", "TREATMENT", 214, 233]]], ["[11] Technologybased tools can effectively support institutions during a pandemic by facilitating the immediate widespread distribution of information, tracking transmission in real-time, creating virtual venues for meetings and day-to-day operations, and, perhaps most importantly, offering telemedicine visits for patients.", [["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324]]], ["[12] [13] [14] [15] [16] During the Ebola outbreak in 2014, attention was brought to the use of the EHR as a potential public health tool.", [["[12] [13] [14] [15] [16", "CHEMICAL", 0, 23], ["Ebola", "DISEASE", 36, 41], ["[12] [13] [14] [15] [16", "SIMPLE_CHEMICAL", 0, 23], ["Ebola", "ORGANISM", 36, 41]]], ["[17] Unfortunately, despite the recent Ebola epidemic, the infrastructure for outbreak management was not present in many United States health systems and their EHR applications.", [["Ebola", "DISEASE", 39, 44], ["Ebola", "ORGANISM", 39, 44], ["the recent Ebola epidemic", "PROBLEM", 28, 53], ["outbreak management", "TREATMENT", 78, 97], ["Ebola", "OBSERVATION", 39, 44]]], ["[18] As we are now facing a pandemic, many institutions are working to rapidly develop supportive and reliable informatics infrastructure in order to prepare for managing an exponential increase in COVID-19-infected patients.", [["COVID-19-infected", "DISEASE", 198, 215], ["COVID-19", "ORGANISM", 198, 206], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["COVID", "TEST", 198, 203]]], ["However, the literature to describe the informatics tools required to successfully manage this novel infection is lacking.OBJECTIVE:Here we discuss the rapid development and implementation of the EHR configuration necessary for outbreak management within a large regional public academic health center in the setting of new and pending COVID-19 cases.", [["infection", "DISEASE", 101, 110], ["this novel infection", "PROBLEM", 90, 110], ["outbreak management", "TREATMENT", 228, 247], ["COVID", "TEST", 336, 341], ["infection", "OBSERVATION", 101, 110], ["large", "OBSERVATION_MODIFIER", 257, 262]]], ["We detail the specific informatics tools we built to support the health system's efforts to prepare for the current pandemic and the challenges associated with this task.MATERIALS AND METHODS:University of California, San Diego Health (UCSDH) is a large regional academic health system encompassing two acute care hospitals, outpatient primary and specialty medical and surgical care, and emergency patient care.", [["patient", "ORGANISM", 399, 406], ["patient", "SPECIES", 399, 406], ["surgical care", "TREATMENT", 370, 383], ["large", "OBSERVATION_MODIFIER", 248, 253]]], ["UCSDH is also one of five academic medical centers within a broader 10-campus University of California system.", [["California system", "ANATOMY", 92, 109]]], ["UCSDH utilizes a commercially available, electronic health record (EHR), Epic (Verona, WI), and also hosts over 300 affiliate physicians across 10 medical groups on this EHR.", [["UCSDH", "CHEMICAL", 0, 5]]], ["An assessment of the institutional current state revealed the need to develop a rapid screening process, hospital-based and ambulatory testing, new orders with clinical decision support, reporting/analytics tools, and the enhancement/expansion of current patient-facing technology.RESULTS:With the guidance of the Incident Command Center, our clinical informatics team prioritized projects related to COVID-19 to enable expedited build and implementation.", [["patient", "ORGANISM", 255, 262], ["COVID-19", "DNA", 401, 409], ["patient", "SPECIES", 255, 262], ["An assessment", "TEST", 0, 13], ["ambulatory testing", "TEST", 124, 142], ["COVID", "TEST", 401, 406]]], ["A protocolized triage system was developed and embedded into multiple EHR templates, which could be rapidly updated as screening guidance evolved ( Table 2) .", [["A protocolized triage system", "TEST", 0, 28], ["screening guidance", "TEST", 119, 137]]], ["These instructions can be easily accessed by call centers and triage nurses, allowing them to provide guidance to patients regarding requirements for home isolation, appropriate locations to obtain COVID-19 testing, and when to visit the emergency department.Screening ToolsIn order to limit exposures and relieve the burden on physical healthcare locations, automated email notifications were sent to patients prior to their clinic appointments indicating that persons with fever and/or new cough call the health system for proper triage before presenting to the health care facility.Screening ToolsTravel and symptoms screening questions were added to the registration/check-in process ( Figure 1) .", [["fever", "DISEASE", 475, 480], ["cough", "DISEASE", 492, 497], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 402, 410], ["persons", "ORGANISM", 462, 469], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 402, 410], ["persons", "SPECIES", 462, 469], ["home isolation", "TREATMENT", 150, 164], ["COVID", "TEST", 198, 203], ["fever", "PROBLEM", 475, 480], ["new cough", "PROBLEM", 488, 497], ["Screening", "TEST", 585, 594], ["symptoms screening", "TEST", 611, 629], ["the registration/check", "TEST", 654, 676]]], ["The EHR was configured to require complete documentation by front desk staff, ensuring all patients being seen for acute and elective care across the institution receive screening.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["acute and elective care", "TREATMENT", 115, 138], ["screening", "TEST", 170, 179]]], ["Positive screening questions in both acute and ambulatory care settings triggered a provider alert with clinical decision support offering appropriate guidance for subsequent clinical care, including any testing or isolation orders needed to facilitate next steps.", [["subsequent clinical care", "TREATMENT", 164, 188], ["any testing", "TEST", 200, 211], ["isolation orders", "TREATMENT", 215, 231]]], ["Again, this set of tools in the EHR can be rapidly adjusted based on evolving recommendations.Ordering ToolsWe constructed order panels in the EHR for inpatient, emergency department, and ambulatory settings that included a defaulted, pre-populated COVID-19 lab order, appropriate isolation orders and options for additional laboratory testing or imaging studies.", [["additional laboratory testing", "TEST", 314, 343], ["imaging studies", "TEST", 347, 362]]], ["UCSDH elected to use in-house COVID-19 testing for patients in the hospital and emergency department, but to have COVID-19 tests obtained in ambulatory and urgent care settings sent out to a reference laboratory due to initial existing limitations in testing capacity.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["COVID", "TEST", 114, 119], ["urgent care settings", "TEST", 156, 176], ["testing capacity", "TEST", 251, 267]]], ["As such, engineering the correct order to appear in the correct setting was essential to avoid confusion and process failures.Ordering ToolsAdditionally, modifications were made to our existing respiratory pathogen panel, as several tests for non-COVID-19 coronaviruses were already present in the system.", [["confusion", "DISEASE", 95, 104], ["coronaviruses", "ORGANISM", 256, 269], ["non-COVID-19 coronaviruses", "SPECIES", 243, 269], ["confusion", "PROBLEM", 95, 104], ["process failures", "PROBLEM", 109, 125], ["our existing respiratory pathogen panel", "TEST", 181, 220], ["several tests", "TEST", 225, 238], ["non-COVID", "TEST", 243, 252], ["coronaviruses", "PROBLEM", 256, 269]]], ["In order to avoid confusion for both clinicians and patients, these tests were clearly labeled to delineate between COVID-19 and other coronaviruses unrelated to the current pandemic or \"NON-COVID-19Ordering Toolscoronavirus.\"Ordering ToolsClinical decision support at the moment of ordering was provided by including screening criteria, information on specimen acquisition, requirements for personal protective equipment, and expectations on test result turnaround time for easy review.", [["specimen", "ANATOMY", 353, 361], ["confusion", "DISEASE", 18, 27], ["patients", "ORGANISM", 52, 60], ["coronaviruses", "ORGANISM", 135, 148], ["patients", "SPECIES", 52, 60], ["confusion", "PROBLEM", 18, 27], ["these tests", "TEST", 62, 73], ["COVID", "TEST", 116, 121], ["other coronaviruses", "PROBLEM", 129, 148], ["screening criteria", "TEST", 318, 336], ["specimen acquisition", "TEST", 353, 373], ["personal protective equipment", "TREATMENT", 392, 421]]], ["In addition, a series of questions were added to the COVID-19 orders, requiring the ordering provider to document the testing criteria met by the patient.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["the testing criteria", "TEST", 114, 134]]], ["Our build construct allowed for rapid editing to maintain alignment with operational needs as screening requirements and lab handling processes frequently changed following the initial implementation.", [["screening requirements", "TEST", 94, 116], ["lab handling processes", "TREATMENT", 121, 143]]], ["Similar COVID-19 ordering workflows were instituted in our occupational health department to prepare for the potential of increased healthcare worker exposures.Team communication and coordination of health system effortsTo better respond to the rapidly evolving care needs during this outbreak, UCSDH assembled a seven-person \"Ambulatory COVID Team (ACT).\"", [["person", "SPECIES", 319, 325]]], ["Team members included two infectious disease physicians, three primary care physicians (our community care physician lead, an epidemiology expert, and our ambulatory Chief Medical Information Officer), and two nurses.", [["infectious disease", "DISEASE", 26, 44]]], ["We used a secured messaging platform (SMP) within the EHR to enable rapidReporting and AnalyticsHaving the ability to monitor the evolving current state of the health system was a key request from the Incident Command Center.", [["a secured messaging platform (SMP", "TREATMENT", 8, 41]]], ["The reports were automatically distributed, accessible on mobile devices, and used to inform operational decisions on expanding testing capacity, patient isolation procedures, geographic cohorting of patients, and to monitor adherence to patient screening processes.", [["patient", "ORGANISM", 146, 153], ["patients", "ORGANISM", 200, 208], ["patient", "ORGANISM", 238, 245], ["patient", "SPECIES", 146, 153], ["patients", "SPECIES", 200, 208], ["patient", "SPECIES", 238, 245], ["mobile devices", "TREATMENT", 58, 72], ["expanding testing capacity", "TEST", 118, 144], ["patient isolation procedures", "TREATMENT", 146, 174], ["patient screening processes", "TEST", 238, 265]]], ["We also created a COVID-19 Operational Dashboard with real-time data on the number of patients tested, test results, bed availability in the intensive care unit, availability of ventilator units, and volume of ambulatory visits (Figure 2 ).", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["ventilator units", "TREATMENT", 178, 194]]], ["In addition, UCSDH had previously granted broad access to the EHR self-service analytics tool, with which key personnel can create ad hoc reports on items such as the use of isolation and testing frequency.Patient-facing technologiesUCSDH prioritized moving in-person clinic visits to telemedicine-based visits when appropriate in order to avoid unnecessary patient and staff exposure.", [["patient", "ORGANISM", 358, 365], ["Patient", "SPECIES", 206, 213], ["patient", "SPECIES", 358, 365], ["isolation", "TREATMENT", 174, 183], ["testing frequency", "TEST", 188, 205]]], ["Prior to the advent of the COVID-19 outbreak, UCSD had already developed and implemented a telemedicine infrastructure for use by multiple outpatient clinics.", [["the COVID", "TEST", 23, 32]]], ["In response to the federal government loosening of telehealth requirements, and local desire to convert existing outpatient visits to video, we expanded access to all outpatient areas and created online self-guided learning videos on the conduct of virtual patient care (Figure 3) .", [["patient", "ORGANISM", 257, 264], ["patient", "SPECIES", 257, 264], ["loosening of telehealth requirements", "PROBLEM", 38, 74], ["all outpatient areas", "TREATMENT", 163, 183], ["virtual patient care", "TREATMENT", 249, 269]]], ["Within 72 hours of the executive proclamation of a national emergency, over 300 unique health employees were trained in telemedicine and ~1,000 video visits were scheduled.Patient-facing technologiesOver 200,000 patients at UCSDH use the patient portal functionality within the EHRtethered patient portal (Epic MyChart), which allows patients to utilize the video visit capability described above in addition to scheduling appointments, secure messaging with the care team, and viewing and downloading test results.", [["patients", "ORGANISM", 212, 220], ["patient", "ORGANISM", 238, 245], ["patient", "ORGANISM", 290, 297], ["patients", "ORGANISM", 334, 342], ["Patient", "SPECIES", 172, 179], ["patients", "SPECIES", 212, 220], ["patient", "SPECIES", 238, 245], ["patient", "SPECIES", 290, 297], ["patients", "SPECIES", 334, 342], ["downloading test", "TEST", 490, 506], ["portal", "ANATOMY", 246, 252], ["portal", "ANATOMY", 298, 304]]], ["22 The aforementioned modification of the display names for our pre-existing coronavirus assay ensured non-COVID coronavirus lab results displayed to patients as \"non-COVID-19.\"", [["coronavirus", "ORGANISM", 77, 88], ["coronavirus", "ORGANISM", 113, 124], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["our pre-existing coronavirus assay", "TEST", 60, 94]]], ["An early operational decision was made to delay the release of positive COVID-19-specific test results to allow UCSDH to directly contact and inform patients.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["positive COVID", "TEST", 63, 77]]], ["However, we elected to immediately post negative COVID-19 test results to MyChart as testing volume made it more challenging to contact all tested patients in a timely fashion.DISCUSSION:We describe a series of EHR enhancements designed to support the rapid deployment of new policies, procedures, and protocols across a healthcare system in response to the COVID-19DISCUSSION:pandemic.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["testing volume", "TEST", 85, 99], ["procedures", "TREATMENT", 286, 296], ["pandemic", "PROBLEM", 377, 385]]], ["[10, 18] As our own institution faced a growing number of known and suspected COVID-19 cases, as well as a variety of patient care and operational needs related to the pandemic, we recognized the importance of the EHR and other technology-based tools as an enabling adjunct to accelerated process design and implementation.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125]]], ["The development of a multidisciplinary task force involving institutional leaders, infectious disease and infection prevention specialists, and technology experts is a critical first step in addressing hospital-specific concerns and developing open and productive communication.", [["infectious disease", "DISEASE", 83, 101], ["infection", "DISEASE", 106, 115], ["infectious", "OBSERVATION_MODIFIER", 83, 93]]], ["[23] [24] [25] An initial needs-based assessment was done of the current state to determine the necessary operational processes for outbreak management, the existing informatics structure to support these processes, and the gaps that needed to be bridged in a timely fashion.", [["An initial needs-based assessment", "TEST", 15, 48], ["outbreak management", "TREATMENT", 132, 151]]], ["Doing so allowed us to expediently configure the EHR to support COVID-19DISCUSSION:outbreak management as detailed in this report. information can serve to assist governments and regional health systems in combatting the outbreak.", [["outbreak management", "TREATMENT", 83, 102]]], ["However, to our knowledge no reports have detailed the specific tools within an EHR that can be developed and leveraged to support the efforts of the public health response against COVID-19.", [["COVID", "TEST", 181, 186]]], ["[29] Online questionnaires were utilized to risk stratify travelers so that low risk citizens were automatically sent a health declaration border pass while high-risk individuals were quarantined at home and remotely monitored for the development of symptoms with mobile device applications.", [["individuals", "ORGANISM", 167, 178], ["low risk citizens", "PROBLEM", 76, 93], ["symptoms", "PROBLEM", 250, 258], ["mobile device applications", "TREATMENT", 264, 290]]], ["[29] Healthcare systems in Houston, Texas, developed remote communication channels between physicians and emergency responders to assist with triaging.", [["triaging", "TEST", 142, 150]]], ["[14] Virtual home visits for high risk individuals and remote ICU monitoring is also being employed to reduce hospital-staff contact with patients with suspected or confirmed cases of COVID-19.", [["COVID-19", "CHEMICAL", 184, 192], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["high risk individuals", "PROBLEM", 29, 50], ["remote ICU monitoring", "TEST", 55, 76], ["COVID", "TEST", 184, 189]]], ["[14] Multiple institutions across the United States have transitioned to telemedicine in an effort to reduce emergency room visits through remote triaging.", [["telemedicine", "TREATMENT", 73, 85]]], ["[23] Telemedicine has already proved useful during epidemiological emergencies, including through use of live video counseling with patients, virtual patient monitoring, and mobile applications for symptom observation.", [["patients", "ORGANISM", 132, 140], ["patient", "ORGANISM", 150, 157], ["patients", "SPECIES", 132, 140], ["patient", "SPECIES", 150, 157], ["virtual patient monitoring", "TEST", 142, 168], ["mobile applications", "TREATMENT", 174, 193], ["symptom observation", "TEST", 198, 217]]], ["[15] Telemedicine can be used in the setting of emergency medicine to triage patients, decrease the rate of discharge without complete treatment and proper follow-up, and reduce the number of in-person visits and subsequent risk of transmission of infection.", [["infection", "DISEASE", 248, 257], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Telemedicine", "TREATMENT", 5, 17], ["emergency medicine", "TREATMENT", 48, 66], ["complete treatment", "TREATMENT", 126, 144], ["infection", "PROBLEM", 248, 257], ["infection", "OBSERVATION", 248, 257]]], ["[12] [13] An additional application is in early symptom identification and triaging as a mitigation strategy for potential delays in access to healthcare.", [["a mitigation strategy", "TREATMENT", 87, 108]]], ["[30] This was previously observed in Wuhan, China during the initial outbreak of COVID-19 when 89% of patients were not hospitalized until at least 5 days into their illness.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["COVID", "TEST", 81, 86]]], ["[30] Enhancing existing EHR platforms with tools for triaging and screening for symptoms has the potential to identify symptomatic patients earlier and decrease the physical burden on healthcare systems.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["triaging", "TEST", 53, 61], ["screening", "TEST", 66, 75], ["symptoms", "PROBLEM", 80, 88]]], ["[31] At our own institution, much of the informatics framework to support outbreak balancing the need to focus on the pandemic while maintaining high-quality healthcare and operations unrelated to the novel infection in order to provide service to all aspects of the community.", [["infection", "DISEASE", 207, 216], ["operations", "TREATMENT", 173, 183], ["the novel infection", "PROBLEM", 197, 216], ["infection", "OBSERVATION", 207, 216]]], ["Finally, the frequently changing landscape of a pandemic, with often daily guideline and protocol updates that generally require approval from multiple stakeholders within a large and complex health system, presented challenges to maintaining the rapid project momentum.DISCUSSION:The most significant mitigation strategy for these challenges was the establishment of a24-hour Incident Command Center that included representation from UCSDH InformationServices.", [["large", "OBSERVATION_MODIFIER", 174, 179]]], ["This enabled real-time identification of failures and successes, a focus on evolving needs, and feedback on subsequent interventions.", [["failures", "PROBLEM", 41, 49], ["subsequent interventions", "TREATMENT", 108, 132], ["failures", "OBSERVATION", 41, 49]]], ["The COVID-19 pandemic has highlighted the importance of a multidisciplinary team approach to medical care and building cohesive systems capable of sustaining unanticipated trials.CONCLUSION:In the face of the COVID-19 pandemic, healthcare systems can best prepare by following guidelines and recommendations set forth by federal and global institutions.", [["a multidisciplinary team approach", "TREATMENT", 56, 89], ["medical care", "TREATMENT", 93, 105]]], ["The electronic health record and associated technologies are vital and requisite tools in supporting outbreak management that should be leveraged to their full potential, and we hope that our experiences in developing these tools will be helpful to other health systems facing the same challenge.ACKNOWLEDGEMENTS:We", [["supporting outbreak management", "TREATMENT", 90, 120]]]], "PMC7114272": [["During 2002\u20132003, an outbreak of severe acute respiratory syndrome coronavirus (SARS-CoV) infection spreads quickly from South China to more than 25 countries worldwide (WHO; http://www.who.int/csr/don/2003_04_17/en/).", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["SARS-CoV) infection", "DISEASE", 80, 99], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 33, 78], ["SARS-CoV", "ORGANISM", 80, 88], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV", "SPECIES", 80, 88], ["severe acute respiratory syndrome coronavirus (SARS-CoV) infection", "PROBLEM", 33, 99], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome coronavirus", "OBSERVATION", 46, 78]]], ["About 8000 individuals were infected and the mortality rate was 10% (Ksiazek et al., 2003).", [["individuals", "ORGANISM", 11, 22], ["the mortality rate", "TEST", 41, 59]]], ["In 2003, angiotensin-converting enzyme 2 (ACE2) was identified as a cellular receptor of SARS-CoV (Li et al., 2003), and the binding of SARS-CoV spike protein (SARS-S protein) and ACE2 was clearly shown to be a required initial step for viral entry (Li et al., 2003, Wong et al., 2004).", [["cellular", "ANATOMY", 68, 76], ["angiotensin", "CHEMICAL", 9, 20], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 9, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["cellular", "CELL", 68, 76], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["SARS-CoV spike protein", "GENE_OR_GENE_PRODUCT", 136, 158], ["SARS-S protein", "GENE_OR_GENE_PRODUCT", 160, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 180, 184], ["angiotensin-converting enzyme 2", "PROTEIN", 9, 40], ["ACE2", "PROTEIN", 42, 46], ["SARS-CoV spike protein", "PROTEIN", 136, 158], ["SARS-S protein", "PROTEIN", 160, 174], ["ACE2", "PROTEIN", 180, 184], ["SARS-CoV", "SPECIES", 89, 97], ["SARS-CoV", "SPECIES", 136, 144], ["angiotensin", "TEST", 9, 20], ["enzyme", "TEST", 32, 38], ["SARS", "PROBLEM", 89, 93], ["CoV (Li et al.", "TEST", 94, 108], ["SARS", "PROBLEM", 136, 140], ["CoV spike protein", "TEST", 141, 158], ["SARS-S protein", "TEST", 160, 174], ["ACE2", "TEST", 180, 184]]], ["Based on an analysis of the molecular interaction between ACE2 and SARS-S protein and the subsequent process of viral entry (Kuhn et al., 2007), several targets are now available for developing antiviral compounds (Liu et al., 2004, Simmons et al., 2005, Sui et al., 2004).", [["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["SARS-S", "GENE_OR_GENE_PRODUCT", 67, 73], ["ACE2", "PROTEIN", 58, 62], ["SARS-S protein", "PROTEIN", 67, 81], ["an analysis", "TEST", 9, 20], ["ACE2", "TEST", 58, 62], ["SARS-S protein", "TEST", 67, 81]]], ["Since recurrent outbreaks of SARS-CoV can reemerge, developing compounds that will prevent SARS-CoV are critically important.", [["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 91, 95], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "PROBLEM", 29, 33], ["SARS", "PROBLEM", 91, 95]]]], "544435b574e6321a593853861bf792ac022e5be8": [["The ray of light that runs through a dark room reveals the existence of numerous small grains of dust that can float in the air for a long time.", [["numerous", "OBSERVATION_MODIFIER", 72, 80], ["small", "OBSERVATION_MODIFIER", 81, 86], ["grains", "OBSERVATION_MODIFIER", 87, 93], ["dust", "OBSERVATION", 97, 101], ["air", "ANATOMY", 124, 127]]], ["A famous observation of this effect is documented in Lucretius's poem De Rerum Natura, written around 50 BC.", [["BC", "CANCER", 105, 107]]], ["In addition to the empirical description of the phenomenon, and following the tradition of Democritus and Epicurus, Lucretius also proposed an atomistic explanation for the support of particles in the air, according to which their weight would be compensated by the collisions of air atoms.", [["air", "OBSERVATION", 201, 204], ["air atoms", "OBSERVATION", 280, 289]]], ["1 However, the behavior of tiny bodies immersed in fluids was only understood from the 19th century on owing to the works of Robert Brown, 2 George Gabriel Stokes, and finally with Einstein's famous work of 1905, On the movement of small particles in suspension within liquids at rest.", [["tiny bodies", "PROBLEM", 27, 38], ["tiny", "OBSERVATION_MODIFIER", 27, 31], ["bodies", "OBSERVATION", 32, 38], ["fluids", "OBSERVATION", 51, 57]]]]}